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Many complex biological processes are regulated by cell signaling, where a secreted ligand
travels short or long distances through an organism or tissue until it is recognized by a cell
surface receptor. These receptors, proteins residing in the cellular membrane, function as a
communication channel between the extra- and intracellular space, translating the binding
of a ligand into a variety of signaling cascades which ultimately lead to a cellular response.
Receptor expression is cell-type specific so that the ligands that bind them exert a localized
effect. This principle is essential for maintaining normal tissue homeostatis and dysregu-
lation of cellular communication lies at the basis of a variety of diseases, such as cancer or
autoimmune diseases. In his pioneering work in the early 20th century, Paul Ehrlich pro-
posed the presence of a ligand-receptor interaction and the possibilities that this provides
for selective targeting of chemotherapeutics. 1 With his studies on the cellular localization
of colored dyes he laid the groundwork for the realisation that the chemical properties
of a compound, in combination with the cell on which it acts, determine the effects. He
recognized the potential of organic chemistry as a means to create those molecules that
interact with a specific cellular target as indicated by his statement "wir müssen zielen ler-
nen, chemisch zielen lernen" ("we have to learn how to aim, aim chemically"). 2,3 More than
a hundred years later, the search for Ehrlich’s "magic bullet" has not ceased and the area
of drug targeting approaches is still very much alive. In this chapter, current strategies for
the targeted delivery of imaging or therapeutic agents that employ ligand-receptor inter-
actions will be highlighted. In line with the projects discussed in the later chapters of this




General principles of receptor-mediated targeted delivery
When discussing targeted delivery, it is important to distinguish which kind of targeting is
envisaged, systemic, intracellular or both. In the ideal case, the ligand-drug conjugate en-
ters the circulation, and accumulates at the site where its action is needed by being captured
by the surface receptors. For this to happen, the affinity of the ligand and the expression
levels of the receptor should be sufficiently high. Ideally, the receptor is only expressed on
the diseased cells, such as tumor cells, because even when overexpressed, the lower levels
on the more abundant healthy cells will compete for binding and can thus act as a sink.
Non-specific interaction with surrounding cells should preferably be very low.
Once arrived at the site of action, multiple options for further, intracellular, delivery
exist, depending on the nature of the ligand and the design of the ligand-drug conjugate.
Ligands are generally classified as agonists, which activate receptors, or antagonists, which
block the receptor and thereby prevent activation. Over the years it has become clear that
this classification does not cover all possibilities, with ligands being able to induce full
or partial effects that can even be opposite to that generated by an endogenous agonist. 4
Moreover, besides the orthosteric binding site where the endogenous ligand binds, there
are often other, allosteric, sites where ligand binding can occur. Some receptors contain
multiple ligand recognition domains, leading to enhanced affinity for multivalent ligands,
examples of which will be discussed in more detail later on. Binding of a ligand, typically
an agonist, to the receptor might result in receptor-ligand internalization. Depending on
the type of targeted therapy, this might be an advantage or a disadvantage. The two-step
antibody-directed enzyme prodrug therapy (ADEPT) is designed such that an enzyme,
required to release the active drug, is delivered to the binding site so that the drug can









































Figure 1.1: Strategies for controlled release in the lysosomes of paclitaxel or doxorubicin by em-
ploying Cathepsin B-cleavable (Phe-Lys) or acid labile (hydrazone) linkers. PABC: self-immolative
p-aminobenzylcarbamate linker. Linker regions are indicated in grey.
In most cases drugs or drug formulations need to be delivered intracellularly by receptor-
mediated endocytosis to exert their effect. For some therapies, such as enzyme replace-
ment therapy for lysosomal storage disorders, the endolysosomal pathway is the endpoint
of the delivery. In many other cases, the drug needs to be released from the endolysosomes
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to reach its intracellular target, requiring alternative strategies such as synthetic cleavable
linkers between the ligand and the drug. The use of a cathepsin B cleavable dipeptide
linker (1, Figure 1.1) has been used to release the cytotoxic anticancer drugs paclitaxel (act-
ing on microtubules), doxorubicin (DOX) (a DNA intercalator), and mitomycin C (a DNA
crosslinker) from the lysosomes. 6,7 Making use of the increasingly acidic pH of the en-
dolysosomes is another means of controlled drug release as shown by the introduction of
an acid labile hydrazone linkage onto DOX, which was released in the lysosomes (2, Fig-
ure 1.1). 8,9 In case of targeted delivery for diagnostic purposes, such as a fluorescent dye
or a radiotracer, it will depend on the final goal whether an antagonist or an agonist is the
preferred ligand. Antagonists are the ligands of choice to visualize a receptor population
on the cell membrane without inducing a direct effect, whereas if receptor-ligand internal-



















Figure 1.2: General structure of constructs for targeted drug delivery.
The general structure of the (bio)molecules employed for targeted delivery thus con-
sists of the receptor-binding ligand, a (cleavable) linker and ’cargo’ (Figure 1.2). The cargo
could involve a therapeutic agent such as a drug or a protein and alternatively it could be
a reporter group, such as a fluorescent dye, to visualize and study the delivery process
and/or an activity-based probe to assess the activity of an intracellular enzyme. This gen-
eral structure forms the basis of the synthesized constructs that are presented in this thesis.
In Chapters 2 and 5 fluorescent DCG-04, an activity-based probe for lysosomal cathepsins
was introduced as cargo, in Chapter 4 the protein Hsp70, and in Chapters 7-9 fluorescent
dyes for visualization and carboranes as potential drugs. The ligands that are found in
the literature can be divided in two main categories: antibodies (or fragments thereof) di-
rected to a specific cell receptor or antigen, or non-antibody receptor ligands, spanning a
wide variety of synthetic and endogenous ligands. Even though the antibody category has
its distinct advantages in the sense of affinity and selectivity, the synthetic ligands hold a
lot of promise because of the relatively easy access to large amounts of defined material
which can be chemically tuned to contain the properties of interest (see Chapters 2, 4-8).
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In the following sections selected literature examples of synthetic ligands that are used as
targeting devices are discussed, based on the receptor type that they bind.
G protein-coupled receptors
The large family of G protein-coupled receptors (GPCRs) is one of the most druggable and
many synthetic small molecules or peptides have been developed that are able to act on
these receptors. 10,11 Endogenous ligands for GPCRs span a wide range of biomolecules,
from small compounds such as neurotransmitters to large protein hormones. Although
the structural features of individual GPCRs vary considerably, they are all characterized
by a seven-transmembrane domain (Figure 1.3). A heterotrimeric G-protein is bound to
the C-terminus which dissociates upon activation of the receptor. Depending on the na-
ture of the α-subunit of the G-protein (Gs, Gi,Gq or G12/13) distinct intracellular signaling
cascades are set in motion. 12 An elaborate desensitization/resensitization mechanism is
used to prevent overstimulation of the system. G protein-coupled receptor kinases (GRKs)
phosphorylate the receptor, 13 enabling the binding of β-arrestins. Arrestin binding pre-
vents the binding of G-proteins, thereby desensitizing the receptor for further stimulation.
In a next step, the receptor is sequestered from the cell membrane in clathrin-coated vesi-
cles. This can either lead to resensitization, in which the receptor is dephosphorylated and
recycled back to the surface in an active form, or to downregulation of the receptor from
the cell membrane by degradation in the endolysosomal pathway. 14 The fate of the ligand
upon endocytosis varies. If the receptor-ligand complex is stable, the ligand might recycle


























Figure 1.3: Graphic representation of agonist-induced internalization of GPCRs and a possible traf-
ficking route of the ligand-drug conjugate.
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Alternatively, the ligand dissociates from the receptor in the endolysosomal pathway. It
is then either trafficked further to the lysosomes, or it diffuses out of the vesicles into the
cytoplasm (Figure 1.3).
The discovery of allosteric binding sites, topographically distant from the orthosteric
site, created novel opportunities for the design and development of structurally diverse
ligands. 15–17 The glycoprotein hormone receptors, follicle-stimulating hormone receptor
(FSHR), luteinizing hormone receptor (LH/hCGR) and thyroid-stimulating hormone re-
ceptor (TSHR), for example have a large N-terminal hormone binding domain and an al-
losteric binding site in the seven-transmembrane domain. 18 Many low molecular weight
ligands that bind to the allosteric sites of these receptors have been developed 19–22 to in-
terfere with their biological activity. There are, however, only limited examples of small-
molecule GPCR ligands that are used for targeting purposes. One of the reasons for this is
that structural alterations, required to introduce a chemical ligation handle needed for at-
tachment of a label or a drug, can have a large influence on the affinity, potency and selectiv-
ity of a small molecule. For this approach to work, detailed structure-activity relationship
(SAR) studies are often needed to arrive at the most optimal structure that still complies
with these criteria. 23 Based on a low molecular weight dihydropyridine (DHP) agonist of
the FSHR, 24,25 a SAR study was conducted to find the optimal length and positioning of
a ligation handle-containing PEG-spacer (see Chapter 6). The optimal structure obtained
from this was employed in the synthesis of DHP-analogues containing a fluorescent dye,
with the aim to develop a diagnostic tool to visualize receptor binding, internalization and
















Figure 1.4: Structures of small fluoro-
phores dansyl, naphtylamine and NBD.
Fluorescent ligands for several GPCRs have
been reported in the literature, sometimes with
unexpected changes in the pharmacological
profile from agonist to antagonist. 26,27 Most ex-
amples make use of relatively small fluoropho-
res such as dansyl 3, naphthylamine 4 or NBD 5
(7-nitrobenz-2-oxa-1,3-diazol-4-yl) (Figure 1.4)
to diminish the influence of the dye on the
binding properties of the ligand. A drawback
hereof is that these dyes consequently have
short emission and excitation wavelengths, limiting their use in a cell- or tissue-based sys-
tem because of high levels of autofluorescence (Figure 1.4). 26,28 Some recent studies have
successfully employed red-emitting dyes in the synthesis of low molecular weight fluo-
rescent ligands to visualize receptors. Holtke et al. synthesized a near-infrared Cy5.5-
conjugate of the nonpeptidyl selective endothelin A receptor antagonist PD156707 (6, Fig-
ure 1.5) which was shown to bind to the receptor with similar affinity as the lead compound
and could be used to visualize the receptor on different cell types. 29 By introduction of a
conjugation handle onto the core of SR144528, a cannabinoid CB2 receptor ligand, Bai et al.
could introduce a near-infrared dye. No thorough studies were performed on the phar-
5
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macological properties of the resulting fluorescent ligand NIR-mbc94 (7, Figure 1.5), but it
was shown that receptor expressing cells were much more fluorescent than wildtype cells
and that this fluorescence could be competed with non-labeled SR144528. 30 In a follow-up
study, NIR-mbc94 was shown to be indeed a selective ligand for the CB2 receptor albeit
with a much lower binding affinity than the lead SR144528 (Ki =260 nM vs 1 nM). Endoge-
nous levels of receptor could be fluorescently labeled and quantified using this fluorescent
ligand, showing its potential for use in a high-throughput screen for novel CB2 receptor
ligands. 31 The potential of fluorescent ligands when used together with advanced confocal
fluorescence microscopy techniques, such as fluorescence correlation spectroscopy (FCS),
has been shown with fluorescently labeled adenosine A1 and A3 receptor ligands. In these
studies, the ligand-receptor interactions could be thoroughly studied which led to the iden-
tification of two distinct agonist-occupied receptor populations, based on their motility in




































Figure 1.5: Near-infrared fluorescent GPCR ligands Cy5.5-PD156707 6 and NIR-mbc94 7.
GPCRs that have endogenous peptide or protein ligands have been more often explored
for targeted delivery, because of the ease of access to a synthetic peptide (fragment) by solid-
phase peptide synthesis (SPPS). Besides, SPPS enables peptide modification by extension
of its N- or C- terminus or by introduction of an unnatural amino acid. The Y receptor
family is regulated by abundantly present endogenous neuropeptide Y (NPY) ligands. 34
Shorter fragments of the endogenous peptides or peptide-like structures resembling the
C-terminus have been synthesized and were shown to be antagonist or agonists for the dif-
ferent subtypes of Y receptors. 35 The scope of the use of NPY ligands has expanded by the
discovery of the presence of the Y1-receptor subtype on breast and metastatic tumors.
36
Radiolabeled Y1-selective peptides were subsequently used in vitro as well as in vivo as a
diagonistic tool to visualize the overexpressed receptor in breast tumor tissue and metas-
tases sites. 37 This result prompted the researchers to investigate the use of NPY ligands
6
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to deliver a cytotoxic agent to the tumor site. In an approach analogous to that described
in Chapter 8, the agent of choice was an o-carborane moiety. Carboranes are boron-rich
lipophilic polyhedral structures with potential application in a binary anti-cancer therapy
named boron-neutron capture therapy (BNCT). 38 Both individual components (carboranes
and thermal neutrons) are relatively non-toxic in themselves, whereas a combination of
both leads to a nuclear reaction and release of high energy particles that are detrimental
for the cells which are exposed to it. A prerequisite for effective therapy is a high con-
centration of boron preferentially accumulated in tumor cells as opposed to healthy cells.
Intracellular delivery would allow for the most efficient approach, since the trajectory of
energy release by the formed α-particles is estimated to coincide with the average diameter











ent depictions of o-
carborane
Attachment of o-carborane (8, Figure 1.6) to a Y1R selective [F
7,
P34]-NPY derivative via the ǫ-amino group of lysine-4 resulted in
a slight loss in binding affinity and diminished activity compared
to [F7, P34]-NPY. Affinity and activity were still in the nanomo-
lar range, however, and the ligand was shown to be selective for
the Y1R over the Y2R subtypes. This peptide was also capable
of inducing receptor-internalization of only Y1R as seen by mi-
croscopy studies on HEK293 cells transiently expressing human
Y1R conjugated to enhanced yellow fluorescent protein (EYFP). It remains elusive what
the fate of the carborane-containing ligand was in this system, since it could not be visual-
ized. 40
The overexpression of peptide hormone receptors such as the somatostatin receptor
and the gonadotropin-releasing hormone (GnRH) receptor in various tumor tissues has
also been established. 41 The activities of toxic conjugates of a peptide-based GnRH recep-
tor agonist with doxorubicin or an analogue hereof, 2-pyrrolino-DOX, were compared with
that of the cytotoxic drug alone. Targeted analogues were shown to be much less toxic
in vivo while having significantly more antitumor activity on tumors that did express the
receptor. 42,43 The doxorubicin containing analogue (AN-152) is currently being evaluated
in clinical trials. 44 The somatostatin receptor (sst) is present on many neuroendocrine tu-
mors. 45 Synthetic analogues with enhanced plasma stability and affinity towards sst com-
pared to endogenous somatostatin peptides have been described. These analogues, octreo-
tates, consist of the pharmacophoric part of somatostatin and contain a threonine at the
C-terminus (9, Figure 1.7). Various radiolabeled octreotate analogues have been reported
that find use as radiotracers or in radionuclide therapy. 46,47 Conjugation of a cyanine dye to
octreotate yielded a fluorescent analogue (10, Figure 1.7) that was shown to be internalized
in sst-expressing cells and accumulated specifically in primary human neuroendocrine tu-
mor cells. This example shows the potential of synthetic ligands for tumor visualization. 48
The use of octreotate as a tumor targeting entity for BNCT has also been explored. Mier
et al. have attached closo-borane mercaptoundecahydrododecaborate (BSH) to maleimide-
conjugated Tyr3-octreotate, but no biological studies were conducted. 49 In a more recent
7
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study by Betzel and co-workers, one or two o-carboranes were attached to octreotate via
linkers of different size. In vitro radioligand binding studies showed these analogues to be
potent binders of the various sst-subtypes with enhanced selectivity for the sst2-subtype
compared to the reference peptide somatostatin 28 (SRIF-28). Binding was shown to be
dependent on spacer length, with increased binding at longer length, and on the number
of carboranes attached, with one (11, Figure 1.7) being favored over two (12, Figure 1.7).
Although these compounds show potential for use as targeting agents for BNCT, no speci-



















































Figure 1.7: Synthetic somatostatin analogue (octreotate) used to target fluorescent dyes or carboranes
for BNCT to sst-expressing tissues.
Lectin receptors
Proteins that are able to recognize and bind carbohydrates such as glycan chains present
on glycoproteins, are collectively named lectins. These can be soluble or membrane-bound,
and the latter category encompasses an increasing variety of lectin receptors. 51 With the ad-
vancements in carbohydrate synthesis, such as solid-phase methods, more complex oligo-
saccharide structures have become within reach. Although the lectin binding properties of
these oligosaccharides have often been investigated, little work has been done on the use of
synthetic carbohydrates as targeting entities. 52 In analogy with the work discussed above
and in Chapter 8, some work on carbohydrate-carborane compounds as targeted BNCT-
agents has been performed. An additional advantage of the use of carbohydrates in this
context is their hydrophilicity, thereby somewhat compensating the hydrophobic nature of
the carborane cage. Orlova et al. conjugated the disaccharide lactose to o-carboranylacetic
acid with the aim of targeting lactose-binding lectins on melanoma cells. No biological
evaluation of the compounds was conducted however, and in a follow-up study it was
found that o-carborane at the α-position of a carbonyl results in deboronation to the corre-
sponding nido compound when dissolved in water or methanol. 53 Tietze et al. have pub-
lished several papers on the subject of glycoside modified carboranes for BNCT. 54,55 In their
studies, carboranes were introduced by the reaction of decaborane with a terminal or in-
8
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ternal alkyne on either O- or C-glycosides. In vitro studies on C6 rat glioma cells and B-16
melanoma cells showed dose-dependent uptake of a maltoside-carborane construct result-
ing in much higher intracellular boron levels than obtained with currently approved BNCT
agents. In vivo studies in rat showed accumulation in brain tumor tissue, but similar con-
centrations were found in the blood, resulting in unwanted side-effects. 54 It remains elusive
whether these constructs are taken up by cells in a receptor-dependent fashion and if so,
which receptor is responsible for the uptake.
Cells of the immune system, especially dendritic cells (DCs) and macrophages, express
different C-type lectin receptors which are characterized by their calcium dependency in
ligand binding and conserved carbohydrate recognition domains (CRD). An important
member is the macrophage mannose receptor (MR, CD206) which recognizes oligosaccha-
rides terminating in mannose, fucose or N-acetylglucosamine. The receptor contains eight
CRDs (Figure 1.8), which have been re-named C-type lectin-like domains (CTLDs) because
most of the domains lack ligand binding activity. 56,57 Both CTLD4 and CTLD5 have been
implied as the domains involved in ligand binding. 58 Having two ligand binding domains
within one polypeptide chain allows for a stronger interaction with multivalent ligands
and possibly ligand specificity, although the MR is also able to capture antigens with sin-
gle mannose residues. 59,60 Besides the MR, dendritic cells express other mannose-binding
C-type lectins, such as dendritic cell-specific intercellular adhesion molecule-3-grabbing
non-integrin (DC-SIGN, CD209) (Figure 1.8).
Domain containing bronectin 
type II repeats
Cysteine rich domain




Triad of acetic amino acids
DC-SIGN
cytoplasm
Figure 1.8: Schematic representation of the mannose receptor and DC-SIGN.
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DC-SIGN belongs to type II C-type lectins, with an intracellular N-terminus, whereas the
MR is a type I receptor, with an extracellular N-terminus. DC-SIGN contains only one CRD,
but has been shown to multimerize in order to bind multivalent ligands with high affin-
ity. 59,61 Furthermore, structural examination of DC-SIGN bound to either a high-mannose
N-linked oligosaccharide or a complex-type N-linked glycan showed an unexpected in-
teraction between the receptor and internal mannose residues. 62 Both receptors share an
intracellular motif that allows internalization of the receptor in clathrin-coated pits. Tar-
geting of either receptor might thus result in the selective internalization of ligands into
the endolysosomal pathway of professional antigen-presenting cells.
Kikkeri et al. used carbohydrate modified quantum dots which showed enhanced up-
take in liver cells when used in vivo compared to unmodified quantum dots. This finding
suggests that receptor-mediated uptake, via the mannose receptor when using mannose
or the asialoglycoprotein receptor when using D-galactose conjugated to quantum dots,
plays a role in their endocytosis. 63 In a study by Hillaert et al., six propargyl mannoses were
clicked onto an azide-modified peptide scaffold in order to obtain a multivalent ’mannose
cluster’. This cluster was conjugated to the fluorescent activity-based probe (ABP) BODIPY-
DCG-04 with the aim to deliver the ABP to the lysosomes of DCs and macrophages. It was
indeed shown that incorporation of the cluster led to temperature-dependent internaliza-
tion of the compound 13 (Figure 1.9), indicating a receptor-mediated process. Uptake and
subsequent cathepsin labeling by the ABP could be blocked by addition of mannan, a nat-
ural occurring oligomannoside, to the medium of DCs, further establishing the receptor
dependency. In Chapter 2 an extension of this work is described. Instead of a regular BO-
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“mannose cluster-BODIPY-DCG-04”
13
Figure 1.9: Targeted fluorescent activity-based probe for cathepsins.
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The pH at which the BODIPY dye becomes fluorescent is dependent on the alkyl-sub-
stituents on the meso-aniline group and is thus synthetically tunable (see also Chapter
3). With the use of multiple constructs incorporating BODIPY dyes with differing pH-
dependencies, live-cell imaging experiments could be performed to study the trafficking
of these compounds in the endolysosomal pathway. 64
Targeting of larger cargo, such as proteins, to lysosomes of specific cell-types lies at
the basis of therapeutic intervention in lysosomal storage disorders. Enzyme replacement
therapy (ERT) relies on the uptake of recombinant lysosomal enzyme into the endolyso-
somal pathway of disease-affected cells, to restore normal lysosomal function. In case of
Gaucher disease, β-glucocerebrosidase (GBA1) is the enzyme of interest which needs to
be targeted to mannose-binding lectins on macrophage (Gaucher) cells. Current ERTs for
Gaucher use different approaches for glycan remodeling in order to expose core mannose
or high mannose glycan chains on the recombinant GBA1. In Chapter 4 an alternative
approach is investigated to target a protein to dendritic cells. Recombinant heat shock pro-
tein 70 (Hsp70) containing a C-terminal ’sortase sequence’ (LPETGG) was conjugated to
GGG-BODIPY-mannose cluster by employing the bacterial enzyme Sortase A. Uptake of
the resulting Hsp70-BDP-MC in DCs was studied by confocal microscopy and gel analysis,
showing that a relatively small synthetic entity such as the mannose cluster can function
as a targeting device for a large protein.
In Chapter 5 the mannose cluster is modified to contain mannose-6-phosphate residues
instead of mannoses, with the aim of targeting the mannose-6-phosphate receptor (MPR).
The main role of the MPRs is to route newly synthesized lysosomal proteins from the trans-
Golgi network to the lysosomes. Although mainly localized intracellulary, a fraction of the
receptor population is continously recycling between the cell membrane and the intracellu-
lar environment. Zhu et al. have used synthetic M6P-containing oligosaccharides to target
recombinant acid α-glucosidase to M6PR-expressing muscle cells affected by Pompe dis-
ease. 65,66 Dephosphorylation of M6P by serum phosphatases, yielding mannose, results in
enhanced uptake by MR-expressing liver cells and less or no selective delivery to the in-
tended target site. More stable M6P analogues that do have receptor affinity but are not a
substrate for phosphatases are therefore interesting alternatives. Several isosteric and non-
isosteric analogues of M6P have been synthesized and tested for their receptor binding
affinities. 67 Isosteric mannose-6-phosphonate (M6Pn) was shown to have similar affinity
for the CI-M6PR as M6P and would be a suitable alternative as targeting entity. 68 As an
example hereof, Barragan et al. have shown that vesicles containing M6Pn coupled to a
steroid are targeted to MCF-7 breast cancer cells. Although promising, conclusive exper-





The best studied example of a small molecule used to target a cell membrane receptor is
likely that of folic acid targeting the folate receptor. Folic acid is the oxidized form of fo-
late, an essential vitamin for mammals. Capturing of exogenous folate by cells is thus of
great importance. Two transporters for folate have been identified, the "reduced-folate car-
rier" system, a low affinity carrier which is present on virtually all cells, and the folate
receptor (FR), a high affinity binder of folic acid and highly overexpressed on various tu-
mor cells. 70 The low affinity of the reduced-folate carrier system for folic acid, combined
with the favorable expression pattern of the FR makes folic acid a highly suited organic
molecule for tumor targeting. 71 Furthermore, folic acid retains its high affinity for the FR
when conjugated through its γ-carboxyl group, is stable, readily available and cheap. 72
Leamon and Low demonstrated for the first time that covalent attachment of folic acid
to macromolecules such as serum albumin or horseradish peroxidase results in their up-
take in living cells via the folate receptor. 73,74 Since then many examples have appeared in
the literature of folic acid-conjugates for various application such as radiotherapy, contrast
agents and immuno- or chemotherapy. 70,75,76 A near-infrared dye was conjugated to folic
acid, resulting in a tumor-targeted imaging agent that was shown to accumulate in ovarian
cancer tissue in vivo. 77
FR-mediated endocytosis occurs in caveolae, in a clathrin-independent fashion. 78 The
resulting endosomes have been shown to be recycling and because folic acid retains its high
receptor-affinity inside endosomes, the amount of folate-conjugated drug which is released
inside the cell is limited. The pH of the FR-containing endosomes remains relatively high
(average ∼6.5) and folate-drug conjugates that rely on an acid-cleavable linker system for
drug release have been shown to be ineffective. 76,79 A better strategy is to make use of the
reducing properties of the endosome by introduction of a self-immolative disulfide linker
between folic acid and a drug of choice. 80 The applicability of this approach was shown
by Yang et al. who introduced a FRET pair (BODIPY-FL/rhodamine) onto folic acid via
an S-S linkage (14, Figure 1.10). Upon cleavage of the disulfide linker in the endosomes,
the two dyes are dissociated resulting in loss of the FRET signal and recovery of the green
fluorescent signal. 81 Conjugation of the maytansinoid DM1, a highly cytotoxic drug, to
folic acid via an S-S-containing linker led to selective targeting of and cytotoxicity in FR-
expressing cells. 82 The many successful in vitro and in vivo examples of folate receptor-
mediated targeting open up the way for clinical trials to further investigate the potential of
folate conjugates as targeted immuno- or chemo-therapeutic agents.
Conclusion
The examples highlighted in this chapter show that small-molecule synthetic ligands hold
a lot of promise as targeting entities. Organic chemistry allows for a thorough evaluation
of possible sites of ligand modification and linker systems and for the development of new
classes of ligands for unexplored receptors. Furthermore, synthetic dyes have greatly ad-
vanced the imaging applications and synthetic approaches to cytotoxic molecules such as



























































































Figure 1.10: Endosomal uptake via the folate receptor was studied using a FRET dye pair linked
to folic acid via an S-S linker. Irradiation with 488 nm light resulted in a red (595 nm) FRET
signal. Upon cleavage of the disulfide bridge under endosomal reducing conditions, the two dyes were
dissociated and fluorescence emission changed to green (520 nm).
either as diagnostics or therapies, however, in vitro binding assays to assess the ligand-
receptor interaction are insufficient. Biochemical experiments addressing receptor phar-
macology, and the behaviour of the ligand-cargo constructs in a more complex setting such
as cells, tissue or in vivo are essential. When chemistry and biology are highly integrated
much can be gained, as shown by the few examples that have resulted in well-defined
receptor-ligand pairs that can be used for efficient targeting. In that way, a variety of ’magic
bullets’, each with its own target can be accomplished.
Aim and outline of this thesis
The research described in this thesis aims at the development of constructs containing a
receptor-targeting entity covalently bound to biologically active cargo. Chemical and bi-
ological approaches are combined to arrive at the ultimate goal: selective delivery of the
cargo to a cell-type, tissue or organelle of interest. In all cases, a fluorescent dye is incor-
porated to visualize the construct by fluorescence microscopy or in-gel fluorescence scan-
ning. In Chapters 2, 3 and 8, pH-dependent BODIPY dyes are investigated with the aim
to selectively visualize intracellular acidic compartments. Targeted receptors that will be
13
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discussed include mannose-binding lectins (Chapters 2 and 4), the mannose-6-phosphate
receptor (Chapter 5) and the follicle-stimulating hormone receptor (Chapters 6-9). With
the exception of the work described in Chapter 9, where recombinant FSH is used as the
targeting entity, the ligands that are employed are synthetic and (relatively) low molecular
weight in nature. A variety of cargo is introduced, ranging from an activity-based probe
(Chapters 2 and 5), carboranes for BNCT (Chapter 8) to the protein Hsp70 (Chapter 4). In
the concluding Chapter 10 the findings are summarized and alternative and future strate-
gies towards targeted delivery of these receptors are discussed. Broader applications of
some of the synthesized entities, such as pH-dependent dyes and functionalized carbo-
ranes, are presented here as well.
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ifunctional, pH-activatable BODIPY dyes were developed in this chapter and
incorporated in mannose cluster-containing activity-based probes for cysteine
proteases. Mannose receptor-dependent uptake of the probes in dendritic cells,
followed by trafficking to acidic cellular compartments resulted in fluorescence as




Fluorescent dyes are applied in many different areas of chemical biology. Among these
dyes, boron-dipyrromethene (BODIPY) derivatives are frequently used due to their excel-
lent photochemical properties and relative stability under physiological conditions. 2,3 For
example, covalent attachment of a BODIPY dye to an activity-based probe (ABP) facili-
tates the study of its target enzyme, by means of fluorescence scanning and microscopy. 4–9
Urano et al. recently developed a series of acidic pH-activatable BODIPY dyes. 10 Due to
photoinduced electron transfer (PeT) of the meso aniline substituent toward the BODIPY
fluorophore, fluorescence is quenched at neutral or basic pH. 11–13 Upon protonation of the
aniline nitrogen, fluorescence is restored. Depending on the choice of alkyl substituents
on the aniline nitrogen, the pKa and thus the pH-dependency of the fluorophore can be
tuned. 10 A great advantage of these kind of fluorophores is that they do not fluoresce when
unprotonated, making them convenient tools to study in-cell processes with fluorescence
microscopy. Since a (slightly) acidic pH is a prerequisite for fluorescence, these fluoro-



















Figure 2.1: Schematic overview of the expected internalization and fluorescence properties of the
constructs described in this chapter in mannose-receptor expressing cells.
In a previous study, Hillaert et al. have shown that lysosomal targeting of the epoxy-
succinate activity-based probe DCG-04 14 can be accomplished by attachment of a syn-
thetic mannose cluster. 4 This mannose cluster binds to the mannose receptor, which is
predominantly present on professional antigen-presenting cells such as dendritic cells and
macrophages. Mannose receptor-mediated internalization of the construct is followed by
trafficking in the endocytic pathway towards the lysosomes. Subsequently, multiple lysoso-
mal cysteine proteases of the cathepsin 15 family are covalently and irreversibly addressed
18
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by the ABP. In this chapter the incorporation of a pH-activatable fluorophore in the pre-
viously reported mannose-cluster-BODIPY-DCG-04 construct (13, Figure 1.9) is described.
The aim is to investigate whether this leads to less background because of selective fluo-
rescence in the cellular compartments of interest as depicted in Figure 2.1. The synthesis
of bifunctional pH-dependent BODIPY dyes with orthogonal ligation handles, needed for
incorporation in the larger construct, is reported and their spectroscopic properties are in-
vestigated. Furthermore, the uptake and (pH-dependent) fluorescence of constructs 21a-d
in dendritic cells is studied.
2.2 Results and Discussion
Synthesis. To obtain the large mannose cluster-pH-dependent-DCG-04 constructs, a mod-
ular synthetic approach was followed, in which the constructs were assembled from three
building blocks in the two final steps. The mannose cluster 20 and cathepsin inhibitor
DCG-04-amine were synthesized as previously reported. 4,14 To obtain bifunctional pH-
dependent BODIPY dyes, the synthetic route of Urano and coworkers 10 was modified and
extended (Scheme 2.1).





















































Reagents and conditions: [a] i) cat. TFA, DCM; ii) DDQ; iii) base, BF3 · OEt2, a: 28%, b,c: 19%;
[b] i) DCE, reflux; ii) TEA, BF3 · OEt2, d: 23%; [c] NaOH (aq), MeOH/dioxane, a: quant, b: 88%, c:
45%, d: 53% ; [d] i) EDC · HCl, HOBt, TEA, DMF, spacer 17a; ii) N-hydroxysuccinimide, EDC · HCl,
DCM, a: 34%, b: 52%, c: 43%, d: 33%.
Starting from commercially available N,N-dialkylaminobenzaldehydes and methyl 2,4-
dimethyl-3-pyrrolepropionate, 16 symmetrical pH-dependent dyes 15a-c were obtained by
a three-step, one-pot procedure. The "always on" control dye 15d was synthesized from
benzoyl chloride and methyl 2,4-dimethyl-3-pyrrolepropionate, followed by reaction with
BF3 · OEt2 and base to yield the BODIPY core. The methyl esters were saponified us-
ing sodium hydroxide in MeOH/dioxane, providing symmetrical dicarbonyl BODIPYs 16.
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Several strategies were employed to obtain asymmetrical dyes, and mixtures of unreacted
starting material and once or twice functionalized BODIPYs were unavoidable even when
using substoichiometric amounts of PEG-spacer compared to BODIPY. Since mixtures of
BODIPYs containing one or two carboxylic acid groups turned out to be poorly separable,
any remaining carboxylic acids after reaction with PEG-spacer 17a were converted to the
N-hydroxysuccinimide esters. Di-OSu and di-azido-BODIPYs could be separated from the




























































































































































Figure 2.2: Synthesized pH-activatable mannose cluster-BODIPY-DCG-04 constructs.
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BODIPYs 18a-d and DCG-04 amine followed by ligation to the mannose cluster 20 by cop-
per(I) catalyzed Huisgen 1,3-cycloaddition 17,18 gave constructs 21a-d (Figure 2.2).
To assess the fluorescence properties of the dyes, fluorescence-pH curves of probes 21a-
d in a citric acid/phosphate buffer system were measured (Figure 2.3A, B). The resulting
curves for 21a-c (Figure 2.3B) were shifted to the left as compared to the curves reported
by Urano et al., 10 indicative of a shift in pKa values. Upon addition of a low amount (0.2%)
of the detergent sodium dodecyl sulphate (SDS) the values resembled the expected pKa’s.
Since the pH of the lysosomes in antigen-presenting cells such as macrophages is estimated
to be 4.5-4.9 19 probe 21c, with pKa∼5.1 was expected to be the best candidate for imaging
in living cells.



































































Figure 2.3: pH-dependency of compounds 21a-c. A) Normalized absorption and emission spectra
of pH-activatable compounds 21a-c and the "always on" control 21d. B) Fluorescence measurements
as a function of pH in citrate/phosphate buffer with or without 0.2% SDS. C) Apparent pKa values
(50% fluorescence) as determined by the curves shown in B).
Biological evaluation. The ability of probes 21a-d to label lysosomal cysteine proteases
was first examined by incubation of mouse liver lysates with various concentrations of
the construct, followed by resolution of the proteins on SDS-PAGE. The bands could be
visualized by overnight incubation of the gel in acidic fixing solution (MeOH/H2O/acetic
acid), thereby lowering the pH to allow in-gel fluorescence scanning. Labeling was shown
to be concentration-dependent and the profile corresponded well with that seen for the
previously reported mannose cluster-BODIPY-DCG-04 probe, with a MW-shift of 3-4 kDa
compared to BODIPY-DCG-04 4,20 22 (β-DCG-04; Figure 2.4), consistent with the molecular
weight of the probes (Figure 2.4). 4 In a competition experiment with β-DCG-04 22 it was
shown that the constructs competed for the same set of cysteine proteases.
21
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Figure 2.4: Liver lysate cathepsin labeling. 12.5% SDS-PAGE analysis; fluorescence scanning images
(upper, white bands: Cy2 BODIPY fluorescence; black: Cy3 fluorescence) and coomassie staining
for total protein (lower) are shown. DC: dual color prestained protein marker. Incubation of mouse
liver lysate with probes 21a-d showed concentration-dependent labeling of cathepsins (white bands,
lanes 2-6). The probes competed for the same set of cathepsins as the known cathepsin inhibitor
β-DCG-04 (black bands, lanes 7-9) and the bands were shifted consistent with the molecular weight
of the probes.
Next, the behaviour of probes 21a-d in living cells was investigated. Immature mouse
dendritic cells (DCs) were incubated with 1 µM of probe and studied with live-cell fluo-
rescence microscopy. Brightly fluorescent vesicles appeared inside the cells after 30 min of
incubation, with increasing fluorescence upon prolonged exposure to the probe. In contrast
to the "always on" construct 21d, no background signal was detected for the pH-activatable
probes 21a-c and therefore cells could be imaged without any additional washing steps
(Figure 2.5). In accordance with the observed pKa values, the signal for the methyl-methyl
(21a) and methyl-ethyl (21b) probes was less strong and took longer to appear (Figure 2.5B).
This clearly indicates that the probes were indeed trafficked to increasingly acidic cellular
compartments over time. Subsequent cell lysis and SDS-PAGE analysis showed a labeling
profile of cysteine proteases identical to that found in lysates (Figure 2.6B).
Dendritic cells, being professional antigen-presenting cells, can take up macromolecules
from the environment by macropinocytosis. 21 Therefore, incubation times for follow-up ex-
periments were set to two hours, to diminish the amount of probe internalized by means
other than mannose receptor-mediated internalization. Indeed, under these conditions,
pre-incubation of the cells with mannan, a naturally occurring polymannoside that binds
the mannose receptor, abolished the uptake of the probes and subsequent labeling of cathep-
22
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ethyl-methylbefore washing after washing methyl-methylethyl-ethyl
A B abcdd 2121212121
Figure 2.5: Fluorescence (upper) and brightfield phase contrast images (lower) of immature den-
dritic cells treated with the different probes 21a-d. A) The "always on" control probe cannot be
used without washing due to a large amount of background. B) After 3 h of treatment, fluorescence
intensities for the diethyl probe 21c were strongest of all pH-activatable probes.
sins (Figure 2.6, cond. 2). Pre-incubation of the cells with non-fluorescent azido-DCG-04
23 (Figure 5.2) did not prevent the probes from entering the cell, as seen by live-cell imag-
ing. However, no labeling of cathepsins was seen on SDS-PAGE, indicating that the probes
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Figure 2.6: Uptake and cathepsin labeling in live dendritic cells. A) Confocal microscopy images
of DCs incubated for 2 h with probes 21c or 21d, under different conditions (1-6) show mannose
receptor-dependent uptake of the constructs. Scale bar (white) corresponds to 10 µm. B) Cell lysis
and analysis of cells treated as in A) shows inhibition of cathepsin labeling by azido-DCG-04, which
is partly restored after overnight washing.
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the already blocked, cathepsins (Figure 2.6, cond. 3). Interestingly, in-cell fluorescence
remained even after prolonged washing of the cells (Figure 2.6A, cond. 6). To further in-
vestigate this, cells were lysed after washing and analyzed by SDS-PAGE. As shown in
Figure 2.6B, cond. 6, labeling of cathepsins was largely restored. Also, more cathepsins
were labeled after overnight washing compared to immediate lysis in the control experi-
ment (Figure 2.6B, cond. 5). Because of their size, the probes were probably retained in the
cells, where they could bind any newly formed cathepsins.
In a next experiment, the intracellular pH was increased by addition of ammonium
chloride to the medium. 22 Ammonia passively diffuses into the cell and acts as a weak base,
thereby increasing the pH up to 6 in lysosomes in a reversible manner. 19,23 Almost no in-cell
fluorescence was detectable for both the ethyl-ethyl (21c) and control probe (21d) after pre-
incubation with 10 mM NH4Cl, even after extensive washing at normal pH, indicating that
the levels of internalized probe were low (Figure 2.6A, cond. 4). This is in accordance with
the postulation of Tietze et al., that an increased cellular pH decreases receptor recycling,
which leads to lower levels of cell surface receptors. 24 SDS-PAGE analysis on the other
hand, revealed that not all cathepsin activity was gone, as seen by, albeit weak, labeling
on gel (Figure 2.6B, cond. 5). This finding illustrates the efficiency with which the probes
were internalized and processed in the endocytic pathway.
2.3 Conclusion
In this chapter a series of pH-activatable fluorophores that contain orthogonal ligation han-
dles were developed. These dyes were incorporated in large mannose cluster containing
ABPs, thereby facilitating their imaging without influencing their uptake or distribution
in dendritic cells. These kind of molecules might find use in studies concerning antigen
cross-presentation and the role of cysteine proteases herein. Moreover, the ease of access
to the panel of bifunctional, tunable, pH-activatable dyes should allow their incorporation
in bioconjugates quite different from those presented here. Potential drawbacks of the dyes,
such as their spectral properties (absorption and emission maxima between standard Cy2
and Cy3 laser/filter settings) and their symmetry, which makes mono-functionalization
difficult are addressed in Chapter 3. The ability of the mannose cluster to function as a tar-
geting device to deliver (bio)molecules other than ABPs to dendritic cells will be examined
in Chapter 4. The modular synthetic approach followed here allows for easy exchange
of the different parts of the construct. In this fashion, alternative receptors (such as the
mannose-6-phosphate receptor (Chapter 5)) can be targeted to specifically deliver cargo to
endocytic compartments with the aim to interfere with a variety of subcellular targets.
2.4 Experimental Section
Absorption and Fluorescence Spectroscopy. All spectroscopic experiments were performed in cit-
rate/phosphate buffer (McIlvaine) 25 at a concentration of ca. 1 µM (absorption) or 100 nM (flu-
24
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orescence) of 21a-d. Measurements were conducted on a Shimadzu UV1700 pharmaspec UV-VIS
spectrophotometer (absorbance) and a Shimadzu RF-5301PC spectrofluorometer (fluorescence). For
pH-fluorescence curves, the pH was set using different ratios of citric acid (0.1 M stock solution) vs
phosphate buffer (0.2 M stock solution). The excitation wavelength was set equal to the maximum
of the corresponding absorption spectrum and the emission spectrum recorded. Experiments were
conducted at a concentration of 25 nM in a total volume of 2 mL and performed in quadruplicate.
SDS was added to a final concentration of 0.2% from a 10% stock solution in water.
Cell culture of primary cells. Immature dendritic cells were obtained from the bone marrow of
C75BL/6 mice. The use of animals was approved by the ethics committee of Leiden University.
Mice were sedated, bone marrow of tibiae and femurs was flushed out and washed with PBS. Cells
were grown in dendritic cell selection medium (IMDM containing granulocyte-macrophage colony
stimulating factor (GM-CSF) 2:1 vol/vol) containing 8% FCS, penicillin/streptomycin (100 units/mL),
glutamax (2 mM) and beta-mercaptoethanol (20 µM). Cells were selected for 10 days (37 ◦C; 5%
CO2) after which they were either used directly or frozen and stored at -80
◦C until further use.
Live-cell microscopy. Experiments were conducted on a Leica TCS SPE confocal microscope, using
GFP or dsRed filter settings (λex 488 or 532 nm). Immature dendritic cells (DCs, 30-75 x 104
cells/well) were seeded onto sterile Labtek II 4- or 8-chamber borosilicate coverglass systems (Fisher
Emergo). Stock solutions of probes and other reagents were prepared in conditioned DC medium. For
time-course experiments cells were treated with 10 µM of probe 21a-d, incubated for the indicated
time (37 ◦C; 5% CO2) and imaged. Removal of the probe-containing medium followed by addition
of fresh cell culture medium was required for the "always on" control probe 21d. Experiments that
required pre-treatment were conducted as follows: cells were incubated (37 ◦C; 5% CO2) with mannan
(3 mg/mL), NH4Cl (10 mM), or N3-DCG-04 (10 µM) for 2 h. Probes 21a-d (1 µM) were added
directly to the medium, and incubation was continued for 2 h, after which the medium was refreshed
and cells imaged. Alternatively, cells were washed with PBS (2 x 0.5 mL) incubated overnight in
medium and imaged after 16 h. All experiments were performed at least in duplicate.
SDS-PAGE analysis - Labeling of cathepsins in lysate. Mouse liver lysate (40 µg) in 25 mM MES
buffer pH 5.0 was incubated with 0, 0.5, 1 , 5 or 10 µM of probes 21a-d for 1 h at 37 ◦C. For
competition experiments, lysate was pre-incubated with BODIPY-DCG-04 (1 µM) for 1 h at 37 ◦C,
followed by incubation with probes 21a-d (1 µM). Subsequently, samples were boiled with 4x Laemli’s
sample buffer under reducing conditions and resolved on a 12.5% SDS-PAGE gel. To visualize the pH-
dependent probes, gels were fixed overnight in MeOH/H2O/acetic acid (50/40/10). After washing
with H2O/acetic acid (90/10), gels were imaged on a Typhoon 2000 imager (GE Healthcare) using
the Cy2 (λex 532 nm; λem 526 nm) and TAMRA (λex 532 nm; λem 580 nm) settings. After imaging,
gels were stained with coomassie brilliant blue to visualize total protein loaded. Gel images were
coloured with ImageJ.
Labeling of cathepsins in live-cells. Immature mouse dendritric cells were seeded onto tissue-coated
24-wells plates for same-day experiments or on borosilicate 4-chamber microscope slides for overnight
experiments (2 x 105 cells/well). Stock solutions of probes and other reagents were prepared in
conditioned DC medium. For labeling experiments cells were treated with 1 µM of probe 21a-d,
incubated for 2 h (37 ◦C; 5% CO2), washed with ice-cold PBS (2x 0.5 mL) and lysed (35 µL
Invitrogen complete cell extraction buffer). Experiments that required pre-treatment were conducted
as follows: cells were incubated (37 ◦C; 5% CO2) with mannan (3 mg/mL), NH4Cl (10 mM),
or N3-DCG-04 (10 µM) for 2 h. Probes 21a-d (1 µM) were added directly to the medium, and
incubation was continued for 2 h. Cells were washed with ice-cold PBS (2x 0.5 mL) and lysed in
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35 µL lysis buffer (Invitrogen cell extraction buffer, supplemented with 1 mM PMSF and protease
inhibitor cocktail (Roche)). For the overnight time-point, cells were incubated in fresh medium after
the washing step for 16 h before lysis. Lysates were collected, centrifuged (4 ◦C, 14.000 rpm, 10
min) and stored at -80 ◦C until further use. Lysates were thawed and the protein concentration was
determined by a DC (detergent-compatible) protein assay (Biorad). Samples (20 µg protein/well)
were boiled with 4x Laemli’s sample buffer under reducing conditions and resolved on a 12.5% SDS-
PAGE gel. To visualize the pH-dependent probes, gels were fixed overnight in MeOH/H2O/acetic
acid (50/40/10). After washing with H2O/acetic acid (90/10), gels were imaged on a Typhoon 2000
imager (GE Healthcare) using the Cy2 settings (λex 532 nm; λem 526 nm). After imaging, gels were
stained with coomassie brilliant blue to visualize total protein loaded. Gel images were coloured with
ImageJ.
Synthesis
General. All reagents were of commercial grade and used as received unless stated otherwise. Reaction
solvents were of analytical grade and when used under anhydrous conditions stored over flame-dried
3 Å molecular sieves. Dichloromethane was distilled over CaH2 prior to use. Solvents used for column
chromatography were of technical grade and distilled before use. All moisture and oxygen sensitive
reactions were performed under an argon atmosphere. Flash chromatography was performed on silica
gel (Screening Devices BV, 0.04-0.063 mm, 60 Å). Reactions were routinely monitored by TLC analysis
on DC-alufolien (Merck, Kieselgel60, F254) with detection by UV-absorption (254/366 nm) where ap-
plicable and spraying with a solution of (NH4)6Mo7O24 · 4 H2O (25 g/l) and (NH4)4Ce(SO4)4 · 2 H2O
(10 g/l) in 10% sulfuric acid in water followed by charring at ∼150 ◦C. 1H and 13C NMR spectra
were recorded on a Bruker AV-400 (400 MHz) or Bruker DMX-600 (600 MHz). Chemical shifts are
given in ppm (δ) relative to the residual solvent peak or TMS (0 ppm) as internal standard. Coupling
constants are given in Hz. Peak assignments are based on 2D 1H-COSY and 13C-HSQC NMR experi-
ments. IR measurements (thin film) were conducted on an IRaffinity-1 apparatus and evaluated using
IRSolutions software (Shimadzu, Kyoto, Japan). LC-MS measurements were conducted on a Thermo
Finnigan LCQ Advantage MAX ion-trap mass spectrometer (ESI+) coupled to a Surveyor HPLC
system (Thermo Finnigan) equipped with a standard C18 (Gemini, 4.6 mmD x 50 mmL, 5µ particle
size, Phenomenex) analytical column and buffers A: H2O, B: ACN, C: 0.1% aq.TFA. High resolution
mass spectra were recorded on a LTQ Orbitrap (Thermo Finnigan) mass spectrometer equipped with
an electronspray ion source in positive mode (source voltage 3.5 kV, sheath gas flow 10 mL min−1,
capillary temperature 250 ◦C) with resolution R=60000 at m/z 400 (mass range m/z=150-2000) and
dioctylphtalate (m/z = 391.28428) as a "lock mass". The high resolution mass spectrometer was
calibrated prior to measurements with a calibration mixture (Thermo Finnigan). For reversed-phase
HPLC purification of the final compounds an automated HPLC system equipped with a C18 semiprep









1, 3, 5, 7-Tetramethyl-2,6-bis-(2-methoxycarbonylethyl)-8-[4-(N,N-
dimethylamino)phenyl] -4, 4-difluoro-4-bora-3a, 4a-diaza-s-indacene
(15a).
Methyl 2,4-dimethyl-3-pyrrolepropionate (1.43 g, 7.9 mmol, 2.2 eq)
and N,N-dimethylaminobenzaldehyde (0.54 g, 3.6 mmol, 1 eq) were
dissolved in dry dichloromethane (100 mL) followed by addition of a
catalytic amount of TFA. The reaction mixture was stirred overnight
at room temperature under an argon atmosphere. 2,3-Dichloro-5,6-
dicyanobenzoquinone (DDQ, 0.98 g, 4.3 mmol, 1.2 eq) was added and stirring was continued for 1 h.
The reaction was concentrated in vacuo, dissolved in dichloroethane (100 mL) followed by addition
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of diisopropylethylamine (DIPEA, 2.5 mL, 14.4 mmol, 4 eq) and BF3 · OEt2 (2.5 mL, 20 mmol, 5.5
eq). The mixture was stirred for 2h, washed with water (2 x 50 mL), dried (MgSO4), filtered and
concentrated under reduced pressure. Purification by silica column chromatography (1 → 13% EtOAc
in toluene) gave the product as an orange powder (0.53 g, 1 mmol, 28%). R f = 0.6 (4:1 toluene:
EtOAc) 1H NMR (400 MHz, CDCl3): δ 7.06 (d, J = 8.7 Hz, 2H, 2 x CHar), 6.80 (d, J = 8.7 Hz, 2H,
2 x CHar), 3.68 (s, 6H, 2 x CH3), 3.05 (s, 6H, 2 x CH3), 2.71 - 2.63 (m, 4H, 2 x CH2), 2.56 (s, 6H, 2
CH3), 2.42 - 2.33 (m, 4H, 2 x CH2), 1.43 (s, 6H, 2 x CH3).
13C NMR (101 MHz, CDCl3): δ 173.30,
153.41, 150.81, 142.49, 139.74, 131.78, 128.96, 128.84, 122.69, 112.51, 51.78, 40.48, 34.42, 19.50,
12.66, 12.27. ESI-HRMS (m/z): calcd. for [C29H36BF2N3O4 + H]









1, 3, 5, 7-Tetramethyl-2,6-bis-(2-methoxycarbonylethyl)-8-[4-(N,N-
ethylmethylamino)phenyl] -4, 4-difluoro-4-bora-3a, 4a-diaza-s-inda-
cene (15b).
Methyl 2,4-dimethyl-3-pyrrolepropionate (1.23 g, 6.8 mmol, 2.2 eq)
and N,N-ethylmethylaminobenzaldehyde (0.49 g, 3.0 mmol, 1 eq) were
dissolved in dry dichloromethane (100 mL) followed by addition of a
catalytic amount of TFA. The reaction mixture was stirred overnight
at room temperature under an argon atmosphere. DDQ (0.82 g, 3.6
mmol, 1.2 eq) was added and stirring was continued for 1 h. The reaction was concentrated in
vacuo, dissolved in dichloroethane (100 mL) followed by addition of TEA (1.25 mL, 9 mmol, 3 eq
) and BF3 · OEt2 (1.9 mL, 15 mmol, 5 eq). The mixture was refluxed for 40 min, cooled to room
temperature, washed with water (2 x 50 mL), dried (MgSO4), filtered and concentrated under reduced
pressure. Purification by repeated silica column chromatography (1 → 25% EtOAc in toluene/ 1 →
25% EtOAc in PE + 1% AcOH) gave the product as orange crystals (0.31 g, 0.56 mmol, 19%). R f
= 0.6 (4:1 toluene: EtOAc) 1H NMR (400 MHz, CDCl3): δ 7.02 (d, J = 8.6 Hz, 2H, 2 x CHar),
6.77 (d, J = 8.6 Hz, 2H, 2 x CHar), 3.65 (s, 6H, 2 x CH3), 3.46 (q, J = 7.0 Hz, 2H, CH2), 2.97
(s, 3H, CH3), 2.68 - 2.60 (m, 4H, 2 x CH2), 2.53 (s, 6H, 2 x CH3), 2.39 - 2.32 (m, 4H, 2 x CH2),
1.42 (s, 6H, 2 x CH3), 1.16 (t, J = 7.0 Hz, 3H, CH3).
13C NMR (101 MHz, CDCl3): δ 173.28,
153.39, 149.57, 142.62, 139.75, 131.84, 129.11, 128.86, 122.39, 112.60, 51.75, 46.96, 37.55, 34.45,











1, 3, 5, 7-Tetramethyl-2,6-bis-(2-methoxycarbonylethyl)-8-[4-(N,N-
diethylamino)phenyl] -4, 4-difluoro-4-bora-3a, 4a-diaza-s-indacene
(15c).
Methyl 2,4-dimethyl-3-pyrrolepropionate (1.81 g, 10 mmol, 2.2 eq) and
N,N-diethylaminobenzaldehyde (0.83 g, 4.7 mmol, 1 eq) were dissolved
in dry DCM (100 mL) followed by addition of a catalytic amount of
TFA. The reaction mixture was stirred overnight at room temperature
under an argon atmosphere. DDQ (1.18 g, 5.2 mmol, 1.1 eq) was
added and stirring was continued for 1 h. The reaction was concentrated in vacuo, dissolved in
dichloroethane (100 mL) followed by addition of TEA (1.96 mL, 14.1 mmol, 3 eq ) and BF3 · OEt2
(2.95 mL, 23.5 mmol, 5 eq). The mixture was refluxed for 40 min, cooled to room temperature,
washed with water (2 x 50 mL), dried (MgSO4), filtered and concentrated under reduced pressure.
Purification by repeated silica column chromatography (1 → 25% EtOAc in PE + 1% AcOH) gave
the product as orange crystals (0.50 g, 0.87 mmol, 19%). R f = 0.75 (3:1 toluene: EtOAc) 1H NMR
(400 MHz, CDCl3): δ 6.99 (d, J = 8.7 Hz, 2H, 2 x CHar), 6.74 (d, J = 8.7 Hz, 2H, 2 x CHar),
3.65 (s, 6H, 2 x CH3), 3.41 (q, J = 7.0 Hz, 4H, 2 x CH2), 2.72 - 2.57 (m, 4H, 2 x CH2), 2.53 (s,
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6H, 2 x CH3), 2.41 - 2.29 (m, 4H, 2 x CH2), 1.44 (s, 6H, 2 x CH3), 1.20 (t, J = 7.0 Hz, 6H, 2
x CH3).
13C NMR (101 MHz, CDCl3): δ 173.26, 153.19, 148.24, 142.73, 139.71, 131.78, 129.09,
128.73, 121.62, 112.09, 51.73, 44.45, 34.38, 19.46, 12.60, 12.44, 12.28. ESI-HRMS (m/z): calcd.
for [C31H40BF2N3O4 + H]







1, 3, 5, 7-Tetramethyl-2,6-bis-(2-methoxycarbonylethyl)-8-phenyl-
4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (15d).
Methyl 2,4-dimethyl-3-pyrrolepropionate (0.9 g, 5 mmol, 2.2 eq) was
dissolved in dichloroethane (20 mL). Benzoyl chloride (0.29 mL, 2.5
mmol, 1 eq) was added and the mixture was heated to reflux for 3 h.
After cooling to room temperature, TEA (1.04 mL, 7.5 mmol, 3 eq) and
BF3 · OEt2 (1.57 mL, 12.5 mmol, 5 eq) were added and the reaction
mixture was stirred for 16 h. The mixture was washed with water (2 x 50 mL), dried (MgSO4), filtered
and concentrated under reduced pressure. Purification by repeated silica column chromatography (1
→ 12% EtOAc in PE) gave the product as an orange powder (0.29 g, 0.58 mmol, 23%). R f = 0.8
(1:1 toluene: EtOAc). 1H NMR (400 MHz, CDCl3): δ 7.52 - 7.45 (m, 3H, 3 x CHar), 7.28 - 7.23
(m, 2H, 2 x CHar), 3.65 (s, 6H, 2 x CH3), 2.67 - 2.57 (m, 4H, 2 x CH2), 2.55 (s, 6H, 2 x CH3), 2.39
- 2.32 (m, 4H, 2 x CH2), 1.29 (s, 6H, 2 x CH3).
13C NMR (101 MHz, CDCl3): δ 173.20, 154.16,
141.02, 139.59, 135.54, 131.02, 129.30, 129.25, 129.08, 128.19, 51.81, 34.35, 19.45, 12.74, 11.95.
ESI-HRMS (m/z): calcd. for [C27H31BF2N2O4 + H]











15a (230 mg, 0.43 mmol) was dissolved in methanol/dioxane (1:1,
20 mL). NaOH (aq, 1M, 5 mL) was added and the mixture was
heated to 40 ◦C for 50 min. The mixture was neutralized with HCl
(aq, 1M, 5.5 mL), followed by addition of water and extraction with
EtOAc. The mixture was dried (MgSO4), filtered and concentrated
in vacuo to give the product as an orange powder in quantitative
yield (217 mg, 0.43 mmol, quant.). R f = 0.3 (2:1 toluene: EtOAc + AcOH) 1H NMR (400 MHz,
CDCl3/MeOD): δ 7.06 (d, J = 8.7 Hz, 2H, 2 x CHar), 6.85 (d, J = 8.7 Hz, 2H, 2 x CHar), 3.03
(s, 6H, 2 x CH3), 2.65 (t, J = 7.8 Hz, 4H, 2 x CH2), 2.51 (s, 6H, 2 x CH3), 2.34 (t, J = 7.8
Hz, 4H, 2 x CH2), 1.45 (s, 6H, 2 x CH3).
13C NMR (101 MHz, CDCl3/MeOD): δ 176.28, 154.10,
151.98, 143.53, 140.61, 132.48, 129.95, 129.68, 123.38, 113.37, 40.60, 35.15, 20.16, 12.69, 12.51.
ESI-HRMS (m/z): calcd. for [C27H32BF2N3O4 + H]












Compound 15b (37 mg, 0.067 mmol) was dissolved in methanol/
dioxane (1:1, 3 mL). NaOH (aq, 1M, 0.84 mL) was added and the
mixture was heated to 40 ◦C for 1 h. The mixture was neutral-
ized with HCl (aq, 1M, 1 mL), followed by addition of water and
extraction with EtOAc. The mixture was dried (MgSO4), filtered
and concentrated in vacuo. Pure product (31 mg, 0.059 mmol, 88%) was obtained by silica column
chromatography (10 → 30% EtOAc in toluene + 1% AcOH). R f = 0.3 (2:1 toluene: EtOAc + AcOH)
1H NMR (400 MHz, CDCl3/MeOD): δ 7.00 (d, J = 8.4 Hz, 2H, 2 x CHar), 6.83 (d, J = 8.5 Hz, 2H,
2 x CHar), 3.47 (q, J = 6.8 Hz, 2H, CH2), 2.96 (s, 3H, CH3), 2.64 (t, J = 7.6 Hz, 4H, 2 x CH2),
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2.49 (s, 6H, 2 x CH3), 2.33 (t, J = 7.6 Hz, 4H, 2 x CH2), 1.45 (s, 6H, 2 x CH3), 1.14 (t, J = 6.9 Hz,
3H, CH3).
13C NMR (101 MHz, CDCl3/MeOD): δ 176.35, 154.18, 150.67, 143.76, 140.66, 132.58,
130.06, 129.92, 123.03, 113.41, 47.49, 37.73, 35.20, 20.21, 12.68, 12.52, 11.24. ESI-HRMS (m/z):
calcd. for [C28H34BF2N3O4 + H]










mino)phenyl] -4, 4-difluoro-4-bora-3a, 4a-diaza-s-indacene (16c).
Compound 15c (0.45 g, 0.8 mmol) was dissolved in methanol/diox-
ane (1:1, 20 mL). NaOH (aq, 4M, 2.4 mL) was added and the
mixture was heated to 40 ◦C for 1h. The mixture was neutralized
with HCl (aq, 1M, 10 mL), followed by addition of water and ex-
traction with EtOAc. The mixture was dried (MgSO4), filtered and
concentrated in vacuo. Pure product (0.2 g, 0.36 mmol, 45%) was
obtained by silica column chromatography (10 → 20% EtOAc in toluene + 1% AcOH). R f = 0.3
(2:1 toluene: EtOAc + AcOH) 1H NMR (400 MHz, CDCl3/MeOD): δ 6.99 (d, J = 8.7 Hz, 2H, 2 x
CHar), 6.79 (d, J = 8.7 Hz, 2H, 2 x CHar), 3.47 - 3.36 (m, 4H, 2 x CH2), 2.65 (t, J = 7.9 Hz, 4H,
2 x CH2), 2.52 (s, 6H, 2 x CH3), 2.35 (t, J = 7.9 Hz, 4H, 2 x CH2), 1.47 (s, 6H, 2 x CH3), 1.20 (t,
J = 7.0 Hz, 6H, 2 x CH3).
13C NMR (101 MHz, CDCl3/MeOD): δ 176.08, 153.75, 148.95, 143.50,
140.46, 132.32, 129.69, 129.66, 122.19, 112.83, 45.01, 34.97, 19.98, 12.68, 12.58, 12.54. ESI-HRMS
(m/z): calcd. for [C29H36BF2N3O4 + H]









Compound 15d (30 mg, 0.06 mmol) was dissolved in methanol/
dioxane (1:1, 4 mL). NaOH (aq, 1M, 0.84 mL) was added and
the mixture was heated to 40 ◦C for 15 min. The mixture was
neutralized with HCl (aq, 1M, 1 mL), followed by addition of water
and extraction with EtOAc. The mixture was dried (MgSO4), filtered
and concentrated in vacuo. Pure product (15 mg, 0.032 mmol, 53%) was obtained by silica column
chromatography (10 → 20% EtOAc in toluene + 1% AcOH). R f = 0.45 (1:1 toluene: EtOAc +
AcOH). 1H NMR (400 MHz, CDCl3): δ 7.59 - 7.46 (m, 3H, 3 x CHar), 7.35 - 7.21 (m, 2H, 2 x CHar),
2.65 (t, J = 7.8 Hz, 4H, 2 x CH2), 2.53 (s, 6H, 2 x CH3), 2.35 (t, J = 7.8 Hz, 4H, 2 x CH2), 1.34
(s, 6H, 2 x CH3).
13C NMR (101 MHz, CDCl3): δ 176.05, 168.66, 154.79, 141.95, 140.41, 136.19,
131.65, 130.25, 129.97, 129.80, 128.90, 96.94, 34.98, 20.03, 12.75, 12.17 ESI-HRMS (m/z): calcd.
for [C25H27BF2N2O4 + H]





General procedure for the monoreduction of diazido-PEG spacers (17a,b).
To a cooled (0 ◦C) solution of diazido-PEG spacers (5 mmol) in toluene (15
mL), 5% aq HCl (15 mL) was added, followed by the addition of PPh3 (4.75
mmol, 0.95 eq). The mixture was warmed to rt and stirred for 16 h. The
waterlayer, containing the product, was separated, concentrated and co-evaporated with toluene (3x)
to give a colorless oil.
11-azido-3,6,9-trioxaundecan-1-amine hydrochloride (17a). Yield: 1.2 g, 4.7 mmol, 94%. R f = 0.7
(9:1 MeOH:NH4OH).
1H NMR (400 MHz, MeOD): δ 3.75 - 3.70 (m, 2H, CH2), 3.68 (d, J = 5.5
Hz, 10H, 5 x CH2), 3.43 - 3.37 (m, 2H, CH2), 3.16 - 3.10 (m, 2H, CH2).
13C NMR (101 MHz,
MeOD): δ 71.57, 71.47, 71.36, 71.20, 71.01, 67.80, 51.77, 40.68. FT-IR (thin film) v 3052, 2878,
2360, 2344, 2102, 1560, 1116 cm−1.
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14-azido-3,6,9,12-tetraoxatetradecan-1-amine hydrochloride (17b). Yield: 1.32 g, 4.4 mmol, 89%.
R f = 0.7 (9:1 MeOH:NH4OH).
1H NMR (400 MHz, MeOD): δ 3.72 - 3.67 (m, 2H, CH2), 3.64 (d,
J = 4.2 Hz, 14H, 7 x CH2), 3.40 - 3.34 (m, 2H, CH2), 3.13 - 3.08 (m, 2H, CH2).
13C NMR (101
MHz, MeOD): δ 71.47, 71.43, 71.38, 71.11, 70.98, 67.82, 51.79, 40.66. FT-IR (thin film) v 3036,
















16a (97 mg, 0.19 mmol, 1 eq) was dissolved in DMF (10
mL). PEG-spacer 17a (43 mg, 0.17 mmol, 0.9 eq), triethy-
lamine (40 µL, 0.29 mmol, 1.5 eq) and HOBt (23 mg, 0.17
mmol, 0.9 eq) were added, the mixture was cooled to 0 ◦C
and EDC · HCl (32 mg, 0.17 mmol, 0.9 eq) was added. After stirring for 16 h at ambient temperature,
DMF was evaporated and the solids were dissolved in DCM (, 20 mL). N-hydroxysuccinimide (175
mg, 1.52 mmol, 8 eq) and EDC · HCl (291 mg, 1.52 mmol, 8 eq) were added and after 3h stirring at
room temperature, the reaction was finished according to TLC. The mixture was washed with HCl
(aq, pH 3) and water, dried (MgSO4), filtered and concentrated. Pure compound (53 mg, 0.065
mmol) was obtained by silica column chromatography (0 → 1% MeOH in DCM) in 34% yield. R f
= 0.75 (10:1 DCM: MeOH) 1H NMR (400 MHz, CDCl3): δ 7.04 (d, J = 8.7 Hz, 2H, 2 x CHar),
6.78 (d, J = 8.7 Hz, 2H, 2 x CHar), 6.30 (s, 1H, NH), 3.73 - 3.56 (m, 10H, 5 x CH2), 3.53 (t, J =
5.0 Hz, 2H, CH2), 3.41 (dd, J = 10.1, 5.1 Hz, 2H, CH2), 3.39 - 3.34 (m, 2H, CH2), 3.03 (s, 6H,
2 x CH3), 2.83 (d, J = 8.4 Hz, 4H, 2 x CH2), 2.79 - 2.70 (m, 2H, CH2), 2.71 - 2.61 (m, 4H, 2 x
CH2), 2.53 (s, 6H, 2 x CH3), 2.30 - 2.18 (m, 2H, CH2), 1.42 (s, 6H, 2 x CH3).
13C NMR (101 MHz,
CDCl3): δ 172.43, 171.94, 169.21, 167.85, 154.42, 152.37, 150.80, 142.64, 140.33, 139.36, 132.00,
131.49, 129.75, 128.88, 127.27, 122.43, 112.50, 70.70, 70.65, 70.52, 70.28, 70.06, 69.92, 50.72,
40.45, 39.45, 36.70, 31.32, 25.67, 25.55, 25.47, 20.02, 19.13, 12.74, 12.62, 12.33, 12.29. ESI-HRMS
(m/z): calcd. for [C39H52BF2N8O8 +Na]
















16b (63 mg, 0.12 mmol, 1 eq) was dissolved in DMF (5
mL). PEG-spacer 17a (28 mg, 0.11 mmol, 0.9 eq), TEA
(15 µL, 0.11 mmol, 0.9 eq) and HOBt (15 mg, 0.11 mmol,
0.9 eq) were added, the mixture was cooled to 0 ◦C and
EDC · HCl (21 mg, 0.11 mmol, 0.9 eq) was added. After stirring for 16 h at ambient temperature,
DMF was evaporated and the solids were dissolved in DCM (10 mL). N-hydroxysuccinimide (115 mg,
0.96 mmol, 8 eq) and EDC · HCl (184 mg, 0.96 mmol, 8 eq) were added and after 2 h stirring at room
temperature, the reaction was finished according to TLC. The mixture was washed with HCl (aq, pH
3) and water, dried (MgSO4), filtered and concentrated. Pure compound (51 mg, 0.062 mmol) was
obtained by silica column chromatography (0 → 1% MeOH in DCM) in 52% yield. R f = 0.6 (15:1
DCM: MeOH) 1H NMR (600 MHz, CDCl3): δ 7.02 (s, 2H, 2 x CHar), 6.78 (s, 2H, 2 x CHar), 5.99
(t, J = 5.2 Hz, 1H, NH), 3.66 - 3.56 (m, 10H, 5 x CH2), 3.52 (t, J = 5.1 Hz, 2H, CH2), 3.47 (dd, J
= 13.8, 6.8 Hz, 2H, CH2), 3.44 - 3.39 (m, 2H, CH2), 3.38 - 3.33 (m, 2H, CH2), 2.98 (s, 3H, CH3),
2.83 (s, 4H, 2 x CH2), 2.78 - 2.71 (m, 2H, CH2), 2.70 - 2.59 (m, 4H, 2 x CH2), 2.52 (d, J = 16.9
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Hz, 6H, 2 x CH3), 2.24 - 2.17 (m, 2H, CH2), 1.43 (s, 6H, 2 x CH3), 1.17 (t, J = 6.9 Hz, 3H, CH3).
13C NMR (151 MHz, CDCl3): δ 172.04, 169.15, 167.88, 154.41, 152.45, 149.57, 142.78, 140.29,
139.39, 132.07, 131.57, 129.84, 129.09, 127.34, 122.15, 112.58, 70.82, 70.77, 70.65, 70.42, 70.17,
69.97, 50.79, 39.46, 36.82, 31.39, 25.72, 20.01, 19.21, 12.81, 12.67, 12.38, 12.33, 11.16. ESI-HRMS
(m/z): calcd. for [C40H53BF2N8O8 + Na]
















Compound 16c (35 mg, 0.064 mmol, 1 eq) was dissolved
in DMF (3 mL). PEG-spacer 17a (17 mg, 0.06 mmol, 0.9
eq), TEA (8 µL, 0.06 mmol, 0.9 eq) and HOBt (8 mg,
0.06 mmol, 0.9 eq) were added, the mixture was cooled to
0 ◦C and EDC · HCl (12 mg, 0.06 mmol, 0.9 eq) was added. After stirring for 16 h at ambient tem-
perature, DMF was evaporated and the solids were dissolved in DCM (10 mL). N-hydroxysuccinimide
(37 mg, 0.32 mmol, 5 eq) and EDC · HCl (61 mg, 0.32 mmol, 5 eq) were added and after 2 h stirring
at room temperature, the reaction was finished according to TLC. The mixture was washed with HCl
(aq, pH 3) and water, dried (MgSO4), filtered and concentrated. Pure compound (23 mg, 0.027
mmol) was obtained by silica column chromatography (0 → 2% MeOH in DCM) in 43% yield. R f =
0.8 (15:1 DCM: MeOH) 1H NMR (400 MHz, CDCl3): δ 6.99 (d, J = 8.6 Hz, 2H, 2 x CHar), 6.74
(d, J = 8.7 Hz, 2H, 2 x CHar), 6.09 (s, 1H, NH), 3.72 - 3.57 (m, 10H, 5 x CH2), 3.52 (t, J = 4.9
Hz, 2H, CH2), 3.47 - 3.34 (m, 8H, 4 x CH2), 2.89 - 2.79 (m, 4H, 2 x CH2), 2.79 - 2.72 (m, 2H,
CH2), 2.71 - 2.60 (m, 4H, 2 x CH2), 2.54 (s, 6H, 2 x CH3), 2.22 (t, J = 7.7 Hz, 2H, CH2), 1.45 (s,
6H, 2 x CH3), 1.20 (t, J = 7.0 Hz, 6H, 2 x CH3).
13C NMR (101 MHz, CDCl3): δ 171.99, 169.15,
169.07, 167.76, 154.17, 152.15, 148.20, 142.82, 140.21, 139.28, 131.98, 131.47, 129.63, 128.98,
127.12, 121.35, 112.00, 70.66, 70.62, 70.49, 70.25, 70.02, 69.85, 50.64, 44.38, 39.31, 36.68, 31.25,
















Compound 15d (27 mg, 0.06 mmol, 1 eq) was dissolved in
DMF (2 mL). PEG-spacer 17a (16 mg, 0.054 mmol, 0.9
eq), TEA (7.5 µL, 0.054 mmol, 0.9 eq) and HOBt (7 mg,
0.054 mmol, 0.9 eq) were added, the mixture was cooled to 0 ◦C and EDC · HCl (10.5 mg, 0.054
mmol, 0.9 eq) was added. After stirring for 24 h at ambient temperature, DMF was evaporated
and the solids were dissolved in DCM (5 mL). N-hydroxysuccinimide (55 mg, 0.48 mmol, 8 eq) and
EDC · HCl (92 mg, 0.48 mmol, 8 eq) were added and after 2 h stirring at room temperature, the
reaction was finished according to TLC. The mixture was washed with HCl (aq, pH 3) and water,
dried (MgSO4), filtered and concentrated. Pure compound (15 mg, 0.02 mmol) was obtained by
silica column chromatography (0 → 1% MeOH in DCM) in 33% yield. R f = 0.7 (15:1 DCM: MeOH)
1H NMR (400 MHz, CDCl3): δ 7.56 - 7.44 (m, 3H, 3 x CHar), 7.35 - 7.23 (m, 2H, 2 x CHar), 6.02
(s, 1H, NH), 3.70 - 3.56 (m, 10H, 5 x CH2), 3.53 (t, J = 5.0 Hz, 2H, CH2), 3.45 - 3.40 (m, 2H,
CH2), 3.39 - 3.31 (m, 2H, CH2), 2.84 (s, 4H, 2 x CH2), 2.77 - 2.70 (m, 2H, CH2), 2.70 - 2.58 (m,




NMR (101 MHz, CDCl3): δ 171.90, 169.01, 167.68, 155.10, 153.07, 141.06, 140.02, 139.15, 135.28,
132.06, 130.66, 130.11, 129.22, 129.05, 128.03, 127.56, 70.67, 70.62, 70.50, 70.26, 70.04, 69.81,
50.64, 39.34, 36.56, 31.19, 29.71, 25.59, 19.82, 19.01, 12.74, 12.61, 11.92, 11.87. ESI-HRMS (m/z):
calcd. for [C37H46BF2N7O8 + Na]








































µmol, 1 eq) was dis-
solved in DMF (0.5 mL)
and DIPEA (1 eq) was
added. A solution of
DCG-04 amine 14 (0.95
eq) in DMF was drop-
wise added. The mix-
ture was stirred for 3 h
at room temperature, concentrated and isolated using silica column chromatography (3 → 7% MeOH
in DCM). The product was lyophilized from t-butanol/H2O to give a hygroscopic orange powder.
N,N-dimethylamino BODIPY-DCG-04 (19a).
Yield: 10 mg (7.3 µmol, 37%). R f = 0.45 (10:1 DCM:MeOH). 1H NMR (600 MHz, MeOD): δ 7.05
(d, J = 8.4 Hz, 2H, 2 x CHar), 7.01 (d, J = 8.3 Hz, 2H, 2 x CHar), 6.88 (d, J = 8.8 Hz, 2H, 2 x
CHar), 6.69 (d, J = 8.2 Hz, 2H, 2 x CHar), 4.45 (t, J = 7.6 Hz, 1H, CH), 4.41 - 4.36 (m, 1H, CH),
4.31 - 4.21 (m, 3H, CH2, CH), 3.68 - 3.51 (m, 12H, 5 x CH2, 2 x CH), 3.47 (t, J = 5.5 Hz, 2H,
CH2), 3.34 - 3.32 (m, 4H, 2 x CH2), 3.17 - 3.07 (m, 3H, CH2, CH2-H
a), 3.08 - 2.99 (m, 7H, 2 x CH3,
CH2-H
b), 2.99 - 2.93 (m, 1H, CH2-H
a), 2.85 - 2.78 (m, 1H, CH2-H
b), 2.65 (dd, J = 13.5, 7.2 Hz,
4H, 2 x CH2), 2.49 (s, 6H, 2 x CH3), 2.28 - 2.17 (m, 6H, 3 x CH2), 1.81 - 1.73 (m, 1H, CH2-H
a),
1.67 - 1.60 (m, 1H, CH2-H
b), 1.60 - 1.32 (m, 18H, 6 x CH2, 2 x CH3), 1.30 (t, J = 7.2 Hz, 3H,
CH3), 1.25 - 1.16 (m, 2H, CH2), 0.93 (d, J = 6.4 Hz, 3H, CH3), 0.89 (d, J = 6.4 Hz, 3H, CH3).
13C
NMR (151 MHz, MeOD): δ 177.16, 176.12, 175.14, 174.97, 173.67, 173.08, 169.22, 168.35, 157.31,
154.81, 154.57, 152.56, 143.88, 141.04, 140.85, 132.79, 132.73, 131.36, 130.55, 130.44, 130.10,
128.90, 123.71, 116.24, 113.68, 71.61, 71.56, 71.47, 71.31, 71.11, 70.60, 63.22, 56.46, 54.41, 54.24,
53.40, 53.04, 51.75, 41.65, 40.57, 40.52, 40.20, 40.18, 38.20, 37.44, 37.27, 36.66, 32.79, 30.01,
29.84, 27.41, 26.50, 25.88, 24.34, 23.31, 22.03, 21.28, 21.18, 14.37, 12.79, 12.56, 12.53. ESI-HRMS
(m/z): calcd. for [C68H98BF2N13O14 + H]
+ 1370.75011; obsd. 1370.75147.
N,N-ethylmethylamino BODIPY-DCG-04 (19b).
Yield: 9 mg (6.5 µmol, 43%). R f = 0.45 (10:1 DCM:MeOH). 1H NMR (600 MHz, MeOD): δ 7.06
- 6.98 (m, 4H, 4 x CHar), 6.87 (d, J = 8.8 Hz, 2H, 2 x CHar), 6.69 (d, J = 8.5 Hz, 2H, 2 x CHar),
4.45 (t, J = 7.6 Hz, 1H, CH), 4.39 (dd, J = 9.1, 5.9 Hz, 1H, CH), 4.31 - 4.19 (m, 3H, CH2, CH),
3.67 - 3.56 (m, 10H, 4 x CH2, 2 x CH), 3.56 - 3.52 (m, 2H, CH2), 3.52 - 3.44 (m, 4H, 2 x CH2),
3.34 - 3.32 (m, 4H, 2 x CH2), 3.18 - 3.08 (m, 3H, CH2, CH2-H
a), 3.07 - 3.01 (m, 1H, CH2-H
b),
2.99 - 2.93 (m, 4H, CH3, CH2-H
a), 2.85 - 2.79 (m, 1H, CH2-H
b), 2.66 (dd, J = 13.8, 7.2 Hz, 4H,
2 x CH2), 2.47 (s, 6H, 2 x CH3), 2.28 - 2.19 (m, 6H, 3 x CH2), 1.81 - 1.73 (m, 1H, CH2-H
a), 1.67
- 1.60 (m, 1H, CH2-H
b), 1.59 - 1.32 (m, 18H, 6 x CH2, 2 x CH3), 1.30 (t, J = 7.1 Hz, 3H, CH3),
1.23 - 1.17 (m, 2H, CH2), 1.15 (t, J = 7.0 Hz, 3H, CH3), 0.93 (d, J = 6.4 Hz, 3H, CH3), 0.89 (d,
J = 6.4 Hz, 3H, CH3).
13C NMR (151 MHz, MeOD): δ 177.15, 176.12, 175.15, 174.97, 173.68,
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173.08, 168.73, 168.41, 157.31, 154.76, 154.51, 151.09, 143.97, 141.03, 140.85, 132.82, 132.76,
131.36, 130.53, 130.42, 130.23, 128.90, 123.28, 116.24, 113.64, 71.61, 71.56, 71.48, 71.32, 71.11,
70.61, 63.21, 56.48, 54.38, 54.24, 53.39, 53.18, 51.75, 47.62, 41.65, 40.52, 40.20, 40.18, 38.20,
37.76, 37.44, 37.27, 36.66, 32.79, 30.01, 29.84, 27.42, 26.50, 25.89, 24.34, 23.31, 22.02, 21.29,




Yield: 12 mg (8.6 µmol, 31%). R f = 0.3 (10:1 DCM:MeOH). 1H NMR (600 MHz, CDCl3/MeOD):
δ 7.03 - 6.95 (m, 4H, 4 x CHar), 6.77 (d, J = 8.7 Hz, 2H, 2 x CHar), 6.74 - 6.69 (m, 2H, 2 x CHar),
4.45 (t, J = 7.5 Hz, 1H, CH), 4.40 (t, J = 7.3 Hz, 1H, CH), 4.33 - 4.23 (m, 3H, CH2, CH), 3.67 -
3.60 (m, 9H, 4 x CH2, CH), 3.60 - 3.56 (m, 2H, CH2), 3.55 (d, J = 1.8 Hz, 1H, CH), 3.50 (t, J =
5.3 Hz, 2H, CH2), 3.42 (q, J = 7.0 Hz, 4H, 2 x CH2), 3.39 - 3.32 (m, 4H, 2 x CH2), 3.20 - 3.08 (m,
3H, CH2, CH2-H
a), 3.05 - 2.98 (m, 1H, CH2-H
b), 2.94 (dd, J = 13.7, 7.8 Hz, 1H, CH2-H
a), 2.89 -
2.81 (m, 1H, CH2-H
b), 2.64 (dd, J = 15.2, 7.0 Hz, 4H, 2 x CH2), 2.50 (s, 6H, 2 x CH3), 2.26 - 2.17
(m, 6H, 3 x CH2), 1.81 - 1.73 (m, 1H, CH2-H
a), 1.66 - 1.58 (m, 1H, CH2-H
b), 1.58 - 1.49 (m, 6H,
3 x CH2), 1.46 (s, 6H, 2 x CH3), 1.40 - 1.29 (m, 7H, 2 x CH2, CH3), 1.22 - 1.17 (m, 6H, 2 x CH3),
1.17 - 1.10 (m, 2H, CH2), 0.91 (d, J = 5.9 Hz, 3H, CH3), 0.88 (d, J = 5.8 Hz, 3H, CH3).
13C
NMR (151 MHz, CDCl3/MeOD): δ 176.00, 175.08, 174.02, 173.68, 172.45, 171.84, 167.90, 167.20,
156.22, 153.71, 153.62, 148.82, 143.21, 140.42, 140.33, 132.14, 130.74, 129.73, 129.66, 129.46,
129.37, 127.93, 121.89, 115.78, 115.72, 112.62, 70.99, 70.89, 70.54, 70.44, 70.04, 62.88, 55.50,
53.96, 53.20, 52.82, 52.29, 51.06, 44.84, 41.11, 39.79, 39.54, 39.49, 37.76, 36.93, 36.84, 36.18,
32.05, 29.19, 29.00, 26.60, 25.74, 25.69, 25.19, 23.40, 23.07, 21.85, 20.68, 20.57, 14.19, 12.62,




Yield: 8.4 mg (6 µmol, 31%). R f = 0.3 (10:1 DCM:MeOH). 1H NMR (600 MHz, CDCl3/MeOD):
δ 7.54 - 7.47 (m, 3H, 3 x CHar), 7.27 - 7.22 (m, 2H, 2 x CHar), 7.01 (d, J = 8.5 Hz, 2H, 2 x CHar),
6.73 (d, J = 8.5 Hz, 2H, 2 x CHar), 4.49 - 4.39 (m, 2H,2 x CH), 4.39 - 4.23 (m, 3H, CH2, CH), 3.69
- 3.64 (m, 9H, 4 x CH2, CH), 3.61 - 3.56 (m, 2H, CH2), 3.54 - 3.49 (m, 3H, CH2, CH), 3.39 - 3.33
(m, 4H, 2 x CH2), 3.24 - 3.06 (m, 3H, CH2, CH2-H
a), 3.05 - 2.97 (m, 1H, CH2-H
b), 2.96 - 2.82
(m, 2H, CH2), 2.69 - 2.60 (m, 4H, 2 x CH2), 2.53 (s, 6H, 2 x CH3), 2.27 - 2.12 (m, 6H, 3 x CH2),
1.85 - 1.73 (m, 1H, CH2-H
a), 1.69 - 1.58 (m, 1H, CH2-H
b), 1.57 - 1.41 (m, 6H, 3 x CH2), 1.36 -
1.28 (m, 13H, 3 x CH3, 2 x CH2), 1.16 - 1.05 (m, 2H, CH2), 0.96 - 0.86 (m, 6H, 2 x CH3).
13C
NMR (151 MHz, CDCl3/MeOD): δ 175.56, 174.67, 173.46, 171.97, 171.43, 167.49, 166.70, 155.91,
141.15, 139.96, 139.86, 135.49, 131.08, 130.49, 129.97, 129.83, 129.43, 129.29, 128.22, 127.61,
115.53, 70.77, 70.68, 70.64, 70.26, 70.19, 69.87, 62.69, 55.25, 53.80, 52.78, 52.71, 51.82, 50.83,
40.99, 39.50, 39.34, 39.18, 38.13, 37.62, 36.64, 36.52, 35.98, 31.79, 29.33, 28.90, 28.69, 26.24,
25.37, 24.96, 23.03, 22.91, 21.74, 20.33, 20.21, 14.05, 12.54, 11.86. ESI-HRMS (m/z): calcd. for
[C66H93BF2N12O14 + H]
+ 1327.70789; obsd. 1327.70956.
General procedure for mannose cluster-BODIPY-DCG-04 derivatives (21a-d).
BODIPY-DCG-04 derivative 19a-d (∼5 µmol, 1 eq) dissolved in DMF (degassed, 1 mL) was added to
mannose cluster 20 4 (0.9 eq) in H2O (degassed, 1 mL) under an argon atmosphere. Sodium ascorbate
(1 eq) and CuSO4 (10 mol%), as solution in water (degassed), were added to the mixture followed by
heating to 80 ◦C for 12 h. The reaction was monitored by LC-MS. When needed, additional sodium
ascorbate and CuSO4 were added. Upon prolonged heating (>48 h), decomposition of starting
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materials was observed, and so the reaction was terminated by concentration under reduced pressure
and semi-preparative HPLC (C18 column, solvent A: 0.2% TFA in H2O; solvent B: acetonitrile)
purification. HPLC fractions containing the product were combined and lyophilized, yielding the
compound as a hygroscopic orange/reddish powder.
Mannose cluster -N,N-dimethylamino BODIPY-DCG-04 (21a).
Hydrolysis of the ethyl ester of DCG-04 was observed and this compound was isolated besides the title
compound. HPLC (27-41% B in 12’, 450 µL injection) yielded 13% (2.5 mg, 0.55 µmol) product and
10% (1.9 mg, 0.42 µmol) hydrolyzed product. ESI-HRMS (m/z): calcd. for [C199H312BF2N45O66
+ 3H]3+ 1370.75011; obsd. 1370.75147.
Mannose cluster -N,N-ethylmethylamino BODIPY-DCG-04 (21b).
HPLC (27-41% B in 12’, 450 µL injection) yielded 29% (6.2 mg, 1.4 µmol) product. ESI-HRMS
(m/z): calcd. for [C200H314BF2N45O66 + 3H]
3+ 1485.43157; obsd. 1485.43328.
Mannose cluster -N,N-diethylamino BODIPY-DCG-04 (21c).
This reaction proceeded very sluggishly, and was terminated after 24 h to prevent decomposition of
the formed product as well as remaining starting materials. HPLC (21-36% B in 12’, 450 µL injection)
yielded 4% (0.56 mg, 0.13 µmol) product. ESI-HRMS (m/z): calcd. for [C201H316BF2N45O66 +
3H]3+ 1490.10345; obsd. 1490.10513.
Mannose cluster -phenyl BODIPY-DCG-04 (21d).
HPLC (27-41% B in 12’, 450 µL injection) yielded 20% (3.3 mg, 0.75 µmol) product. ESI-HRMS
(m/z): calcd. for [C197H307BF2N44O66 + 3H]
3+ 1466.41228; obsd. 1466.41367.
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Synthesis of pH-activatable red
fluorescent BODIPY dyes with
distinct functionalities1
T
his chapter describes the synthesis of a series of tunable pH-dependent BO-
DIPY dyes that were functionalized using a Knoevenagel-type condensation
reaction. In this fashion, monofunctional dyes containing an alkyne, azide or car-
boxylic acid (masked as its methyl ester) as ligation sites as well as asymmetrical
bifunctional dyes were obtained, without compromising their pH-dependency. In
addition, fluorescence excitation and emission maxima for these dyes were shown




In recent years fluorescent dyes have found widespread use in chemical biology applica-
tions. An important class of dyes are those based on the 4,4-difluoro-4-bora-3a,4a-diaza-s-
indacene (BODIPY) scaffold. BODIPY dyes usually show excellent photochemical proper-
ties, such as high molar absorption coefficients, high quantum yields and narrow emission
bandwidths. Moreover, they are relatively stable under physiological conditions. 2–4
Synthetic efforts have been directed towards the formation of analyte-sensitive dyes
and numerous reports can be found in the literature. 4 Particularly useful examples are
the pH-sensitive BODIPY dyes that are responsive to protonation. 5–9 Intracellular pH is
an important factor in many physiological processes and by using a pH-activatable dye
selective visualization of processes in acidic cellular compartments becomes possible. pH-
sensitivity is usually accomplished by incorporation of a p-(N,N-dialkyl)aniline moiety at
the meso-position of the BODIPY core. 7,10–13 Due to photo-induced electron transfer (PeT)
fluorescence is quenched at neutral or basic pH. 13–15 Upon protonation of the aniline nitro-
gen fluorescence intensity increases drastically.
In a recent paper by Urano et al., the development of a series of pH-activatable dyes with
varying pKa-values is described. 11 These can be easily transformed into bifunctional dyes,
but for mono-conjugation they are less convenient due to their symmetry, as described in
Chapter 2. 12 Other groups have investigated the tetramethyl-BODIPY scaffold with a meso-
aniline substituent. 10,13,16 The methyl groups adjacent to the nitrogens are susceptible to
a Knoevenagel-type condensation with benzaldehydes, yielding dyes with red-shifted ab-
sorption and emission maxima. 5–7,9,17–21 The potential of the Knoevenagel reaction to extend
the conjugated system is widely acknowledged and the reaction has been used to construct
large libraries of (pH-independent) BODIPY dyes. 22–25 The use of the Knoevenagel reaction
to incorporate ligation handles in the BODIPY dye has not been employed, although that
would allow covalent attachment to other (bio-active) molecules, which is vital for applica-
tions in chemical biology. Often used ligation reactions comprise the Staudinger-Bertozzi
ligation (involving azides), 26 the copper(I) catalyzed Huisgen 1,3-cycloaddition (involving
azides or alkynes) 27,28 and, in a more traditional fashion, amide/ester formation (involving
carboxylic acids). This chapter concerns the synthesis of a series of pH-dependent BODIPY
dyes that are functionalized by means of the Knoevenagel reaction. The pH-dependency
and spectroscopic properties of these novel dyes are investigated. Finally, one of the dyes
is subjected to a ligation reaction to study the synthetic stability of these dyes.
3.2 Results and Discussion
Starting from commercially available N,N-dialkylamino benzaldehydes (or benzaldehyde
in case of 24a, the "always on" dye) and 2,4-dimethylpyrrole synthesis of non-functionalized
BODIPY dyes 24a-e proved straightforward, with yields ranging between 32 and 50%
(Scheme 7.1). 13,29 To obtain mono-functional BODIPY dyes 29-31a-e, three benzaldehydes
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were synthesized, containing either an alkyne (25), 30 azide (27) 31 or a methyl ester (28) 32 as
the functional group. The use of a tert-butyl ester has been reported in a related study, 18
however, literature precedence shows that methyl esters can be saponified using (mild)
basic conditions while leaving the BODIPY core intact. 1,11,33 Subsequently, these benzalde-
hydes were used in a Knoevenagel condensation reaction with BODIPYs 24a-e.





















































Reagents and conditions: [a] i) cat. TFA, DCM; ii) DDQ; iii) DiPEA, BF3 · OEt2, 32-50%; [b] ArCHO
25-28, pyrrolidine, acetic acid, EtOH or MeOH, microwave, 13-35%; [c] ArCHO, pyrrolidine, acetic
acid, EtOH or MeOH, microwave, 32: 42%, 33: 12%
Reaction times using classical Knoevenagel conditions (refluxing in toluene in the pres-
ence of piperidine/acetic acid) can be extensive (12-24 h). 3,4,18 Recent reports show that the
use of microwave irradation considerably shortens reaction times (5-20 min). 25,34 Therefore,
microwave conditions were used in this study, in order to synthesize various BODIPYs
in a relatively short period of time. In case of benzaldehyde 28, the reaction solvent was
changed from ethanol to methanol to prevent transesterification of the methyl ester. Typ-
ically, reaction yields of the Knoevenagel reaction are low, 5,6,17,18,34 and although this case
forms no exception, the envisaged 15 mono-functional BODIPYs 29-31a-e were all readily
obtained. Importantly, a significant amount (30-50%) of unreacted starting material could
easily be recovered by silica column chromatography.
BODIPY dyes 24a-e contain two reactive methyl groups (at the 3 and 5 positions) and
the main byproduct observed in the reaction was indeed the symmetrical distyryl substi-
tuted BODIPY. Under these conditions, no formation of tetrastyryl substituted BODIPY
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Table 3.1: Spectroscopic properties measured in TFA
(135 mM) /methanol
λabs (nm) λem (nm) Φf
b,c pKd
e
24a 497 510 0.63b -
24b 500 514 0.35b 4.49a/2.14
24c 500 513 0.44b 5.10a/2.95
24d 500 514 0.40b 5.06a/3.97
24e 500 513 0.56b 5.81a/4.05
29a 563 574 1.09c -
29b 567 582 0.66c 2.13
29c 569 582 0.84c 2.93
29d 568 582 0.85c 3.92
29e 568 582 0.84c 4.07
30a 564 578 1.01c -
30b 568 586 0.59c 2.08
30c 568 586 0.69c 2.93
30d 570 586 0.81c 3.91
30e 570 587 0.82c 4.05
31a 562 574 1.10c -
31b 566 580 0.67c 2.08
31c 567 581 0.78c 2.96
31d 567 581 0.87c 3.94
31e 567 581 0.87c 4.10
32 640 655 -d 4.10
33 643a 660a -d 5.81a
a Measured in citric acid/phosphate buffer.b Relative
quantum yield (±0.1) with fluorescein (Φf = 0.925 ±
0.015 in 0.1 M NaOH) 35 as standard.c Relative quan-
tum yield (±0.1) with rhodamine 101 (Φf = 1.00 ±
0.02 in ethanol) 36 as standard.d No standard available.e
Apparent dissociation constant determined from curves
of fluorescence vs p[TFA] (in MeOH) or pH (pKa =
-log Kd).
dyes was observed. 19,21 Taking ad-
vantage of the acidity of the sec-
ond methyl group, mono-func-
tional dye 29e was subjected to an-
other cycle of Knoevenagel con-
densation with benzaldehyde 28
to obtain bifunctional BODIPY
dye 32, containing two orthog-
onal ligation handles. As an
alternative strategy, the second
methyl group can be used to al-
ter the solubility properties of the
dye. BODIPY dyes tend to be
fairly lipophilic and poorly water-
soluble, which can be improved
by introduction of polar moi-
eties such as sulfonic acids 37–39
or polyethylene glycol. 19,20 By in-
troduction of a disulfonic acid-
containing styryl moiety via the
Knoevenagel reaction water-sol-
uble BODIPY dye 33 was syn-
thesized in 12% yield. The low
yield of this reaction was mostly
due to extensive purification pro-
cedures to separate the product
from pyrrolidinium acetate.
Evaluation of the spectroscopic
properties of the dyes (Table 3.1)
revealed small Stokes shifts, char-
acteristic of BODIPY dyes, and
moderate to excellent relative quan-
tum yields∗. The fluorescence absorption and emission maxima of the dyes were shifted
approximately 70 nm towards the red end of the spectrum with each Knoevenagel reac-
tion (Table 3.1, Figure 3.1A). For biological applications such as live-cell fluorescence mi-
croscopy this is a great advantage, since levels of autofluorescence are lower at the red end
of the spectrum. Besides, as a result of their narrow absorbance and emission peaks, the
bifunctional dyes are compatible for use in the same experiment as other pH-dependent
dyes, such as the ones described in Chapter 2.
∗Some controversy about the actual quantum yield of rhodamine 101 exists in the literature. 40,41
Since quantum yields reported here are relative values, this would explain the values greater than
40
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Figure 3.1: A) Absorbance (dashed line) and emission (solid line) spectra of compounds 24a-e (left),
29-31a-e (middle) and 32, 33 (right) in TFA/methanol. B) Fluorescence intensity vs pH curves
for compounds 24b-e. C, D) Fluorescence intensity vs p[TFA] curves for compounds 29b-e and for
non-functionalized (24e), monofunctional (29-31e) and bifunctional (32) diethylaniline derivatives.
To assess whether modifications of the BODIPY core by one or two Knoevenagel reac-
tions would lead to any change in pH-dependency, the fluorescence intensities at different
pH-values were measured for all pH-activatable fluorophores (Figure 3.1B-D). Since the
water-solubility of dyes 29-31 was low, their fluorescence was determined as a function
of the concentration of trifluoroacetic acid (TFA) in methanol. The apparent pKa (in aq.
buffer) or pKd (in methanol/TFA)
4 of the dyes decreases in the order diethyl > piperidino
> ethylmethyl > dimethyl (Figure 3.1B,C, Table 3.1), which corresponds to the electron-
donating properties of the substituted amines and the trend found for previously reported
pH-dependent dyes (2). 11,12,16 No change in pH-dependency was observed for the vari-
ous mono- and bifunctional dyes compared to their non-functionalized counterparts (Fig-
ure 3.1D, Table 3.1). It is therefore likely that attachment of these dyes via their ligation
handle to (bio)active molecules will result in constructs with the same advantageous fluo-
rescence characteristics as the original dyes.
Finally, to examine the stability of the dyes when used in a ligation reaction, dye 29e
was used in a traditional copper(I) catalyzed Huisgen 1,3-cycloaddition 27,28 with the azide-
modified proteasome inhibitor epoxomicin. 42 This resulted in the pH-dependent BODIPY-
epoxomicin 34 in good yield (Scheme 3.2).
unity (although within the estimated error of measurement) for dyes 29-31a.
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Reagents and conditions: [a] 29e, sodium ascorbate, CuSO4, H2O/toluene/t-BuOH, 80
◦C, 89%
3.3 Conclusion
This chapter describes a series of tunable pH-dependent BODIPY dyes that contain a (bio)-
conjugation handle for incorporation in larger constructs. The Knoevenagel-type conden-
sation reaction that was used provides a fast and easy means to a large variety of red-shifted
BODIPY dyes. Because of the red-shift in the fluorescence properties of these dyes, they
should be more suited for live-cell fluorescence microscopy than their greener counterparts
discussed in Chapter 2, as non-invasive tools to selectively image cellular compartments of
interest, based on their acidity. Because of the generality of the approach, the methodology
can be extended towards the development of many other (analyte-sensitive) BODIPY dyes
containing the functionality or property of interest, an example hereof will be discussed in
Chapter 8.
3.4 Experimental Section
Absorption and Fluorescence Spectroscopy. All spectroscopic experiments were performed in 135
mM TFA in methanol (spectroscopic grade) or a citric acid/phosphate buffer pH 1.8, at a concen-
tration of 1 µM (absorption) or 100 nM (fluorescence). For fluorescence experiments the excitation
wavelength was set equal to the maximum of the corresponding absorption spectrum and the emis-
sion spectrum recorded. Measurements were conducted on a Shimadzu UV1700 pharmaspec UV-VIS
spectrophotometer (absorbance) and a Shimadzu RF-5301PC spectrofluorometer (fluorescence). For
the determination of relative quantum yields the slit width was set to 3 nm for both excitation and
emission. For the determination of relative quantum yields the slit width was set to 3 nm for both
excitation and emission. Quantum yields were calculated using equation 3.1∗:
∗Quantum yields were determined according to the method described in:
http://www.jobinyvon.com/usadivisions/Fluorescence/applications/quantumyieldstrad.pdf
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where x denotes the unknown and st the standard. Φ is the quantum yield, Grad is the gradient
from the plot of integrated fluorescence vs absorbance (absorbances between 0.01 and 0.1) and η is
the refractive index of the solvent used (1.3288 for methanol, 1.36 for ethanol and 1.333 for water).
Quantum yields were determined with rhodamine 101 (Φf = 1.00 ± 0.02 in ethanol) 36 and fluorescein
(Φf = 0.925 ± 0.015 in 0.1 M NaOH) 35 as standards. The error in the measurements is estimated
to be ±0.1.
Determination of pH-dependency. Fluorescence intensity was measured on a FLUOstar Optima
platereader (BMG Labtech) using the following filter settings:
Dyes 24b-e: λex 480-12; λem 505-10; Dyes 29-31b-e: λex 520-10; λem 570-10; Dyes 32, 33: λex
620-10; λem 660-10. All compounds were prepared as a stock solution in DMSO (100 µM). Intensity
was measured of 1 µM solutions of compounds 24a-e, 29a-e, 30a-e, 31a-e and 32 in freshly prepared
solutions of trifluoroacetic acid in methanol in a 96-wells plate. Alternatively, for compounds 24a-e
and 33 measurements were conducted in a citric acid/phosphate buffer of different pH, containing
0.2% SDS. All experiments were conducted at least in triplicate. Data was analyzed using GraphPad
Prism 5.0 and curves were corrected for background fluorescence of the solvent.
Synthesis
General. All reagents were of commercial grade and used as received unless stated otherwise. Reaction
solvents were of analytical grade and when used under anhydrous conditions stored over flame-dried
3 Å molecular sieves. Dichloromethane was distilled over CaH2 prior to use. Solvents used for column
chromatography were of technical grade and distilled before use. All moisture and oxygen sensitive
reactions were performed under an argon atmosphere. Flash chromatography was performed on silica
gel (Screening Devices BV, 0.04-0.063 mm, 60 Å). Reactions were routinely monitored by TLC analysis
on DC-alufolien (Merck, Kieselgel60, F254) with detection by UV-absorption (254/366 nm) where ap-
plicable and spraying with a solution of (NH4)6Mo7O24 · 4 H2O (25 g/l) and (NH4)4Ce(SO4)4 · 2 H2O
(10 g/l) in 10% sulfuric acid in water followed by charring at ∼150 ◦C. 1H and 13C NMR spectra
were recorded on a Bruker AV-400 (400 MHz) or Bruker DMX-600 (600 MHz). Chemical shifts are
given in ppm (δ) relative to the residual solvent peak or TMS (0 ppm) as internal standard. Coupling
constants are given in Hz. Peak assignments are based on 2D 1H-COSY and 13C-HSQC NMR experi-
ments. IR measurements (thin film) were conducted on an IRaffinity-1 apparatus and evaluated using
IRSolutions software (Shimadzu, Kyoto, Japan). LC-MS measurements were conducted on a Thermo
Finnigan LCQ Advantage MAX ion-trap mass spectrometer (ESI+) coupled to a Surveyor HPLC
system (Thermo Finnigan) equipped with a standard C18 (Gemini, 4.6 mmD x 50 mmL, 5µ particle
size, Phenomenex) analytical column and buffers A: H2O, B: ACN, C: 0.1% aq.TFA. High resolution
mass spectra were recorded on a LTQ Orbitrap (Thermo Finnigan) mass spectrometer equipped with
an electronspray ion source in positive mode (source voltage 3.5 kV, sheath gas flow 10 mL min−1,
capillary temperature 250 ◦C) with resolution R=60000 at m/z 400 (mass range m/z=150-2000) and
dioctylphtalate (m/z = 391.28428) as a "lock mass". The high resolution mass spectrometer was
calibrated prior to measurements with a calibration mixture (Thermo Finnigan). For reversed-phase
HPLC purification of the final compounds an automated HPLC system equipped with a C18 semiprep
column (Gemini C18, 250x10 mm, 5µ particle size, Phenomenex) was used. Microwave syntheses









c: R1= MeNEt 
d: R1= piperidino
e: R1= Et2N
General procedure for the synthesis of non-functionalized BODIPYs
(24a-e).
To a solution of 2,4-dimethylpyrrole (0.5 mL, 0.46 g, 4.4 mmol, 2 eq)
in dry DCM (100 mL) the appropriate benzaldehyde (2.2 mmol, 1 eq)
was added followed by a catalytic amount of trifluoroacetic acid (TFA).
After overnight stirring of the resulting reddish solution, 2,3-dichloro-5,6-
dicyanobenzoquinone (DDQ, 1.2 eq) was added and the mixture stirred
for 1 h. If TLC analysis (4:1 PE:EtOAc + 1% triethylamine) revealed
incomplete oxidation, another 0.5 eq of DDQ was added. All reactions
were complete after 2 h, upon which N,N-diisopropylethylamine (DIPEA, 3 mL) and BF3.OEt2 (3.5
mL) were added. After 1 h the mixture was concentrated in vacuo, redissolved in EtOAc and washed
with water. The water layer was extracted with EtOAc and the combined organic layers were dried
(MgSO4), filtered and concentrated under reduced pressure. Silica column chromatography (toluene)
yielded 24a-e as orange powders. R f = 0.5 (4:1 PE:EtOAc)
1, 3, 5, 7-Tetramethyl-8-phenyl-4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (24a). Yield: 287 mg,
0.89 mmol, 40%. 1H NMR (400 MHz, CDCl3): δ 7.67 - 7.36 (m, 3H, 3 x CHar), 7.38 - 7.10 (m, 2H,
2 x CHar), 5.98 (s, 2H, 2 x CH), 2.56 (s, 6H, 2 x CH3), 1.37 (s, 6H, 2 x CH3).
13C NMR (101 MHz,
CDCl3): δ 155.55, 143.29, 141.85, 135.11, 131.56, 129.26, 129.06, 128.05, 121.33, 14.73, 14.48.
FT-IR (thin film) v 2922, 1533, 1504, 1301, 1177, 1150, 1051, 966, 718 cm−1. ESI-HRMS (m/z):
calcd. for [C19H19BF2N2 + H]
+ 325.16821; obsd. 325.16822.
1, 3, 5, 7-Tetramethyl-8-[4-(N,N-dimethylamino)phenyl]-4,4-difluoro-4-bora-3a,4a-diaza-s-indace-
ne (24b). Yield: 350 mg, 0.95 mmol, 32%; based on 3 mmol benzaldehyde. 1H NMR (400 MHz,
CDCl3): δ 7.15 - 7.00 (m, 2H, 2 x CHar), 6.77 (d, J = 8.7 Hz, 2H, 2 x CHar), 5.97 (s, 2H, 2 x CH),
3.02 (s, 6H, 2 x NCH3), 2.55 (s, 6H, 2 x CH3), 1.49 (s, 6H, 2 x CH3).
13C NMR (101 MHz, CDCl3):
δ 154.86, 150.83, 143.37, 132.34, 128.88, 122.33, 120.96, 112.47, 40.46, 14.82, 14.69. FT-IR (thin
film) v 2916, 2854, 1610, 1504, 1302, 1182, 1153, 1074, 1047, 974,806 cm−1. ESI-HRMS (m/z):
calcd. for [C21H24BF2N3 + H]
+ 368.21041; obsd. 368.21077.
1, 3, 5, 7-Tetramethyl-8-[4-(N,N-ethylmethylamino)phenyl]-4,4-difluoro-4-bora-3a,4a-diaza-s-in-
dacene (24c). Yield: 420 mg, 1.1 mmol, 50%. 1H NMR (400 MHz, CDCl3): δ 7.03 (d, J = 8.6
Hz, 2H, 2 x CHar), 6.76 (d, J = 8.6 Hz, 2H, 2 x CHar), 5.97 (s, 2H, 2 x CH), 3.45 (q, J = 7.1
Hz, 2H, NCH2), 2.96 (s, 3H, NCH3), 2.55 (s, 6H, 2 x CH3), 1.50 (s, 6H, 2 x CH3), 1.15 (t, J =
7.1 Hz, 3H, CH3).
13C NMR (101 MHz, CDCl3): δ 154.75, 149.45, 143.36, 132.31, 128.93, 121.86,
120.93, 112.43, 46.90, 37.51, 14.82, 14.69, 11.17. FT-IR (thin film) v 2918, 2850, 1732, 1543, 1263,
1195, 1083, 734, 704 cm−1. ESI-HRMS (m/z): calcd. for [C22H26BF2N3 + H]
+ 382.22606; obsd.
382.22656.
1, 3, 5, 7-Tetramethyl-8-[4-(piperidino)phenyl]-4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (24d).
Yield: 382 mg, 0.94 mmol, 43%. 1H NMR (400 MHz, CDCl3): δ 7.07 (d, J = 8.7 Hz, 2H, 2 x CHar),
7.00 (d, J = 8.8 Hz, 2H, 2 x CHar), 5.96 (s, 2H, 2 x CH), 3.28 - 3.15 (m, 4H, 2 x NCH2), 2.54 (s,
6H, 2 x CH3), 1.80 - 1.69 (m, 4H, 2 x CH2 ), 1.66 - 1.55 (m, 2H, CH2), 1.46 (s, 6H, 2 x CH3).
13C
NMR (101 MHz, CDCl3): δ 154.98, 152.56, 143.35, 142.88, 132.12, 128.76, 124.87, 121.02, 116.32,
50.19, 25.75, 24.36, 14.75, 14.67. FT-IR (thin film) v 2916, 2850, 1730, 1543, 1263, 1157, 1060,
732, 704 cm−1. ESI-HRMS (m/z): calcd. for [C24H28BF2N3 + H]
+ 408.24171; obsd. 408.24179.
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1, 3, 5, 7-Tetramethyl-8-[4-(N,N-diethylamino)phenyl]-4,4-difluoro-4-bora-3a,4a-diaza-s-indacene
(24e). Yield: 332 mg, 0.84 mmol, 38%. 1H NMR (400 MHz, CDCl3): δ 7.01 (d, J = 8.7 Hz, 2H,
2 x CHar), 6.73 (d, J = 8.7 Hz, 2H, 2 x CHar), 5.96 (s, 2H, 2 x CH), 3.40 (q, J = 7.0 Hz, 4H, 2 x
NCH2), 2.54 (s, 6H, 2 x CH3), 1.51 (s, 6H, 2 x CH3), 1.19 (t, J = 7.0 Hz, 6H, 2 x CH3).
13C NMR
(101 MHz, CDCl3): δ 154.68, 148.28, 143.38, 132.38, 129.02, 121.27, 120.90, 112.04, 44.47, 14.86,
14.69, 12.51. FT-IR (thin film) v 2924, 2878, 1726, 1603, 1501, 1466, 1265, 1192, 1044, 970, 814
cm−1. ESI-HRMS (m/z): calcd. for [C23H28BF2N3 + H]
+ 396.24171; obsd. 396.24170.
O
OH
4-(propargyloxy)-benzaldehyde (25). 30 4-hydroxybenzaldehyde (6.1 g, 50 mmol) was
dissolved in acetone (250 mL). Potassium carbonate (9.7 g, 70 mmol, 1.4 eq) was
added and the mixture was refluxed for 30 minutes before propargylbromide (11.1 mL,
100 mmol, 2 eq) was added. After 2 h of refluxing, the solvent was evaporated in
vacuo. The residue was dissolved in water and extracted with EtOAc (4 x 75 mL).
The combined organic layers were washed with water and brine, dried over MgSO4,
filtered and concentrated under reduced pressure. The crude mixture was purified by silica column
chromatography (0 → 10% EtOAc in toluene) resulting in compound 25 in 98% yield (7.8 g, 48.9
mmol). R f = 0.8 (5:1 toluene:EtOAc) 1H NMR (400 MHz, CDCl3): δ 9.91 (s, 1H, HCO), 7.93 -
7.80 (m, 2H, 2 x CHar), 7.10 (d, J = 7.2 Hz, 2H, 2 x CHar), 4.79 (s, 2H, CH2), 2.58 (s, 1H, CH).
13C NMR (101 MHz, CDCl3): δ 190.91, 162.47, 132.02, 130.71, 115.29, 109.74, 77.66, 76.50, 56.07.
FT-IR (thin film) v 3205, 2121, 1678, 1600, 1573, 1238, 1168, 1006, 825, 651 cm−1. ESI-HRMS
(m/z): calcd. for [C10H8O2 + H]




4-(3-chloropropoxy)benzaldehyde (26). To a solution of 4-hydroxybenzaldehyde (6.1 g,
50 mmol) in acetone (50 mL) K2CO3 (8.1 g, 55 mmol, 1.1 eq) was added and the solution
was heated to reflux. After 30 minutes 1-bromo-3-chloropropane (5.45 mL, 55 mmol, 1.1
eq) was added and the mixture was refluxed overnight. The solvent was evaporated in
vacuo, the residue dissolved in EtOAc, washed with water, dried (MgSO4), filtered and
concentrated. Silica column chromatography (0 → 10% EtOAc in PE) afforded pure
compound 26 (9.76 g, 49 mmol) as an oil in 98% yield. R f = 0.7 (3:1 PE:EtOAc). 1H
NMR (400 MHz, CDCl3): δ 9.89 (s, 1H, COH), 7.99 - 7.70 (m, 2H, 2 x CHar), 7.10 -
6.87 (m, 2H, 2 x CHar), 4.21 (t, J = 5.9 Hz, 2H, CH2), 3.76 (t, J = 6.2 Hz, 2H, CH2), 2.28 (p, J =
6.0 Hz, 2H, CH2).
13C NMR (101 MHz, CDCl3): δ 190.87, 163.80, 132.10, 130.19, 114.85, 64.70,




4-(3-azidopropoxy)benzaldehyde (27). 31 Compound 26 (9.65 g, 48.7 mmol) was dis-
solved in DMF (50 mL). Sodium azide ( 3.9 g, 60 mmol, 1.2 eq) was added and the
mixture heated to 95 ◦C for 16 h. The solvent was evaporated under reduced pressure,
the residue was taken up in DCM (50 mL), washed with water and brine, dried over
MgSO4, filtered and concentrated in vacuo. The crude product was purified by silica co-
lumn chromatography (0 → 13% EtOAc in PE) resulting in compound 27 as a yellowish
oil in 88% yield (8.87 g, 43 mmol). R f = 0.55 (4:1 PE:EtOAc). 1H NMR (400 MHz,
CDCl3): δ 9.86 (s, 1H, COH), 7.82 (d, textitJ = 7.9 Hz, 2H, 2 x CHar), 6.99 (d, J = 7.8
Hz, 2H, 2 x CHar), 4.12 (d, J = 5.4 Hz, 2H, CH2), 3.53 (d, J = 6.0 Hz, 2H, CH2), 2.08 (d, J =
5.8 Hz, 2H, CH2).
13C NMR (101 MHz, CDCl3): δ 190.62, 163.56, 131.84, 129.95, 114.63, 64.81,
47.91, 28.45. FT-IR (thin film) v 2094 (N3), 1684, 1598, 1576, 1508, 1250, 1157 cm
−1. ESI-HRMS
(m/z): calcd. for [C10H11N3O2 + H]







4-((1-methylacetate)oxy)-benzaldehyde (28). 32 To a solution of 4-hydroxybenzaldehyde
(6.1 g, 50 mmol) in acetone (125 mL) potassium carbonate (11 g, 80 mmol, 1.6 eq)
was added and the mixture was stirred vigorously. Methylbromoacetate (5.7 mL, 60
mmol, 1.2 eq) was added and the mixture was stirred for 3.5 h at room temperature.
The mixture was concentrated in vacuo, dissolved in EtOAc, washed with H2O, dried
(Na2SO4), filtered and concentrated under reduced pressure yielding the product as a colorless oil
that solidified over time (9.7 g, 50 mmol, quant). R f = 0.4 (6:1 toluene:EtOAc). 1H NMR (400
MHz, CDCl3): δ 9.90 (s, 1H, HCO), 7.85 (d, J = 8.8 Hz, 2H, 2 x CHar), 7.01 (d, J = 8.8 Hz, 2H,
2 x CHar), 4.73 (s, 2H, CH2), 3.82 (s, 3H, CH3).
13C NMR (101 MHz, CDCl3): δ 190.68, 168.50,
162.53, 131.97, 130.78, 114.87, 65.08, 52.45. FT-IR (thin film) v 2959, 1749, 1693, 1682, 1600,


















General procedure for the synthesis of monofunctional BODIPYs
(29 and 30a-e).
BODIPY 24a-e (∼0.15 mmol) was dissolved in dry ethanol (0.7 mL).
Benzaldehyde 25 or 27 (1 eq) was added, followed by acetic acid
(10 eq) and pyrrolidine (10 eq). The mixture was put under an ar-
gon atmosphere before it was subjected to microwave irradiation (10
min, 130 ◦C, 1 min pre-stirring). After removal of the solvent under
reduced pressure the mixture was purified by silica column chroma-
tography (2 (starting material) → 4 (product) → 10% (double sub-
stituted) acetone in PE) In most cases 40-50% unreacted starting
material could be recovered. Mono-substituted products compound-
pHBDPalka-e and 30a-e were crystallized from DCM/hexanes to give
purple crystals. R f = 0.35 (4:1 PE: EtOAc)
1, 5, 7-Trimethyl-3-[4-(propargyloxy)styryl] -8-phenyl-4,4-difluoro-4-bora-3a,4a-diaza-s-indacene
(29a). Yield: 16 mg, 0.035 mmol, 23%. 1H NMR (400 MHz, CDCl3): δ 7.55 (s, 3H, 2 x CHar,
CH=), 7.48 (s, 3H, 3 x CHar), 7.30 (s, 2H, 2 x CHar ), 7.19 (d, J = 15.9 Hz, 1H, CH=), 6.98 (s,
2H, 2 x CHar), 6.58 (s, 1H, CH), 6.00 (s, 1H, CH), 4.72 (s, 2H, CH2), 2.59 (s, 3H, CH3), 2.54 (s,
1H, CH), 1.42 (s, 3H, CH3), 1.38 (s, 3H, CH3).
13C NMR (101 MHz, CDCl3): δ 158.24, 154.95,
153.11, 142.52, 140.17, 135.66, 135.13, 132.80, 131.74, 130.26, 129.08, 128.92, 128.21, 121.18,
117.56, 117.46, 115.19, 78.26, 75.80, 55.86, 14.72, 14.60, 14.36. FT-IR (thin film) v 2965, 1597,
1535, 1493, 1296, 1196, 1173, 938, 725 cm−1. ESI-HRMS (m/z): calcd. for [C29H25BF2N2O +
H]+ 467.21008; obsd. 467.20989.
1, 5, 7-Trimethyl-3-[4-(propargyloxy)styryl] -8-[4-(N,N-dimethylamino)phenyl] -4,4-difluoro-4-bo-
ra-3a,4a-diaza-s-indacene (29b). Yield: 16 mg, 0.031 mmol, 21%. 1H NMR (400 MHz, CDCl3):
δ 7.61 - 7.51 (m, 3H, 2 x CHar, CH=), 7.17 (d, J = 16.3 Hz, 1H, CH=), 7.08 (d, J = 8.6 Hz,
2H, 2 x CHar), 6.97 (d, J = 8.7 Hz, 2H, 2 x CHar), 6.78 (d, J = 8.6 Hz, 2H, 2 x CHar), 6.58
(s, 1H, CH), 5.99 (s, 1H, CH), 4.72 (d, J = 2.3 Hz, 2H, CH2), 3.02 (s, 6H, 2 x NCH3), 2.58 (s,
3H, CH3), 2.54 (s, 1H, CH), 1.53 (s, 3H, CH3), 1.50 (s, 3H, CH3).
13C NMR (101 MHz, CDCl3):
δ 158.23, 154.54, 152.62, 150.81, 142.89, 142.79, 141.86, 135.18, 133.70, 132.68, 130.55, 129.09,
128.96, 122.44, 121.00, 117.92, 117.22, 115.30, 112.44, 78.43, 75.90, 56.01, 40.49, 15.09, 14.86.
FT-IR (thin film) v 2887, 1614, 1523, 1462, 1232, 1198, 1157, 1045, 818 cm−1. ESI-HRMS (m/z):
calcd. for [C31H30BF2N3O + H]
+ 510.25228; obsd. 510.25240.
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1, 5, 7-Trimethyl-3-[4-(propargyloxy)styryl] -8-[4-(N,N-ethylmethylamino)phenyl] -4,4-difluoro-4-
bora-3a,4a-diaza-s-indacene (29c). Yield: 15 mg, 0.029 mmol, 19%. 1H NMR (400 MHz, CDCl3):
δ 7.61 - 7.50 (m, 3H, 2 x CHar, CH=), 7.17 (d, J = 16.3 Hz, 1H, CH=), 7.06 (d, J = 8.5 Hz, 2H,
2 x CHar), 6.97 (d, J = 8.6 Hz, 2H, 2 x CHar), 6.77 (d, J = 8.6 Hz, 2H, 2 x CHar), 6.58 (s, 1H,
CH), 5.99 (s, 1H, CH), 4.72 (d, J = 2.0 Hz, 2H, CH2), 3.46 (q, J = 6.9 Hz, 2H, NCH2), 2.96 (s,
3H, NCH3), 2.58 (s, 3H, CH3), 2.54 (s, 1H, CH), 1.55 (s, 3H, CH3), 1.51 (s, 3H, CH3), 1.16 (t,
J = 7.0 Hz, 3H, CH3).
13C NMR (101 MHz, CDCl3): δ 158.21, 154.48, 152.56, 149.50, 142.88,
142.80, 141.97, 135.14, 133.70, 132.70, 130.55, 129.18, 128.94, 122.05, 120.98, 117.91, 117.21,
115.28, 112.46, 78.43, 75.90, 55.99, 46.93, 37.53, 15.07, 14.84, 11.19. FT-IR (thin film) v 2924,
1734, 1463, 1373, 1265, 1242, 1045, 734, 704 cm−1. ESI-HRMS (m/z): calcd. for [C32H32BF2N3O
+ H]+ 524.26793; obsd. 524.26814.
1, 5, 7-Trimethyl-3-[4-(propargyloxy)styryl] -8-[4-(piperidino)phenyl]-4,4-difluoro-4-bora-3a,4a-di-
aza-s-indacene (29d). Yield: 11 mg, 0.02 mmol, 16%. 1H NMR (400 MHz, CDCl3): δ 7.64 - 7.54
(m, 3H, 2 x CHar, CH=), 7.21 (d, J = 16.3 Hz, 1H, CH=), 7.13 (d, J = 8.6 Hz, 2H, 2 x CHar),
7.06 - 6.97 (m, 4H, 4 x CHar), 6.60 (s, 1H, CH), 6.02 (s, 1H, CH), 4.75 (d, J = 2.3 Hz, 2H, CH2),
3.31 - 3.21 (m, 4H, 2 x NCH2), 2.61 (s, 3H, CH3), 2.57 (t, J = 2.3 Hz, 1H, CH), 1.82 - 1.72 (m,
4H, 2 x CH2), 1.69 - 1.60 (m, 2H, CH2), 1.55 (s, 3H, CH3), 1.51 (s, 3H, CH3).
13C NMR (101
MHz, CDCl3): δ 158.12, 154.53, 152.63, 152.45, 142.71, 141.24, 135.20, 133.31, 132.34, 130.36,
128.88, 128.84, 124.91, 120.94, 117.70, 117.17, 116.19, 115.15, 78.28, 75.79, 55.86, 50.11, 25.65,
24.26, 14.91, 14.67. FT-IR (thin film) v 2926, 1735, 1458, 1373, 1236, 1157, 1045, 985, 736 cm−1.
ESI-HRMS (m/z): calcd. for [C34H34BF2N3O + H]
+ 550.28358; obsd. 550.28326.
1, 5, 7-Trimethyl-3-[4-(propargyloxy)styryl] -8-[4-(N,N-diethylamino)phenyl] -4,4-difluoro-4-bora-
3a,4a-diaza-s-indacene (29e). Yield: 22 mg, 0.041 mmol, 27%. 1H NMR (400 MHz, CDCl3): δ
7.61 - 7.53 (m, 3H, 2 x CHar, CH=), 7.17 (d, J = 16.3 Hz, 1H, CH=), 7.03 (d, J = 8.4 Hz, 2H, 2
x CHar), 6.97 (d, J = 8.5 Hz, 2H, 2 x CHar), 6.74 (d, J = 8.5 Hz, 2H, 2 x CHar), 6.58 (s, 1H, CH),
5.99 (s, 1H, CH), 4.72 (d, J = 1.8 Hz, 2H, CH2), 3.40 (q, J = 7.0 Hz, 4H, 2 x NCH2), 2.58 (s, 3H,
CH3), 2.54 (s, 1H, CH), 1.56 (s, 3H, CH3), 1.53 (s, 3H, CH3), 1.20 (t, J = 7.0 Hz, 6H, 2 x CH3).
13C NMR (101 MHz, CDCl3): δ 158.22, 154.44, 152.51, 148.34, 142.91, 142.81, 142.17, 135.07,
133.74, 132.75, 130.60, 129.28, 128.94, 121.48, 120.97, 117.97, 117.19, 115.31, 112.10, 111.87,
78.45, 75.89, 56.01, 44.50, 15.10, 14.88, 12.54. FT-IR (thin film) v 2974, 1604, 1487, 1196, 1159,
986, 808 cm−1. ESI-HRMS (m/z): calcd. for [C33H34BF2N3O + H]
+ 538.28358; obsd. 538.28383.
1, 5, 7-Trimethyl-3-[4-((3-azidopropyl)oxy)styryl] -8-phenyl-4,4-difluoro-4-bora-3a,4a-diaza-s-in-
dacene (30a). Yield: 26 mg, 0.051 mmol, 35%. 1H NMR (400 MHz, CDCl3): δ 7.62 - 7.42
(m, 6H, 5 x CHar, CH=), 7.33 - 7.27 (m, 2H, 2 x CHar), 7.19 (d, J = 16.3 Hz, 1H, CH=), 6.89 (d,
J = 8.5 Hz, 2H, 2 x CHar), 6.58 (s, 1H, CH), 5.99 (s, 1H, CH), 4.08 (t, J = 5.9 Hz, 2H, CH2), 3.53
(t, J = 6.6 Hz, 2H, CH2), 2.59 (s, 3H, CH3), 2.11 - 2.01 (m, 2H, CH2), 1.42 (s, 3H, CH3), 1.38 (s,
3H, CH3).
13C NMR (101 MHz, CDCl3): δ 159.63, 154.89, 153.46, 142.74, 142.51, 140.21, 136.07,
135.29, 132.97, 131.83, 129.78, 129.21, 129.18, 129.05, 128.37, 121.26, 117.61, 117.32, 114.90,
64.76, 48.36, 28.91, 14.84, 14.73, 14.47. FT-IR (thin film) v 2927, 2097 (N3), 1599, 1537, 1497,
1196, 1173, 1157, 986 cm−1. ESI-HRMS (m/z): calcd. for [C29H28BF2N5O + H]
+ 512.24277;
obsd. 512.24259.
1, 5, 7-Trimethyl-3-[4-((3-azidopropyl)oxy)styryl] -8-[4-(N,N-dimethylamino)phenyl] -4,4-difluoro-
4-bora-3a,4a-diaza-s-indacene (30b). Yield: 16 mg, 0.029 mmol, 20%. 1H NMR (400 MHz, CDCl3):
δ 7.59 - 7.48 (m, 3H, 2 x CHar , CH=), 7.17 (d, J = 16.3 Hz, 1H, CH=), 7.08 (d, J = 8.6 Hz, 2H,
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2 x CHar), 6.88 (d, J = 8.6 Hz, 2H, 2 x CHar), 6.78 (d, J = 8.6 Hz, 2H, 2 x CHar), 6.57 (s, 1H,
CH), 5.99 (s, 1H, CH), 4.08 (t, J = 5.9 Hz, 2H, CH2), 3.53 (t, J = 6.6 Hz, 2H, CH2), 3.02 (s, 6H,
2 x NCH3), 2.59 (s, 3H, CH3), 2.11 - 1.99 (m, 2H, CH2), 1.53 (s, 3H, CH3), 1.50 (s, 3H, CH3).
13C
NMR (101 MHz, CDCl3): δ 159.47, 154.33, 152.81, 150.80, 142.85, 142.73, 141.76, 135.45, 133.69,
132.61, 129.90, 129.09, 129.07, 122.45, 120.93, 117.51, 117.23, 114.85, 112.43, 64.73, 48.36, 40.46,
28.90, 15.08, 14.82. FT-IR (thin film) v 2926, 2096 (N3), 1600, 1537, 1524, 1494, 1196, 1173, 1159,
986 cm−1. ESI-HRMS (m/z): calcd. for [C31H33BF2N6O + H]
+ 555.28497; obsd. 555.28508.
1, 5, 7-Trimethyl-3-[4-((3-azidopropyl)oxy)styryl] -8-[4-(N,N-ethylmethylamino)phenyl] -4,4-diflu-
oro-4-bora-3a,4a-diaza-s-indacene (30c). Yield: 19 mg, 0.033 mmol, 22%. 1H NMR (400 MHz,
CDCl3): δ 7.60 - 7.49 (m, 3H, 2 x CHar , CH=), 7.17 (d, J = 16.3 Hz, 1H, CH=), 7.06 (d, J =
8.5 Hz, 2H, 2 x CHar), 6.88 (d, J = 8.6 Hz, 2H, 2 x CHar), 6.77 (d, J = 8.6 Hz, 2H, 2 x CHar),
6.58 (s, 1H, CH), 5.99 (s, 1H, CH), 4.08 (t, J = 5.9 Hz, 2H, CH2), 3.53 (t, J = 6.6 Hz, 2H, CH2),
3.46 (q, J = 7.0 Hz, 2H, NCH2), 2.96 (s, 3H, NCH3), 2.59 (s, 3H, CH3), 2.06 (m, 2H, CH2), 1.55
(s, 3H, CH3), 1.51 (s, 3H, CH3), 1.16 (t, J = 7.0 Hz, 3H, CH3).
13C NMR (101 MHz, CDCl3):
δ 159.48, 154.30, 152.78, 149.53, 142.86, 142.75, 141.89, 135.42, 133.74, 132.66, 129.93, 129.21,
129.07, 122.10, 120.93, 117.55, 117.23, 114.87, 112.47, 64.75, 48.37, 46.94, 37.53, 28.92, 15.08,
14.83, 11.19. FT-IR (thin film) v 2926, 2096 (N3), 1601, 1537, 1524, 1510, 1495, 1198, 1173, 1159,
986 cm−1. ESI-HRMS (m/z): calcd. for [C32H35BF2N6O + H]
+ 569.30062; obsd. 569.30086.
1, 5, 7-Trimethyl-3-[4-((3-azidopropyl)oxy)styryl] -8-[4-(piperidino)phenyl] -4,4-difluoro-4-bora-
3a,4a-diaza-s-indacene (30d). Yield: 12 mg, 0.020 mmol, 17%. 1H NMR (400 MHz, CDCl3):
δ 7.60 - 7.49 (m, 3H, 2 x CHar, CH=), 7.17 (d, J = 16.3 Hz, 1H, CH=), 7.10 (d, J = 8.6 Hz, 2H,
2 x CHar), 7.01 (d, J = 8.7 Hz, 2H, 2 x CHar), 6.89 (d, J = 8.7 Hz, 2H, 2 x CHar), 6.57 (s, 1H,
CH), 5.99 (s, 1H, CH), 4.08 (t, J = 5.9 Hz, 2H, CH2), 3.53 (t, J = 6.6 Hz, 2H, CH2), 3.27 - 3.19
(m, 4H, 2 x NCH2), 2.58 (s, 3H, CH3), 2.11 - 2.00 (m, 2H, CH2), 1.79 - 1.70 (m, 4H, 2 x CH2),
1.64 - 1.59 (m, 2H, CH2), 1.52 (s, 3H, CH3), 1.48 (s, 3H, CH3).
13C NMR (101 MHz, CDCl3):
δ 159.50, 154.45, 152.95, 152.57, 142.83, 142.69, 141.27, 135.60, 133.50, 132.41, 129.86, 129.09,
129.03, 125.05, 121.00, 117.45, 117.31, 116.32, 114.86, 64.73, 50.25, 48.36, 28.91, 25.78, 24.39,
15.04, 14.83, 14.78. FT-IR (thin film) v 2927, 2096 (N3), 1600, 1539, 1496, 1197, 1172, 985 cm
−1.
ESI-HRMS (m/z): calcd. for [C34H37BF2N6O + H]
+ 595.31627; obsd. 595.31622.
1, 5, 7-Trimethyl-3-[4-((3-azidopropyl)oxy)styryl] -8-[4-(N,N-diethylamino)phenyl] -4,4-difluoro-4-
bora-3a,4a-diaza-s-indacene (30e). Yield: 18 mg, 0.031 mmol, 21%. 1H NMR (400 MHz, CDCl3):
δ 7.59 - 7.50 (m, 3H, 2 x CHar , CH=), 7.17 (d, J = 16.3 Hz, 1H, CH=), 7.03 (d, J = 8.6 Hz, 2H, 2
x CHar), 6.88 (d, J = 8.6 Hz, 2H, 2 x CHar), 6.74 (d, J = 8.6 Hz, 2H, 2 x CHar), 6.58 (s, 1H, CH),
5.99 (s, 1H, CH), 4.07 (t, J = 5.9 Hz, 2H, CH2), 3.53 (t, J = 6.6 Hz, 2H, CH2), 3.40 (q, J = 7.0
Hz, 4H, 2 x NCH2), 2.59 (s, 3H, CH3), 2.11 - 2.02 (m, 2H, CH2), 1.56 (s, 3H, CH3), 1.53 (s, 3H,
CH3), 1.20 (t, J = 7.0 Hz, 6H, 2 x CH3).
13C NMR (101 MHz, CDCl3): δ 159.43, 154.19, 152.67,
148.29, 142.85, 142.74, 142.05, 135.34, 133.75, 132.67, 129.90, 129.25, 129.05, 121.44, 120.88,
117.52, 117.18, 114.83, 112.04, 64.71, 48.35, 44.48, 28.90, 15.12, 14.87, 12.52. FT-IR (thin film) v
2930, 2097 (N3), 1601, 1540, 1522, 1510, 1497, 1198, 1173, 1159, 988 cm
−1. ESI-HRMS (m/z):
calcd. for [C33H37BF2N6O + H]
+ 583.31627; obsd. 583.31633.
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a: R1= H
b: R1= Me2N








O General procedure for the synthesis of monofunctional BODIPYs (31a-
e). BODIPY 24a-e (∼0.15 mmol) was dissolved in dry methanol (0.7
mL). Benzaldehyde 28 (1 eq) was added, followed by acetic acid (10 eq)
and pyrrolidine (10 eq). The mixture was put under an argon atmosphere
before it was subjected to microwave irradiation (10 min, 110 ◦C, 1
min pre-stirring). After removal of the solvent under reduced pressure
the mixture was purified by silica column chromatography (2 (starting
material) → 4 (product) → 10% (double substituted) acetone in PE)
In most cases 40-50% unreacted starting material could be recovered.
Mono-substituted products 31a-e were crystallized from DCM/hexanes
to give purple crystals. R f = 0.30 (4:1 PE: EtOAc)
1, 5, 7-Trimethyl-3-[4-((1-methylacetate)oxy)styryl] -8-phenyl-4,4-difluoro-4-bora-3a,4a-diaza-s-
indacene (31a). Yield: 16 mg, 0,032 mmol, 21%. 1H NMR (400 MHz, CDCl3): δ 7.60 - 7.52 (m,
3H, 2 x CHar , CH=), 7.51 - 7.45 (m, 3H, 3 x CHar), 7.32 - 7.28 (m, 2H, 2 x CHar), 7.18 (d, J = 16.3
Hz, 1H, CH=), 6.91 (d, J = 8.8 Hz, 2H, 2 x CHar), 6.58 (s, 1H, CH), 6.00 (s, 1H, CH), 4.66 (s, 2H,
CH2), 3.82 (s, 3H, OCH3), 2.59 (s, 3H, CH3), 1.42 (s, 3H, CH3), 1.38 (s, 3H, CH3).
13C NMR (101
MHz, CDCl3): δ 169.24, 158.52, 155.17, 153.12, 142.73, 142.65, 140.35, 135.60, 135.22, 132.91,
131.88, 130.62, 129.22, 129.13, 129.06, 128.32, 121.35, 117.82, 117.58, 115.02, 65.42, 52.48, 14.85,
14.72, 14.49. FT-IR (thin film) v 2924, 1767 (C=O), 1597, 1535, 1492, 1196, 1173, 1155, 1061,
976 cm−1. ESI-HRMS (m/z): calcd. for [C29H27BF2N2O3 + H]
+ 501.21556; obsd. 501.21548.
1, 5, 7-Trimethyl-3-[4-((1-methylacetate)oxy)styryl] -8-[4-(N,N-dimethylamino)phenyl] -4,4-diflu-
oro-4-bora-3a,4a-diaza-s-indacene (31b). Yield: 12 mg, 0.022 mmol, 17%. 1H NMR (400 MHz,
CDCl3): δ 7.60 - 7.50 (m, 3H, 2 x CHar, CH=), 7.16 (d, J = 16.3 Hz, 1H, CH=), 7.08 (d, J =
8.6 Hz, 2H, 2 x CHar), 6.90 (d, J = 8.7 Hz, 2H, 2 x CHar), 6.78 (d, J = 8.6 Hz, 2H, 2 x CHar),
6.57 (s, 1H, CH), 5.99 (s, 1H, CH), 4.67 (s, 2H, CH2), 3.82 (s, 3H, OCH3), 3.02 (s, 6H, 2 x
NCH3), 2.58 (s, 3H, CH3), 1.53 (s, 3H, CH3), 1.50 (s, 3H, CH3).
13C NMR (101 MHz, CDCl3):
δ 169.18, 158.25, 154.50, 152.28, 150.67, 142.82, 142.60, 141.78, 134.85, 130.66, 128.94, 128.91,
122.28, 120.90, 117.93, 117.06, 114.87, 112.30, 65.32, 52.35, 40.34, 14.95, 14.73. FT-IR (thin film)
v 2916, 1767 (C=O), 1597, 1508, 1485, 1194, 1171, 1080, 986 cm−1. ESI-HRMS (m/z): calcd. for
[C31H32BF2N3O3 + H]
+ 544.25776; obsd. 544.25758.
1, 5, 7-Trimethyl-3-[4-((1-methylacetate)oxy)styryl] -8-[4-(N,N-ethylmethylamino)phenyl] -4,4-di-
fluoro-4-bora-3a,4a-diaza-s-indacene (31c). Yield: 9 mg, 0.017 mmol, 13%. 1H NMR (400 MHz,
CDCl3): δ 7.60 - 7.51 (m, 3H, 2 x CHar, CH=), 7.16 (d, J = 16.3 Hz, 1H, CH=), 7.06 (d, J = 8.5
Hz, 2H, 2 x CHar), 6.90 (d, J = 8.6 Hz, 2H, 2 x CHar), 6.77 (d, J = 8.6 Hz, 2H, 2 x CHar), 6.57
(s, 1H, CH), 5.99 (s, 1H, CH), 4.67 (s, 2H, CH2), 3.82 (s, 3H, OCH3), 3.46 (q, J = 7.0 Hz, 2H,
NCH2), 2.97 (s, 3H, NCH3), 2.58 (s, 3H, CH3), 1.55 (s, 3H, CH3), 1.52 (s, 3H, CH3), 1.16 (t, J =
7.0 Hz, 3H, CH3).
13C NMR (101 MHz, CDCl3): δ 169.30, 158.38, 154.60, 152.45, 149.52, 142.99,
142.77, 142.03, 134.95, 130.80, 129.18, 129.04, 122.04, 121.03, 118.08, 117.20, 115.00, 112.46,
65.46, 52.49, 46.94, 37.54, 15.07, 14.85, 11.20. FT-IR (thin film) v 2924, 1761 (C=O), 1521, 1508,





1, 5, 7-Trimethyl-3-[4-((1-methylacetate)oxy)styryl] -8-[4-(piperidino)phenyl] -4,4-difluoro-4-bo-
ra-3a,4a-diaza-s-indacene (31d). Yield: 17 mg, 0.029 mmol, 23%. 1H NMR (400 MHz, CDCl3): δ
7.60 - 7.51 (m, 3H, 2 x CHar , CH=), 7.17 (d, J = 16.3 Hz, 1H, CH=), 7.10 (d, J = 8.6 Hz, 2H, 2
x CHar), 7.01 (d, J = 8.7 Hz, 2H, 2 x CHar), 6.90 (d, J = 8.7 Hz, 2H, 2 x CHar), 6.57 (s, 1H, CH),
5.99 (s, 1H, CH), 4.67 (s, 2H, CH2), 3.82 (s, 3H, OCH3), 3.27 - 3.19 (m, 4H, 2 x NCH2), 2.58 (s,
3H, CH3), 1.75 (m, 4H, 2 x CH2), 1.66 - 1.59 (m, 2H, CH2), 1.52 (s, 3H, CH3), 1.48 (s, 3H, CH3).
13C NMR (101 MHz, CDCl3): δ 169.28, 158.43, 154.79, 152.60, 142.94, 142.76, 141.45, 135.14,
132.52, 130.77, 129.07, 129.02, 125.03, 121.12, 118.03, 117.29, 116.32, 115.02, 65.47, 52.49, 50.25,
25.79, 24.41, 15.03, 14.81. FT-IR (thin film) v 2924, 1764 (C=O), 1595, 1489, 1298, 1157, 1080,
989 cm−1. ESI-HRMS (m/z): calcd. for [C34H36BF2N3O3 + H]
+ 584.28906; obsd. 584.28900.
1, 5, 7-Trimethyl-3-[4-((1-methylacetate)oxy)styryl] -8-[4-(N,N-diethylamino)phenyl] -4,4-difluo-
ro-4-bora-3a,4a-diaza-s-indacene (31e). Yield: 11 mg, 0.019 mmol, 15%. 1H NMR (400 MHz,
CDCl3): δ 7.61 - 7.49 (m, 3H, 2 x CHar , CH=), 7.16 (d, J = 16.3 Hz, 1H, CH=), 7.03 (d, J = 8.6
Hz, 2H, 2 x CHar), 6.90 (d, J = 8.7 Hz, 2H, 2 x CHar), 6.74 (d, J = 8.7 Hz, 2H, 2 x CHar), 6.57
(s, 1H, CH), 5.99 (s, 1H, CH), 4.67 (s, 2H, CH2), 3.82 (s, 3H, OCH3), 3.40 (q, J = 7.0 Hz, 4H, 2 x
NCH2), 2.58 (s, 3H, CH3), 1.56 (s, 3H, CH3), 1.53 (s, 3H, CH3), 1.20 (t, J = 7.0 Hz, 6H, 2 x CH3).
13C NMR (101 MHz, CDCl3): δ 169.29, 158.37, 154.52, 152.37, 148.33, 142.98, 142.22, 134.88,
130.82, 129.26, 129.03, 121.43, 121.00, 118.11, 117.17, 115.00, 112.08, 65.46, 52.48, 44.50, 15.10,
14.89, 12.53. FT-IR (thin film) v 2924, 1765 (C=O), 1597, 1524, 1510, 1492, 1194, 1159, 1078,
988 cm−1. ESI-HRMS (m/z): calcd. for [C33H36BF2N3O3 + H]










styryl] -8-[4-(N,N-diethylamino) phenyl] -4,4-difluoro-4-bora-3a,4a-di-
aza-s-indacene (32). BODIPY 29e (16 mg, 0.03 mmol) and benzalde-
hyde 28 (29 mg, 0.15 mmol, 5 eq) were dissolved in methanol (0.5 mL)
and acetic acid (17 µL, 0.3 mmol, 10 eq) and pyrrolidine (25 µL, 0.3
mmol, 10 eq) were added. The mixture was put under an argon atmo-
sphere before it was subjected to microwave irradiation (10 min, 110 ◦C,
1 min pre-stirring). After removal of the solvent under reduced pres-
sure the mixture was purified by repeated silica column chromatography
(3 (starting material) → 10% (product) acetone in PE and 0 → 0.25%
methanol in DCM). After crystallization (DCM/hexanes) product 32 was
obtained as blue crystals in 42% yield (9 mg, 0.013 mmol). R f = 0.7
(1:1 PE:EtOAc). 1H NMR (400 MHz, CDCl3): δ 7.68 - 7.54 (m, 6H, 4 x CHar , 2 x CH=), 7.19 (d,
J = 16.3, 1H, CH=), 7.18 (d, J = 16.3, 1H, CH=), 7.05 (d, J = 8.6 Hz, 2H, 2 x CHar), 7.01 (d, J
= 8.7 Hz, 2H, 2 x CHar), 6.93 (d, J = 8.7 Hz, 2H, 2 x CHar), 6.75 (d, J = 8.7 Hz, 2H, 2 x CHar),
6.60 (s, 2H, 2 x CH), 4.74 (d, J = 2.3 Hz, 2H, CH2), 4.68 (s, 2H, CH2), 3.83 (s, 3H, OCH3), 3.41
(q, J = 7.0 Hz, 4H, 2 x NCH2), 2.55 (t, J = 2.3 Hz, 1H, CH), 1.58 (s, 6H, 2 x CH3), 1.21 (t, J
= 7.0 Hz, 6H, 2 x CH3).
13C NMR (101 MHz, CDCl3): δ 169.32, 158.37, 158.22, 152.25, 152.05,
148.31, 142.37, 142.26, 140.48, 135.06, 134.80, 134.19, 130.94, 130.68, 129.49, 129.08, 129.00,
121.55, 118.27, 118.09, 117.31, 115.32, 115.03, 112.05, 78.46, 75.92, 65.47, 56.01, 52.50, 44.51,
15.12, 12.54. FT-IR (thin film) v 2926, 1755 (C=O), 1595, 1510, 1450, 1196, 1157, 986 cm−1.
ESI-HRMS (m/z): calcd. for [C43H42BF2N3O4 + H]
+ 714.33092; obsd. 714.33139.
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1,7-dimethyl-3-[4-(propargyloxy) styryl] -5-[styryl-2,4-disulfonic acid]-
8-[4-(N,N-diethylamino)phenyl] -4,4-difluoro-4-bora-3a,4a-diaza-s-in-
dacene (33). BODIPY 29e (27 mg, 0.05 mmol) was dissolved in ethanol
(0.7 mL). 4-Formyl-1,3-benzenedisulfonic acid, disodium salt hydrate (78
mg, 0.25 mmol, 5 eq) was added followed by acetic acid (41 µL, 0.5
mmol, 10 eq) and pyrrolidine (27 µL, 0.5 mmol, 10 eq). The mixture
was put under an argon atmosphere before it was subjected to microwave
irradiation (10 min, 130 ◦C, 1 min pre-stirring). After removal of the sol-
vent under reduced pressure and co-evaporation with toluene, the mixture
was purified by size exclusion chromatography (Sephadex, methanol) and
crystallization from DCM/hexanes. This yielded blue compound 33 in
12% yield (5 mg, 6 µmol). R f = 0.35 (1:1:1:1 n-BuOH:H2O:EtOAc:AcOH).
1H NMR (400 MHz,
MeOD): δ 10.95 (s, 1H, SO3H), 8.58 - 8.50 (m, 2H, CHar, SO3H ), 8.40 (d, J = 16.2 Hz, 1H, CH=),
8.05 - 7.97 (m, 2H, 2 x CHar), 7.76 (d, J = 16.5 Hz, 1H, CH=), 7.67 - 7.55 (m, 3H, 2 x CHar ,
CH=), 7.41 (d, J = 16.3 Hz, 1H, CH=), 7.14 - 7.04 (m, 4H, 4 x CHar), 6.91 - 6.86 (m, 3H, CHar,
CH), 6.82 (s, 1H, CH), 4.81 (d, J = 1.9 Hz, 2H, CH2), 3.48 (q, J = 7.0 Hz, 4H, 2 x NCH2), 3.01 (t,
J = 2.2 Hz, 1H, CH), 1.65 (s, 3H, CH3), 1.64 (s, 3H, CH3), 1.22 (t, J = 7.0 Hz, 6H, 2 x CH3).
13C
NMR (101 MHz, MeOD): δ 160.15, 154.93, 151.99, 149.83, 144.73, 142.89, 142.49, 137.77, 137.62,
132.98, 131.50, 130.53, 129.92, 128.88, 127.40, 126.79, 126.37, 122.26, 118.93, 116.47, 113.21,
77.02, 56.72, 45.36, 15.25, 15.05, 12.68. FT-IR (thin film) v 3600-3200 (br, OH), 2922, 1599,

























(34). BODIPY 29e (7 mg, 0.013
mmol) and azido-epoxomicin 43 (8 mg,
0.014 mmol, 1.1 eq) were dissolved in
toluene/t-BuOH/H2O (1:1:1 v/v) and
the solution was degassed (sonication)
under argon. Sodium ascorbate (aq
solution, 0.013 mmol, 1 eq) and cop-
per sulfate (aq solution, 0.0013 mmol,
10 mol%) were added and the mixture
was heated to 80 ◦C for 1 hour. TLC
analysis showed complete conversion
of the BODIPY dye, so the mixture was concentrated and purified by silica column chromatography
(0 → 2.5% methanol in DCM). Additional Sephadex size exclusion (methanol) and recrystallization
(DCM/hexanes) purification steps resulted in purple compound 34 in 89% yield (13 mg, 0.011 mmol).
R f = 0.2 (10:1 DCM:methanol). 1H NMR (400 MHz, CDCl3/MeOD): δ 7.95 (s, 1H, CHtrz), 7.60
- 7.50 (m, 3H, 2 x CHar , CH=), 7.21 (d, J = 16.4 Hz, 1H, CH=), 7.05 (d, J = 8.2 Hz, 2H, 2 x
CHar), 7.00 (d, J = 8.3 Hz, 2H, 2 x CHar), 6.78 (d, J = 8.2 Hz, 2H, 2 x CHar), 6.62 (s, 1H, CH),
6.02 (s, 1H, CH), 5.23 (s, 2H, OCH2), 5.15 (q, J = 12.6 Hz, 2H, CH2), 4.54 (d, J = 10.6 Hz, 1H,
CH), 4.26 - 4.18 (m, 2H, 2 x CH), 4.14 - 4.04 (m, 1H, CH), 3.90 (s, 1H, CH), 3.49 - 3.40 (m, 4H, 2
x NCH2), 3.31 (d, J = 4.6 Hz, 1H, CH2-H
a), 2.92 (d, J = 4.6 Hz, 1H, CH2-H
b), 2.57 (s, 3H, CH3),
1.84 (s, 2H, 2 x CH), 1.68 (s, 1H, CH), 1.64 - 1.44 (m, 11H, 3 x CH3, 2 x CH2-H
a), 1.39 - 1.26
(m, 2H, CH2-H
b, OH), 1.21 (t, J = 6.7 Hz, 6H, 2 x CH3), 1.14 (d, J = 6.1 Hz, 4H, CH3 , CH2-H
b
), 0.99 - 0.79 (m, 18H, 6 x CH3).
13C NMR (101 MHz, CDCl3/MeOD): δ 208.46, 171.81, 171.77,
170.32, 165.69, 158.68, 153.99, 152.27, 148.18, 143.73, 142.80, 142.01, 135.06, 133.44, 132.41,
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130.02, 128.93, 128.70, 124.93, 121.05, 120.72, 117.21, 116.97, 114.88, 111.96, 66.84, 61.45, 59.04,
58.09, 57.60, 52.23, 51.92, 50.63, 44.21, 39.15, 36.68, 36.38, 24.97, 24.68, 24.63, 22.98, 20.75,
18.23, 16.45, 15.01, 14.95, 14.66, 14.43, 14.25, 12.03, 10.64, 10.59. ESI-HRMS (m/z): calcd. for
[C60H81BF2N10O8 + H]
+ 1119.63727; obsd. 1119.63914.
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Targeted delivery of Heat shock
protein 70 by sortase-mediated
ligation with a synthetic mannose
receptor-binding ligand1
H
eat shock protein 70 (Hsp70) is a chaperone protein that is expressed in re-
sponse to cellular stress. This chapter presents a sortase-mediated ligation
strategy to target exogenous recombinant Hsp70 to dendritic cells, via the man-
nose receptor (MR). For this, a sortagging nucleophile was synthesized, contain-
ing a BODIPY dye (BDP) for fluorescent visualization and a MR-targeting man-
nose cluster (MC). Using SrtAstaph, recombinant Hsp70-LPETGG was tranformed
into Hsp70-BDP-MC. Successful uptake of this construct by dendritic cells was
demonstrated to be dependent on the mannose receptor, showing the ability of
the mannose cluster to ensure delivery of a large protein into the lysosomal path-
way. Possible applications of targeted Hsp70 lie in the therapeutic intervention
of lysosomal storage disorders, where exogenous Hsp70 could lead to decreased




The family of heat shock proteins (Hsp) functions as molecular chaperones that assist in the
quality control and folding of newly synthesized proteins. 2 Some of the family members
are constitutively expressed such as Hsc70 (heat shock cognate protein), whereas others
such as the 70 kDa protein Hsp70 (also known as Hsp72 or HSPA1A) are expressed in re-
sponse to cellular stress. 3 The protein isoforms are highly conserved across species. For
example, E. coli derived Hsp70, called DnaK, shares an approximate 50% sequence homol-
ogy with the human protein. 4,5 The structure of Hsp70 contains two major domains, an
N-terminal nucleotide binding domain (NBD) of ∼45 kDa that binds ATP and a C-terminal
substrate binding domain (SBD) of ∼25 kDa that binds short peptides as well as the nascent
chain of newly formed proteins. Both domains are connected by a short linker sequence. 5
The ability of Hsp70 to bind and release polypeptide chains is closely linked to its ATPase
activity, and several co-chaperones have been identified that are essential for enhancing
the ATPase activity and thus proper functioning of Hsp70. 2,5,6 While Hsp70 isoforms can
be found in all cellular compartments, the majority of expressed Hsp70/Hsc70 is located in
the cytosol. 5 However, especially in tumor cells, Hsp70 is also found in lysosomes, where
it enhances lysosome stability by preventing lysosomal membrane permeabilization and
subsequent release of cysteine cathepsins into the cytosol. 7,8
Lysosomes are acidic vesicles containing a plethora of lytic enzymes such as proteases,
glycosidases, nucleases, and lipases, and function as the metabolic center of the cell. Lyso-
somal storage disorders (LSD) are a group of rare but severe diseases in which one of the
key enzymes in lipid metabolism is dysfunctioning, leading to accumulation of cellular
constituents in the lysosomes (ie (glyco)lipids in case of lipidoses). 9 As shown schemati-
cally in Figure 4.1A, parts of the plasma membrane, containing glycosphingolipids (GSL),
are engulfed by a variety of processes and transported through the endolysosomal path-
way. Along the pathway, both the pH and the amount of cholesterol in the membrane
decrease, whereas the amount of bis(monoacylglycero)phosphate (BMP, Figure 4.1A,B) in-
creases. 10 Lysosomes are confined by a limiting membrane, which is secured from prote-
olytical degradation by the presence of a glycocalix. Inside the lysosomes, the remains of
the endocytosed plasma membrane (consisting mainly of BMP and GSL) form intralyso-
somal vesicles and the membranes of these vesicles are the main site of GSL catabolism.
Enzymes that are responsible for the breakdown of GSLs are usually water-soluble and
present in the lysosomal lumen. 10,11 BMP, along with sphingolipid activator proteins (Sa-
posins), forms a bridge between the internal membrane containing the substrate and the
hydrolytic enzymes in the lumen, enabling the catalytic breakdown of GSLs. 12–14
A recent study by Kirkegaard et al. has shown that Hsp70 is able to stabilize lyso-
somes by binding with its amino-terminal NBD domain to the negatively charged BMP,
especially at acidic pH (corresponding to the lysosomal environment, Figure 4.1A). They
have shown that this has important implications for at least one of the lysosomal storage
disorders, Niemann-Pick disease (NPD). 16 Treatment of NPD fibroblasts with exogenous
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Figure 4.1: Proposed mechanism of Hsp70 targeting. A) Schematic representation of MR-dependent
uptake and trafficking of Hsp70-BDP-MC. Also shown is the formation of intralysosomal vesicles,
consisting mainly of glycosphingolipids and BMP. Zoom in shows the working model by Petersen et
al. for the Hsp70-mediated stabilization of lysosomes by binding to BMP. 15,16 B) Example structure
of BMP, containing oleic acid residues.
recombinant Hsp70 resulted in the stimulation of acid sphingomyelinase, stabilization of
the lysosomes and reversal of the associated NPD pathology. 15,16 It is not known whether
the lysosomal stabilization of Hsp70 has a beneficial effect on other LSDs as well. It is
not unlikely that this effect exists, either by a general mechanism (stabilization of the lyso-
somes as a whole) or via direct binding interaction between Hsp70 and a lysosomal en-
zyme, thereby stabilizing it to prevent proteolytical degradation. To study this, efficient
uptake of recombinant Hsp70 into the endolysosomal pathway is a requirement. Targeting
of cell surface receptors that are constitutively or ligand-induced internalized, provides a
point of entry into this pathway. In a previous study by Hillaert et al. and a follow-up
study, described in Chapter 2, a synthetic mannose cluster has been used as a targeting
ligand for mannose receptors on dendritic cells and macrophages, enabling the delivery of
cargo attached to the cluster into the lysosomes. 17,18 In Gaucher disease, an LSD where β-
glucocerebrosidase is deficient, macrophage-like cells form the main population of affected
cells (Gaucher cells)and current enzyme replacement therapies use glycan remodeling to
expose mannoses on the enzyme for delivery to the mannose receptor. 19,20
The research described in this chapter is aimed at the delivery of Hsp70 to the lyso-
somes via the mannose receptor, by ligation to the synthetic mannose cluster. For this the
enzymatic ligation method termed ’sortagging’ is used, which employs the bacterial en-
zyme Sortase A (SrtA). 21,22 This approach combines organic synthesis, to create the sortag-
ging nucleophile, with molecular biology to obtain recombinant Hsp70 that contains the
SrtA recognition sequence. Optimization of the sortase reaction is described, followed by
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an investigation of the ability of the synthetic ligand to function as a targeting device for a
macromolecule such as Hsp70 in dendritic cells.
4.2 Results and Discussion
Synthesis. The bacterial enzyme Sortase A (SrtA) catalyzes the transpeptidation between
a glycine nucleophile and a polypeptide substrate containing a C-terminal recognition se-
quence, as shown schematically in Figure 4.2A. 23 The triglycine sortagging nucleophile
35 was synthesized by standard solid-phase peptide (SPPS) procedures and cleaved from
the resin using acidic conditions. Under these conditions, the Boc-protected lysine was
deprotected, whereas the Fmoc group on the N-terminal glycine was still in place. This
allowed for selective modification of the ǫ-amino group of lysine with azido-BODIPY-OSu
36 24 (Scheme 4.1), resulting in Fmoc-protected 37 in 91% yield. This intermediate was de-
protected using DBU in DMF, followed by quenching with HOBt and immediate purifica-
tion by RP-HPLC. The HPLC fractions were lyophilized resulting in the TFA salt of sortase
ligand "GGG-BDP" 38 in 16% yield. Other purification procedures, yielding the free amine,
resulted in significant degradation of the BODIPY dye, whereas the TFA salt proved to be
stable.



























































































Reagents and conditions: [a] N3-BODIPY-OSu 36,
24 DiPEA, DMF, 91%; [b] mannose cluster 20,
CuSO4, sodium ascorbate, DMF/H2O; [c] i) DBU, DMF; ii) RP-HPLC purification, 38: 16%; 40:
24% over 2 steps.
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Alternatively, compound 37 was used in a Cu(I)-catalyzed Huisgen cycloaddition 25,26 with
mannose cluster 20. 17 After Fmoc removal with DBU and RP-HPLC purification, the en-
visaged sortagging ligand "GGG-BDP-MC" 40 was obtained in 24% (two steps).
Sortase-mediated ligation. Sortase A from Staphylococcus aureus lacking the membrane
anchoring domain (SrtAstaph∆59, referred to here as "WT") has been shown to catalyze the
transpeptidation reaction between a triglycine nucleophile and protein in vitro. 27 In case
of C-terminal sortagging, the protein of interest needs to contain the sortase recognition
sequence (LPXTGG, where X can be any amino acid) 28 near its C-terminus. Recombinant
Hsp70 was designed with an LPETGG sortase sequence, followed by a His6 tag for purifica-
tion purposes at its C-terminus. As depicted in Figure 4.2A, reaction of "Hsp70-LPETGG"
with either one of the sortagging nucleophiles 38 or 40 (Scheme 4.1) would result in the




























































Figure 4.2: Optimization of the sortase-mediated ligation of Hsp70 and a triglycine nucleophile.
A) Schematic representation of sortase-mediated ligation of Hsp70-LPETGG with GGG-BDP or GGG-
BDP-MC using either wild-type SrtAstaph-∆59 (WT) or P94S/D160N/K196T triple mutant SrtAstaph
(mut). B) 7.5% SDS-PAGE of the reaction between Hsp70-LPETGG (1 µg, 1 eq), SrtA WT or
mut (5 eq) and GGG-BDP 38 or GGG-BDP-MC 40 (25 eq), 16 h, 37 ◦C. C) 7.5% SDS-PAGE
of Hsp70-LPETGG (1 µg, 1 eq), SrtA WT or mut (5 eq) and GGG-BDP 38 or GGG-BDP-MC
40 (25 eq) samples that were reacted for 65 h at different temperatures. White bands correspond
to the BODIPY fluorescence signal (Cy3), black bands to Coomassie brilliant blue staining (CBB).
Arrowheads: unidentified degradation products.
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formation of fluorescently labeled Hsp70, with (Hsp70-BDP-MC) or without (Hsp70-BDP)
a targeting entity. A recent report by Chen et al. has identified a sortase triple mutant
(P94S/ D160N/ K196T, here referred to as "mut") with enhanced affinity for the LPETGG
sequence and higher catalytic activity allowing for much more efficient transpeptidation. 29
Hsp70-LPETGG, SrtA-WT and SrtA-mut were expressed in E. coli and purified using
nickel-affinity chromatography on an automated AKTA system. Fractions containing the
protein of interest were pooled and buffer exchanged to 50 mM Tris, 150 mM NaCl, pH
8.0. All proteins were sufficiently pure after chromatography to be used directly in the
transpeptidation reaction. The ability of the novel triglycine compounds 38 and 40 to func-
tion as a nucleophile in the sortagging reaction with Hsp70-LPETGG was first tested on
a small scale. Briefly, Hsp70-LPETGG (1 µg, 1 eq) was reacted with GGG-BDP or GGG-
BDP-MC (25 eq) in the presence of SrtA-WT or SrtA-mut for 16 h, 37 ◦C in SrtA reaction
buffer (10µL 50 mM Tris, 150 mM NaCl, 10 mM CaCl2, pH 7.5). The proteins were resolved
on 7.5% SDS-PAGE and the gel slabs scanned for fluorescence of the BODIPY, before total
protein staining with coomassie brilliant blue. As shown in Figure 4.2B, more product was
formed in case of the mutant enzyme (lane 5), compared to wild-type (lane 2), when using
GGG-BDP 38. For the larger nucleophile GGG-BDP-MC 40 it was more difficult to assess
the progress of the reaction, because of similar molecular weights of the starting protein
Hsp70-LPETGG (lane 8) and the product Hsp70-BDP-MC (lanes 3, 6). When the nucle-
ophile was excluded from the reaction mixture (lanes 4 and 7), no reaction was observed in
case of the WT enzyme (lane 4) whereas almost all starting Hsp70-LPETGG was converted
to a lower molecular weight protein by the mutant enzyme (lane 7). The lower molecu-
lar weight protein most likely corresponds to the hydrolyzed Hsp70-LPET-OH, which is
formed by nucleophilic attack of H2O on the SrtA-Hsp70 intermediate. It was also formed
when nucleophile was included in the reaction, as judged by the presence of a lower run-
ning band in lane 6. In case of nucleophile 38 the product and by-product have similar
molecular weights, so these could not be distinguished.
Figure 4.3 shows the proposed mechanism for sortase-mediated ligation. 30 Most of the
steps in this mechanism are equilibria and thus reversible. The only irreversible step is
the hydrolysis reaction, leading to the unwanted Hsp70-LPET-OH as the end-point of the
reaction. For wild-type SrtAstaph, the formation of the acyl-enzyme intermediate is the rate-
limiting step, and water is recognized very poorly as the nucleophile. 30,31 The greater rate
of hydrolysis for the mutant enzyme is likely explained by its enhanced affinity for the
LPXTGG sequence, thereby accelerating the formation of the acyl-enzyme intermediate.
Both loss of selectivity for the nucleophile and slower rates for the transpeptidation reac-
tion might contribute to the increased formation of the hydrolysed product. 29 In order to
increase the amount of product formation for SrtA-WT and decrease the amount of hydrol-
ysis in favor of product formation for SrtA-mut, reactions were performed at different tem-
peratures for longer periods of time (Figure 4.2C). Prolonged (65 h) reaction times at 37 ◦C
with the wildtype enzyme led to degradation of Hsp70, as seen by multiple bands of lower
molecular weight on SDS-PAGE. A similar degradation pattern can be observed in lane 4
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(Figure 4.2C), where no enzyme was present, indicating that it reflects inherent instability
of Hsp70. Remarkably, SrtA-mut was still able to catalyze the transpeptidation reaction
at 4 ◦C, albeit slower than at 16 ◦C. At 16 ◦C, complete reaction of Hsp70-LPETGG with
GGG-BDP was observed, but both the mixture containing GGG-BDP-MC 40 or no nucle-
ophile again showed a lower running band, corresponding to hydrolysis. Since all residues
C-terminally of the threonine of the sortase sequence are removed in the transpeptidation
or hydrolysis reaction, only the starting Hsp70-LPETGG contained a His6-tag. To be able
to purify the envisaged product Hsp70-BDP-MC, removal of unreacted starting protein
with nickel-affinity chromatography seemed more promising than removal of untagged
Hsp70-LPET-OH by for instance size exclusion chromatography. Therefore, wildtype sor-
tase was chosen as the most convenient enzyme for large scale transpeptidation reactions,




















































Figure 4.3: Proposed mechanism for the SrtA-mediated ligation of a target protein containing the
C-terminal LPXTGG recognition sequence and a glycine nucleophile. 30
Preparative scale sortagging was performed on Hsp70-LPETGG (0.5 mg) with GGG-
BDP-MC 40 (25 eq) in the presence of SrtAstaph-WT (5 eq) for 20 h at 37
◦C in sortase reac-
tion buffer. A small amount (0.05%) of Tween-80 was included in the reaction buffer and in
buffers of all subsequent steps to prevent aspecific interactions of the amphiphilic sortag-
ging nucleophile with tubes, proteins or beads. After the reaction, all His-tagged proteins
(unreacted Hsp70-LPETGG, SrtA and SrtA-Hsp70 intermediate) were removed by nickel-
affinity chromatography. From each step of the purification, a small sample was analyzed
by SDS-PAGE, followed by fluorescence scanning, Coomassie brilliant blue staining or anti-
His western blotting. As shown in Figure 4.4A (left), one Ni-column was not sufficient to
remove all His-tagged proteins and therefore the flow-through of the first column was sub-
jected to a second nickel purification step (Figure 4.4A, right), which resulted in a mixture
free of any His-tagged proteins as judged by an anti-His western blot (WB). All fluores-
cent signal, corresponding to the product Hsp70-BDP-MC was found in the flow-through
and washing steps, indicating that indeed the His-tag was lost during the reaction and
that aspecific interaction of the protein with the beads was negligable under the conditions
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used. Removal of excess nucleophile 40 was attempted using 30 kDa MWCO filters, but
this did not succeed, probably due to formation of HMW aggregates or a lack of globu-
larity of the molecule. Therefore, the mixture was subjected to gel filtration to remove the
excess of nucleophile. Fractions were analyzed for the presence of fluorescent protein using
in-gel fluorescence scanning. As shown in Figure 4.4B, the first fractions contained a ∼75
kDa protein, corresponding to the MW of Hsp70-BDP-MC, and later fractions contained an
unknown degradation product of about 30 kDa and finally the excess of nucleophile. Frac-
tions containing pure Hsp70-BDP-MC were pooled, concentrated and again analyzed on
SDS-PAGE. As can be seen in Figure 4.4C, final sample "20" contained one major band, as
seen by fluorescence and coomassie staining, which was positively immunostained by an
anti-Hsp70 antibody. In conclusion, Hsp70-BDP-MC was successfully obtained by sortase-
mediated ligation between Hsp70-LPETGG and GGG-BDP-MC 40, in 27% overall yield of
sortagging and purification procedures.
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Figure 4.4: Large scale sortase-mediated ligation of Hsp70-LPETGG with GGG-BDP-MC and
purification of Hsp70-BDP-MC. A) Hsp70-LPETGG (0.5 mg) was treated with SrtAstaph WT (5
eq) and GGG-BDP-MC 40 (25 eq) for 20 h at 37 ◦C. Unreacted Hsp70-LPETGG, Hsp70-SrtA
intermediate and SrtA were removed with two subsequent Ni-NTA agarose columns. Shown are
10% SDS-PAGE gels of samples taken from the Ni-purification steps, followed by in-gel fluorescence
scanning, Coomassie brilliant blue staining or anti-His Western blotting. B) The semi-pure Hsp70-
BDP-MC obtained was subjected to gel filtration using a Vision chromatography system to remove
excess nucleophile. Shown is a 12% SDS-PAGE in-gel fluorescence scan of fractions eluted from
the Vision. Arrowhead: unidentified degradation products. C) 10% SDS-PAGE of Hsp70-LPETGG
and Hsp70-BDP-MC before and after Vision gel filtration, followed by in-gel fluorescence scanning,
Coomassie brilliant blue staining or anti-Hsp70 immunoblotting.
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Next, it was investigated whether the synthetic mannose cluster could function as a
targeting agent for Hsp70. For this, immature mouse dendritic cells (DCs) were incubated
with 10 µg/mL purified Hsp70-BDP-MC for 2 h, 37 ◦C. Cells were extensively washed,
fixed with 4 % formaldehyde, nuclei were stained with Draq5 32 and imaged using a confo-
cal fluorescence microscope. Bright intracellular vesicles were observed, as shown in Fig-
ure 4.5A. Moreover, entry of Hsp70-BDP-MC could be completely blocked by pre-incuba-
tion with the yeast polymannoside mannan (3 mg/mL), indicating that the internalization
was mediated by mannose-binding lectins such as the mannose receptor (MR). An alterna-
tive control experiment would be to make use of Hsp70-BDP, with the fluorophore suited
for microscopy, but without the mannose cluster for targeting, to study the efficiency of
MR-dependent uptake. Purification of Hsp70-BDP from remaining nucleophile GGG-BDP
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Figure 4.5: MR-dependent uptake of Hsp70-BDP-MC in immature dendritic cells. A) Repre-
sentative micrographs of immature mouse dendritic cells that were treated for 2 h with purified
Hsp70-BDP-MC (10 µg/mL) or pre-incubated for 1 h with mannan (3 mg/mL) followed by 2 h
treatment with Hsp70-BDP-MC. Cells were washed with PBS, fixed (4 % formaldehyde in PBS),
nuclei were stained with Draq5 (dark grey) and cells imaged for BODIPY fluorescence (white). B)
Cells were treated as in A), or with unsortagged Hsp70-LPETGG (10 µg/mL) instead of Hsp-BDP-
MC. After incubation, cells were washed with PBS and PBS containing ovalbumin (1 mg/mL) to
reduce aspecific binding. Cells were lysed and analyzed by 7.5 % SDS-PAGE, followed by fluorescence
scanning/anti-His WB and CBB staining of total protein or anti-S6 (ribosomal protein) WB as loading
control. M: molecular weight protein marker, thick black band corresponds to 70 kDa.
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to conduct this experiment. In a next experiment, cells were treated using the same con-
ditions, and unsortagged Hsp70-LPETGG was included as a control. Instead of imaging,
cells were washed with PBS containing ovalbumin (1 mg/mL, to reduce aspecific binding)
and lysed. The lysates were analyzed by 7.5% SDS-PAGE. Gels were scanned for fluores-
cence, and either stained with Coomassie brilliant blue or immunoblotted against His6 to
show Hsp70-LPETGG (Figure 4.5B). In-gel fluorescence showed the presence of a ∼75 kDa
band corresponding to Hsp70-BDP-MC both in samples with and without pre-incubation
with mannan. Quantification of the fluorescent signal, normalized against total protein,
showed that ∼2.5-fold more Hsp70-BDP-MC was present in lysates of DCs that were un-
treated compared to those that were treated with mannan. Unexpectedly, immunoblotting
showed the presence of Hsp70-LPETGG.
The discrepancy between the SDS-PAGE analysis and the microscopy results, where no
signal was detected upon pre-treatment with mannan, can be explained by several factors.
Hsp70, being a chaperone, can be expected to interact with a variety of macromolecules
present in the medium or on the cell membrane. For example, it has been shown that Hsp70
is able to bind to scavenger receptors such as LOX-1 on dendritic cells. 33,34 Even though the
cells were washed several times before lysis in the presence of a large excess of ovalbumin,
it is quite likely that some Hsp70-BDP-MC or Hsp70-LPETGG remained, which was then
included in the cell lysate. The fluorescence signal in intracellular vesicles is much easier
to detect using confocal microscopy than a diffuse binding pattern on the cell membrane,
which might explain the lack of fluorescence in mannan-treated cells. Overall, it can be
concluded that the synthetic mannose cluster, although low molecular weight compared
to Hsp70, is able to ensure its targeted delivery into dendritic cells in a mannose-binding
lectin-dependent fashion.
4.3 Conclusion
A sortagging nucleophile containing a BODIPY dye and a synthetic mannose cluster for tar-
geting of the mannose receptor was successfully synthesized and employed in a sortase-
mediated ligation reaction with recombinant Hsp70-LPETGG. The ensuing Hsp70-BDP-
MC protein could be purified by repeated nickel-affinity and gel filtration chromatography.
Treatment of immature dendritic cells with the purified protein resulted in MR-mediated
internalization as shown by confocal microscopy and SDS-PAGE analysis. Sortase-mediated
modification of a protein with a receptor-targeting, fully synthetic ligand, thus enables se-
lective uptake of the macromolecule into the endolysosomal pathway. The next step would
be to determine what the functional consequences are of targeted delivery of Hsp70 to cells
that are affected by a lysosomal storage disorder. The current construct, Hsp70-BDP-MC,
is ideally suited for delivery to Gaucher cells, and because of the flexible synthetic nature
of the sortagging nucleophile, targeting of other receptors is within easy reach.
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4.4 Experimental Section
Cloning, expression and purification of Hsp70-LPETGG-His6. Wild-type Hsp70 RNA was iso-
lated from HEK293T cells using RNA-Bee (Bio Connect) and converted to cDNA by RT-PCR. The
HSP gene was then PCR amplified using the following primers: 5’-CATATGGCCAAAGCCGCGGCG-
3’ (sense) and 5’-GCGGCCGCCTAATCTACCTCCTCAATGGT-3’ (anti-sense) containing Nde1 and
Not1 restriction sites, respectively. The PCR product (2000 bp) was ligated into the pGEM-T
plasmid (Promega). The C-terminal LPETGG-sequence was then introduced by PCR amplification
using the following primers: sense primer ’5-CATATGGCCAAAGCCGCGGCG-3’ and anti-sense primer
5’-GCGGCCGCTCCGCCGGTCTCGGGCAGATCTACCTCCTCAATGGTGGG-3’ containing Nde1 and
Not1 restriction sites, respectively. The PCR product (2000 bp) was again ligated into the pGEM-T
plasmid and then cloned into the expression plasmid Pet21A(+) (Novagen) using the Not1 and Nde1
restriction sites. The resulting construct containing a C-terminal His6-tag after the LPETGG sequence
was transformed into competent E. coli BL21(DE3) cells for expression of the recombinant protein.
Therefore, two 50 mL cultures in LB-Amp medium were grown overnight at 37 ◦C, inoculated into
500 mL LB-Amp medium and grown again at 37 ◦C to an OD600 of ∼0.6. Protein expression was
induced by addition of isopropyl β-D-1-thiogalactopyranoside (IPTG, 1 mM) and cultures were grown
for 4 h before the cells were pelleted (10,000 g, 4 ◦C, 2 x 15 min). The pellets were each lysed for 2 h
at 4 ◦C in 20 mL lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, 0.1% (v/v) Triton
X-100, 100 µM EDTA, 0.5 mg/mL lysozyme, 0.4 µg/mL leupeptin and Roche protease inhibitor
cocktail) while rotating. The cells were then sonicated on ice (10x 10 s with 30 s intervals) and
centrifuged at 10,000 g for 10 min at 4 ◦C, after which the supernatant was collected (43 mL). For
protein purification, 5 mL 10x binding buffer (500 mM Na2HPO4, 1.5 M NaCl, 100 mM imidazole, pH
8.0) was added to the lysates and the mixture was filtered over a 0.45 µm filter. The protein was then
purified on a nickel column (HisPur Ni-NTA chromatography cartridge, Thermo Scientific) using the
AKTA Prime Plus System (HisTag purification program with a linear imidazole gradient of 10 → 500
mM in 50 mM Tris, 150 mM NaCl, pH 8.0). Fractions containing the Hsp70-LPETGG-His6 protein
were combined, concentrated using 30 kDa MWCO filter tubes (Millipore) and buffer exchanged to
50 mM Tris, 150 mM NaCl, pH 8.0, yielding a total of 6 mg protein (1 mL, 6 mg/mL).
Cloning, expression and purification of SrtAstaph wild-type or P94S/D160N/K196T mutant.
SrtAstaph ∆59 (wild-type minus the membrane anchoring domain) in PET28A plasmid was a gift from
H. Ploegh (Whitehead institute, MIT, Boston, USA) and was expressed in E. coli as described pre-
viously. 27 Mutant P94S/D160N/K196T sortase 29 was obtained by multi-site mutagenesis using the
following primers: CCAGGACCAGCAACATCTGAACAATTAAATAGAGG (P94S); GACAAGTATAA-
GAAATGTTAAGCCTACAGATGTAGGAG (D160N); GACAGGCGTTTGGGAAACACGTAAAATCTT-
TGTAGC (K196T) and the QuikChange Lightning Multi Site-Directed Mutagenesis Kit (Agilent
Technologies) per manufacturers’ instructions. Both recombinant sortases contain a His6-tag for
purification purposes. For protein purification 10x binding buffer (500 mM Na2HPO4, 1.5 M NaCl,
100 mM imidazole, pH 8.0) was added to the lysates and the lysate was clarified by filtration over a
0.45 µm filter. The protein was then purified on a nickel column (HisPur Ni-NTA chromatography
cartridge, Thermo Scientific) using the AKTA Prime Plus System (HisTag purification program with
a linear imidazole gradient of 10 → 500 mM in 50 mM Tris, 150 mM NaCl, pH 8.0). Fractions
containing sortase A were combined, concentrated using 10 kDa MWCO filter tubes (Millipore) and
buffer exchanged to 50 mM Tris, 150 mM NaCl, pH 8.0 using a desalting column (HiTrap Desalting,
GE Healthcare). Fractions were pooled, concentrated and glycerol was added to a final concentration
of 10% before storage at -80 ◦C.
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Analytical scale sortase-mediated ligation of Hsp70-LPETGG-His6. To find the optimal conditions
for sortase-mediated ligation of Hsp70, small scale transpeptidation reactions under varying conditions
were performed. A typical reaction contained Hsp70-LPETGG (1 µg, 14 pmol, 1 eq), SrtAstaph WT
or mutant (5 eq) and triglycine nucleophile 38 or 40 (25 eq) in sortase-reaction buffer (10 µL 50
mM Tris, 150 mM NaCl, 10 mM CaCl2, pH 7.5). Reactions times were varied, together with the
temperature. Aspecific interactions between the nucleophile and Hsp70 were examined by excluding
SrtA enzyme from the reaction mixture. Hydrolysis was determined in the absence of nucleophile.
After reaction, 5x Laemli’s sample buffer (including β-mercaptoethanol) was added and the samples
were boiled (100 ◦C, 5 min) and resolved on 7.5% SDS-PAGE. Gels were scanned on a Typhoon 2000
imager (GE Healthcare) using the Cy3 (λex 532 nm; λem 580 nm) settings. Total protein loading was
determined by staining with Coomassie brilliant blue.
Preparative scale sortase-mediated ligation of Hsp70-LPETGG-His6 and subsequent purification
of Hsp70-BDP-MC. Hsp70-LPETGG-His6 (7.1 nmol, 0.50 mg, 83 µL 6 mg/mL in Tris buffer pH
8.0) was treated with StrAstaph ∆59 (36 nmol, 0.60 mg, 0.46 mL 1.3 mg/mL in Tris buffer pH 8.0,
5 eq) and GGG-BDP-MC 40 (178 nmol, 9 µL 20 mM in DMSO, 25 eq) in the presence of sortase
reaction buffer (65 µL 10x buffer: 500 mM Tris, 1.5 M NaCl, 100 mM CaCl2, pH 7.5) and 0.05%
Tween-80 (33 µL 1% in 50 mM Tris pH 8.0). The reaction mixture (0.65 mL) was incubated 20 h
at 37 ◦C while rotating. After reaction, both unreacted Hsp70-LPETGG-His6 and Sortase A could
be removed by Ni-affinity purification. To avoid extensive sticking of the product Hsp70-BDP-MC
to the nickel column, Tween-80 was included in all buffers. Hence, the reaction mixture was diluted
with 75 µL 10x binding buffer (500 mM Na2HPO4, 1.5 M NaCl, 100 mM imidazole, pH 8.0) and
800 µL 1x binding buffer (50 mM Na2HPO4, 150 mM NaCl, 10 mM imidazole, pH 8.0) containing
0.05% Tween-80, before being applied on top of a Ni-NTA agarose (Qiagen) column (0.5 mL column
volume; prewashed 3x with binding buffer and 2x with binding buffer + 0.05% Tween-80). The
flow-through was collected and the column was washed with binding buffer + 0.05% Tween-80 (1.5
mL). The combined flow-through and washes were concentrated using 30 kDa MWCO filter tubes
(Millipore) and buffer-exchanged 3x with 50 mM Tris, 150 mM NaCl and 0.05% Tween-80, pH
7.5 (10x sample volume). The Ni-affinity purification procedure was repeated to further purify the
protein, giving a final volume of 250 µL. Finally, the excess of low molecular weight nucleophile was
removed by applying the sample to a Vision (BioCad, Applied Biosciences) gel filtration column, using
a buffer containing 50 mM Tris and 150 mM NaCl, pH 8.0. The elution fractions containing the
desired protein were combined and concentrated using 30 kDa MWCO filter epps (Millipore) to give
a final volume of 200 µL containing 135 µg Hsp70-BDP-MC (1.9 nmol, 27%). Each step of the
above procedure was monitored by SDS-PAGE analysis of samples containing an estimated 0.5 µg
of Hsp70, followed by fluorescence scanning on a Typhoon 2000 imager (GE Healthcare). The gels
were then either stained with Coomassie brilliant blue for total protein, or the protein was transferred
onto a nitrocellulose membrane using a Bio-Rad Trans-Blot SD Semi-Dry Transfer Cell (1 h, 12V).
The membrane was then blocked (1 h, 2% milk in TBST), and incubated (o/n, 4 ◦C) with primary
antibody (1:500 mouse monoclonal α-His IgG(R&D systems, MAB050) or 1:500 mouse α-Hsp70/72
(Enzo life sciences, mAb C92F3A-5)), followed by washing (3x 20 min TBST) and incubation with
secondary antibody (1:15000 goat α-mouse IRdye 800CW in 2% milk TBST, 1 h, rt, in the dark).
After another wash cycle (3x 20 min TBST + 20 min TBS) the membrane was scanned on an Odyssey
scanner (Licor).
Cell culture of primary cells. Immature dendritic cells were obtained from the bone marrow of
C75BL/6 mice and were a gift from the Biopharmaceutical Department (Leiden University). The
use of animals was approved by the ethics committee of Leiden University. Mice were sedated, bone
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marrow of tibiae and femurs was flushed out and washed with PBS. Cells were grown in dendritic cell
selection medium (IMDM containing granulocyte-macrophage colony stimulating factor (GM-CSF)
2:1 vol/vol) containing 8% FCS, penicillin/streptomycin (100 units/mL), glutamax (2 mM) and beta-
mercaptoethanol (20 µM). Cells were selected for 10 days (37 ◦C; 5% CO2) and subcultured every
2-3 days before use in the assays.
Uptake of Hsp70-BDP-MC - Confocal fluorescence microscopy. Experiments were conducted on a
Leica TCS SPE confocal microscope, using dsRed filter settings (λex 532 nm) for BODIPY fluorescence
and Cy5 filter settings (λex 635 nm) to detect Draq5 nuclear stain (Fisher Scientific). Cells (30-75 x
104 cells/well, 250-400 µL medium) were seeded onto sterile Labtek II 4- or 8-chamber borosilicate
coverglass systems (Fisher Emergo). Dendritic cells were allowed to attach for 2 h before pre-
incubation with mannan (3 mg/mL) (1 h, 37◦C, 5% CO2) and subsequent incubation with Hsp70-
BDP-MC (10 µg/mL, 2 h). Cells were then thoroughly washed (PBS), fixed (4% formaldehyde in
PBS), washed again with PBS, nuclei stained with Draq5 and imaged. All experiments were performed
at least in triplicate.
Uptake of Hsp70-BDP-MC - SDS-PAGE analysis. Immature mouse dendritic cells (200.000 cell-
s/well) were seeded on a 24-wells plate (300 µL medium) and cultured for 2 h (37 ◦C; 5% CO2)
before start of the experiment. For competition experiments, cells were pre-treated with mannan (3
mg/mL) for 1 h. After subsequent incubation with Hsp70-BDP-MC (10 µg/mL, 250 µL) or Hsp70-
LPETGG-His6 (10 µg/mL, 250 µL) for 2 h, cells were washed (2x 0.5 mL PBS, 1x 0.2 mL PBS + 1
mg/mL ovalbumin (Sigma)) and lysed (35 µL Invitrogen complete cell extraction buffer). Proteins
were resolved on 7.5% SDS-PAGE, followed by fluorescence scanning and either Coomassie brilliant
blue staining or anti-His WB as described above. Rabbit α-S6 ribosomal protein (1:4000) primary
antibody was included as a loading control for total protein. After washing, the membrane was in-
cubated with secondary antibodies (1:15000 goat α-mouse IRdye 800CW and 1:15000 goat α-rabbit
IRdye 680CW in 2% milk TBST, 1 h, rt, in the dark). Fluorescence intensities were quantified using
ImageJ, and normalized against total protein to correct for differences in protein levels.
Synthesis
General. All reagents were of commercial grade and used as received unless stated otherwise. Reaction
solvents were of analytical grade and when used under anhydrous conditions stored over flame-dried
3 Å molecular sieves. Dichloromethane was distilled over CaH2 prior to use. Solvents used for column
chromatography were of technical grade and distilled before use. All moisture and oxygen sensitive
reactions were performed under an argon atmosphere. Flash chromatography was performed on silica
gel (Screening Devices BV, 0.04-0.063 mm, 60 Å). Reactions were routinely monitored by TLC analysis
on DC-alufolien (Merck, Kieselgel60, F254) with detection by UV-absorption (254/366 nm) where ap-
plicable and spraying with a solution of (NH4)6Mo7O24 · 4 H2O (25 g/l) and (NH4)4Ce(SO4)4 · 2 H2O
(10 g/l) in 10% sulfuric acid in water followed by charring at ∼150 ◦C. 1H and 13C NMR spectra
were recorded on a Bruker AV-400 (400 MHz) or Bruker AV-500 (500 MHz). Chemical shifts are
given in ppm (δ) relative to the residual solvent peak or TMS (0 ppm) as internal standard. Coupling
constants are given in Hz. Peak assignments are based on 2D 1H-COSY and 13C-HSQC NMR exper-
iments. LC-MS measurements were conducted on a Thermo Finnigan LCQ Advantage MAX ion-trap
mass spectrometer (ESI+) coupled to a Surveyor HPLC system (Thermo Finnigan) equipped with a
standard C18 (Gemini, 4.6 mmD x 50 mmL, 5µ particle size, Phenomenex) analytical column and
buffers A: H2O, B: ACN, C: 0.1% aq.TFA. High resolution mass spectra were recorded on a LTQ
Orbitrap (Thermo Finnigan) mass spectrometer equipped with an electronspray ion source in positive
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mode (source voltage 3.5 kV, sheath gas flow 10 mL min−1, capillary temperature 250 ◦C) with reso-
lution R=60000 at m/z 400 (mass range m/z=150-2000) and dioctylphtalate (m/z = 391.28428) as
a "lock mass". The high resolution mass spectrometer was calibrated prior to measurements with a
calibration mixture (Thermo Finnigan). For reversed-phase HPLC purification of the final compounds
an automated HPLC system equipped with a C18 semiprep column (Gemini C18, 250x10 mm, 5µ
particle size, Phenomenex) was used.
Synthesis of LysAhxGly3Fmoc (35).
The peptide was synthesized using standard solid-phase peptide synthesis protocols. Starting from
Rink amide resin HL (100-200 mesh, 0.78 mmol/g) the following steps were followed:
- Removal of the Fmoc-group with 20% piperidine in NMP for 20 min.
- NMP (3x), DCM (3x), NMP (1x) wash.
- Coupling of the appropriate amino acid (2 eq) with HBTU (2 eq) as the coupling agent, DiPEA (4
eq) as the base, in NMP as the solvent for 5-16 h.
- NMP (3x), DCM (3x), NMP (1x) wash.
Each coupling was monitored by LC/MS analysis and Kaiser test 35 for completion. After the final
coupling step, all acid-labile protecting groups were removed and the peptide cleaved from the resin
by treatment with TFA/H2O/TIS (95:2.5:2.5; v/v/v) for 1 h. The peptide was crystallized from
ice-cold Et2O and collected by centrifugation as a white solid (40 mg, 0.061 mmol, 85%). R f = 0.1
(1:1 DCM:MeOH + TEA). 1H NMR (500 MHz, CDCl3/MeOD): δ 7.78 (d, J = 7.5 Hz, 2H, 2 x
CHar), 7.65 (d, J = 7.4 Hz, 2H, 2 x CHar), 7.40 (t, J = 7.5 Hz, 2H, 2 x CHar), 7.31 (t, J = 7.5 Hz,
2H, 2 x CHar), 4.39 (d, J = 7.0 Hz, 2H, CH2), 4.35 (dd, J = 8.8, 5.3 Hz, 1H, CH), 4.23 (t, J =
6.8 Hz, 1H, CH), 3.90 (s, 2H, CH2), 3.84 (s, 4H, 2 x CH2), 3.21 - 3.13 (m, 2H, CH2), 2.92 - 2.87
(m, 2H, CH2), 2.24 (t, J = 7.3 Hz, 2H, CH2), 1.88 - 1.80 (m, 1H, CH2-H
a), 1.69 - 1.59 (m, 5H, 2 x
CH2, CH2-H
b), 1.54 - 1.48 (m, 2H, CH2), 1.47 - 1.38 (m, 2H, CH2), 1.33 - 1.28 (m, 2H, CH2).
13C
NMR (126 MHz, CDCl3/MeOD): δ 174.86, 174.29, 171.45, 170.23, 169.49, 157.51, 143.27, 140.77,
127.13, 126.45, 124.42, 119.28, 66.65, 52.03, 46.54, 43.55, 42.29, 41.85, 38.78, 38.52, 35.04, 30.71,
28.02, 26.21, 25.49, 24.56, 21.95. LC/MS analysis (linear gradient 10 → 90% ACN) tR : 4.92 min,






















Synthesis of protected sortase nucleophile BODIPY-
Gly3Fmoc (37).
Peptide 35 (65 mg, 0.10 mmol) was dissolved in
dry DMF (10 mL) and azido-BODIPY-OSu 36 24
(56 mg, 0.10 mmol) and DiPEA (36 µL, 0.20
mmol, 2 eq) were added. After 2 h, LC/MS re-
vealed complete consumption of starting materi-
als, toluene was added and the solvents removed in
vacuo. Pure product was obtained by silica column
chromatography (0 → 100 % MeOH in DCM) fol-
lowed by crystallization from DMF/Et2O as a dark-
purple solid (100 mg, 91 µmol, 91%). 1H NMR (400 MHz, DMF-d7): δ 8.47 (t, J = 5.2 Hz, 1H,
NH), 8.24 (t, J = 5.6 Hz, 1H, NH), 8.01 - 7.90 (m, 5H, NH, 4 x CHar), 7.86 (d, J = 8.0 Hz, 1H,
NH), 7.82 - 7.73 (m, 5H, CH2, 3 x CHar), 7.51 - 7.44 (m, 3H, NH, 2 x CHar), 7.38 (t, J = 7.4 Hz,
2H, 2 x CHar), 7.22 (d, J = 4.0 Hz, 1H, CHar), 7.10 (d, J = 8.8 Hz, 2H, 2 x CHar), 7.05 (s, 1H, NH),
6.77 (d, J = 4.0 Hz, 1H, CHar), 4.40 - 4.26 (m, 3H, CH2, CH), 4.21 (t, J = 6.1 Hz, 2H, CH2), 3.92
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(t, J = 5.2 Hz, 4H, 2 x CH2), 3.84 (d, J = 5.8 Hz, 2H, CH2), 3.68 - 3.64 (m, 2H, CH2), 3.19 - 3.10
(m, 4H, 2 x CH2), 2.74 (s, 2H, CH2), 2.56 (s, 3H, CH3), 2.37 (t, J = 7.5 Hz, 2H, CH2), 2.31 (s, 3H,
CH3), 2.24 (t, J = 7.4 Hz, 2H, CH2), 2.11 (p, J = 6.4 Hz, 2H, CH2), 1.83 - 1.71 (m, 1H, CH2-H
a),
1.67 - 1.53 (m, 3H, CH2, CH2-H
b), 1.53 - 1.26 (m, 8H, 4 x CH2).
13C NMR (101 MHz, DMF-d7):
δ 174.50, 172.68, 171.53, 170.49, 169.54, 168.86, 160.09, 159.65, 157.17, 154.35, 144.28, 141.20,
140.93, 135.29, 134.62, 131.69, 130.74, 128.25, 127.80, 127.22, 125.72, 125.50, 124.09, 120.16,
118.00, 114.29, 66.60, 65.04, 52.88, 48.17, 47.11, 44.21, 42.83, 42.44, 38.85, 35.58, 32.03, 29.22,
28.58, 26.40, 25.34, 23.28, 20.15, 12.64, 8.91. LC/MS analysis (linear gradient 10 → 90% ACN) tR :
9.13 min, ESI-MS (m/z): [M + H]+: 1101.33. ESI-HRMS (m/z): calcd. for [C56H67BF2N12O9 +





















Synthesis of sortase nucleophile GGG-BDP (38).
Peptide 37 (50 mg, 0.046 mmol) was dissolved in
DMF (5 mL) and DBU (8.2 µL, 55 µmol, 1.2 eq)
was added. After 40 min at room temperature,
HOBt (31 mg, 0.23 mmol, 5 eq) was added to
quench the reaction and the solvent was removed
under reduced pressure. The product was purified
by RP-HPLC (A: 0.2 % TFA in H2O, B: linear gra-
dient 39 → 50 % ACN in 12’) and lyophilized from
water to give the corresponding TFA salt as a purple
powder (6.4 mg, 7.3 µmol, 16%). LC/MS analysis
(linear gradient 0 → 90% ACN) tR : 7.72 min, ESI-MS (m/z): [M + H]+: 879.33. ESI-HRMS (m/z):
calcd. for [C41H57BF2N12O7 + H]
+ 879.46071; obsd. 879.46174.
Synthesis of GGG-BDP-MC (40).
Mannose cluster 20 (11.6 mg, 3.8 µmol) and peptide 37 (4.2 mg, 4.7 µmol,1.2 eq) were dissolved
in DMF (2 mL) and aqueous solutions of sodium ascorbate (76 µL 100 mM, 2 eq) and CuSO4 (19
µL 100 mM, 0.5 eq) were added. The resulting mixture was heated to 75 ◦C for 24 h. Toluene was
added and the Fmoc-protected peptide 39 was collected by centrifugation and used without further
purification. LC/MS analysis (linear gradient 0 → 90% ACN) tR : 6.60 min, ESI-MS (m/z): [M +
3H]3+: 1391.00. The peptide was again dissolved in DMF and DBU (1.2 µL, 8 µmol, 2 eq) was
added. After 2 h at room temperature, HOBt (5.2 mg, 38 µmol, 10 eq) was added to quench the
reaction and the solvent was removed under reduced pressure. The product was purified by RP-HPLC
(A: 0.2 % TFA in H2O, B: linear gradient 20 → 30 % ACN in 12’, tR : 11.5 min) and lyophilized
from water to give the corresponding TFA salt as a purple powder (3.5 mg, 0.9 µmol, 24%). LC/MS
analysis (linear gradient 10 → 90% ACN) tR :4.88 min, ESI-MS (m/z): [M + 2H]2+: 1974.40. ESI-
HRMS (m/z): calcd. for [C172H271BF2N44O59 + 2H]
2+ 1974.99159; obsd. 1974.99467; calcd. for
[C172H271BF2N44O59 + 3H]
3+ 1316.99682; obsd. 1316.99846.
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Multivalent MPR ligand for
endolysosomal targeting of an
activity-based cathepsin probe1
M
annose-6-phosphate receptors (MPR) are ubiquitously expressed intracel-
lular receptors that sort newly synthesized lysosomal enzymes to the lyso-
somes. A small population of the receptors recycle to the plasma membrane to
recapture missorted phosphorylated proteins. This chapter describes the devel-
opent of a synthetic, multivalent, mannose-6-phosphate (M6P) glycopeptide. Con-
jugation of this cluster to fluorescent DCG-04, an activity-based cysteine cathepsin
probe, enabled fluorescent readout of the receptor targeting properties of this li-
gand. The large M6P cluster-BODIPY-DCG-04 52 was still able to label cathepsins,
as determined by lysate cathepsin labeling experiments. The probe was shown to
be taken up in dendritic cells as well as COS cells and trafficking along the endo-
cytic pathway ensured very efficient cathepsin labeling. The uptake in COS cells
was completely inhibited by addition of mannose-6-phosphate, concluding that
the mannose-6-phosphate cluster indeed targets the MPR and ensures targeted




The 300 kDa cation-independent mannose-6-phosphate receptor (CI-MPR) and its smaller
46 kDa homolog, the cation-dependent mannose 6-phosphate receptor (CD-MPR) are es-
sential for the correct trafficking of newly synthesized lysosomal enzymes from the trans-
Golgi network to the lysosomes. Most of the receptor population resides intracellularly,
but a small (∼ 10%) fraction of the receptors shuttles continuously between the cell mem-
brane and the endocytic pathway (Figure 5.1A). 2 Besides mannose-6-phosphate (M6P)-
containing ligands such as transforming growth-factor β 3 and granzyme B, 4 the CI-MPR
has been shown to bind non-M6P ligands at the cell surface. These include insulin-like
growth factor II (IGF-II, hence it is also named M6P/IGFII-R), 5 retinoic acid, 6 urikinase-
type plasminogen activator receptor and plasminogen. 7 The extracellular region of the CI-
MPR consists of 15 homology domains that are similiar in size and tertiary structure (Fig-
ure 5.1A). 8 Two of those, domains 3 and 9, have been shown to be the mannose-6-phosphate
binding domains. 9 In addition, domain 5 has weak affinity for mannose-6-phosphate but
is able to bind to Man-P-GlcNAc phosphodiesters 10 and domain 11 is the reported IGF-II
binding domain. 11 X-ray crystal structures of the extracytoplasmic domain of the CD-MPR
in absence or presence of mannose-6-phosphate ligands show dimeric structures with one
M6P binding site per monomer (Figure 5.1A). 12,13 The CI-MPR has relatively low affinity
towards M6P (Kd= 7µM), compared to glycoproteins that contain multiple phosphorylated
mannoses (Kd= 2-20 nM).
14 This could either be contributed to multivalent interaction of
one multimeric ligand with the two separate binding domains on the receptor, or by recep-
tor oligomerization, as shown in Figure 5.1B. Evidence points into the direction of the latter
explanation, since Byrd et al. were able to isolate receptor dimers in the absence of ligand. 15
Furthermore, after mutation of the binding site in domain 9, high affinity binding of a mul-
tivalent ligand was still observed, although with reduced stoichiometry. 16 Another study
by York et al. shows that β-glucuronidase, which contains multiple mannose-6-phosphate
residues, enhances CI-MPR internalization rates compared to IGFII, also when one of the
receptor binding domains is mutated. 17
The notion that multivalency increases the affinity of mannose-6-phosphate-containing
ligands towards the receptor, has prompted several groups to investigate synthetic ligands,
since these allow for defined structures both of the glycan chain as well as the spacing
between the phosphate residues. Distler et al. synthesized a series of linear or bianten-
nary di- tri- and oligomannosides with α(1,2), α(1,3) or α(1,6) linkages and terminal or
internal phosphorylation. Only structures with a terminal mannose-6-phosphate were in-
hibitors of the MPRs, and α(1,2) linkage was preferred between the ultimate and penul-
timate residues. Biantennary structures containing two terminal M6P residues were the
most potent inhibitors in this study. Interestingly, p-nitrophenyl-α M6P was a slightly bet-
ter inhibitor than M6P which indicates that the aglycone portion of the mannoside does not
interfere with receptor binding. 20 Franzyk and Christensen followed a different approach
where they attached one or two phosphorylated mono- or di-saccharides to a peptide back-
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Figure 5.1: A) Schematic representations of left: the extracytoplasmic domains of the cation-
dependent (CD) and cation-independent (CI) mannose-6-phosphate receptors (MPR), including the
different binding domains. Each polygon represents one of the homology domains. 2 right: intracellu-
lar trafficking of the MPRs which sorts newly synthesized phosphorylated lysosomal enzymes to the
lysosomes. Lowering of the pH in the late endosomes leads to dissociation of the receptor-ligand
complex. The receptor then either shuttles back to the trans-Golgi network or is re-routed to the
plasma mebrane. 18 B) Proposed models for multivalent receptor binding. left: Multivalent ligands
bound to a CI-MPR dimer; right: multivalent ligand bound to both domain 3 and domain 9 on the
same receptor. 19
bone. Again, structures containing α(1,2)-linked mannose disaccharides were more potent
than their monosaccharide counterparts and the presence of two mannose-6-phosphate
residues resulted in a large increase in potency. 21,22
Insights into the molecular requirements for optimal receptor binding are especially
useful when employed to target M6P-bearing molecules to the endolysosomal pathway of
MPR-expressing cells. Current enzyme replacement therapies for lysosomal storage disor-
ders such as Fabry and Pompe make use of the binding interaction between M6P residues
on the complex N-glycan chains of enzymes recombinantly expressed in CHO cells and
membrane-bound CI-MPRs. 23,24 Internalization of recombinant enzyme bound to the CI-
MPR ensures delivery into the endolysosomal pathway of cells deficient in the lysosomal
enzyme.
In Chapter 2 a synthetic mannose cluster 25 is described that contains six mannoses
that are flexibly spaced and which functions as a ligand for mannose-binding lectins on
dendritic cells. This chapter describes the synthesis and biological evaluation of an anal-
ogous mannose-6-phosphate cluster (M6PC, 51 Scheme 5.1) with the aim of targeting the
mannose-6-phosphate receptor. For this, a propargyl mannose-6-phosphate building block
was designed and synthesized that contained acid-labile t-butyl protective groups on the
phosphate and base-labile benzyl groups on the hydroxyls that were compatible with solid-
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phase peptide synthesis conditions. The flexible nature of the cluster might enable mul-
tivalent binding interactions, thereby increasing the potency and possibly receptor inter-
nalization. 17 To investigate the MPR targeting properties of this ligand, the cluster was
conjugated to fluorescent BODIPY-DCG-04, an activity-based probe for cysteine cathep-
sins. The ability of the M6PC-BODIPY-DCG-04 probe 52 (Scheme 5.1) to label cathepsins
was investigated in lysates, followed by in situ analysis of uptake, trafficking and cathepsin
inhibition in both dendritic cells and COS cells, a fibroblast-like cell line.
5.2 Results and Discussion
Synthesis. The same peptide scaffold as reported for the mannose cluster 25 20 (Chapter
2) was used as a starting point for the solid-phase peptide synthesis (SPPS) approach to
mannose-6-phosphate cluster 51 (Scheme 5.1). Protected propargyl mannose-6-phosphate
47 was attached six times to the peptide 48 on solid support by Cu(I)-catalyzed Huisgen
1,3-cycloaddition. 26,27 Next, the Fmoc group was removed and propiolic acid was coupled
to the primary amine by EEDQ coupling. The ensuing terminal alkyne is more electron-
deficient than the pentynoic chain that was incorporated as a click handle in the mannose
cluster 20. A drawback hereof is its relative instability to strong (nucleophilic) acid and
base conditions, whereas the advantage is its expected greater reactivity in the click re-
action allowing for much milder reaction conditions than those used in Chapter 2. The
peptide was cleaved from the resin using acidic conditions, which also ensured complete
deprotection of the phosphate groups. This is a great advantage compared to previous
methods with either 2,2,2-trichloroethyl (Tce) protection of the phosphate group, which
requires harsh solution phase conditions for cleavage, 21 or the use of unprotected phos-
phate, which results in electronic repulsion and coupling difficulties. 22 Global deprotec-
tion was accomplished using a saturated solution of K2CO3 in methanol, followed by mild
acidic quenching with citric acid. The glycopeptide was purified under neutral NH4OAc
conditions and lyophilized to give the ammonium salt of 51. 31P NMR analysis showed
a very broad peak, indicative of multiple salt forms of the peptide. Therefore, the pep-
tide was ion-exchanged to the sodium form using Chelex-Na+ resin, which resulted in a
homogeneous salt form as seen by a sharp phosphate peak in NMR. However, final com-
pound M6P cluster-BODIPY-DCG-04 52 was only successfully synthesized using the het-
erogeneous NH+4 -phosphate cluster, because of solubility issues of either the starting ma-
terial or the product. In contrast to the conditions necessary to click the mannose cluster
to BODIPY(TMR)-DCG-04 (elevated temperatures, long reaction times), the click reaction
of peptide 51 and BODIPY(TMR)-DCG-04 (22, Chapter 2) proceeded at room temperature
and was finished within one hour. Purification by MS-HPLC under NH4OAc conditions
provided the (mostly) ammonium salt form of probe 52 in 26% yield, which was used with-
out further cation-exchange procedures.
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Reagents and conditions: [a] mannose 47, sodium ascorbate, CuSO4, DCM/H2O; [b] i) 20%
piperidine/NMP; ii) propiolic acid, EEDQ; [c] TFA/TIS (98/2, v/v); [d] K2CO3, MeOH, RP-HPLC
(R=NH+4 , used for [e]), Chelex-Na
+ (R=Na+); [e] BODIPY(TMR)-DCG-04 22, sodium ascorbate,
CuSO4, DMF/H2O, 26%
Biological evaluation. To study the uptake and trafficking of the phosphorylated gly-
copeptide probe 52 in mammalian cells, labeling of cathepsins along the endolysosomal
route was the envisaged read-out. The ability of compound 52 to function as an activity-
based probe for cathepsins was first investigated in lysate labeling experiments. For this,
increasing concentrations of the probe were added to lysates of different origin (mouse
liver, mouse dendritic cells or monkey COS cells) at pH 5.5, the optimal pH for most of
the cathepsin activities. 28 As shown in Figure 5.2A, concentration-dependent labeling of
active cathepsins was observed. Inactivation of the cathepsins by pre-incubation with 1 or
10µM of known cathepsin inhibitors AS44 25 or various DCG-04 derivatives 29 (Figure 5.2B)































































Figure 5.2: Lysate cathepsin labeling A) Mouse liver, immature mouse DC or COS cell lysate (10-20
µg total protein) was incubated (1 h, 37 ◦C) with increasing concentration of probe 52 at pH 5.5.
Alternatively, lysates were incubated (1 h, 37 ◦C) with azido-DCG-04 (23, 1 or 10 µM), AS44 (54,
10 µM) or BODIPY(FL)-DCG-04 (53, 1 or 10 µM), before treatment with 52 (1 µM, 1 h, 37 ◦C).
Proteins were resolved on 12.5% SDS-PAGE, followed by fluorescence scanning (Cy2: BODIPY(FL),
Cy3: BODIPY(TMR)) and total protein staining with CBB. B) Chemical structures of cathepsin
inhibitors AS44 (54) and various DCG-04 derivatives (22, 23 and 53) that were used in competition
experiments.
Having established that attachment of the mannose-6-phosphate cluster did not inter-
fere with cathepsin profiling, the new probe was compared head-to-head with the previ-
ously reported mannose cluster-BODIPY-DCG-04 probe 13 (Figure 1.9). 25 Immature mouse
dendritic cells (DCs) were incubated with 0.1, 0.5 or 1 µM of either probe for 2 h at 37 ◦C.
After cell lysis, the proteome was resolved on SDS-PAGE and the gel was scanned for flu-
orescence. Similar concentration-dependent labeling profiles were found for both probes
(Figure 5.3A). Pre-incubation with 20 µM of non-fluorescent, cell-permeable azido-DCG-
04 23 abolished all labeling for both probes, indicating that indeed cathepsins were labeled.
Blocking of the mannose-binding lectins present on dendritic cells with the yeast oligo-
mannoside mannan resulted in inhibition of the uptake of mannose-cluster probe 13, as
previously reported. 25,30 Uptake and cathepsin binding of phosphorylated probe 52 was
not inhibited by mannan, showing that the uptake of this probe is mediated by means
other than via the mannose receptor. An attempt at uptake inhibition by addition of 1 mM
of mannose-6-phosphate to the medium, did not succeed. The presence of MPRs on mouse
dendritic cells has not been investigated, although it has been shown that rabbit alveolar
macrophages express MPRs on the cell surface. 31 Since the affinity of monovalent mannose-
6-phosphate for the receptor is low, the used concentration of 1 mM might have been in-
sufficient to block the binding of probe 52. Dendritic cells have been shown to be highly
endocytotically active, complicating the experimental design, since other processes besides
receptor-mediated endocytosis, such as macropinocytosis, might play a role. 32 Confocal
fluorescence microscopy of dendritic cells treated with 1 µM of probe 13 or 52, in the pre-
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Figure 5.3: Comparison of uptake and cathepsin labeling of M6PC-BDP-DCG-04 52 and MC-BDP-
DCG-04 13 in immature mouse dendritic cells. A) DCs were treated with varying concentrations
of 52 or 13 (2 h, 37 ◦C) or pre-incubated (1 h, 37 ◦C) with azido-DCG-04 23 (20 µmol), mannan
(3 mg/mL) or mannose-6-phosphate (1 mM), followed by addition of 52 or 13 (1 µM, 2 h, 37 ◦C),
washed with PBS, lysed and resolved on 12.5% SDS PAGE. In-gel fluorescence of BODIPY (Cy3) and
total protein stain (CBB) are shown. B) Representative confocal microscope images of DCs treated
with 1 µM of probes 52 or 13 (left panels) or with mannan (ii, middle) or M6P (iii, right) for 1 h,
followed by treatment with the probes. After treatment, cells were washed with PBS, fixed with 4%
formaldehyde and images using the Cy3 (λex 532 nm) settings.
sence or absence of mannan (3 mg/mL) or M6P (1 mM), confirmed the results found
by SDS-PAGE analysis (Figure 5.3B). In conlusion, these experiments showed that 6-O-
phosphorylation of the mannoses present in the mannose cluster changes its internaliza-
tion properties, without altering its trafficking and subsequent cathepsin labeling in live
dendritic cells.
To further elucidate whether the compound could bind the mannose-6-phosphate re-
ceptor, experiments were conducted using COS cells, an african green monkey fibroblast-
like cell line. Cells were incubated for 16 h with 0.5 µM of mannose receptor-targeted
probe 13, mannose-6-phosphate targeted probe 52 or cell-permeable fluorescent DCG-04
22 and subsequently analyzed by fluorescence-activated cell sorting (FACS). As shown in
Figure 5.4A, only cells that were treated with probes 52 or 22 showed a shift in population
fluorescence, indicative of probe uptake. Uptake of probe 52 was time-dependent (50%
positive after 6 h, compared to 74% after 16 h of incubation) and was almost completely
inhibited in the presence of 1 mM M6P. COS cells treated for 6 h with 0.5 µM of probe 52
and imaged, using a confocal fluorescence microscope, showed bright intracellular fluores-
cent vesicles, establishing that the compound was taken up in the endocytic pathway (Fig-
ure 5.4B). Next, cathepsin labeling was determined, as additional proof for MPR-dependent
uptake and trafficking of the probe towards the lysosomes. Cells were treated under var-
ious conditions, washed and lysed. Total cell lysates were analyzed by 12.5% SDS-PAGE
followed by in-gel fluorescence scanning. In agreement with the FACS data, no labeling
was observed for mannose cluster-BODIPY-DCG-04 13, in accordance with its selectiv-
ity for mannose-binding lectins. The mannose-6-phosphate probe 52, on the other hand,
showed both concentration and time-dependent labeling of cathepsins (Figure 5.4C,D). As
shown in Figure 5.4E, cathepsin labeling was inhibited by using increasing concentrations
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of mannose-6-phosphate, with almost complete inhibition at 1 mM concentration. Even
when taking into account that the probe contains six mannose-6-phosphate residues, a
large molar excess of monovalent M6P is needed to inhibit its binding and uptake. Pre-
treatment of the cells with non-fluorescent azido-DCG-04 23 did not result in inhibition of
cathepsin labeling by the targeted probe. This is in agreement with COS cathepsin labeling
studies with fluorescent non-targeted DCG-04 53, which only gave background bands and
not the expected labeling as seen in lysates (Figure 5.2) (data not shown). The most likely
explanation for this would be that the non-targeted probes are not able to diffuse into the




























































































































Figure 5.4: Uptake and cathepsin labeling of M6PC-BDP-DCG-04 (52) in COS cells. A) FACS
analysis of COS cells that were treated with 0.5 µM M6PC-BDP-DCG-04 (52, 6 h or 16 h), MC-BDP-
DCG-04 (13, 16 h), the non-targeted probe BODIPY(TMR)-DCG-04 (22, 16 h) or first with 1 mM
M6P (16 h), followed by treatment with probe 52 for 6 h. Mean percentages of cells in negative (left)
and positive (right) populations from 3 independent experiments are given. B) Representative confocal
microscope image of live COS cells treated with probe 52 (0.5 µM) for 6 h, showing fluorescently
labeled intracellular compartments. C, D) COS cells were treated with increasing concentrations of
probe 52 or MC-BDP-DCG 13 for 16 h (C) or with a 0.5 µM concentration of 52 for different times
(D), washed, lysed and analyzed by 12.5% SDS-PAGE. Representative fluorescence scans (Cy3) and
total protein stains (CBB) are depicted. E) Competition experiments between different concentrations
of mannose-6-phosphate (M6P) or azido-DCG-04 (23) (16 h, 37 ◦C) and 52 (0.5 µM, 6 h, 37 ◦C).
After treatment, cells were washed with PBS, lysed and resolved on a 12.5% SDS-PAGE gel.
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cathepsin labeling has been described. 33 This finding does highlight the efficiency by which
the targeted probe was taken up by MPR-mediated endocytosis and trafficked to the en-
dolysosomal compartments, leading to inactivation of cathepsins.
5.3 Conclusion
Modification of the previously reported mannose cluster 20 by attachment of six propargyl
mannose-6-phosphates instead of mannoses on the peptide scaffold resulted in a multi-
valent mannose-6-phosphate glycopeptide. To assess the receptor-binding and internal-
ization properties of this ligand, it was ’clicked’ to the fluorescent activity-based probe
BODIPY-DCG-04 22. Attachment of the cluster had no effect on cathepsin labeling as seen
by lysate labeling experiments and thus the probe was used on live dendritic cells to com-
pare it with the mannose cluster-BODIPY-DCG-04 probe (13). Indeed, both compounds
were internalized by the cells, and able to label cathepins along the endocytic pathway, but
only for the mannose-cluster containing probe could this process be inhibited by blockage
of mannose-binding lectins by mannan. In COS cells that do not express the mannose re-
ceptor, only the novel mannose-6-phosphate construct 52 was endocytosed in a process that
was inhibited by addition of mannose-6-phosphate to the medium. Taken together, these
results showed that 6-O-phosphorylation of the mannoses in the MR-ligand completely
altered the targeting properties of the ligand, from the mannose receptor to the mannose-
6-phosphate receptor. Since this receptor is widely expressed on a variety of cells and tis-
sues, the M6P-cluster provides an efficient means of broad targeted delivery. Conjugation
of this M6P-cluster to other biological entities, such as recombinant lysosomal enzymes,
might therefore be a suitable alternative for their targeted delivery into various cell types
affected by a lysosomal storage disorder such as Pompe or Fabry disease.
5.4 Experimental Section
Cell culture conditions COS-7 cells, a monkey fibroblast-like cell line, were a kind gift from the
Medicinal Biochemistry department (AMC, the Netherlands) and were maintained in Iscove’s Mod-
ified Dulbecco’s Medium (IMDM) containing 5% FCS, 2 mM glutamax (Gibco) and 0.1 mg/mL
penicillin/streptomycin at 37 ◦C, 5% CO2.
Cell culture of primary cells. Immature dendritic cells were obtained from the bone marrow of
C75BL/6 mice and were a gift from the Biopharmaceutical Department (Leiden University). The
use of animals was approved by the ethics committee of Leiden University. Mice were sedated, bone
marrow of tibiae and femurs was flushed out and washed with PBS. Cells were grown in dendritic cell
selection medium (IMDM containing granulocyte-macrophage colony stimulating factor (GM-CSF)
2:1 vol/vol) containing 8% FCS, penicillin/streptomycin (100 units/mL), glutamax (2 mM) and beta-
mercaptoethanol (20 µM). Cells were selected for 10 days (37 ◦C; 5% CO2) and subcultured every
2-3 days before use in the assays.
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Labeling of cathepsins in mouse liver, immature dendritic cell or COS cell lysate. Lysates (10-20
µg total protein, determined on a Qubit 2.0 fluorometer, Life Technologies-Invitrogen) in 50 mM
sodium citrate pH 5.5, 5 mM DTT, 0.2 % CHAPS, and 0.1% Triton X-100, were incubated with the
indicated concentration of probe (total volume: 10 µL) for 1 h at 37 ◦C. For competition experiments,
lysates were first incubated with N3-DCG-04 (1 or 10 µM), AS44
25 (10 µM) or BDP(FL)-DCG-04
(53, 1 or 10 µM) for 1 h, 37 ◦C, before addition of the probe and continued incubation for 1 h. After
treatment, 5x Laemli’s sample buffer (including β-mercaptoethanol) was added and the samples were
boiled (100 ◦C, 5 min) and resolved on 12.5% SDS-PAGE. Gels were scanned on a Typhoon 2000
imager (GE Healthcare) using the Cy2 (λex 532 nm; λem 526 nm) and Cy3 (λex 532 nm; λem 580
nm) settings. Total protein loading was determined by staining with Coomassie brilliant blue and
subsequent scanning on a BioRad GS800 calibrated densitometer. Image processing was done with
ImageJ, representative gels from at least three independent experiments are shown.
Labeling of cathepsins in live-cells
Immature mouse dendritic cells: Cells were seeded onto tissue-culture coated 24-wells plates (200.000
cells/well, 250 µL medium) and allowed to attach for 2 h (37 ◦C; 5% CO2), before addition of inhibitor
or probe to the medium. Pre-incubations with N3-DCG-04 (20 µM), mannan (3 mg/mL) or mannose-
6-phosphate (1 mM) were conducted for 1 h, followed by addition of compound 52 or 13 (1 µM) and
continued incubation for 2 h. For direct labeling experiments, cells were cultured for 2 h (37 ◦C; 5%
CO2) in the presence of probes 52 or 13 (0.1, 0.5 or 1 µM). After incubation, cells were washed with
PBS (2x), lysed (35 µL Invitrogen complete cell extraction buffer) and proteins resolved on 12.5 %
SDS-PAGE, followed by fluorescence scanning (Cy3 settings) and CBB staining.
COS cells: Cells (200.000 cells/well) were cultured in full medium (300 µL) on a tissue-culture coated
24-wells plate for 24-48 h (confluency ∼80-90%). Cells were gently washed with PBS and (pre)-
incubations were started by addition of compounds/inhibitors in serum-free medium. Concentration-
dependent labeling of cathepsins was conducted by incubation with increasing concentrations (0.1,
0.25, 0.5, 0.75 or 1 µM) of compound 52 or 13, for 16 h (37 ◦C; 5% CO2). For time-course
experiments, cells were changed to serum-free medium on t=0, which was also the start of the o/n
(∼20 h) incubation time-point, followed by addition of probe (0.5 µM) after 14 h (start of 6 h) or 18
h (start of 2 h). For competition experiments, cells were cultured in the presence of M6P (0, 1, 10,
50, 100 µM or 1 mM) or N3-DCG-04 (10 or 100 µM) for 16 h in serum-free medium (250 µL) before
treatment with 52 (0.5 µM) for 6 h. At the end of the incubation period, medium was removed and
the cells were washed twice with ice-cold PBS. Cells were harvested in PBS, centrifuged (1500 rpm,
5 min) and the pellet was lysed in 30 µL lysis buffer (25 mM KPi pH 6.5, 0.1% Triton X-100, 20 µM
23, protease inhibitor cocktail (Roche)). Labeling was analyzed on 12.5% SDS-PAGE as described
above.
Confocal fluorescence microscopy. Experiments were conducted on a Leica TCS SPE confocal
microscope, using dsRed filter settings (λex 532 nm). Cells (30-75 x 104 cells/well) were seeded
onto sterile Labtek II 4- or 8-chamber borosilicate coverglass systems (Fisher Emergo). Dendritic
cells were allowed to attach for 2 h before pre-incubation with M6P (1 mM) or mannan (3 mg/mL)
(1 h, 37◦C, 5% CO2) and subsequent probe incubation (1 µM, 2 h). Cells were then thoroughly
washed (PBS), fixed (4% formaldehyde in PBS), washed again with PBS and imaged. COS cells
were cultured on chamberslides for 24-48 h (∼90% confluent), before incubation with probe 52 (0.5
µM, 6 h) in serum-free medium. Cells were washed with PBS, new medium (without phenol-red)
was added and cells were imaged. All experiments were performed at least in triplicate.
Fluorescence activated cell sorting (FACS) analysis. COS cells were cultured on 12-wells plates
for 24 h, before being subjected to 16 h M6P (1 mM) or compounds 52, 13 or 22 (0.5 µM) in
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IMDM without FCS. The next day, probe 52 (0.5 µM) was added to the M6P-containing medium
and incubation was continued for 6 h. The cells were washed with PBS (2x) and harvested in PBS.
The resulting single-cell suspension (50 µL, 0.5 x 106 cells/mL) was analyzed on a Beckman Coulter
Cell Lab Quanta SC flow cytometer. The forward scatter (FSC) and side scatter (SSC) were detected
simultaneously and the FSC treshold was adjusted to exclude cell debris. Cells that were positive for
BODIPY were detected in the FL2 channel (λex:488 nm, λem: 575 BP filter). Analysis was performed
using the Quanta SC software and based on 5-10 x 103 events per sample and three independent
experiments.
Synthesis
Scheme 5.2: Synthesis of protected propargyl mannose-6-phosphate














































Reagents and conditions: [a] propargyl alcohol, BF3 · OEt2, DCM, reflux, 89%; [b] NaOMe, MeOH,
80%; [c] TBDPSCl, imidazole, DMF, quant; [d] benzoyl chloride, pyridine, 0 ◦C → rt, 97%; [e]
TBAF, THF, 99%; [f] i) phenyltetrazole, di-t-butylphosphoramidite, DCM; ii) H2O2, TEA, 0
◦C →
rt, 41% 34
General. All reagents were of commercial grade and used as received unless stated otherwise. Reaction
solvents were of analytical grade and when used under anhydrous conditions stored over flame-dried
3 Å molecular sieves. Dichloromethane was distilled over CaH2 prior to use. Solvents used for column
chromatography were of technical grade and distilled before use. All moisture and oxygen sensitive
reactions were performed under an argon atmosphere. Flash chromatography was performed on silica
gel (Screening Devices BV, 0.04-0.063 mm, 60 Å). Reactions were routinely monitored by TLC analysis
on DC-alufolien (Merck, Kieselgel60, F254) with detection by UV-absorption (254/366 nm) where ap-
plicable and spraying with a solution of (NH4)6Mo7O24 · 4 H2O (25 g/l) and (NH4)4Ce(SO4)4 · 2 H2O
(10 g/l) in 10% sulfuric acid in water followed by charring at ∼150 ◦C. 1H, 13C NMR and 31P spectra
were recorded on a Bruker AV-400 (400 MHz) or Bruker DMX-600 (600 MHz). Chemical shifts are
given in ppm (δ) relative to the residual solvent peak or TMS (0 ppm) as internal standard. Coupling
constants are given in Hz. Peak assignments are based on 2D 1H-COSY and 13C-HSQC NMR exper-
iments. Chloroform was neutralized by filtration over basic Al2O3 before use with t-butyl-protected
phosphates. IR measurements (thin film) were conducted on an IRaffinity-1 apparatus and evaluated
using IRSolutions software (Shimadzu, Kyoto, Japan). LC-MS measurements were conducted on a
Thermo Finnigan LCQ Advantage MAX ion-trap mass spectrometer (ESI+) coupled to a Surveyor
HPLC system (Thermo Finnigan) equipped with a standard C18 (Gemini, 4.6 mmD x 50 mmL, 5µ
particle size, Phenomenex) analytical column and buffers A: H2O, B: ACN, C: 0.1% aq.TFA. High
resolution mass spectra were recorded on a LTQ Orbitrap (Thermo Finnigan) mass spectrometer
equipped with an electronspray ion source in positive mode (source voltage 3.5 kV, sheath gas flow
10 mL min−1, capillary temperature 250 ◦C) with resolution R=60000 at m/z 400 (mass range
m/z=150-2000) and dioctylphtalate (m/z = 391.28428) as a "lock mass". The high resolution mass
spectrometer was calibrated prior to measurements with a calibration mixture (Thermo Finnigan). For
reversed-phase HPLC purification of the final compounds an automated HPLC system equipped with a
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C18 semiprep column (Gemini C18, 250x10 mm, 5µ particle size, Phenomenex) was used. HPLC-MS
purifications were performed on an Agilent Technologies 1200 series automated HPLC system with a
Quadropole MS 6130, equipped with a semi-preparative Gemini C18 column (Phenomenex, 250x10,
5µ particle size).Optical rotations were measured on a Propol automatic polarimeter (Sodium D-








To a solution of peracetylated mannose 41 (19.5 g, 50 mmol, 1 eq) in dry DCM
(300 mL) propargyl alcohol (4.4 mL, 75 mmol, 1.5 eq) and BF3 · OEt2 (9.3 mL,
75 mmol, 1.5 eq) were added. The mixture was refluxed for 20 h, after which the
reaction was cooled to rt and quenched by addition of powdered K2CO3 (13.5
g, 100 mmol, 2 eq). After stirring for 30 min, the solution was filtered over a
glass filter and concentrated in vacuo. Silica column chromatography (0 → 10% EtOAc in toluene)
afforded compound 42 in 89% yield (16.5 g, 44 mmol) R f = 0.5 (1:1 PE:EtOAc). All analytical data








Acetylated propargyl mannose 42 (16.5 g, 44 mmol) was dissolved in MeOH (45
mL) and a solution of NaOMe (30% in MeOH, 0.79 mL, 0.1 eq) was added.
Upon completion of the reaction (1 h), Dowex-H+ was added till pH∼7, the
solution was filtered over a small plug of silica and concentrated under reduced
pressure. Crystallization from EtOH/heptane yielded propargyl mannose 43 (7.67









Propargyl mannose 43 (0.21 g, 0.96 mmol) was dissolved in dry DMF (5 mL)
and imidazole (0.13 g, 2 mmol, 2 eq) was added. After dropwise addition of
tert-butyldiphenylsilyl chloride (0.28 mL, 1.05 mmol, 1.1 eq) the reaction was
stirred for 1 h at room temperature, before being concentrated in vacuo. The
residue was dissolved in chloroform (10 mL), washed with HCl (aq, pH 3, 2 x
20 mL) and water (20 mL). The aqueous layers were extracted with DCM (2 x 30 mL) and the
combined organic layers were dried over MgSO4, filtered and concentrated under reduced pressure.
Pure product was obtained by silica column chromatography (10 → 50% EtOAc in pentane) as a
colorless oil in quantitative yield (0.44 g, 0.96 mmol). R f = 0.7 (EtOAc). 1H NMR (400 MHz,
CDCl3): δ 7.72 - 7.62 (m, 4H, 4 x CHar), 7.41 - 7.33 (m, 6H, 6 x CHar), 4.93 (s, 1H, H-1), 4.38
(s, 1H, OH), 4.11 (s, 2H, CH2), 3.93 (dd, J = 10.6, 4.2 Hz, 1H, H-6), 3.89 - 3.65 (m, 6H, H-6,
H-2, H-3, H-4, 2 x OH), 3.65 - 3.57 (m, 1H, H-5), 2.32 (t, J = 2.2 Hz, 1H, CH≡), 1.03 (s, 9H, 3 x
CH3).
13C NMR (101 MHz, CDCl3): δ 135.69, 133.05, 132.96, 129.92, 127.87, 98.05, 78.78, 75.04,
72.06, 71.71, 70.32, 69.43, 64.82, 53.98, 26.87, 19.24. FT-IR (thin film) v 3418, 3303, 2930, 2857,
1106, 1043 cm−1. [α]20
D










TBDPSO Propargyl 2, 3, 4-tri-O-benzoyl-6-O-(tert-butyldiphenylsilyl)-α-D-mannopyra-
noside (45). Compound 44 (0.40 g, 0.88 mmol) was dissolved in pyridine (10
mL) and benzoyl chloride (1.02 mL, 8.8 mmol, 10 eq) was dropwise added at 0
◦C. The mixture was stirred for 2 h at room temperature, before quenching of
the reaction with sat aq NaHCO3 (30 mL). The water layer was extracted with
EtOAc (3 x 20 mL), dried (MgSO4), filtered and concentrated in vacuo. Silica
column chromatography (0 → 10% EtOAc in pentane) yielded compound 45 as a colorless oil (0.65
g, 0.85 mmol, 97%). R f = 0.9 (6:1 pentane:EtOAc). 1H NMR (400 MHz, CDCl3): δ 8.16 (d, J =
6.9 Hz, 2H, 2 x CHar), 7.94 (d, J = 7.0 Hz, 2H, 2 x CHar), 7.88 (d, J = 7.0 Hz, 2H, 2 x CHar),
7.75 (d, J = 5.8 Hz, 2H, 2 x CHar), 7.61 (d, J = 6.4 Hz, 2H, 2 x CHar), 7.57 - 7.46 (m, 2H, 2 x
CHar), 7.44 - 7.38 (m, 2H, 2 x CHar), 7.38 - 7.08 (m, 11H, 11 x CHar), 6.25 (t, J = 9.9 Hz, 1H,
H-4), 5.91 (d, J = 9.5 Hz, 1H, H-3), 5.80 (s, 1H, H-2), 5.36 (s, 1H, H-1), 4.37 (s, 2H, CH2), 4.21
(d, J = 9.0 Hz, 1H, H-5), 4.04 - 3.83 (m, 2H, H-6), 2.48 (s, 1H, CH≡), 1.10 (s, 9H, 3 x CH3).
13C
NMR (101 MHz, CDCl3): δ 165.57, 165.50, 165.26, 135.72, 135.54, 133.77, 133.50, 133.27, 133.12,
132.94, 132.83, 130.03, 129.78, 129.74, 129.70, 129.64, 129.35, 129.30, 129.15, 128.59, 128.42,
128.30, 127.70, 127.63, 96.24, 78.27, 75.56, 71.87, 70.57, 70.50, 66.45, 62.31, 54.76, 26.67, 19.24.
[α]20
D









Propargyl 2, 3, 4-tri-O-benzoyl-α-D-mannopyranoside (46). Compound 45
(0.57 g, 0.74 mmol) was dissolved in THF (10 mL) and acetic acid (0.21 mL, 3.7
mmol, 5 eq) and TBAF (1 M in THF, 1.11 mL, 1.11 mmol, 1.5 eq) were added.
After 72 h, deprotection was complete and brine was added to the mixture, fol-
lowed by extraction with EtOAc. The organic layer was dried (MgSO4), filtered
and concentrated under reduced pressure. Silica column chromatography (0 →
50% EtOAc in pentane) yielded compound 128 as a colorless oil (0.39 g, 0.73 mmol, 99%). R f =
0.3 (2:1 pentane:EtOAc). 1H NMR (400 MHz, CDCl3): δ 8.12 (d, J = 7.4 Hz, 2H, 2 x CHar), 7.98
(d, J = 7.5 Hz, 2H, 2 x CHar), 7.84 (d, J = 7.4 Hz, 2H, 2 x CHar), 7.57 (t, J = 7.4 Hz, 1H, CHar),
7.50 - 7.43 (m, 3H, 3 x CHar), 7.40 - 7.31 (m, 3H, 3 x CHar), 7.21 (t, J = 7.8 Hz, 2H, 2 x CHar),
6.02 (dd, J = 10.1, 3.3 Hz, 1H, H-3), 5.92 (t, J = 10.0 Hz, 1H, H-4), 5.77 (dd, J = 2.9, 1.6 Hz,
1H, H-2), 5.35 (s, 1H, H-1), 4.39 (d, J = 2.1 Hz, 2H, CH2), 4.17 (d, J = 9.5 Hz, 1H, H-5), 3.95 -
3.76 (m, 2H, H-6), 3.05 (s, 1H, OH), 2.57 (t, J = 2.2 Hz, 1H, CH≡). 13C NMR (101 MHz, CDCl3):
δ 166.19, 165.31, 165.29, 133.57, 133.51, 133.12, 129.80, 129.73, 129.53, 129.00, 128.86, 128.53,
128.40, 128.18, 96.29, 78.12, 75.74, 71.40, 70.20, 69.53, 66.96, 61.09, 55.01. FT-IR (thin film) v
3418, 3303, 2930, 1724, 1450, 1260, 1107, 1065 cm−1. [α]20
D
= -118◦(c = 1, CHCl3). ESI-HRMS
(m/z): calcd. for [C30H26O9 + Na]










Propargyl 2, 3, 4-tri-O-benzoyl-6-O-(di-tert-butoxyphosphoryl)-α-D-mannopy-
ranoside (47). Compound 46 (0.52 g, 0.98 mmol) was co-evaporated with diox-
ane (2x), dissolved in dry DCM (10 mL) and added to a flame-dried flask with
activated molecular sieves. Phenyltetrazole (287 mg, 2 mmol, 2 eq) and di-tert-
butylphosphoramidite (0.49 mL, 1.5 mmol, 1.5 eq) were added. After 30 minutes
at room temperature, TLC (R f = 0.95, 2:1 pentane:EtOAc) indicated complete
conversion of the starting material, so the mixure was cooled to 0 ◦C and TEA
(1 mL, 7.5 eq) and H2O2 (aq, 30%, 0.35 mL, 3.1 eq) were added. TLC indicated complete oxidation
after 1 h at room temperature. DCM was added and the organic layer was washed with H2O and
NaHCO3 (aq, sat), dried over Na2SO4, filtered and concentrated. Silica column chromatography (0
→ 30 % EtOAc in PE + 1% pyridine) yielded protected mannose-6-phosphate 47 as a yellowish oil
83
Chapter 5
(0.29 g, 0.4 mmol, 41%). R f = 0.15 (2:1 pentane:EtOAc). 1H NMR (400 MHz, CDCl3): δ 8.11
(d, J = 7.3 Hz, 2H, 2 x CHar), 7.96 (d, J = 7.4 Hz, 2H, 2 x CHar), 7.83 (d, J = 7.4 Hz, 2H, 2 x
CHar), 7.61 (t, J = 7.4 Hz, 1H, CHar), 7.49 (q, J = 7.2 Hz, 3H, 3 x CHar), 7.44 - 7.33 (m, 3H,
3 x CHar), 7.25 (t, J = 7.8 Hz, 2H, 2 x CHar), 5.93 - 5.85 (m, 2H, H-3, H-4), 5.73 (s, 1H, H-2),
5.33 (s, 1H, H-1), 4.42 (d, J = 2.3 Hz, 2H, CH2), 4.38 (s, 1H, H-5), 4.24 - 4.19 (m, 2H, H-6), 2.55
(t, J = 2.3 Hz, 1H, CH≡), 1.45 (s, 9H, 3 x CH3), 1.42 (s, 9H, 3 x CH3).
13C NMR (101 MHz,
CDCl3): δ 165.39, 165.36, 133.56, 133.47, 133.17, 129.92, 129.74, 129.70, 129.23, 129.01, 128.93,
128.58, 128.43, 128.27, 95.92, 82.69 (d, J = 3 Hz, Cq tBut), 82.61 (d, J = 3 Hz, Cq tBut), 78.00,
75.82, 70.37, 70.21 (d, J = 8 Hz, C-5), 70.03, 66.82, 65.28 (d, J = 6 Hz, C-6), 54.95, 29.80, 29.76,
29.72. 31P NMR (162 MHz, CDCl3): δ -9.42. FT-IR (thin film) v 2980 2934, 1726, 1450, 1250,
1105, 1067, 991 cm−1. [α]20
D
= -73◦(c = 2, CHCl3). LC/MS analysis (linear gradient 50% → 90%
ACN) tR : 7.94 min, ESI-MS (m/z): [M + H]+: 722.93. ESI-HRMS (m/z): calcd. for [C38H43O12P






























Synthesis of mannose-6-phosphate cluster (51). Tentagel S-
HMPB-Ahx-Lys(spacerN3)6-Ahx-Fmoc (48, obtained as reported
previously 25) (0.5 g, 0.08-0.1 mmol), propargyl mannose 47 (667
mg, 0.92 mmol, 9.2 eq), sodium ascorbate (160 mg in 1 mL H2O,
0.8 mmol, 8 eq) and CuSO4 (100 mg in 1 mL H2O, 0.4 mmol,
4 eq) in DCM (5 mL) were shaken for 72 h. The supernatant
was collected, the resin washed with DCM and H2O and the com-
bined supernatants were extracted to recover unreacted mannose
47 (recovered yield: 0.3 mmol, 221 mg, after silica column chro-
matography). The resin was washed with NMP, MeOH, DCM,
H2O and Et2O for drying. Dry resin 49 (1 eq) was swollen again
in DCM, washed with NMP and subsequently deprotected with
20% piperidine in NMP. After washing (NMP, DCM, NMP, all
2x), EEDQ (10 eq) and propiolic acid (10 eq) were added in DCM
and the mixture was shaken for 1.5 h. Resin 50 was washed again
(NMP, DCM, NMP, all 2x) and subjected to a cocktail of TFA/TIS (98/2, v/v, 3 x 15’) to deprotect
the t-butyl groups and cleave the peptide from the resin. The cleaved peptide was crashed from
icecold Et2O and collected by centrifugation.(ESI-HRMS (m/z): calcd. for [C255H288N32O88P6 +
3H]3+ 1799.25964; obsd. 1799.25926). The crude peptide was debenzoylated by additon of a so-
lution of K2CO3 (50 mM) in MeOH and subsequent stirring for 24 h at room temperature. The
reaction was quenched by carefull addition of citric acid (aq) to pH∼5 and the solvents removed in
vacuo. The residue was taken up in t-BuOH/H2O/MeCN (1:1:1), purified by RP-HPLC (A: 50 mM
NH4OAc, B: linear gradient 5 → 15% ACN in 12’, tR : 10.5 min) and lyophilized to give mannose-6-
phosphate cluster 51 (R = NH+4 , this salt form is required for successful use in the subsequent click
reaction, due to solubility issues) as a hygroscopic white powder. The peptide was dissolved in H2O
and ion-exchanged to the sodium form 51 (R = Na+) by flushing it over a plug of Chelex-Na+. 1H
NMR (600 MHz, D2O): δ 8.19 (s, 5H, 6 x CHtrz), 5.08 (s, 6H, 6 x H-1), 4.96 (d, J = 12.4 Hz, 6H,
CH2-H
a), 4.79 (d, J = 12.4 Hz, 6H, CH2-H
b), 4.59 - 4.53 (m, 12H, 6 x CH2), 4.44 - 4.35 (m, 6H,
4 x CHα), 4.31 - 4.27 (m, 2H, 2 x CHα), 4.26 - 4.17 (m, 6H, 6 x H-6), 4.07 - 4.00 (m, 19H, 6 x
H-2, H-4, H-6, 1 x CH≡), 3.92 (dd, J = 10.0, 3.1 Hz, 6H, 6 x H-3), 3.81 (d, J = 9.6 Hz, 6H, 6
x H-4), 3.37 - 3.17 (m, 16H, 8 x CH2), 2.42 - 2.25 (m, 26H, 13 x CH2), 1.94 - 1.80 (m, 12H, 6 x
CH2), 1.74 - 1.55 (m, 24H, 12 x CH2), 1.55 - 1.34 (m, 36H, 18 x CH2).
13C NMR (151 MHz, D2O):
δ 184.53, 182.40, 180.23, 177.87, 175.50, 174.28, 171.95, 171.60, 169.16, 144.40, 144.18, 126.13,
100.61, 76.15 (HSQC cross-coupling), 73.39 (d, J = 6 Hz, C-5) 70.99, 70.95, 66.78, 63.36 (d, J
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= 4.5 Hz, C-6), 60.66, 54.95, 54.56, 50.56, 40.12, 40.01, 38.42, 36.15, 33.40, 31.39, 29.03, 28.75,
26.93, 26.66, 26.42, 23.38. 31P NMR (162 MHz, D2O): δ 5.03. LC/MS analysis (linear gradient 0%
→ 90% ACN) tR : 4.71 min, ESI-MS (m/z): [M + 2H]2+: 1760.93.
Synthesis of M6P cluster-BODIPY-DCG-04 (52). Peptide 51 (2.64 mg, 700 nmol) was dissolved in
H2O (400 µL) and BODIPY-DCG-04 22 (0.9 mg, 800 nmol, 1.14 eq) in DMF (400 µL) was added,
followed by sodium ascorbate (35 µL, 100 mM in H2O, 5 eq) and CuSO4 (3.5 µL, 100 mM in H2O,
0.5 eq). The resulting mixture was stirred for 1 h at room temperature, before being concentrated
and co-evaporated with toluene. Purification by HPLC-MS (A: 25 mM NH4OAc, B: linear gradient
20 → 35% ACN in 12’) and lyophilization from H2O yielded the final compound (0.85 mg, 180 nmol,
26%). 1H NMR (600 MHz, D2O): δ 8.52 (s, 1H, CHtrz), 8.17 - 8.08 (m, 6H, 6 x CHtrz), 7.80 (d, J
= 8.3 Hz, 2H, 2 x CHar), 7.58 (s, 1H, CHar), 7.23 (d, J = 3.6 Hz, 1H, CHar), 7.12 (d, J = 8.4 Hz,
2H, 2 x CHar), 6.92 - 6.82 (m, 4H, 4 x CHar), 6.69 (d, J = 3.8 Hz, 1H, CHar), 5.07 (s, 6H, 6 x H-1),
4.96 - 4.91 (m, 6H, 6 x CH2-H
a), 4.76 (t, J = 10.9 Hz, 6H, 6 x CH2-H
b), 4.59 - 4.46 (m, 13H, 6
x CH2, CH), 4.46 - 4.43 (m, 1H, CH), 4.41 - 4.31 (m, 6H, 6 x CH), 4.30 - 4.25 (m, 1H, CH), 4.25
- 4.17 (m, 8H, 6 x H-6, CH2), 4.15 - 4.11 (m, 2H, CH2), 4.08 - 3.99 (m, 18H, 6 x H-6, H-2, H-4),
3.91 (d, J = 9.7 Hz, 7H, 6 x H-3, CH), 3.86 (d, J = 1.7 Hz, 1H, CH), 3.80 (d, J = 9.5 Hz, 6H, 6
x H-5), 3.45 (d, J = 6.9 Hz, 2H, CH2), 3.34 - 3.28 (m, 2H, CH2), 3.25 - 2.90 (m, 18H, 9 x CH2),
2.85 (d, J = 3.7 Hz, 2H, CH2), 2.58 - 2.50 (m, 7H, 2 x CH2, CH3), 2.38 - 2.19 (m, 33H, 15 x CH2,
CH3), 1.93 - 1.06 (m, 90H, CH, 43 x CH2, CH3), 0.95 (d, J = 6.0 Hz, 3H, CH3), 0.90 (d, J = 6.0
Hz, 3H, CH3).
31P NMR (162 MHz, D2O): δ 4.67 (very broad). LC/MS analysis (linear gradient 0%
→ 90% ACN) tR : 6.41 min, ESI-MS (m/z): [M + 3H]3+: 1549.73. ESI-HRMS (m/z): calcd. for
[C185H290BF2N43O81P6 + 3H]























Synthesis of BODIPY(FL)-DCG-04 (53). DCG-
04 amine (5.9 mg, 8.7 µmol), BODIPY(FL)-OSu
(3.4 mg, 8.7 µmol) and DiPEA (1.6 µL, 8.7
µmol) were dissolved in DMF (1 mL) and stirred
for 2 h at room temperature. The product was
crashed from Et2O, collected and lyophilized to
give the product as an orange powder (7.9 mg,
8.3 µmol, 95%). R f = 0.5 (10:1 DCM:MeOH).
1H NMR (600 MHz, CDCl3/MeOD): δ 7.22 (s,
1H, CHar), 6.98 (d, J = 8.1 Hz, 2H, 2 x CHar),
6.92 (d, J = 3.8 Hz, 1H, CHar), 6.70 (d, J =
8.1 Hz, 2H, 2 x CHar), 6.26 (d, J = 3.8 Hz, 1H,
CHar), 6.14 (s, 1H, CHar), 4.43 (t, J = 7.4 Hz, 1H, CH), 4.38 (t, J = 7.0 Hz, 1H, CH), 4.33 - 4.17
(m, 3H, CH2, CH), 3.64 (s, 1H, CHepox), 3.53 (s, 1H, CHepox), 3.22 (t, J = 7.6 Hz, 2H, CH2), 3.18
- 3.10 (m, 3H, CH2, CH2-H
a), 3.04 - 2.96 (m, 1H, CH2-H
b), 2.96 - 2.89 (m, 1H, CH2-H
a), 2.86 -
2.79 (m, 1H, CH2-H
b), 2.58 (t, J = 7.6 Hz, 2H, CH2), 2.51 (s, 3H, CH3), 2.25 (s, 3H, CH3), 2.17
(d, J = 8.7 Hz, 2H, CH2), 1.82 - 1.72 (m, 1H, CH2-H
a), 1.66 - 1.56 (m, 1H, CH2-H
b), 1.56 - 1.45
(m, 7H, 3 x CH2, CH), 1.38 - 1.24 (m, 7H, CH3, 2 x CH2), 1.14 - 1.09 (m, 2H, CH2), 0.90 - 0.84
(m, 6H, 2 x CH3).
13C NMR (151 MHz, CDCl3/MeOD): δ 176.14, 175.22, 173.74, 172.57, 171.96,
167.99, 167.32, 160.81, 157.67, 156.32, 144.97, 135.82, 134.01, 130.80, 128.95, 128.03, 124.78,
120.99, 117.27, 115.84, 115.78, 62.91, 55.59, 54.01, 53.39, 52.85, 52.43, 41.17, 39.63, 39.47, 37.81,
36.22, 35.73, 32.07, 29.31, 29.07, 26.68, 25.77, 25.26, 25.20, 23.39, 23.09, 21.88, 14.99, 14.21,
11.37. ESI-HRMS (m/z): calcd. for [C47H65BF2N8O10 + H]
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studies towards functionalization of
dihydropyridine FSHR agonists1
L
ow molecular weight agonists for the follicle-stimulating hormone receptor
(FSHR) are promising lead candidates for profertility treatments. Dihydropy-
ridine (DHP) ligands have been shown to be nanomolar potent, allosteric agonists
for the FSHR. Modification of the DHP core to introduce a ligation handle for fur-
ther conjugation to a fluorescent moiety or cytotoxic drug might enable selective
targeting of fluorescent ligands or therapeutic agents to tissues that express the
FSHR. A structure-activity relationship study to find the optimum positioning
and length of an azide-containing spacer on the DHP core is presented, which
resulted in the identification of a nanomolar potent FSHR agonist m-74a. Attach-
ment of a bulky group (another DHP, peptide or fluorophore) to this monomeric
ligand was shown to be possible with minor loss of potency. This study provides a




G protein-coupled receptors (GPCRs) are a large family of heptahelical transmembrane
receptors that respond to a variety of extracellular signals, such as odorants, pheromones,
neurotransmitters and hormones. Upon binding of the ligand, a conformational change
takes place in the receptor which leads to exchange of GDP to GTP on the α-subunit of
the trimeric G-protein bound to the receptor. This in turn enables the dissociation of the
α-subunit from the β/γ-subunits. Both parts of the G-protein induce a diverse array of
downstream intracellular signaling events. 2,3
The glycoprotein hormone receptors belong to the rhodopsin-like family of GPCRs
and are characterized by a large N-terminal hormone-binding ectodomain. 4 The glyco-
protein hormones, luteinizing hormone (LH), follicle-stimulating hormone (FSH), thyroid-
stimulating hormone (TSH) and human chorionic gonadotropin (hCG), all share a common
alpha subunit, but have a unique beta-subunit, which confers receptor-selectivity (except
for LH and hCG that share a receptor). 5 The luteinizing hormone/choriogonadotropin re-
ceptor (LH/CGR) and the follicle-stimulating hormone receptor (FSHR) are the key re-
ceptors in regulating human reproduction, 6–8 whereas the thyroid-stimulating hormone
receptor (TSHR) is important for thyroid function. 9 Current fertility treatments involve the
use of recombinant FSH (rFSH), but drawbacks hereof are the heterogeneity of the protein
preparation in terms of glycosylation and sialylation, the instability of the protein at higher
temperatures and the lack of oral bio-availability. In addition, the long half-life of rFSH
increases the risk of ovarian hyperstimulation syndrome when used in controlled ovarian
stimulation protocols.
In the last years, research has been directed to the development of low molecular weight
(LMW) ligands for the LH/CGR and FSHR as modulators of human fertility. 10,11 Several
LMW agonists for the FSHR have been reported in the literature such as thienopyrimidines
(also active on LHR), 12 thiazolidinones 13–15 and diketopiperazines. 16,17 Another class of
FSHR agonists are the dihydropyridines (DHPs) that were reported by Organon in 2006. 18
In a recent publication by van Koppen et al., the signaling properties of a member of this
class of LMW ligands, Org 214444-0, were investigated. It was shown that this compound
is a nanomolar potent agonist, selective for the FSHR over the LHR (>200-fold) and TSHR
(>1000-fold). In addition, the compound binds to an allosteric site on the receptor and
does not compete for FSH binding. Activation of the FSHR by this small molecule leads to
increased levels of the second messenger cyclic AMP (cAMP) as shown by a CRE-luciferase
assay and to production of estradiol in human granulosa cells. Stimulation of U2OS cells
expressing an eGFP-tagged FSHR with this small molecule led to the translocation of the
FSHR from the plasma membrane to intracellular vesicles, albeit with an EC50 value ∼2
orders of magnitude higher than that for the stimulation of cAMP. In vivo studies in rats
showed that this compound has similar action as FSH in supporting the follicular phase. 19
The research described in this chapter, as well as in Chapters 7 and 8 involves the syn-
thesis and biological evaluation of a variety of DHP analogues. As schematically depicted
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Figure 6.1: Proposed agonist-induced internalization of the FSHR as a means of selective drug
targeting. Upon binding of the ligand, the receptor is activated which ultimately leads to inter-
nalization of the receptor-ligand complex, thereby delivering the agent for boron neutron capture
therapy (BNCT) into the FSHR expressing cells. Synthesis and evaluation of agonists with a con-
jugation handle will be discussed in this chapter, followed by fluorescent agonists in Chapter 7 and
carborane-containing fluorescent agonists in Chapter 8.
in Figure 6.1, the ultimate goal is to arrive at ligands that are taken up into the endocytic
pathway of cells that express the FSHR. Since the expression of the FSHR in mammals is
limited to the ovaries (in females) and the testis (in males), 20 this could provide a very se-
lective targeting methodology for these tissues. Furthermore, the presence of the FSHR
on blood vessels that are formed by tumor angiogenesis implicates the FSHR as potential
tumor marker. 21 Fluorescent ligands for the FSHR could therefore be used as diagnostic
tools, whereas attachment of a cytostatic drug to the DHP targeting ligand could allow for
targeted anti-cancer therapy of, for example, ovarian tumors. These possibilities will be
examined in Chapters 7 and 8, respectively.
Alterations of a small molecule, such as the incorporation of a fluorescent tag or drug,
can result in big changes in its ability to bind to and activate receptors. So thorough phar-
macological evaluation of the final constructs for their agonistic potencies on the FSHR is a
requirement. This chapter explores a potential structure-activity relationship for the incor-
poration of a ligation handle onto the DHP 55 core. A general overview of the compounds
that are presented in this chapter (as well as Chapters 7 and 8) is shown in Figure 6.2. The
synthesis of four different analogues is described, followed by the attachment of a PEG
spacer of varying length (n=3, n=4). The resulting azide-containing monomeric ligands
are further conjugated to another FSHR agonist to provide dimeric ligands or to a BODIPY
dye to give a first series of fluorescent ligands. All synthesized compounds are evaluated
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Figure 6.2: General overview of the low molecular weight FSHR agonists described in this thesis.
Detailed structures can be found in Scheme 6.1, Scheme 6.2 and Scheme 6.3. Fluorescent (carborane-
containing) agonists will also be discussed in Chapters 7 and 8.
6.2 Results and Discussion
Synthesis. Lead compound DHP 55 18 was the starting point for all synthetic routes. Direct
substitution with propargyl bromide resulted in the first derivative 56 (Scheme 6.1). The
second set of analogues required ortho-, meta-, and para-hydroxymethyl benzoate esters for
use in a DIAD/PPh3 mediated Mitsunobu reaction with DHP 55. Meta- and para-esters 58
and 59 (Scheme 6.1) were readily obtained and used in the Mitsunubo reaction. The ortho-
variant, however, proved unattainable due to an intramolecular esterification reaction to the
more stable phthalide. Therefore ethyl 2-(bromomethyl)benzoate 57 22 was used in a nu-
cleophilic substitution reaction instead. Separation of esters 60, 61 and 62 from unreacted
starting material 55 proved difficult in this stage, but after saponification using sodium
hydroxide, pure o,m,p-derivatives 63, 64, 65 were isolated. The dihydropyridine scaffold
was found to be easily oxidized to the corresponding pyridine under aerobic conditions,
and although these molecules were separable by column chromatography, anaerobic con-
ditions during synthesis are recommended to keep yields high. It is important to note that
the corresponding pyridine analogues do not exhibit FSHR agonistic activity.
With four analogues of DHP 55 in hand, monomeric, dimeric and fluorescent ligands
could be synthesized. As shown in Scheme 6.2, compound 56 was used in a Cu(I)-catalyzed
[2+3] Huisgen-cycloaddition (’click’reaction) 23,24 with PEG-spacers n = 3 (66a) or n = 4
(66b) to give monomeric ligands 67a,b when an excess of spacer was used and predom-
90
SAR studies towards functionalization of dihydropyridine FSHR agonists































































Reagents and conditions: [a] K2CO3, propargyl bromide, acetone, reflux, 75%; [b] K2CO3, ethyl 2-
(bromomethyl)benzoate 57, acetone, reflux; [c] hydroxymethylbenzoate 58 or 59, PPh3, DIAD, THF,
p-62: 50%; [d] MeOH, NaOH, 40 ◦C, o-63: 52% (2 steps), m-64: 65% (2 steps), p-65: 85%.
inantly dimeric ligands 70a,b when 0.5 eq of spacer was used. Staudinger reduction of the
monomeric azides 67a,b with PPh3, followed by EEDQ-coupling
25 of the primary amine
with propiolic acid yielded alkyne ligands 69a,b in good yields. Pre-activation of propiolic
acid in the presence of other coupling agents than EEDQ resulted in rapid degradation as
seen by the change in color of the solution from colorless to almost black. Click reaction of
alkynes 69a,b with azido-BODIPY-benzyl, 26 resulted in the first set of fluorescent ligands
71a,b in 93% and 71% yield, respectively.
In case of o,m,p-substituted derivatives 63-65, mono-amino PEG spacers n=3 or n=4,
were coupled to the carboxylic acid using EEDQ (Scheme 6.3). For this, bisazido-PEG
spacers 66a,b were mono-reduced using PPh3 in a two-phase system of toluene and 5%
aq HCl, resulting in the HCl salt of spacers 17a,b in good yield. Coupling of spacers 17a,b
with o,m,p-substituted DHPs resulted in the formation of azido-monomeric ligands o-/m-
/p-74a,b in 74-91% yield. Analogous to the route described in Scheme 6.2, Staudinger
reduction of the azide was attempted to obtain the primary amine 76. Because reaction
progress was slow and isolated yields were low as a result of significant byproduct for-
mation, a different approach towards the amine was followed, as depicted in Scheme 6.3.
Spacers 17 were reacted with Boc2O resulting in mono-protected azido-spacers 72 which
were again subjected to PPh3 to reduce the remaining azide. Coupling of mono-protected
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Reagents and conditions: [a] Diazido-spacer 66 a or b, CuSO4, sodium ascorbate, t-
BuOH/ACN/H2O, 67a: 72%, 67b: 92%; [b] PPh3, THF/H2O, 68a: 66%, 68b: 62%; [c] propiolic
acid, EEDQ, DCM, 69a: 71%, 69b: 81%; [d] Diazido-spacer 66 a or b, CuSO4, sodium ascorbate,
t-BuOH/ACN/H2O, 70a: 50% + 42% monomer 67a, 70b: 48% + 26% monomer 67b; [e] azido-
BODIPY-benzyl, CuSO4, sodium ascorbate, t-BuOH/ACN/H2O, 71a: 93%, 71b: 71%.
diamino-PEG spacers 73a,b to ortho-, meta- or para-acids 63-65, resulted in Boc-protected in-
termediates o-/m-/p-75a,b in good yields. The Boc-group was easily removed with TFA to
yield amine ligands o-/m-/p-76a,b. For the synthesis of homodimeric ligands, these were
coupled to o,m,p-DHPs 63-65, using EDC · HCl and HOBt as the coupling agents. Isolated
yields for this reaction dropped because of the presence of two oxidizable core structures,
giving rise to mono-and di-oxidized dimer byproducts. Alternatively, amines 76 were cou-
pled to propiolic acid using EEDQ, resulting in terminal alkynes 78a,b that were used in a
click reaction with azido-BODIPY-benzyl, 26 to yield the second set of fluorescent ligands
79a,b. As discussed below, biological evaluation showed that meta- or para-substituted
derivatives with spacer length n=3 were the most potent of the series. Therefore a third
set of fluorescent ligands was synthesized based on these two compounds. Click reaction
of m-/p-78a with azido-BODIPY-acid 88 27 (see also Chapter 7) yielded compounds m-/p-
80 with a free carboxylic acid instead of a benzylamide on the BODIPY dye, with the aim
to reduce the lipophilicity of the compounds.
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Reagents and conditions: insert: [i] Boc2O, TEA, DCM, 72a: 95%, 72b: 94 %; [ii] PPh3, THF/H2O,
73a: 72%, 73b: 78%. [a] spacer 17a or b, EEDQ, DiPEA, DCM, o-74a: 79%, o-74b: 75%, m-74a:
74%, m-74b: 84%, p-74a: 91%, p-74b: 79%; [b] spacer 73a or b, EEDQ, DCM, o-75a: 93%, o-75b:
82%, m-75a: 90%, m-75b: 72%, p-75a: 89%, p-75b: 79%; [c] 1:1 TFA/DCM; [d] Acid 63, 64 or
65, EDC · HCl, HOBt, TEA, DCM, o,o-77a: 58%, o,o-77b: 37%, m,m-77a: 26%, m,m-77b: 38%,
p,p-77a: 30%, p,p-77b: 34%; [e] propiolic acid, EEDQ, DCM, o-78a: 68%, o-78b: 78%, m-78a:
90%, m-78b: 47%, p-78a: 63%, p-78b: quant; [f] azido-BODIPY-benzyl or azido-BODIPY-acid 88,
CuSO4, sodium ascorbate, DCM/H2O, R=NHBn: o-79a: 59%, o-79b: 57%, m-79a: 51%, m-79b:
60%, p-79a: 29%, p-79b: 65%, R=OH: m-80a: 38%, p-80a: 59%.
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Scheme 6.4 shows the synthesis of heterodimeric ligands, based on the FSHβ33-53 pep-
tide, which has been used as an FSH-derived agonist. 28 This peptide was synthesized using
automated solid-phase peptide synthesis (SPPS), with incorporation of an N- or C-terminal
propargylglycine for subsequent ligation to the LMW ligand. Attachment of DHP to either
terminus of the peptide might interfere with binding of the peptide to the receptor, so both
options were included to enhance the chance of finding an active heterodimer. The natu-
rally occurring cysteine in the sequence was replaced by a serine, to prevent the formation
of peptide-dimers. 28 Peptides C-,N-81 were reacted with azido-monomeric ligands m-74a,b
in a Cu(I)-catalyzed click reaction and purified by size-exclusion chromatography to give
the four envisaged heterodimeric FSHβ33-53-DHP ligands 82.


























Reagents and conditions: [a] Azide m-74a or b, CuSO4, sodium ascorbate, dioxane/H2O, N-82a:
69%, N-82b: 50%, C-82a: 51%, C-82b: 69%.
Biological evaluation. All compounds were evaluated for their potency to activate the
human FSH receptor. A CHO cell line stably expressing human FSHR (hFSHR), together
with a CRE-luciferase reporter gene was used for this purpose. Recombinant FSH (200
pM, rFSH) was included in the assay and the response was normalized against the max-
imal effect obtained for rFSH. The pEC50 values obtained from the dose-response curves
were used to calculate EC50 values (the concentration at which half-maximum stimula-
tion is observed), shown in Table 6.1. The objective was to get more insight in a possible
structure-activity relationship (SAR) for the various modifications on the lead compound
DHP 55 (Scheme 6.1). The first variation that was introduced was the way in which the
spacer was attached to the DHP core; either directly via a triazole moiety or indirectly by
installment of an additional phenyl group containing an o, m, p-carboxylic acid handle.
This was then used to connect the ligand to the spacer via an amide bond. The second
variation concerned the length of the PEG-spacer, with either n=3 or n=4 ethylene glycol
units. Large differences in potency were found for the monomeric DHP ligands (Table 6.1).
Direct functionalization of DHP as for ligands 67 resulted in poor agonists with EC50 val-
ues of 300-500 nM. Also, ortho-functionalized monomeric ligands o-74 were ∼10-fold less
potent than the best agonist of the series. Meta- or para- substitution did not result in big
differences. Overall, compounds with spacer length n=3 proved to be slightly better ago-
nists than those with linker n=4. Both para- and meta-74a were shown to be low nanomolar
potent agonists for the FSHR.
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Table 6.1: Mean agonistic potency (EC50) values of monomeric, dimeric and fluorescent DHP ana-
logues.









67a n = 3 269 6.57 1








o-74a n = 3 54 7.27 ± 0.05 1
o-74b n = 4 100 7.00 1
m-74a n = 3 6.0 8.22 ± 0.10 3
m-74b n = 4 7.8 8.11 ± 0.08 3
p-74a n = 3 8.3 8.08 1
p-74b n = 4 14 7.86 1
FSHβ33-53
C or N terminus
81
N-81 - N.A. N.A. 2












70a n = 3 2.1 µM 5.67 1











o,o-77a n = 3 501 6.30 1
o,o-77b n = 4 724 6.14 1
m,m-77a n = 3 48 7.32 ± 0.10 3
m,m-77b n = 4 59 7.23 ± 0.10 3
p,p-77a n = 3 76 7.12 1











N-82a n = 3 10 7.98 ± 0.11 3
N-82b n = 4 9.8 8.01 ± 0.13 3
C-82a n = 3 8.7 8.06 ± 0.07 3














71a n = 3 5.0 µM 5.30 1
















o-79a n = 3 912 6.04 1
o-79b n = 4 1.5 µM 5.83 1
m-79a n = 3 83 7.08 ± 0.07 4
m-79b n = 4 105 6.98 1
p-79a n = 3 100 7.00 ± 0.01 2
p-79b n = 4 427 6.37 1
m-80a n = 3 26 7.58 ± 0.07 12
p-80a n = 3 21 7.67 1
The mean EC50 values are calculated from the pEC50 (mean ± SEM) values from N indepent exper-
iments performed in duplicate. N.A. not active at 100 µM.
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In contrast to earlier reports, FSHβ33-53 peptides 81 did not show any agonistic activity
up to 100 µM concentrations. 28 The predicted FSHR binding sequences in this peptide are
the TRDL (aa 34-37) and KTCT (aa 49-52) residues, which are unmodified in the here de-
scribed peptide, except for the cysteine residue. 29 It is unlikely that the cysteine to serine
modification lies at the basis of this result, because the study of Santa Coloma et al. em-
ployed a carboxymethylated variant of the peptide which showed the same potency as the
free cysteine. 28 In a study by Zhang et al., the cysteine residue was used as a ligation han-
dle for a fluorophore, without loss of receptor binding. 30 The additional propargyl glycine
residue could have an influence on the agonistic potency of the peptide, which is why both
C- and N-terminal modified peptides were synthesized. Since a C-terminal extended pep-
tide is described without loss of potency, the additional residue was not expected to have
a significant effect. 31 Most of the previous reports have used 125I-FSH binding displace-
ment, 125I-FSHβ33-53 binding or estradiol biosynthesis in Sertoli cells as the biochemical
readout for agonistic activity of these peptides, which differ from the here used luciferase
assay and might lead to different EC50 values.
28,31 For solubility reasons, no concentrations
higher than 100 µM were used in the assay, but it is possible that effects would be visible
at higher concentrations of peptide. Future experiments could include circular dichroism
(CD) measurements to be able to compare the structures of the peptides described here
with those previously reported.
The classical view of a single receptor that is activated by a single ligand has been op-
posed by a large amount of studies addressing the homo- or heterodimerization and even
higher oligomerization of GPCRs. 32–34 The crystal structure of the hormone binding do-
main of the FSHR (FSHRHB) in complex with FSH has been determined by Fan and Hen-
drickson and they reported the presence of dimers in the crystal. 35 With the use of bivalent
ligands, containing two copies of a receptor binding ligand, the occurence and pharmaco-
logical properties of these receptor dimer complexes can be studied. In some cases, dimeric
ligands show enhanced potency compared to monomeric ligands. 36,37 Figure 6.3 shows pos-
sible modes of bivalent binding of dimeric ligands, either to two copies of the receptor or
to two different binding sites on the same receptor. Homodimeric ligands, consisting of
two copies of either o-, m- or p- substituted DHP, were assessed for their potency on the
FSH receptor. As shown in Table 6.1, EC50 values for dimers were 7-10-fold higher than
for the monomers. However, the same structure-activity relationship could be deduced,
with direct functionalized DHP ligands 70 being the poorest activators and m,m-77a (n=3)
the best agonist. Surprisingly, heterodimeric FSHβ33-53-m-DHP ligands 82 all showed po-
tencies around 10 nM, which is comparable to the values found for the monomers. These
dimers were designed to potentially bind the receptor as shown in Figure 6.3B, because
the binding site of the peptide is believed to be in the ectodomain of the receptor, whereas
the low molecular weight DHP ligand binds to an allosteric site in the transmembrane do-
main. 19,28 No differences were found in terms of spacer length (82a vs b) or orientation of
the peptide and DHP (82 N- vs C-), which, especially in combination with the inactivity
of precursor peptides 81 in the luciferase assay, makes a dual interaction with the receptor
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unlikely. No conclusion can be drawn whether it is a bivalence effect which explains the
difference in potency between hetero- and homo-dimeric ligands. Alternatively, it could
be that the spatial orientation of the peptide is such that there is enough room outside the
DHP-binding site in the receptor to accomodate it without loss of binding affinity, whereas
the second DHP ligand might have negative (steric) interaction with the receptor. Bonger
et al. previously reported a series of dimeric FSHR antagonists based on the low molecular
tetrahydroquinoline (THQ) scaffold. 38 These dimeric ligands also showed a significant loss
of potency upon dimerization of the ligand. The loss of potency found for both the THQ-
dimeric antagonists and DHP-dimeric agonists, but not (or less) for THQ heterodimers con-
taining one inactive copy of the ligand or DHP-peptide heterodimers (where the peptide
monomer was also inactive), might be explained by a negative cooperativity effect. Upon
binding of one of the ligands, the affinity for the second ligand to the receptor (dimer) is





A B C D
Figure 6.3: Different modes of bivalent binding of dimeric ligands. A) Binding of neighbouring
receptors. B) Binding of two separate sites on a receptor monomer. C) Enhanced local concentration
upon binding of one of the ligands. D) Ligand-induced receptor dimerization.
From the various dimeric structures it can be concluded that attachment of bulk to the
DHP-ligand not necessarily leads to detrimental effects on its agonistic activity towards the
FSHR. This strengthens the hypothesis that this low molecular weight ligand could be used
as a targeting device to deliver cargo to cells expressing the FSH receptor. The next series of
fluorescent ligands that was synthesized explored this concept further and completed the
structure-activity relationship studies. Addition of azido-BODIPY-benzyl to the various
monomeric ligands led to a decrease in potency that was slightly larger than that found
for the homodimeric compounds. Again, spacer n=3 gave somewhat better results than
spacer n=4 and meta- and para-substituted DHPs were superior over ortho-substitution or
direct functionalization. In an attempt to increase the hydrophilicity of the compounds,
the benzyl group of the BODIPY was removed to give the carboxylic acid (m-/p-80a). This
resulted in a 3-4-fold increase in potency compared to compounds m-/p-79 and resulted
in fluorescent agonists of the FSHR with ∼20-30 nM potency. To have a better estimate of
EC50 values and allow comparison to the compounds in Chapters 7 and 8, luciferase assays
for all meta-substituted ligands were repeated and meta substitution in combination with





Even small synthetic modifications of a low molecular weight ligand can have large ef-
fects on its pharmacological properties. The aim of this chapter was to deduce a structure-
activity relationship for possible modifications of the FSHR agonist, DHP 55. The first
objective was to find the optimal positioning on the DHP core and length of a spacer con-
taining a ligation handle for further conjugation. The second objective was to investigate
whether homo- or heterodimerization of DHP would lead to enhanced agonistic poten-
cies. The third objective was closely related to the second, namely to examine the change
in potency upon attachment of steric bulk to the DHP ligand. Four different derivatives
with two different spacer lengths were designed and synthesized and further conjugated
to another DHP (homodimers), an FSHβ33-53 peptide (heterodimers) or a fluorescent BO-
DIPY dye. From the luciferase assays it became apparent that direct functionalization of
the DHP or incorporation of an ortho-substituted phenyl ring led to a drastic decrease in
agonistic potency. The use of PEG spacers with three ethylene glycol units (n=3) led to bet-
ter agonists than the longer n=4 spacers. Meta- and para-substituted DHPs of all series were
comparable, with a slight lead for the meta-compounds. Overall, it can be concluded that
meta-substituted compounds with attachment of a PEG n=3 spacer are the most promising
lead candidates for future studies, such as described in Chapters 7 and 8. The dimeric lig-
ands described in this chapter did not show enhanced potency compared to the monomeric
ligands, although the heterodimers were still very potent agonists. No evidence was found
that supported a bivalent interaction between these ligands and the receptor (dimer). While
attachment of bulk, either a fluorophore or another DHP, in most cases led to a decrease
in potency, fluorescent agonists with an EC50 of 20-30 nM were obtained. In conclusion, a
ligation handle was successfully introduced onto the DHP core with only minor loss of ago-
nistic potency compared to the lead compound. Attachment of a fluorophore or peptide to
this ligation handle resulted in functionalized FSH ligands while preserving the agonistic
activity. These insights will contribute to the development of DHP-based constructs as a
means of targeted delivery to cells expressing the FSH receptor.
6.4 Experimental Section
Cell culture conditions. CHO cells stably expressing the human FSH receptor together with a lu-
ciferase reporter gene (CHO-hFSHR_luc cells) and control cells without receptor but with luciferase
gene (CHO_luc cells) were provided by MSD, Oss, The Netherlands. Cells were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) and Ham’s F12 medium (1:1) with glutamine, penicillin/strep-
tomycin (0.1 mg/mL) and fetal calf serum (FCS) (5%) in a humidified atmosphere at 37 ◦C and
5% CO2. CHO-hFSHR_luc cells were maintained under constant selection with Hygromycin B (0.8
mg/mL). Cells were subcultured twice weekly at a ratio of 1:10-1:15.
Measurement of CRE-induced luciferase expression. Protocol 1- Initial screening of compounds was
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done at MSD, Oss, the Netherlands according to the following protocol: On the day of the exper-
iment, frozen CHO-hFSHR_luc or CHO_luc cell aliquots were thawed, washed with assay medium
(Dulbecco’s MEM/Nutrient Mix F12 supplemented with 1 mg/L bovine insulin (Sigma), 5 mg/L
apo-transferrin (Sigma), penicillin G (100 units/mL) and streptomycin (0.1 mg/mL)) and then resus-
pended in assay medium. The compounds were tested in duplicate at 10 concentrations ranging from
final concentrations of 10 µM to 0.316 nM with half log intervals. In the agonistic assays, 10 µL
of assay medium containing test compound and 3% DMSO, 10 µL of assay medium containing 3%
DMSO with rFSH (final concentration of 200 pM) or 10 µL of assay medium containing 3% DMSO
alone were added to the wells of a 384-well white culture plate followed by the addition of 10 µL of
assay medium. Then, 10 µL of cell suspension containing 7,500 cells was added to the wells. The
final concentration of DMSO was 1%. After incubation for 4 h in a humidified atmosphere in 5%
CO2 at 37
◦C, plates were allowed to adjust to room temperature for 1 h. Then, 15 µL of Steadylite
solution (PerkinElmer) was added to the incubation mixture. Following 60 min at room temperature
in the dark, luciferase activity was measured in an Envision 2102 multilabel reader (PerkinElmer).
Agonistic effects of the compounds were determined as percentage of the (maximal) effect induced
by rFSH. Data analysis and curve fitting was done with GraphPad Prism 5 (GraphPad Software, La
Jolla, USA).
Protocol 2 - The most potent compounds as determined from the initial screen were re-tested using
the following protocol: CHO_luc or CHO-hFSHR_luc cells were cultured to ∼80% confluency before
use in the assay. On the day of the experiment, cells were harvested using enzyme-free dissociation
solution (Millipore), counted (Biorad TC10 automated cell counter) and resuspended in assay medium
(DMEM-F12 (1:1), without phenol-red, with pen/strep (100 µg/mL) supplied with 1 µg/mL bovine
insulin (Tebu-Bio) and 5 µg/mL human apo-transferrin (Sigma)) to a concentration of 7.5 x 105
cells/mL. Experiments were conducted in 96-wells white Optiplates (Perkin Elmer) and each well
contained 30 µL of test compound, recombinant FSH (200 pM, positive control) or assay medium
(negative control), 30 µL of assay medium and 30 µL cell suspension. Final concentration of DMSO
was 1% for all compounds, including controls. After 4 h of stimulation, 50 µL Neolite (PerkinElmer)
was added to each well and luminescence signal was detected on a Microbeta Trilux 1450 Lumi-
nescence Counter (PerkinElmer). To control for non-FSHR mediated effects on luciferase activity,
highest compound concentrations used in the dose-response experiments were tested on CHO_luc
cells. As a positive control, forskolin (3 µM, gift from the Medicinal Chemistry department, Leiden
University) was included. Data was analyzed using GraphPad Prism 5 (GraphPad Software, La Jolla,
USA), and values were normalized to the maximal effect obtained for recombinant human FSH (200
pM, rFSH, Org32489, gift from MSD, Oss, The Netherlands). Each experiment was performed on
duplicate plates and mean ± SEM values of at least three independent experiments are given.
Synthesis
General. All reagents were of commercial grade and used as received unless stated otherwise. Reaction
solvents were of analytical grade and when used under anhydrous conditions stored over flame-dried
3 Å molecular sieves. Dichloromethane was distilled over CaH2 prior to use. Solvents used for column
chromatography were of technical grade and distilled before use. All moisture and oxygen sensitive
reactions were performed under an argon atmosphere. Flash chromatography was performed on silica
gel (Screening Devices BV, 0.04-0.063 mm, 60 Å). Reactions were routinely monitored by TLC analysis
on DC-alufolien (Merck, Kieselgel60, F254) with detection by UV-absorption (254/366 nm) where ap-
plicable and spraying with a solution of (NH4)6Mo7O24 · 4 H2O (25 g/l) and (NH4)4Ce(SO4)4 · 2 H2O
(10 g/l) in 10% sulfuric acid in water followed by charring at ∼150 ◦C. 1H and 13C NMR spectra
were recorded on a Bruker AV-400 (400 MHz) or Bruker DMX-600 (600 MHz). Chemical shifts are
given in ppm (δ) relative to the residual solvent peak or TMS (0 ppm) as internal standard. Coupling
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constants are given in Hz. Peak assignments are based on 2D 1H-COSY and 13C-HSQC NMR experi-
ments. IR measurements (thin film) were conducted on an IRaffinity-1 apparatus and evaluated using
IRSolutions software (Shimadzu, Kyoto, Japan). LC-MS measurements were conducted on a Thermo
Finnigan LCQ Advantage MAX ion-trap mass spectrometer (ESI+) coupled to a Surveyor HPLC
system (Thermo Finnigan) equipped with a standard C18 (Gemini, 4.6 mmD x 50 mmL, 5µ particle
size, Phenomenex) analytical column and buffers A: H2O, B: ACN, C: 0.1% aq.TFA. High resolution
mass spectra were recorded on a LTQ Orbitrap (Thermo Finnigan) mass spectrometer equipped with
an electronspray ion source in positive mode (source voltage 3.5 kV, sheath gas flow 10 mL min−1,
capillary temperature 250 ◦C) with resolution R=60000 at m/z 400 (mass range m/z=150-2000) and
dioctylphtalate (m/z = 391.28428) as a "lock mass". The high resolution mass spectrometer was
calibrated prior to measurements with a calibration mixture (Thermo Finnigan). For reversed-phase
HPLC purification of the final compounds an automated HPLC system equipped with a C18 semiprep
column (Gemini C18, 250x10 mm, 5µ particle size, Phenomenex) was used. Optical rotations were








propyl-1,4,5,6,7,8-hexahydroquinoline-3-carbonitrile (56). Potassium carbon-
ate (100 mg, 0.68 mmol) was added to a solution of DHP 55 (228 mg, 0.5
mmol) in acetone (50 mL) and heated to reflux for 45 min, after which propar-
gyl bromide (80% in toluene, 0.1 mL, 1 mmol) was added and heating continued
for 20 h. The solvent was evaporated in vacuo, the residue dissolved in EtOAc,
washed with H2) and brine, dried (MgSO4) and concentrated. Purification by
silica column chromatography (0 → 30% EtOAc in PE) yielded pure compound
56 (181 mg, 0.37 mmol, 75%) as a yellowish oil. R f = 0.4 (1:1 EtOAc:PE). 1H
NMR (400 MHz, CDCl3): δ 7.53 (s, 1H, NH), 6.85 (s, 1H, CHar), 6.84 (s, 1H, CHar), 4.70 (d, J
= 2.1 Hz, 2H, CH), 4.52 (s, 1H, CH), 4.14 - 4.02 (m, 2H, CH), 2.51 (s, 1H, CH), 2.50 - 2.36 (m,
2H, 2 x CH-Ha), 2.33 - 2.05 (m, 3H, 2 x CH2-H
b, CH), 2.02 (s, 3H, CH3), 1.43 (t, J = 6.9 Hz, 3H,
CH3), 1.37 - 1.25 (m, 4H, 2 x CH2), 0.90 (t, J = 6.7 Hz, 3H, CH3).
13C NMR (101 MHz, CDCl3):
δ 196.09, 152.62, 150.75, 145.50, 143.10, 142.63, 123.13, 119.36, 118.12, 112.62, 109.36, 87.68,
78.95, 75.62, 64.75, 60.10, 43.32, 38.29, 37.24, 33.67, 33.26, 19.90, 18.27, 14.80, 14.09. ESI-MS











Ethyl 2-((2-bromo-4-( (4R,7S) -3-cyano-2-methyl-5-oxo-7-propyl-1,4,5,6,7,8-
hexahydroquinolin-4-yl)-6-ethoxyphenoxy)methyl)benzoate (60). To a solution
of DHP 55 (227 mg, 0.5 mmol) in acetone (25 mL) K2CO3 (90 mg, 0.65 mmol,
1.3 eq) was added and the mixture was heated to reflux for 30 min. Ethyl 2-
(bromomethyl)benzoate 57 22 (155 mg, 0.65 mmol) as a solution in toluene (2
mL) was added and heating was continued for 48 h, after which the solvent was
evaporated in vacuo. The remaining solids were dissolved in EtOAc, washed
with H2O, brine and dried over MgSO4. Silica column chromatography (0 →
30% EtOAc in PE) yielded pure product 60 (57 mg, 0.094 mmol, 19%) as well
as a mixture of 60 and starting material DHP 55 (237 mg: 80:20 based on
LC/MS analysis), which was taken to the next step without any further purification. R f = 0.7 (15:1
DCM:MeOH). 1H NMR (400 MHz, CDCl3): δ 8.09 (d, J = 7.8 Hz, 1H, CHar), 7.98 (d, J = 7.8
Hz, 1H, CHar), 7.59 (t, J = 7.6 Hz, 1H, CHar), 7.36 (t, J = 7.6 Hz, 1H, CHar), 7.23 (s, 1H, NH),
6.86 (d, J = 4.3 Hz, 2H, 2 x CHar), 5.44 (s, 2H, CH2), 4.54 (s, 1H, CH), 4.32 (q, J = 7.1 Hz, 2H,
CH2), 4.12 - 3.98 (m, 2H, CH2), 2.53 - 2.33 (m, 2H, CH2), 2.33 - 2.22 (m, 1H, CH), 2.21 - 2.08
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(m, 2H, CH2), 2.06 (d, J = 7.9 Hz, 3H, CH3), 1.37 - 1.21 (m, 10H, 2 x CH3 , 2 x CH2), 0.89 (t,
J = 6.5 Hz, 3H, CH3).
13C NMR (101 MHz, CDCl3): δ 195.90, 167.14, 152.82, 149.99, 145.06,
144.75, 141.98, 140.36, 132.45, 130.26, 127.96, 127.73, 126.97, 123.04, 119.35, 118.07, 112.84,
109.86, 88.12, 72.64, 64.68, 61.09, 43.42, 38.24, 37.39, 33.83, 33.50, 19.94, 18.47, 14.77, 14.41,
14.15. FT-IR (thin film) v 2959, 2930, 2363, 2338, 2201, 1713, 1653, 1613, 1490, 1426, 1384, 1274,
1142, 1046 cm−1. LC/MS analysis (linear gradient 50% → 90% ACN) tR : 7.70 min, ESI-MS (m/z):
[M + H]+: 606.93.
OO
OH
Methyl 3-(hydroxymethyl)benzoate (58). Dimethyl isophtalate (1.94 g, 10 mmol)
was dissolved in MeOH (50 mL) and KOH (0.65 g, 12 mmol) was added. The
mixture was stirred for 15 h, concentrated in vacuo followed by the addition of water,
acidification with HCl (aq) and extraction with DCM. After drying (MgSO4), filtration
and concentration, the mixture was dissolved in dry THF (20 mL) and cooled to 0
◦C. BH3.THF (20 mL 1 M in THF, 20 mmol) was slowly added at 0
◦C, followed by stirring at rt
for 45 min, after which the mixture was cooled again and carefully quenched with acetic acid (aq,
50%). The solvent was removed under reduced pressure and the solids dissolved in EtOAc, washed
with water, NaHCO3(sat aq, 4x), dried (Na2SO4) and concentrated. Silica column chromatography
(0 → 30% EtOAc in PE) yielded pure compound 58 (852 mg, 5.1 mmol, 51% over 2 steps) as a
colorless oil. R f = 0.5 (2:1 PE:EtOAc). 1H NMR (400 MHz, CDCl3): δ 8.01 - 7.97 (m, 1H, CHar),
7.92 (d, J = 7.8 Hz, 1H, CHar), 7.56 - 7.51 (m, 1H, CHar), 7.40 (t, J = 7.7 Hz, 1H, CHar), 4.69
(s, 2H, CH2), 3.89 (s, 3H, CH3), 3.07 (s, 1H, OH).
13C NMR (101 MHz, CDCl3): δ 167.17, 141.39,









Methyl 3-((2-bromo-4-( (4R,7S) -3-cyano-2-methyl-5-oxo-7-propyl-1,4,5,6,7,8-
hexahydroquinolin-4-yl)-6-ethoxyphenoxy)methyl)benzoate (61). To a solution
of DHP 55 (0.2 g, 0.45 mmol) in dry THF (10 mL) were added PPh3 (poly-
mer bound, 0.25 g, 0.75 mmol) and methyl 3-(hydroxymethyl)benzoate 58 (82
mg, 0.5 mmol) and the mixture was cooled to 0 ◦C. DIAD (0.1 mL, 0.5 mmol)
was added dropwise and the reaction continued for 48 h at ambient temperature.
LC/MS analysis (linear gradient 10% → 90% ACN/0.1%TFA/H2O, tR :10.2 min)
showed a conversion of ∼90%. The resin was filtered off, the mixture concen-
trated and the crude product was subjected to silica column chromatography (0
→ 30% EtOAc in PE) resulting in an inseparable mixture of product 61 and
starting material 55 (239 mg) which was taken to the next step without any








Methyl 4-((2-bromo-4-( (4R,7S) -3-cyano-2-methyl-5-oxo-7-propyl-1,4,5,6,7,8-
hexahydroquinolin-4-yl)-6-ethoxyphenoxy)methyl)benzoate (62). To a solution
of DHP 55 (0.2 g, 0.45 mmol) in dry THF (10 mL) were added PPh3 (polymer
bound, 0.25 g, 0.75 mmol) and methyl 4-(hydroxymethyl)benzoate 59 40 (82 mg,
0.5 mmol) and the mixture was cooled to 0 ◦C. DIAD(0.1 mL, 0.5 mmol) was
added dropwise and the reaction continued for 18 h at ambient temperature.
The resin was filtered off, the mixture concentrated and the product was purified
by silica column chromatography (0 → 100% EtOAc in PE) resulting in pure
62 (135 mg, 0.23 mmol, 50%) and a mixture of product and starting material
(90 mg), both of which were used in the subsequent step. R f = 0.65 (15:1
DCM:MeOH). 1H NMR (400 MHz, CDCl3): δ 8.04 (d, J = 8.2 Hz, 2H, 2 x
CHar), 7.63 (d, J = 8.2 Hz, 2H, 2 x CHar), 7.16 (s, 1H, NH), 6.88 (d, J = 1.7 Hz, 1H, CHar), 6.85
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(d, J = 1.8 Hz, 1H, CHar), 5.05 (s, 2H, CH2), 4.54 (s, 1H, CH), 4.16 - 4.00 (m, 2H, CH2), 3.92 (s,
3H, CH3), 2.51 - 2.23 (m, 3H, CH2, CH2-H
a), 2.23 - 2.06 (m, 2H, CH2-H
b, CH), 2.04 (s, 3H, CH3),
1.41 (t, J = 7.0 Hz, 3H, CH3), 1.36 - 1.27 (m, 4H, 2 x CH2), 0.90 (t, J = 6.8 Hz, 3H, CH3).
13C
NMR (101 MHz, CDCl3): δ 195.93, 167.24, 152.77, 150.15, 145.08, 144.22, 142.83, 142.33, 129.67,
129.57, 127.93, 123.11, 119.31, 118.07, 112.84, 109.72, 88.11, 73.97, 64.72, 52.24, 43.39, 38.36,
37.33, 33.76, 33.45, 19.93, 18.39, 14.88, 14.13. FT-IR (thin film) v 2956, 2930, 2878, 2362, 2343,
2201, 1718, 1652, 1616, 1489, 1435, 1382, 1274, 1109, 1046 cm−1. ESI-MS (m/z): [M + H]+:
593.07. ESI-HRMS (m/z): calcd. for [C31H33BrN2O5 + H]










hydroquinolin-4-yl)-6-ethoxyphenoxy)methyl)benzoic acid (63). Compound 60
(237 mg, containing 55) was dissolved in MeOH (10 mL) and degassed under
argon with sonication. A degassed solution of NaOH (aq, 2 M, 2.5 mL) was
added and the reaction mixture stirred for 24 h, after which more NaOH (aq, 2
M, 2.5 mL) was added and the reaction heated to 40 ◦C for 2 h. The reaction
was acidified to pH∼5 with HCl (aq, 1 M), extracted with DCM (3x), dried over
MgSO4 and concentrated. Silica column chromatography (30 → 100% EtOAc
in PE) provided compound 63 (121 mg, 0.21 mmol, 52% over 2 steps) in pure
form. R f = 0.25 (15:1 DCM:MeOH). 1H NMR (400 MHz, MeOD): δ 8.06 -
7.94 (m, 2H, 2 x CHar), 7.57 (t, J = 7.5 Hz, 1H, CHar), 7.36 (t, J = 7.5 Hz, 1H, CHar), 6.94 (s, 1H,
CHar), 6.89 (s, 1H, CHar), 5.41 (s, 2H, CH2), 4.48 (s, 1H, CH), 4.10 - 4.00 (m, 2H, CH2), 2.54 (d,
J = 16.9 Hz, 1H, CH2-H
a), 2.46 - 2.32 (m, 2H, CH2), 2.19 - 2.05 (m, 5H, CH3, CH, CH2-H
b), 1.39
- 1.28 (m, 7H, CH3 , 2 x CH2), 0.89 (s, 3H, CH3).
13C NMR (101 MHz, MeOD): δ 198.36, 170.13,
153.98, 153.51, 147.35, 145.75, 144.11, 141.34, 133.23, 131.56, 129.31, 128.89, 128.01, 124.35,
120.40, 118.56, 113.91, 109.99, 88.37, 73.62, 65.71, 44.04, 39.74, 38.12, 34.75, 33.51, 20.92, 18.06,
15.04, 14.49. FT-IR (thin film) v 2957, 2360, 2337, 2202, 1686, 1654, 1611, 1490, 1426, 1384,
1260, 1145 cm−1. [α]20
D
= -135◦(c = 1, CHCl3). ESI-HRMS (m/z): calcd. for [C30H31BrN2O5 +










hydroquinolin-4-yl)-6-ethoxyphenoxy)methyl)benzoic acid (64). Compound 61
(239 mg, containing 55) was dissolved in MeOH (10 mL) and degassed under
argon with sonication. A degassed solution of NaOH (aq, 2 M, 5 mL) was added
and the reaction mixture heated to 40 ◦C for 2 h. The reaction was acidified
to pH∼5 with HCl (aq, 1 M), extracted with DCM (3x), dried over MgSO4 and
concentrated. Silica column chromatography (0 → 10% MeOH in DCM) pro-
vided compound 64 (169 mg, 0.29 mmol, 65% over 2 steps) in pure form. R f
= 0.15 (15:1 DCM:MeOH). 1H NMR (400 MHz, MeOD): δ 8.22 (s, 1H, CHar),
7.98 (d, J = 7.7 Hz, 1H, CHar), 7.72 (d, J = 7.5 Hz, 1H, CHar), 7.45 (t, J =
7.6 Hz, 1H, CHar), 6.92 (s, 1H, CHar), 6.89 (s, 1H, CHar), 5.00 (s, 2H, CH2),
4.47 (s, 1H, CH), 4.14 - 4.03 (m, 2H, CH2), 2.56 (d, J = 16.6 Hz, 1H, CH2-H
a), 2.47 - 2.34 (m,
2H, CH2), 2.23 - 2.03 (m, 5H, CH2-H
b, CH, CH3), 1.43 (t, J = 6.8 Hz, 3H, CH3), 1.35 (s, 4H,
2 x CH2), 0.91 (s, 3H, CH3).
13C NMR (101 MHz, MeOD): δ 1198.36, 169.99, 154.13, 153.56,
147.44, 145.20, 144.40, 139.14, 133.85, 132.46, 130.84, 130.35, 129.37, 124.27, 120.38, 118.74,
113.72, 109.98, 88.33, 75.18, 65.71, 44.05, 39.74, 38.14, 34.80, 33.50, 20.95, 18.04, 15.18, 14.48.
[α]20
D











O OH 4-((2-Bromo-4-( (4R,7S) -3-cyano-2-methyl-5-oxo-7-propyl-1,4,5,6,7,8-hexa-
hydroquinolin-4-yl)-6-ethoxyphenoxy)methyl)benzoic acid (65). Compound 62
(155 mg, 0.26 mmol) was dissolved in MeOH (10 mL) and degassed under argon
with sonication. A degassed solution of NaOH (aq, 2 M, 5 mL) was added and
the reaction mixture heated to 40 ◦C for 2 h followed by stirring at rt for 15 h.
The reaction was acidified to pH∼5 with HCl (aq, 1 M), extracted with DCM
(3x), dried over MgSO4 and concentrated. Silica column chromatography (0 →
10% MeOH in DCM) provided compound 65 (128 mg, 0.22 mmol, 85%) in pure
form. R f = 0.3 (15:1 DCM:MeOH). 1H NMR (400 MHz, MeOD): δ 8.01 (d,
J = 8.1 Hz, 2H, 2 x CHar), 7.60 (d, J = 8.1 Hz, 2H, 2 x CHar), 6.93 (s, 1H,
CHar), 6.89 (s, 1H, CHar), 5.00 (s, 2H, CH2), 4.47 (s, 1H, CH), 4.12 - 4.01 (m, 2H, CH2), 2.59 -
2.50 (m, 1H, CH2-H
a), 2.46 - 2.32 (m, 2H, CH2), 2.18 - 2.03 (m, 5H, CH3, CH, CH2-H
b), 1.38 (t, J
= 6.9 Hz, 3H, CH3), 1.35 - 1.26 (m, 4H, 2 x CH2), 0.89 (s, 3H, CH3).
13C NMR (101 MHz, MeOD):
δ 198.25, 169.56, 154.03, 153.47, 147.36, 145.17, 144.39, 143.94, 131.35, 130.68, 129.05, 124.29,
120.39, 118.67, 113.76, 109.94, 88.33, 74.94, 65.67, 44.04, 39.75, 38.12, 34.73, 33.49, 20.93, 18.07,
15.17, 14.50. FT-IR (thin film) v 2959, 2928, 2872, 2364, 2337, 2202, 1691, 1654, 1617, 1578, 1475,
1407, 1275, 1046 cm−1. [α]20
D
= -87◦(c = 1, CHCl3). ESI-HRMS (m/z): calcd. for [C30H31BrN2O5













General procedure for the synthesis of monomeric ligands (67a,b).
To a solution of compound 56 (50 mg, 0.1 mmol) and diazido-spacer
66a or 66b 41 (1 mmol, 10 eq) in degassed t-BuOH/ACN/H2O (5
mL; 2/2/1; v/v/v) were added degassed aqueous solutions of sodium
ascorbate (0.25 mL 2 M, 0.5 mmol, 5 eq) and CuSO4 (20 µL 1 M,
0.02 mmol, 20 mol%) and the resulting mixture was stirred for 16 h
at room temperature. DCM/MeOH (9:1; v/v) and water were added
and after partioning of the layers, the waterlayer was extracted with
DCM/MeOH (9:1; v/v, 2 x). The combined organic layers were dried
(MgSO4) and concentrated. Silica column chromatography (0 → 1%
MeOH in DCM) afforded compound 67 as an off-white glassy solid. R f = 0.45 (9:1 DCM:MeOH).
FT-IR (thin film) v 2919, 2871, 2360, 2325, 2200, 2104, 1652, 1619, 1496, 1471, 1425, 1384, 1275,
1253, 1123, 1045 cm−1.
(4R,7S)-4-(4-( (1-(11-azido-3,6,9-trioxaundecyl)-1H-1,2,3-triazol-4-yl) methoxy)-3-bromo-5-eth-
oxyphenyl)-2-methyl-5-oxo-7-propyl-1,4,5,6,7,8-hexahydroquinoline-3-carbonitrile (67a).
Yield: 52 mg, 0.072 mmol, 72%. 1H NMR (400 MHz, CDCl3): δ 7.93 (s, 1H, CHtrz), 7.67 (s, 1H,
NH), 6.91 (d, J = 1.9 Hz, 1H, CHar), 6.85 (d, J = 1.9 Hz, 1H, CHar), 5.15 (s, 2H, CH2), 4.62
- 4.52 (m, 3H, CH2, CH), 4.18 - 4.05 (m, 2H, CH2), 3.90 (t, J = 5.1 Hz, 2H, CH2), 3.76 - 3.48
(m, 10H, 5 x CH2), 3.36 (t, J = 5.1 Hz, 2H, CH2), 2.56 - 2.43 (m, 2H, CH2), 2.43 - 2.30 (m, 1H,
CH2-H
b), 2.23 - 2.16 (m, 1H, CH), 2.16 - 2.04 (m, 4H, CH3 , CH2-H
b), 1.43 (t, J = 6.9 Hz, 3H,
CH3), 1.37 - 1.27 (m, 4H, 2 x CH2), 0.88 (t, J = 6.9 Hz, 3H, CH3).
13C NMR (101 MHz, CDCl3):
δ 195.87, 152.70, 150.27, 145.44, 144.52, 143.79, 142.53, 124.79, 123.07, 119.56, 118.18, 112.82,
109.74, 87.90, 70.79, 70.76, 70.70, 70.14, 69.55, 66.16, 64.66, 50.76, 50.54, 43.49, 38.19, 37.53,
33.92, 33.59, 19.92, 18.52, 14.95, 14.16. [α]20
D
= -111◦(c = 0.2, CHCl3). ESI-HRMS (m/z): calcd.
for [C33H43BrN8O6 + H]





Yield: 71 mg, 0.092 mmol, 92%. 1H NMR (400 MHz, CDCl3): δ 8.13 (s, 1H, NH), 7.90 (s, 1H,
CHtrz), 6.91 (d, J = 1.7 Hz, 1H, CHar), 6.86 (d, J = 1.8 Hz, 1H, CHar), 5.15 (s, 2H, CH2), 4.57
(t, J = 4.9 Hz, 3H, CH2, CH), 4.17 - 4.05 (m, 2H, CH2), 3.89 (t, J = 5.1 Hz, 2H, CH2), 3.71 -
3.53 (m, 14H, 7 x CH2), 3.37 (t, J = 5.0 Hz, 2H, CH2), 2.55 - 2.43 (m, 2H, 2 x CH2-H
a), 2.43 -
2.30 (m, 1H, CH2-H
b), 2.23 - 2.04 (m, 5H, CH3 + CH, CH2-H2), 1.43 (t, J = 7.0 Hz, 3H, CH3),
1.36 - 1.25 (m, 4H, 2 x CH2), 0.87 (t, J = 6.9 Hz, 3H, CH3).
13C NMR (101 MHz, CDCl3): δ
195.77, 152.56, 150.58, 145.66, 144.29, 143.61, 142.56, 124.67, 122.98, 119.56, 118.03, 112.71,
109.38, 87.50, 70.66, 70.63, 70.60, 70.56, 70.48, 69.97, 69.43, 65.94, 64.56, 50.66, 50.44, 43.39,
38.13, 37.39, 33.77, 33.29, 19.82, 18.26, 14.84, 14.04. [α]20
D
= -96◦(c = 0.43, CHCl3). ESI-HRMS
(m/z): calcd. for [C35H47BrN8O7 + H]













General procedure for the Staudinger reduction of monomeric ligands
(68a,b). Compound 67 (1 eq) was dissolved in THF (5 mL) and PPh3
(3 eq) was added. Water (0.5 mL) was added after 20 h and the
reaction continued for an additional 24 h, after which the solvents
were removed in vacuo by co-evaporation with toluene. The residue
was taken up in DCM and purified by silica column chromatography
(2.5 → 10% MeOH in DCM, followed by 10% MeOH and 1% TEA in
DCM) to give compound 68 as an off-white glassy solid. R f = 0.15
(9:1:0.1 DCM:MeOH:TEA). FT-IR (thin film) v 3200, 2924, 2872,
2360, 2199, 1651, 1622, 1500, 1474, 1385, 1275, 1124, 1045 cm−1.
(4R,7S)-4-(4-( (1-(11-amino-3,6,9-trioxaundecyl)-1H-1,2,3-triazol-4-yl) methoxy)-3-bromo-5-eth-
oxyphenyl)-2-methyl-5-oxo-7-propyl-1,4,5,6,7,8-hexahydroquinoline-3-carbonitrile (68a).
Yield: 41 mg, 0.058 mmol, 66%. 1H NMR (400 MHz, CDCl3): δ 8.61 (s, 1H, NH), 7.88 (s, 1H,
CHtrz), 6.88 (d, J = 11.0 Hz, 2H, 2 x CHar), 5.15 (s, 2H, CH2), 4.56 (t, J = 4.8 Hz, 3H, CH2, CH),
4.22 - 4.02 (m, 2H, CH2), 3.88 (t, J = 5.0 Hz, 2H, CH2), 3.61 (d, J = 6.0 Hz, 8H, 4 x CH2), 3.51
- 3.45 (m, 2H, CH2), 2.85 (s, 2H), 2.61 - 2.31 (m, 5H, CH2, CH2-H
a, NH2), 2.20 - 2.05 (m, 5H,
CH3, CH, CH2-H
b), 1.43 (t, J = 7.0 Hz, 3H, CH3), 1.37 - 1.28 (m, 4H, 2 x CH2), 0.88 (t, J =
6.8 Hz, 3H, CH3).
13C NMR (101 MHz, CDCl3): δ 195.92, 152.65, 150.93, 145.93, 144.54, 143.66,
142.88, 124.64, 123.14, 119.76, 118.05, 112.83, 109.37, 87.46, 72.63, 70.69, 70.68, 70.52, 70.27,
69.57, 66.19, 64.67, 50.47, 43.52, 41.53, 38.36, 37.51, 33.87, 33.35, 19.92, 18.33, 14.94, 14.16.
[α]20
D
= -112◦(c = 0.28, CHCl3). ESI-HRMS (m/z): calcd. for [C33H45BrN6O6 + H]
+ 701.26567;
obsd. 701.26568.
(4R,7S)-4-(4-( (1-(14-amino-3,6,9,12-tetraoxatetradecyl)-1H-1,2,3-triazol-4-yl) methoxy) -3-bro-
mo-5-ethoxyphenyl)-2-methyl-5-oxo-7-propyl-1,4,5,6,7,8-hexahydroquinoline-3-carbonitrile (68b).
Yield: 30 mg, 0.040 mmol, 62%. 1H NMR (400 MHz, CDCl3): δ 9.21 (s, 1H, NH), 7.85 (s, 1H,
CHtrz), 6.88 (d, J = 1.9 Hz, 2H, 2 x CHar), 5.15 (s, 2H, CH2), 4.60 - 4.49 (m, 3H, CH2 + CH),
4.16 - 3.99 (m, 2H, CH2), 3.87 (t, J = 4.9 Hz, 2H, CH2), 3.67 - 3.51 (m, 16H, 7 x CH2, NH2),
2.99 - 2.90 (m, 2H, CH2), 2.76 - 2.67 (m, 1H, CH2-H
a), 2.51 - 2.33 (m, 2H, CH2), 2.23 - 2.14 (m,
4H, CH3, CH), 2.12 - 2.03 (m, 1H, CH2-H
b), 1.43 (t, J = 7.0 Hz, 3H, CH3), 1.39 - 1.27 (m, 4H,
2 x CH2), 0.87 (t, J = 6.6 Hz, 3H, CH3).
13C NMR (101 MHz, CDCl3): δ 196.09, 152.65, 151.67,
146.48, 144.56, 143.49, 143.22, 124.57, 123.19, 120.00, 117.96, 112.76, 109.03, 87.04, 70.70, 70.56,
70.49, 70.45, 70.43, 70.35, 70.02, 69.63, 66.19, 64.68, 50.36, 43.56, 40.87, 38.43, 37.54, 33.90,
33.27, 19.93, 18.31, 14.94, 14.20. [α]20
D
= -126◦(c = 0.28, CHCl3). ESI-HRMS (m/z): calcd. for
[C35H49BrN6O7 + H]
+ 745.29189; obsd. 745.29128.
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O General procedure for the coupling of amines 68a,b with propiolic
acid (69a,b). Compound 68 (1 eq) was dissolved in DCM (2 mL)
and a pre-activated mixture of propiolic acid (2 eq) and EEDQ (2
eq) in DCM (1 mL) was added. After 1 h, TLC indicated complete
conversion of the starting material. Silica column chromatography
(0 → 2.5% (n=3) or 3% (n=4) MeOH in DCM) gave pure 69 as
a yellowish solid. R f = 0.6 (10:1 DCM:MeOH).
N-(11-(4-((2-bromo-4-( (4R,7S)-3-cyano-2-methyl-5-oxo-7-pro-
pyl-1, 4, 5, 6, 7, 8-hexahydroquinolin-4-yl)-6-ethoxyphenoxy)
methyl) -1H-1,2,3-triazol-1-yl)-3, 6, 9-trioxaundecyl) propiolamide (69a). Yield: 16 mg, 0.021
mmol, 71%. 1H NMR (400 MHz, CDCl3): δ 7.93 (s, 1H, CHtrz), 7.80 (s, 1H, NH), 6.98 (s, 1H, NH),
6.91 (d, J = 1.6 Hz, 1H, CHar), 6.85 (d, J = 1.7 Hz, 1H, CHar), 5.17 (s, 2H, CH2), 4.64 - 4.51 (m,
3H, CH2, CH), 4.17 - 4.04 (m, 2H, CH2), 3.91 (t, J = 5.0 Hz, 2H, CH2), 3.67 - 3.56 (m, 8H, 4 x
CH2), 3.53 (t, J = 5.0 Hz, 2H, CH2), 3.49 - 3.38 (m, 2H, CH2), 2.83 (s, 1H, CH), 2.56 - 2.43 (m, 2H,
CH2), 2.43 - 2.30 (m, 1H, CH2-H
a), 2.19 (s, 1H, CH), 2.14 - 2.02 (m, 4H, CH3, CH2-H
b), 1.43 (t, J
= 7.0 Hz, 3H, CH3), 1.38 - 1.28 (m, 4H, 2 x CH2), 0.88 (t, J = 6.8 Hz, 3H, CH3).
13C NMR (101
MHz, CDCl3): δ 195.90, 152.69, 152.53, 150.44, 145.52, 144.63, 143.79, 142.69, 124.74, 123.08,
119.61, 118.09, 112.89, 109.67, 87.83, 77.41, 73.85, 70.80, 70.65, 70.60, 70.37, 69.61, 69.19, 66.38,
64.70, 50.49, 43.51, 39.76, 38.31, 37.53, 33.90, 33.53, 19.93, 18.49, 14.96, 14.17. [α]20
D
= -113◦(c
= 0.32, CHCl3). ESI-HRMS (m/z): calcd. for [C36H45BrN6O7 + H]
+ 753.26059; obsd. 753.26088.
N-(14-(4-((2-bromo-4-( (4R,7S) -3-cyano-2-methyl-5-oxo-7-propyl-1,4,5,6,7,8-hexahydroquinolin-
4-yl) -6-ethoxyphenoxy) methyl) -1H-1,2,3-triazol-1-yl)-3,6,9,12-tetraoxatetradecyl) propiolamide
(69b). Yield: 15 mg, 0.019 mmol, 81%. 1H NMR (400 MHz, CDCl3): δ 7.91 (s, 1H, CHtrz), 7.58
(s, 1H, NH), 7.03 (s, 1H, NH), 6.92 (d, J = 1.8 Hz, 1H, CHar), 6.83 (d, J = 1.8 Hz, 1H, CHar),
5.17 (s, 2H, CH2), 4.57 (d, J = 7.4 Hz, 3H, CH2, CH), 4.17 - 4.08 (m, 2H, CH2), 3.89 (t, J = 5.0
Hz, 2H, CH2), 3.65 - 3.60 (m, 14H, 7 x CH2), 3.58 - 3.55 (m, 2H, CH2), 3.50 - 3.45 (m, 2H, CH2),
2.83 (s, 1H, CH), 2.52 - 2.43 (m, 2H, 2 x CH2-H
a), 2.43 - 2.33 (m, 1H, CH2-H
b), 2.19 (s, 1H, CH),
2.14 - 2.05 (m, 4H, CH3, CH2-H
b), 1.44 (t, J = 7.0 Hz, 3H, CH3), 1.36 - 1.31 (m, 4H, 2 x CH2),
0.89 (t, J = 6.8 Hz, 3H, CH3).
13C NMR (101 MHz, CDCl3): δ 195.79, 152.71, 152.54, 150.17,
145.39, 144.66, 143.83, 142.54, 124.70, 123.01, 119.56, 118.12, 112.91, 109.79, 87.93, 73.80, 70.79,
70.72, 70.64, 70.62, 70.58, 70.38, 69.64, 69.26, 66.40, 64.72, 50.49, 43.52, 39.82, 38.22, 37.55,
33.94, 33.61, 19.94, 18.55, 14.97, 14.18. [α]20
D
= -91◦(c = 0.3, CHCl3). ESI-HRMS (m/z): calcd.
for [C38H49BrN6O8 + H]





















General procedure for the synthesis of dimeric lig-
ands (70a,b). To a solution of compound 56 (2 eq)
and diazido-spacer 66a or 66b 41 (1 eq) in degassed t-
BuOH/ACN/H2O (5 mL; 2/2/1; v/v/v) were added de-
gassed aqueous solutions of sodium ascorbate (2 M, 5 eq)
and CuSO4 (1 M, 20 mol%) and the resulting mixture
was stirred for 16 h at room temperature. DCM/MeOH
(9:1; v/v) and water were added and after partioning of
the layers, the waterlayer was extracted with DCM/MeOH
(9:1; v/v, 2 x). The combined organic layers were dried
(MgSO4) and concentrated. After silica column chromatography (0 → 5% MeOH in DCM) both
dimeric compound 70 and monomeric compound 67, as a side-product, were isolated as slightly yellow
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solids. R f = 0.4 (9:1 DCM:MeOH). FT-IR (thin film) v 2960, 2924, 2360, 2326, 2201, 1654, 1619,
1497, 1477, 1426, 1384, 1275, 1253, 1149, 1125 cm−1.
Dimeric ligand (70a). Yield: dimer: 35 mg, 0.03 mmol, 50%, monomer: 18 mg, 0.025 mmol, 42%.
1H NMR (400 MHz, MeOD): δ 8.00 (s, 2H, 2 x CHtrz), 6.86 (t, J = 1.7 Hz, 4H, 4 x CHar), 5.12
(s, 4H, 2 x CH2), 4.54 (t, J = 4.9 Hz, 4H, 2 x CH2), 4.51 (s, 2H, 2 x CH), 4.18 - 4.01 (m, 4H, 2
x CH2), 3.83 (t, J = 4.9 Hz, 4H, 2 x CH2), 3.61 - 3.54 (m, 8H, 4 x CH2), 2.55 - 2.29 (m, 6H, 2 x
CH2, 2 x CH2-H
a), 2.18 (s, 2H, 2 x CH), 2.15 - 2.04 (m, 8H, 2 x CH3, 2 x CH2-H
b), 1.42 (t, J = 6.9
Hz, 6H, 2 x CH3), 1.39 - 1.29 (m, 8H, 4 x CH2), 0.90 (t, J = 6.7 Hz, 6H, 2 x CH3).
13C NMR (101
MHz, MeOD): δ 196.63, 152.33, 151.57, 145.90, 143.26, 142.76, 124.89, 122.83, 119.39, 117.57,
112.34, 108.76, 86.94, 70.21, 70.16, 68.89, 65.56, 64.30, 50.35, 49.09, 48.88, 48.66, 48.45, 48.24,
48.02, 47.81, 42.95, 38.10, 37.03, 33.44, 32.50, 19.54, 17.44, 14.34, 13.62. [α]20
D
= -126◦(c = 0.84,
CHCl3). ESI-HRMS (m/z): calcd. for [C58H70Br2N10O9 + H]
+ 1211.37463; obsd. 1211.37644.
Dimeric ligand (70b). Yield: dimer: 30 mg, 0.024 mmol, 48%, monomer: 10 mg, 0.013 mmol, 26%.
1H NMR (400 MHz, CDCl3): δ 8.15 (s, 2H, 2 x NH), 7.91 (s, 2H, 2 x CHtrz), 6.89 (d, J = 1.6 Hz,
2H, 2 x CHar), 6.86 (d, J = 1.7 Hz, 2H, 2 x CHar), 5.15 (s, 4H, 2 x CH2), 4.54 (d, J = 6.8 Hz, 6H,
2 x CH2, 2 x CH), 4.14 - 4.06 (m, 4H, 2 x CH2), 3.86 (t, J = 5.0 Hz, 4H, 2 x CH2), 3.58 (s, 12H,
6 x CH2), 2.55 - 2.41 (m, 4H, 4 x CH2-H
a), 2.40 - 2.25 (m, 2H, 2 x CH2-H
b), 2.23 - 2.04 (m, 10H,
2 x CH3, 2 x CH2-H
b, 2 x CH), 1.42 (t, J = 7.0 Hz, 6H, 2 x CH3), 1.36 - 1.26 (m, 8H, 4 x CH2),
0.86 (t, J = 6.8 Hz, 6H, 2 x CH3).
13C NMR (101 MHz, CDCl3): δ 196.01, 152.71, 150.91, 145.83,
144.46, 143.76, 142.74, 124.81, 123.10, 119.69, 118.12, 112.82, 109.44, 87.62, 70.73, 70.71, 70.55,
69.51, 66.22, 64.70, 50.53, 43.53, 38.34, 37.49, 33.88, 33.38, 19.94, 18.37, 14.97, 14.18. [α]20
D
=


























General procedure for the copper-cataly-
zed click reaction of alkyne-ligands 69
with azido-BODIPY to give fluorescent
ligands (71a,b). To a solution of alkynes
69 (1 eq) and azido-BODIPY-benzyl 26 (1.1
eq) in degassed t-BuOH/ACN (2 mL; 1/1;
v/v) were added degassed aqueous solu-
tions of sodium ascorbate (1.25 mL, 1.2 eq)
and CuSO4 (0.2 mL, 20 mol%) and the re-
sulting mixture was stirred for 24 h at room
temperature. Since the conversion was not
complete, more sodium ascorbate (1 eq) and CuSO4 (20 mol%) were added and stirring was con-
tinued for 16 h. Dichloromethane and water were added, and the product was extracted with DCM
(3x), dried (MgSO4) and concentrated. After silica column chromatography (0 → 2.5% (n=3) or
3% (n=4) MeOH in DCM) the fluorescent ligand was obtained as a purple solid.
Fluorescent ligand (71a). Yield: 13 mg, 10 µmol, 93%. R f = 0.6 (10:1 DCM:MeOH). 1H NMR
(600 MHz, CDCl3): δ 8.07 (s, 1H, CHtrz), 7.90 (s, 1H, CHtrz), 7.85 (d, J = 8.8 Hz, 2H, 2 x CHar),
7.56 (s, 1H, NH), 7.30 - 7.23 (m, 3H, 3 x CHar), 7.20 (t, J = 10.6 Hz, 2H, 2 x CHar), 7.10 - 7.07 (m,
1H, CHBDP), 7.05 (s, 1H, NH), 6.97 (d, J = 4.0 Hz, 1H, CHar), 6.92 (d, J = 8.8 Hz, 2H, 2 x CHar),
6.90 (d, J = 1.6 Hz, 1H, CHar), 6.80 (d, J = 1.7 Hz, 1H, CHBDP), 6.55 (d, J = 4.0 Hz, 1H, CHBDP),
5.94 (t, J = 5.4 Hz, 1H, NH), 5.16 (s, 2H, CH2), 4.61 (t, J = 6.8 Hz, 2H, CH2), 4.58 - 4.50 (m, 3H,
106
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CH2, CH), 4.40 (d, J = 5.7 Hz, 2H, CH2), 4.14 - 4.04 (m, 2H, CH2), 4.03 - 3.95 (m, 2H, CH2), 3.86
(t, J = 5.1 Hz, 2H, CH2), 3.66 - 3.60 (m, 12H, 6 x CH2), 2.79 (t, J = 7.4 Hz, 2H, CH2), 2.51 (s, 3H,
CH3), 2.46 - 2.38 (m, 3H, CH2, CH2-H
a), 2.37 - 2.31 (m, 3H, CH2 , CH2-H
b), 2.31 - 2.23 (m, 1H,
CH2-H
b), 2.20 - 2.12 (m, 4H, CH3, CH), 2.08 - 2.02 (m, 4H, CH3, CH2-H
b), 1.42 (t, J = 6.9 Hz, 3H,
CH3), 1.34 - 1.26 (m, 4H, 2 x CH2), 0.87 (t, J = 6.7 Hz, 3H, CH3.
13C NMR (151 MHz, CDCl3):
δ 195.75, 171.59, 160.27, 159.70, 159.20, 155.38, 152.74, 149.82, 145.15, 144.68, 143.94, 143.39,
142.32, 140.29, 138.15, 135.08, 134.60, 130.92, 130.71, 128.85, 128.06, 127.88, 127.67, 126.20,
125.80, 124.68, 123.16, 122.89, 119.47, 118.49, 118.16, 114.30, 112.91, 109.93, 88.08, 70.74, 70.71,
70.57, 69.80, 69.65, 66.55, 64.71, 63.97, 50.42, 47.66, 43.83, 43.44, 39.08, 38.13, 37.52, 36.46,
33.91, 33.60, 29.94, 20.18, 19.90, 18.54, 14.94, 14.19, 13.36, 9.77. ESI-HRMS (m/z): calcd. for
[C66H76BBrF2N12O9 + H]
+ 1309.51755; obsd. 1309.51908.
Fluorescent ligand (71b). Yield: 10 mg, 7 µmol, 71%. R f = 0.5 (10:1 DCM:MeOH). 1H NMR (400
MHz, CDCl3): δ 8.07 (s, 1H, CHtrz), 7.91 - 7.80 (m, 3H, 2 x CH2, CHtrz), 7.55 (s, 1H, NH), 7.30 -
7.22 (m, 3H, 3 x CHar), 7.20 - 7.16 (m, 2H, 2 x CHar), 7.07 (s, 1H, CHBDP), 7.00 (s, 1H, NH), 6.96
(d, J = 4.1 Hz, 1H, CHar), 6.93 (d, J = 8.9 Hz, 2H, 2 x CHar), 6.90 (d, J = 1.9 Hz, 1H, CHar),
6.78 (d, J = 1.9 Hz, 1H, CHBDP), 6.54 (d, J = 4.1 Hz, 1H, CHBDP), 5.87 (s, 1H, NH), 5.17 (s, 2H,
CH2), 4.62 (t, J = 6.8 Hz, 2H, CH2), 4.55 - 4.49 (m, 3H, CH2, CH), 4.40 (d, J = 5.7 Hz, 2H, CH2),
4.16 - 4.05 (m, 2H, CH2), 4.01 (t, J = 5.7 Hz, 2H, CH2), 3.84 (t, J = 5.2 Hz, 2H, CH2), 3.68 -
3.54 (m, 16H, 8 x CH2), 2.79 (t, J = 7.5 Hz, 2H, CH2), 2.51 (s, 3H, CH3), 2.47 - 2.26 (m, 7H, 3 x
CH2, CH2-H
a), 2.19 - 2.12 (m, 4H, CH3, CH), 2.12 - 2.04 (m, 4H, CH3, CH2-H
b), 1.42 (t, J = 7.0
Hz, 3H, CH3), 1.34 - 1.25 (m, 4H, 2 x CH2), 0.87 (t, J = 6.8 Hz, 3H, CH3).
13C NMR (151 MHz,
CDCl3): δ 195.72, 171.58, 160.31, 159.73, 159.18, 155.35, 152.76, 149.85, 145.20, 143.86, 142.34,
140.30, 138.16, 135.09, 134.61, 130.93, 130.72, 128.85, 128.04, 127.89, 127.67, 126.24, 125.84,
124.71, 123.16, 122.85, 119.51, 118.46, 118.22, 114.30, 112.91, 109.89, 96.64, 88.05, 70.77, 70.67,
70.58, 70.55, 69.84, 69.63, 66.48, 64.73, 63.97, 50.49, 47.69, 43.84, 43.45, 39.14, 38.13, 37.53,
36.47, 33.92, 33.58, 29.95, 20.18, 19.93, 18.52, 14.96, 14.20, 13.37, 9.78. ESI-HRMS (m/z): calcd.
for [C68H80BBrF2N12O10 + H]





General procedure for the Bocylation of mono-aminoPEG spacers 17
(72a,b). To a cooled (0 ◦C) solution of spacer 17 (0.5 mmol) and TEA
in DCM (10 mL), Boc2O (131 mg, 0.6 mmol, 1.2 eq) was added, and the
reaction stirred for 1 h at rt, after which the solvent was removed in vacuo.
The compound was purified by silica column chromatography (0 → 2% MeOH in DCM) to give a
colorless oil.
tert-Butyl (11-azido-3,6,9-trioxaundecyl)carbamate (72a). Yield: 151 mg, 0.47 mmol, 95%. R f =
0.85 (EtOAc). 1H NMR (400 MHz, CDCl3): δ 5.09 (s, 1H, NH), 3.76 - 3.59 (m, 10H, 5 x CH2),
3.54 (t, J = 5.2 Hz, 2H, CH2), 3.39 (t, J = 5.0 Hz, 2H, CH2), 3.31 (d, J = 4.9 Hz, 2H, CH2), 1.44
(s, 9H, 3 x CH3).
13C NMR (101 MHz, CDCl3): δ 155.97, 79.08, 70.69, 70.62, 70.60, 70.24, 70.19,
70.04, 50.67, 40.38, 28.41. FT-IR (thin film) v 3352, 2977, 2872, 2098, 1710, 1508, 1276, 1249,
1170, 1110 cm−1. LC/MS analysis (10% → 90% ACN) tR : 7.04 min, ESI-MS (m/z): [M + H]+:
318.87.
tert-Butyl (14-azido-3,6,9,12-tetraoxatetradecyl)carbamate (72b). Yield: 171 mg, 0.47 mmol,
94%. R f = 0.85 (EtOAc). 1H NMR (400 MHz, CDCl3): δ 5.09 (s, 1H, NH), 3.73 - 3.60 (m, 14H, 7
x CH2), 3.54 (t, J = 5.1 Hz, 2H, CH2), 3.39 (t, J = 5.0 Hz, 2H, CH2), 1.44 (s, 9H, 3 x CH3).
13C
NMR (101 MHz, CDCl3): δ 155.99, 79.15, 70.70, 70.67, 70.62, 70.60, 70.52, 70.25, 70.03, 50.69,
107
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40.39, 28.43. FT-IR (thin film) v 3349, 2924, 2869, 2102, 1710, 1506, 1276, 1250, 1169, 1112 cm−1.





General procedure for the reduction of BocNH-PEG-azido spacers 72
(73a,b). Spacer 72 (1 eq) was dissolved in THF and PPh3 (1.2 eq) was
added. After 1 h stirring at ambient temperature, water (0.5 mL) was added
and stirring was continued for 20 h. Toluene was added, followed by washing
with HCl (aq, 1 M, 3x). The waterlayer was alkalized with NaOH (aq, 1 M) and extracted with
EtOAc (3x) and DCM (3x). The combined organic layers were dried over MgSO4 and concentrated
to afford compound 73.
tert-Butyl (11-amino-3,6,9-trioxaundecyl)carbamate (73a). Yield: 57 mg, 0.19 mmol, 72%. 1H
NMR (400 MHz, CDCl3): δ 5.36 (s, 1H, NH), 3.72 - 3.60 (m, 8H, 4 x CH2), 3.54 (t, J = 5.1 Hz,
4H, 2 x CH2), 3.31 (s, 2H, CH2), 2.90 (s, 2H, CH2), 2.39 (s, 2H, NH2), 1.44 (s, 9H, 3 x CH3).
13C
NMR (101 MHz, CDCl3): δ 156.13, 79.11, 72.95, 70.58, 70.56, 70.33, 70.26, 41.56, 40.43, 28.49.
LC/MS analysis (10% → 90% ACN) tR : 4.16 min, ESI-MS (m/z): [M + H]+: 293.07.
tert-Butyl (14-amino-3,6,9,12-tetraoxatetradecyl)carbamate (73b). Yield: 141 mg, 0.39 mmol,
78%. 1H NMR (400 MHz, CDCl3): δ 5.39 (s, 1H, NH), 3.70 - 3.60 (m, 12H, 6 x CH2), 3.57 - 3.49
(m, 4H, 2 x CH2), 3.34 - 3.28 (m, 2H, CH2), 2.88 (s, 2H, CH2), 2.29 (s, 2H, NH2), 1.44 (s, 9H, 3
x CH3).
13C NMR (101 MHz, CDCl3): δ 156.04, 78.97, 70.52, 70.51, 70.48, 70.47, 70.23, 70.17,
41.55, 40.32, 28.39. FT-IR (thin film) v 3355, 2872, 1702, 1508, 1365, 1279, 1250, 1169, 1100













General procedure for the coupling of mono-azido spacers 17 with
ortho-, meta-, or para-functionalized DHP to give monomeric ligands
(o-/m-/p-74a,b). To a solution of 63, 64 or 65 (30 mg, 0.052 mmol, 1
eq) in DCM (1 mL) were added spacer 17 (1 mL as a solution in DCM,
0.052 mmol, 1 eq), EEDQ (15 mg, 0.06 mmol, 1.2 eq) and DiPEA
(26 µL, 0.15 mmol, 3 eq). Reaction progress was slow, so after 24 h
another 2 eq of EEDQ and 1.5 eq of spacer were added. The reaction
was monitored by TLC, and upon completion, the mixture was washed
with HCl (aq, 1 M, 2x), water (2x), dried (MgSO4) and concentrated.
Pure monomers were obtained by silica column chromatography (0 →
2% MeOH in DCM). R f = 0.7 (12:1 DCM:MeOH). FT-IR (thin film) v 3294, 2924, 2866, 2360,
2343, 2201, 2110, 1644, 1498, 1426, 1384, 1275, 1124, 1045 cm−1.
N-(11-azido-3,6,9-trioxaundecyl) -2-((2-bromo-4-( (4R,7S) -3-cyano-2-methyl-5-oxo-7-propyl-1, 4,
5, 6, 7, 8-hexahydroquinolin-4-yl)-6-ethoxyphenoxy)methyl)benzamide (o-74a).
Yield: 32 mg, 0.041 mmol, 79%. 1H NMR (400 MHz, CDCl3): δ 7.63 - 7.55 (m, 2H, CHar, NH),
7.52 (s, 1H, NH), 7.43 - 7.33 (m, 3H, 3 x CHar), 6.82 (s, 2H, 2 x CHar), 5.16 (s, 2H, CH2), 4.53 (s,
1H, CH), 4.02 - 3.87 (m, 2H, CH2), 3.69 - 3.54 (m, 14H, 7 x CH2), 3.37 - 3.28 (m, 2H, CH2), 2.49
- 2.34 (m, 2H, 2 x CH2-H
a), 2.31 - 2.20 (m, 1H, CH2-H
b), 2.17 - 2.02 (m, 5H, CH3 , CH, CH2-H
b),
1.29 (t, J = 6.9 Hz, 7H, CH3, 2 x CH2), 0.88 (t, J = 6.7 Hz, 3H, CH3).
13C NMR (101 MHz,
CDCl3): δ 195.69, 169.41, 152.66, 150.11, 145.33, 143.24, 142.70, 136.81, 134.19, 130.93, 130.24,
128.55, 128.11, 123.12, 119.41, 118.03, 112.59, 109.67, 87.82, 72.68, 70.67, 70.65, 70.48, 70.03,
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-103◦(c = 0.5, CHCl3). ESI-HRMS (m/z): calcd. for [C38H47BrN6O7 + H]
+ 779.27624; obsd.
779.27650.
N-(14-azido-3, 6, 9, 12-tetraoxatetradecyl) -2-((2-bromo-4-( (4R,7S) -3-cyano-2-methyl-5-oxo-7-
propyl-1, 4, 5, 6, 7, 8-hexahydroquinolin-4-yl)-6-ethoxyphenoxy)methyl)benzamide (o-74b).
Yield: 32 mg, 0.039 mmol, 75%. 1H NMR (400 MHz, CDCl3): δ 7.63 - 7.57 (m, 1H, CHar), 7.53 -
7.45 (m, 2H, 2 x NH), 7.42 - 7.35 (m, 3H, 3 x CHar), 6.83 (s, 1H, CHar), 6.82 (s, 1H, CHar), 5.16
(s, 2H, CH2), 4.53 (s, 1H, CH), 4.02 - 3.87 (m, 2H, CH2), 3.72 - 3.49 (m, 18H, 9 x CH2), 3.36 (t,
J = 5.0 Hz, 2H, CH2), 2.49 - 2.33 (m, 2H, CH2), 2.30 - 2.20 (m, 1H, CH2-H
a), 2.19 - 1.99 (m,
5H, CH3, CH, CH2-H
b), 1.33 - 1.20 (m, 7H, CH3, 2 x CH2), 0.88 (t, J = 6.5 Hz, 3H, CH3).
13C
NMR (101 MHz, CDCl3): δ 195.66, 169.40, 152.66, 150.05, 145.33, 143.30, 142.63, 136.76, 134.26,
130.87, 130.23, 128.51, 128.08, 123.08, 119.42, 118.03, 112.59, 109.68, 87.81, 72.66, 70.73, 70.67,
70.61, 70.57, 70.46, 70.05, 69.73, 64.47, 50.76, 43.48, 40.10, 38.28, 37.45, 33.83, 33.44, 19.88,
18.42, 14.67, 14.17. [α]20
D
= -135◦(c = 0.5, CHCl3). ESI-HRMS (m/z): calcd. for [C40H51BrN6O8
+ H]+ 823.30245; obsd. 823.30316.
N-(11-azido-3,6,9-trioxaundecyl) -3-((2-bromo-4-( (4R,7S) -3-cyano-2-methyl-5-oxo-7-propyl-1, 4,
5, 6, 7, 8-hexahydroquinolin-4-yl)-6-ethoxyphenoxy)methyl)benzamide (m-74a).
Yield: 30 mg, 0.039 mmol, 74%. 1H NMR (400 MHz, CDCl3): δ 8.07 (s, 1H, CHar), 7.73 (d, J =
7.8 Hz, 1H, CHar), 7.66 (d, J = 10.1 Hz, 2H, CHar, NH), 7.45 (t, J = 7.7 Hz, 1H, CHar), 7.00 (s,
1H, NH), 6.91 (d, J = 1.8 Hz, 1H, CHar), 6.86 (d, J = 1.9 Hz, 1H, CHar), 5.03 (s, 2H, CH2), 4.55
(s, 1H, CH), 4.19 - 4.03 (m, 2H, CH2), 3.75 - 3.54 (m, 14H, 7 x CH2), 3.40 - 3.27 (m, 2H, CH2),
2.48 - 2.23 (m, 3H, CH2, CH2-H
a), 2.17 - 2.02 (m, 5H, CH3, CH, CH2-H
b), 1.43 (t, J = 7.0 Hz, 3H,
CH3), 1.33 - 1.18 (m, 4H, 2 x CH2), 0.85 (t, J = 6.9 Hz, 3H, CH3).
13C NMR (101 MHz, CDCl3):
δ 195.93, 168.01, 152.71, 150.35, 145.39, 144.04, 142.57, 138.42, 134.68, 131.34, 128.63, 127.13,
126.44, 123.14, 119.57, 118.09, 113.03, 109.70, 87.87, 74.01, 70.75, 70.67, 70.41, 70.08, 69.80,
64.68, 50.74, 43.54, 40.05, 38.43, 37.50, 33.92, 33.51, 19.84, 18.44, 14.95, 14.15. [α]20
D
= -102◦(c
= 0.5, CHCl3). ESI-HRMS (m/z): calcd. for [C38H47BrN6O7 + H]
+ 779.27624; obsd. 779.27652.
N-(14-azido-3, 6, 9, 12-tetraoxatetradecyl) -3-((2-bromo-4-( (4R,7S) -3-cyano-2-methyl-5-oxo-7-
propyl-1, 4, 5, 6, 7, 8-hexahydroquinolin-4-yl)-6-ethoxyphenoxy)methyl)benzamide (m-74b).
Yield: 36 mg, 0.044 mmol, 84%. 1H NMR (400 MHz, CDCl3): δ 8.08 (s, 1H, CHar), 7.76 - 7.71
(m, 2H, NH, CHar), 7.66 (d, J = 7.5 Hz, 1H, CHar), 7.45 (t, J = 7.7 Hz, 1H, CHar), 7.07 (s, 1H,
NH), 6.92 (s, 1H, CHar), 6.86 (s, 1H, CHar), 5.03 (s, 2H, CH2), 4.55 (s, 1H, CH), 4.12 (dd, J =
6.9, 2.0 Hz, 2H, CH2), 3.73 - 3.55 (m, 18H, 9 x CH2), 3.35 (t, J = 4.8 Hz, 2H, CH2), 2.46 - 2.26
(m, 3H, CH2, CH2-H
a), 2.26 - 1.99 (m, 5H, CH3, CH, CH2-H
b), 1.43 (t, J = 6.9 Hz, 3H, CH3),
1.35 - 1.18 (m, 4H, 2 x CH2), 0.85 (t, J = 6.6 Hz, 3H, CH3).
13C NMR (101 MHz, CDCl3): δ
195.91, 167.99, 152.69, 150.35, 145.42, 144.04, 142.56, 138.41, 134.65, 131.34, 128.61, 127.21,
126.44, 123.12, 119.58, 118.08, 113.03, 109.69, 87.84, 74.02, 70.73, 70.64, 70.41, 70.07, 69.83,
64.67, 50.75, 43.55, 40.07, 38.42, 37.50, 33.92, 33.50, 19.84, 18.44, 14.95, 14.15. [α]20
D
= -123◦(c
= 0.5, CHCl3). ESI-HRMS (m/z): calcd. for [C40H51BrN6O8 + H]
+ 823.30245; obsd. 823.30294.
N-(11-azido-3,6,9-trioxaundecyl) -4-((2-bromo-4-( (4R,7S) -3-cyano-2-methyl-5-oxo-7-propyl-1, 4,
5, 6, 7, 8-hexahydroquinolin-4-yl)-6-ethoxyphenoxy)methyl)benzamide (p-74a).
Yield: 37 mg, 0.047 mmol, 91%. 1H NMR (400 MHz, CDCl3): δ 7.79 (d, J = 8.2 Hz, 2H, 2 x CHar),
7.62 (d, J = 8.3 Hz, 2H, 2 x CHar), 7.31 (s, 1H, NH), 6.94 (d, J = 5.1 Hz, 1H, NH), 6.90 (d, J
= 1.9 Hz, 1H, CHar), 6.83 (d, J = 1.9 Hz, 1H, CHar), 5.04 (s, 2H, CH2), 4.55 (s, 1H, CH), 4.16 -




a), 2.37 - 2.23 (m, 1H, CH2-H
b), 2.22 - 2.04 (m, 5H, CH3, CH, CH2-H
b), 1.42 (t, J = 7.0
Hz, 3H, CH3), 1.36 - 1.25 (m, 4H, 2 x CH2), 0.89 (t, J = 6.9 Hz, 3H, CH3).
13C NMR (101 MHz,
CDCl3): δ 195.79, 167.83, 152.77, 149.94, 145.11, 144.19, 142.37, 141.40, 134.05, 128.33, 127.10,
123.11, 119.41, 118.08, 113.00, 109.89, 88.13, 73.91, 70.78, 70.76, 70.69, 70.41, 70.14, 69.82, 64.72,
50.77, 43.48, 40.00, 38.32, 37.45, 33.86, 33.56, 19.93, 18.51, 14.94, 14.17. [α]20
D
= -97◦(c = 0.5,
CHCl3). ESI-HRMS (m/z): calcd. for [C38H47BrN6O7 + H]
+ 779.27624; obsd. 779.27670.
N-(14-azido-3, 6, 9, 12-tetraoxatetradecyl) -4-((2-bromo-4-( (4R,7S) -3-cyano-2-methyl-5-oxo-7-
propyl-1, 4, 5, 6, 7, 8-hexahydroquinolin-4-yl)-6-ethoxyphenoxy)methyl)benzamide (p-74b).
Yield: 34 mg, 0.041 mmol, 79%. 1H NMR (400 MHz, CDCl3): δ 7.80 (d, J = 8.0 Hz, 2H, 2 x CHar),
7.62 (d, J = 7.3 Hz, 3H, 2 x CHar, NH), 7.14 - 7.08 (m, 1H, NH), 6.90 (s, 1H, CHar), 6.84 (s, 1H,
CHar), 5.03 (s, 2H, CH2), 4.55 (s, 1H, CH), 4.19 - 3.98 (m, 2H, CH2), 3.72 - 3.58 (m, 18H, 9 x
CH2), 3.34 (t, J = 5.0 Hz, 2H, CH2), 2.52 - 2.36 (m, 2H, CH2), 2.34 - 2.22 (m, 2H, CH2), 2.14 -
2.01 (m, 4H, CH3, CH), 1.42 (t, J = 6.9 Hz, 3H, CH3), 1.36 - 1.26 (m, 4H, 2 x CH2), 0.89 (t, J =
6.7 Hz, 3H, CH3).
13C NMR (101 MHz, CDCl3): δ 195.82, 167.86, 152.74, 150.17, 145.27, 144.14,
142.44, 141.36, 134.00, 128.28, 127.13, 123.09, 119.48, 118.05, 112.93, 109.74, 87.95, 73.89, 70.72,
70.63, 70.38, 70.06, 69.83, 64.68, 50.73, 43.46, 40.02, 38.31, 37.42, 33.83, 33.45, 19.91, 18.42,
14.93, 14.16. [α]20
D















General procedure for the coupling of mono-Boc-diaminospacers
73 with ortho-, meta-, or para-functionalized DHP to give Boc-
protected monomeric ligands (o-/m-/p-75a,b). To a solution of
63, 64 or 65 (20 mg, 0.034 mmol, 1 eq) in DCM (1 mL) were added
spacer 73 (1 mL as a solution in DCM, 0.053 mmol, 1.5 eq) and
EEDQ (17 mg, 0.07 mmol, 2 eq). The reaction was monitored by
TLC, and upon completion (16-36 h), the mixture was loaded onto
a silica column (0 → 4% MeOH in DCM) to give the Boc-protected
monomers as slightly yellow solids. R f = 0.35 (15:1 DCM:MeOH).
tert-Butyl (1-(2-((2-bromo-4-( (4R,7S) -3-cyano-2-methyl-5-oxo-7-propyl-1, 4, 5, 6, 7, 8-hexahy-
droquinolin-4-yl)-6-ethoxyphenoxy)methyl) phenyl) -1-oxo-5,8,11-trioxa-2-azatridecan-13-yl) car-
bamate (o-75a). Yield: 27 mg, 0.032 mmol, 93%. 1H NMR (400 MHz, CDCl3): δ 7.64 - 7.58 (m,
1H, CHar), 7.57 - 7.45 (m, 2H, 2 x NH), 7.40 - 7.34 (m, 3H, 3 x CHar), 6.84 (d, J = 1.8 Hz, 1H,
CHar), 6.81 (d, J = 1.8 Hz, 1H, CHar), 5.16 (s, 2H, CH2), 5.09 (s, 1H, NH), 4.54 (s, 1H, CH),
4.04 - 3.86 (m, 2H, CH2), 3.71 - 3.49 (m, 12H, 6 x CH2), 3.47 (t, J = 5.2 Hz, 2H, CH2), 3.29 -
3.22 (m, 2H, CH2), 2.49 - 2.37 (m, 2H, 2 x CH2-H
a), 2.34 - 2.22 (m, 1H, CH2-H
b), 2.19 - 2.02
(m, 5H, CH3, CH, CH2-H
b), 1.43 (s, 9H, 3 x CH3), 1.33 - 1.26 (m, 7H, CH3, 2 x CH2), 0.89 (t,
J = 6.7 Hz, 3H, CH3).
13C NMR (101 MHz, CDCl3): δ 195.63, 169.36, 156.27, 152.68, 149.98,
145.27, 143.30, 142.64, 136.94, 134.12, 131.00, 130.20, 128.59, 128.25, 123.04, 119.39, 118.07,
112.63, 109.79, 87.90, 79.45, 72.76, 70.56, 70.54, 70.49, 70.27, 70.17, 69.85, 64.51, 43.50, 40.50,
40.10, 38.25, 37.48, 33.86, 33.50, 28.55, 19.90, 18.46, 14.68, 14.17. [α]20
D
= -91◦(c = 0.44, CHCl3).
ESI-HRMS (m/z): calcd. for [C43H57BrN4O9 + H]
+ 853.33817; obsd. 853.33933.
tert-Butyl (1-(3-((2-bromo-4-( (4R,7S) -3-cyano-2-methyl-5-oxo-7-propyl-1, 4, 5, 6, 7, 8-hexahy-
droquinolin-4-yl)-6-ethoxyphenoxy)methyl) phenyl) -1-oxo-5,8,11,14-tetraoxa-2-azahexadecan-16-
yl) carbamate (o-75b). Yield: 25 mg, 0.028 mmol, 82%. 1H NMR (400 MHz, CDCl3): δ 7.64 -
7.59 (m, 1H, CHar), 7.54 (s, 2H, 2 x NH), 7.41 - 7.34 (m, 3H, 3 x CHar), 6.84 (d, J = 1.6 Hz, 1H,
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CHar), 6.81 (d, J = 1.8 Hz, 1H, CHar), 5.16 (s, 2H, CH2), 5.12 (s, 1H, NH), 4.54 (s, 1H, CH), 3.95
(qd, J = 9.3, 2.2 Hz, 2H, CH2), 3.67 (s, 4H, 2 x CH2), 3.64 - 3.52 (m, 12H, 6 x CH2), 3.50 (t, J =
5.1 Hz, 2H, CH2), 3.33 - 3.24 (m, 2H, CH2), 2.48 - 2.36 (m, 2H, 2 x CH2-H
a), 2.34 - 2.22 (m, 1H,
CH2-H
b), 2.20 - 2.03 (m, 5H, CH3, CH, CH2-H
b), 1.44 (s, 9H, 3 x CH3), 1.35 - 1.24 (m, 7H, CH3,
2 x CH2), 0.89 (t, J = 6.5 Hz, 3H, CH3).
13C NMR (101 MHz, CDCl3): δ 195.66, 169.37, 156.26,
152.68, 150.01, 145.33, 143.32, 142.62, 136.84, 134.23, 130.89, 130.20, 128.53, 128.20, 123.02,
119.45, 118.06, 112.57, 109.74, 87.84, 79.42, 72.75, 70.59, 70.54, 70.45, 70.31, 69.86, 64.48, 43.51,
40.48, 40.08, 38.23, 37.50, 33.88, 33.49, 28.55, 19.90, 18.47, 14.69, 14.18. [α]20
D
= -94◦(c = 0.5,
CHCl3). ESI-HRMS (m/z): calcd. for [C45H61BrN4O10 + H]
+ 897.36438; obsd. 897.36608.
tert-Butyl (1-(3-((2-bromo-4-( (4R,7S) -3-cyano-2-methyl-5-oxo-7-propyl-1, 4, 5, 6, 7, 8-hexahy-
droquinolin-4-yl)-6-ethoxyphenoxy)methyl) phenyl) -1-oxo-5,8,11-trioxa-2-azatridecan-13-yl) car-
bamate (m-75a). Yield: 22 mg, 0.026 mmol, 90%. 1H NMR (400 MHz, CDCl3): δ 8.06 (s, 1H,
CHar), 7.75 (d, J = 7.5 Hz, 1H, CHar), 7.64 (d, J = 7.7 Hz, 1H, CHar), 7.52 (s, 1H, NH), 7.43 (t,
J = 7.7 Hz, 1H, CHar), 7.00 (s, 1H, NH), 6.91 (d, J = 1.8 Hz, 1H, CHar), 6.84 (d, J = 1.8 Hz,
1H, CHar), 5.06 (t, J = 5.5 Hz, 1H, NH), 5.03 (s, 2H, CH2), 4.54 (s, 1H, CH), 4.15 - 4.07 (m, 2H,
CH2), 3.68 - 3.56 (m, 12H, 6 x CH2), 3.48 (t, J = 5.2 Hz, 2H, CH2), 3.28 - 3.20 (m, 2H, CH2),
2.45 - 2.27 (m, 3H, CH2, CH2-H
a), 2.19 - 1.99 (m, 5H, CH3, CH, CH2-H
b), 1.43 (d, J = 6.4 Hz,
12H, 4 x CH3), 1.30 - 1.23 (m, 4H, 2 x CH2), 0.86 (t, J = 6.8 Hz, 3H, CH3).
13C NMR (101 MHz,
CDCl3): δ 195.83, 167.94, 156.22, 152.73, 150.12, 145.27, 144.11, 142.50, 138.33, 134.70, 131.30,
128.62, 127.05, 126.63, 123.10, 119.51, 118.09, 113.09, 109.84, 88.00, 81.79, 74.09, 70.61, 70.58,
70.43, 70.28, 69.96, 64.72, 43.55, 40.48, 40.03, 38.37, 37.53, 33.95, 33.58, 28.55, 19.87, 18.51,
14.95, 14.16. [α]20
D
= -84◦(c = 0.44, CHCl3). ESI-HRMS (m/z): calcd. for [C43H57BrN4O9 + H]
+
853.33817; obsd. 853.33937.
tert-Butyl (1-(3-((2-bromo-4-( (4R,7S) -3-cyano-2-methyl-5-oxo-7-propyl-1, 4, 5, 6, 7, 8-hexahy-
droquinolin-4-yl)-6-ethoxyphenoxy)methyl) phenyl) -1-oxo-5,8,11,14-tetraoxa-2-azahexadecan-16-
yl) carbamate (m-75b). Yield: 22 mg, 0.025 mmol, 72%. 1H NMR (400 MHz, CDCl3): δ 8.07 (s,
1H, CHar), 7.75 (d, J = 7.5 Hz, 1H, CHar), 7.66 (d, J = 7.3 Hz, 2H, CHar, NH), 7.44 (t, J = 7.6
Hz, 1H, CHar), 7.07 (s, 1H, NH), 6.92 (s, 1H, CHar), 6.85 (s, 1H, CHar), 5.12 (s, 1H, NH), 5.03 (s,
2H, CH2), 4.55 (s, 1H, CH), 4.18 - 4.05 (m, 2H, CH2), 3.74 - 3.52 (m, 16H, 8 x CH2), 3.50 (t, J =
4.9 Hz, 2H, CH2), 3.28 (d, J = 4.6 Hz, 2H, CH2), 2.48 - 2.28 (m, 3H, CH2, CH2-H
a), 2.21 - 1.99
(m, 5H, CH3, CH, CH2-H
b), 1.43 (s, 12H, 4 x CH3), 1.27 (m, 4H, 2 x CH2), 0.86 (t, J = 6.5 Hz,
3H, CH3).
13C NMR (101 MHz, CDCl3): δ 195.88, 167.94, 156.21, 152.70, 150.26, 145.38, 144.05,
142.54, 138.35, 134.67, 131.31, 128.60, 127.14, 126.56, 123.09, 119.58, 118.08, 113.02, 109.75,
87.88, 79.37, 74.05, 70.63, 70.59, 70.41, 70.34, 70.28, 69.93, 64.67, 43.56, 40.46, 40.04, 38.38,
37.53, 33.95, 33.53, 28.55, 19.86, 18.48, 14.96, 14.17. [α]20
D
= -91◦(c = 0.44, CHCl3). ESI-HRMS
(m/z): calcd. for [C45H61BrN4O10 + H]
+ 897.36438; obsd. 897.36615.
tert-Butyl (1-(4-((2-bromo-4-( (4R,7S) -3-cyano-2-methyl-5-oxo-7-propyl-1, 4, 5, 6, 7, 8-hexahy-
droquinolin-4-yl)-6-ethoxyphenoxy)methyl) phenyl) -1-oxo-5,8,11-trioxa-2-azatridecan-13-yl) car-
bamate (p-75a). Yield: 26 mg, 0.03 mmol, 89%. 1H NMR (400 MHz, CDCl3): δ 7.79 (d, J =
7.5 Hz, 2H, 2 x CHar), 7.61 (d, J = 7.9 Hz, 2H, 2 x CHar), 7.22 (s, 1H, NH), 6.90 (s, 2H, NH,
CHar), 6.82 (s, 1H, CHar), 5.05 (s, 1H, NH), 5.02 (s, 2H, CH2), 4.55 (s, 1H, CH), 4.16 - 4.06 (m,
2H, CH2), 3.71 - 3.57 (m, 12H, 6 x CH2), 3.50 (t, J = 5.1 Hz, 2H, CH2), 3.27 (d, J = 4.4 Hz, 2H,
CH2), 2.51 - 2.37 (m, 2H, 2 x CH2-H
a), 2.37 - 2.26 (m, 1H, CH2-H
b), 2.23 - 2.04 (m, 5H, CH3,
CH, CH2-H
b), 1.46 - 1.40 (m, 12H, 4 x CH3), 1.36 - 1.28 (m, 4H, 2 x CH2), 0.89 (t, J = 6.7 Hz,
3H, CH3).
13C NMR (101 MHz, CDCl3): δ 195.72, 191.97, 167.77, 157.18, 156.19, 152.76, 149.80,
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146.81, 145.04, 144.21, 142.34, 141.31, 139.61, 134.07, 128.34, 127.15, 123.10, 119.39, 118.09,
113.07, 109.97, 100.11, 88.19, 81.39, 73.96, 70.62, 70.59, 70.40, 70.30, 69.97, 64.73, 43.49, 40.47,
39.99, 38.30, 37.48, 33.89, 33.61, 28.55, 19.93, 18.55, 14.95, 14.79, 14.16. [α]20
D
= -77◦(c = 0.52,
CHCl3). ESI-HRMS (m/z): calcd. for [C43H57BrN4O9 + H]
+ 853.33817; obsd. 853.33898.
tert-Butyl (1-(4-((2-bromo-4-( (4R,7S) -3-cyano-2-methyl-5-oxo-7-propyl-1, 4, 5, 6, 7, 8-hexahy-
droquinolin-4-yl)-6-ethoxyphenoxy)methyl) phenyl) -1-oxo-5,8,11,14-tetraoxa-2-azahexadecan-16-
yl) carbamate (p-75b). Yield: 24 mg, 0.027 mmol, 79%. 1H NMR (400 MHz, CDCl3): δ 7.82 (d,
J = 8.1 Hz, 2H, 2 x CHar), 7.61 (d, J = 8.1 Hz, 2H, 2 x CHar), 7.42 (s, 1H, NH), 7.16 (s, 1H,
NH), 6.90 (d, J = 1.8 Hz, 1H, CHar), 6.82 (d, J = 1.8 Hz, 1H, CHar), 5.18 (s, 1H, NH), 5.03 (s,
2H, CH2), 4.55 (s, 1H, CH), 4.18 - 4.05 (m, 2H, CH2), 3.69 - 3.48 (m, 18H, 9 x CH2), 3.33 - 3.24
(m, 2H, CH2), 2.51 - 2.38 (m, 2H, 2 x CH2-H
a), 2.37 - 2.07 (m, 6H, CH3, CH, 2 x CH2-H
b), 1.46
- 1.39 (m, 12H, 4 x CH3), 1.35 - 1.27 (m, 4H, 2 x CH2), 0.89 (t, J = 6.8 Hz, 3H, CH3).
13C
NMR (101 MHz, CDCl3): δ 195.77, 167.80, 156.20, 152.74, 149.95, 145.14, 144.14, 142.38, 141.27,
134.06, 128.28, 127.19, 123.05, 119.45, 118.08, 112.96, 109.87, 88.08, 79.32, 73.94, 70.64, 70.61,
70.35, 70.27, 69.98, 64.68, 43.48, 40.45, 40.00, 38.28, 37.47, 33.88, 33.55, 28.55, 19.92, 18.52,
14.95, 14.17. [α]20
D






















General procedure for the synthesis of dimeric ligands
(o,o-/m,m-/p,p-77a,b). Compound 75 (10-20 µmol)
was subjected to DCM/TFA (2 mL, 1:1, v/v) for 30 min
- 1 h, upon which TLC indicated complete removal of
the Boc-group. The mixture was diluted with toluene
and concentrated in vacuo. Silica column chromatogra-
phy (2.5% → 5% MeOH in DCM + 1% TEA) afforded
amine 76 (R f = 0.5 (10:1:1 DCM:MeOH:TEA). a: ESI-
MS (m/z): [M + H]+: 753.33. b: ESI-MS (m/z): [M
+ H]+: 797.33.). A pre-activated mixture of 63, 64 or
65 (1 eq), EDC (2 eq), HOBt (2 eq) and TEA (2 eq) in DCM (2 mL) was added to the corresponding
ortho-, meta-, or para-monomeric amine 76 (1.05 eq). The reaction was monitored by TLC, and
upon completion (1-2 h), DCM was added and the solution was washed with HCl (aq, 1 M, 2x),
water (1x), dried (MgSO4) and concentrated. Pure dimeric compounds were obtained after silica
column chromatography (0 → 3% MeOH in DCM) as white solids. R f = 0.5 (10:1 DCM:MeOH).
FT-IR (thin film) v 3285, 2923, 2860, 2360, 2342, 2201, 1648, 1498, 1384, 1274, 1125, 1046 cm−1.
Dimeric ligand (o,o-77a). Yield: 5.2 mg, 4 µmol, 58%. 1H NMR (600 MHz, CDCl3): δ 7.62 (d, J
= 6.6 Hz, 2H, 2 x CHar), 7.58 (s, 2H, 2 x NH), 7.44 (s, 2H, 2 x NH), 7.39 - 7.31 (m, 6H, 6 x CHar),
6.83 (s, 2H, 2 x CHar), 6.79 (s, 2H, 2 x CHar), 5.15 (s, 4H, 2 x CH2), 4.54 (d, J = 13.4 Hz, 2H, 2
x CH), 3.93 (dd, J = 15.2, 7.5 Hz, 4H, 2 x CH2), 3.67 - 3.58 (m, 8H, 4 x CH2), 3.49 (s, 4H, 2 x
CH2), 3.42 (s, 4H, 2 x CH2), 2.45 (dd, J = 15.8, 2.9 Hz, 2H, 2 x CH2-H
a), 2.38 (d, J = 14.5 Hz,
2H, 2 x CH2-H
a), 2.29 - 2.23 (m, 2H, 2 x CH2-H
b), 2.16 (s, 2H, 2 x CH), 2.11 - 2.05 (m, 8H, 2 x
CH3, 2 x CH2-H
b), 1.30 - 1.27 (m, 14H, 2 x CH3, 4 x CH2), 0.89 (d, J = 6.4 Hz, 6H, 2 x CH3).
13C
NMR (151 MHz, CDCl3): δ 195.82, 169.49, 152.69, 150.27, 145.37, 143.19, 142.66, 137.07, 133.88,
131.26, 130.33, 128.79, 128.48, 122.97, 119.46, 118.13, 112.47, 109.71, 87.93, 72.89, 70.45, 70.41,
69.78, 64.53, 43.52, 40.18, 38.18, 37.53, 33.91, 33.58, 19.92, 18.51, 14.70, 14.21. [α]20
D
= -120◦(c =
0.1, CHCl3). ESI-HRMS (m/z): calcd. for [C68H78Br2N6O11 + H]
+ 1315.41476; obsd. 1315.41678.
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Dimeric ligand (o,o-77b). Yield: 5 mg, 3.7 µmol, 37%. 1H NMR (600 MHz, CDCl3/MeOD): δ
78.83 (s, 2H, 2 x NH), 7.90 (s, 2H, 2 x CHar), 7.61 - 7.54 (m, 2H, 2 x CHar), 7.43 (d, J = 6.1 Hz,
2H, 2 x CHar), 7.41 - 7.36 (m, 4H, 2 x CHar, 2 x NH), 6.83 (d, J = 10.5 Hz, 4H, 4 x CHar), 5.19 -
5.12 (m, 4H, 2 x CH2), 4.51 (s, 2H, 2 x CH), 4.07 - 3.91 (m, 4H, 2 x CH2), 3.64 - 3.48 (m, 20H,
10 x CH2), 2.51 - 2.42 (m, 4H, 4 x CH2-H
a), 2.34 (dd, J = 16.5, 9.0 Hz, 2H, 2 x CH2-H
b), 2.18
(s, 2H, 2 x CH), 2.13 - 2.06 (m, 8H, 2 x CH3, 2 x CH2-H
b), 1.35 (s, 8H, 4 x CH2), 1.30 (t, J =
6.9 Hz, 6H, 2 x CH3), 0.91 (t, J = 6.4 Hz, 6H, 2 x CH3).
13C NMR (151 MHz, CDCl3/MeOD):
δ 196.47, 169.98, 152.52, 151.24, 145.86, 143.14, 142.79, 136.17, 134.26, 130.46, 130.15, 128.30,
127.84, 122.99, 119.52, 117.83, 112.34, 109.07, 87.18, 72.48, 70.25, 70.18, 70.06, 69.75, 64.34,
43.19, 39.91, 38.17, 37.25, 33.63, 32.76, 19.73, 17.73, 14.41, 13.90. [α]20
D
= -120◦(c = 0.1, CHCl3).
ESI-HRMS (m/z): calcd. for [C70H82Br2N6O12 + H]
+ 1359.44098; obsd. 1359.44324.
Dimeric ligand (m,m-77a). Yield: 2.4 mg, 1.8 µmol, 26%. 1H NMR (600 MHz, CDCl3): δ 8.01
(s, 2H, 2 x CHar), 7.79 (d, J = 7.7 Hz, 2H, 2 x CHar), 7.60 (d, J = 7.6 Hz, 2H, 2 x CHar), 7.42
(t, J = 7.6 Hz, 2H, 2x CHar), 7.04 (s, 2H, 2 x NH), 6.98 (s, 2H, 2 x NH), 6.90 (d, J = 1.3 Hz,
2H, 2 x CHar), 6.80 (d, J = 1.6 Hz, 2H, 2 x CHar), 5.10 - 4.98 (m, 4H, 2 x CH2), 4.54 (s, 2H, 2
x CH), 4.16 - 4.05 (m, 4H, 2 x CH2), 3.65 - 3.58 (m, 16H, 8 x CH2), 2.45 (dd, J = 16.1, 3.8 Hz,
2H, 2 x CH2-H
a), 2.43 - 2.36 (m, 2H, 2 x CH2-H
a), 2.31 (dd, J = 16.4, 9.2 Hz, 2H, 2 x CH2-H
b),
2.17 (dd, J = 9.3, 4.8 Hz, 2H, 2 x CH), 2.11 - 2.04 (m, 8H, 2 x CH3, 2 x CH2-H
b), 1.45 - 1.38 (m,
6H, 2 x CH3), 1.34 - 1.28 (m, 8H, 4 x CH2), 0.88 (t, J = 6.9 Hz, 6H, 2 x CH3).
13C NMR (151
MHz, CDCl3): δ 195.91, 167.89, 152.79, 149.95, 145.05, 144.10, 142.45, 138.13, 134.70, 131.24,
128.75, 127.15, 126.60, 123.00, 119.48, 118.11, 112.97, 109.90, 88.21, 74.14, 70.64, 70.42, 69.83,
64.73, 43.51, 39.94, 38.37, 37.52, 33.92, 33.68, 19.93, 18.59, 14.97, 14.20. [α]20
D
= -108◦(c = 0.05,
CHCl3). ESI-HRMS (m/z): calcd. for [C68H78Br2N6O11 + H]
+ 1315.41476; obsd. 1315.41673.
Dimeric ligand (m,m-77b). Yield: 4.7 mg, 3.5 µmol, 38%. 1H NMR (600 MHz, CDCl3): δ 8.01
(s, 2H, 2 x CHar), 7.77 (d, J = 7.6 Hz, 2H, 2 x CHar), 7.63 (d, J = 7.6 Hz, 2H, 2 x CHar), 7.43
(t, J = 7.7 Hz, 2H, 2 x CHar), 7.37 (s, 2H, 2 x NH), 7.09 (s, 2H, 2 x NH), 6.90 (d, J = 9.2 Hz,
2H, 2 x CHar), 6.82 (d, J = 1.4 Hz, 2H, 2 x CHar), 5.07 - 4.96 (m, 4H, 2 x CH2), 4.54 (s, 2H,
2 x CH), 4.15 - 4.02 (m, 4H, 2 x CH2), 3.64 - 3.57 (m, 20H, 10 x CH2), 2.48 - 2.35 (m, 4H, 2 x
CH2-H
a), 2.31 (dd, J = 16.4, 9.2 Hz, 2H, 2 x CH2-H
b), 2.15 (d, J = 11.8 Hz, 2H, 2 x CH), 2.10
- 2.03 (m, 8H, 2 x CH3, 2 x CH2-H
b), 1.42 (t, J = 6.9 Hz, 6H, 2 x CH3), 1.33 - 1.25 (m, 8H, 4 x
CH2), 0.87 (t, J = 6.9 Hz, 6H, 2 x CH3).
13C NMR (151 MHz, CDCl3): δ 195.99, 168.02, 152.78,
150.28, 145.28, 144.09, 142.52, 138.19, 134.68, 131.31, 128.71, 126.99, 126.81, 123.05, 119.57,
118.12, 112.94, 109.77, 88.03, 74.13, 70.58, 70.34, 69.93, 64.71, 43.53, 40.00, 38.39, 37.52, 33.93,
33.60, 19.91, 18.53, 14.98, 14.20. [α]20
D
= -106◦(c = 0.094, CHCl3). ESI-HRMS (m/z): calcd. for
[C70H82Br2N6O12 + H]
+ 1359.44098; obsd. 1359.44324.
Dimeric ligand (p,p-77a). Yield: 4 mg, 3 µmol, 30%. 1H NMR (600 MHz, CDCl3): δ 7.76 (d, J =
8.2 Hz, 4H, 4 x CHar), 7.57 (d, J = 8.1 Hz, 4H, 4 x CHar), 6.92 (s, 2H, 2 x NH), 6.90 - 6.87 (m,
4H, 2 x CHar, 2 x NH), 6.80 (d, J = 1.8 Hz, 2H, 2 x CHar), 5.03 (q, J = 11.4 Hz, 4H, 2 x CH2),
4.54 (s, 2H, 2 x CH), 4.13 - 4.03 (m, 4H, 2 x CH2), 3.67 - 3.58 (m, 16H, 8 x CH2), 2.45 (dd, J =
16.1, 3.8 Hz, 2H, 2 x CH2-H
a), 2.38 (dd, J = 16.3, 4.3 Hz, 2H, 2 x CH2-H
a), 2.29 (dd, J = 16.4,
9.2 Hz, 2H, 2 x CH2-H
b), 2.22 - 2.10 (m, 2H, 2 x CH), 2.12 - 2.02 (m, 8H, 2 x CH3, 2 x CH2-H
b),
1.44 - 1.39 (m, 6H, 2 x CH3), 1.36 - 1.29 (m, 8H, 4 x CH2), 0.89 (t, J = 6.9 Hz, 6H, 2 x CH3).
13C NMR (151 MHz, CDCl3): δ 195.83, 167.78, 152.79, 149.80, 144.97, 144.08, 142.27, 141.13,
134.14, 128.46, 127.14, 123.05, 119.40, 118.19, 112.95, 109.97, 88.27, 74.01, 70.62, 70.35, 69.83,
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64.73, 43.50, 39.90, 38.29, 37.50, 33.92, 33.69, 19.93, 18.60, 14.97, 14.19. [α]20
D
= -118◦(c = 0.08,
CHCl3). ESI-HRMS (m/z): calcd. for [C68H78Br2N6O11 + H]
+ 1315.41476; obsd. 1315.41639.
Dimeric ligand (p,p-77b). Yield: 2.8 mg, 2.1 µmol, 34%. 1H NMR (600 MHz, CDCl3): δ 7.79 (d,
J = 8.1 Hz, 4H, 4 x CHar), 7.58 (d, J = 8.1 Hz, 4H, 4 x CHar), 7.07 (s, 2H, 2 x NH), 6.89 (s, 2H,
2 x CHar), 6.81 (d, J = 1.5 Hz, 2H, 2 x CHar), 6.77 (s, 2H, 2 x NH), 5.10 - 4.99 (m, 4H, 2 x CH2),
4.55 (d, J = 9.4 Hz, 2H, 2 x CH), 4.16 - 4.04 (m, 4H, 2 x CH2), 3.65 - 3.58 (m, 20H, 10 x CH2),
2.46 (dd, J = 16.1, 3.6 Hz, 2H, 2 x CH2-H
a), 2.38 (dd, J = 16.2, 4.0 Hz, 2H, 2 x CH2-H
a), 2.30
(dd, J = 16.3, 9.2 Hz, 2H, 2 x CH2-H
b), 2.18 (d, J = 4.2 Hz, 2H, 2 x CH), 2.13 - 2.06 (m, 8H, 2
x CH3, 2 x CH2-H
b), 1.42 (t, J = 6.9 Hz, 6H, 2 x CH3), 1.36 - 1.29 (m, 8H, 4 x CH2), 0.91 - 0.86
(m, 6H, 2 x CH3).
13C NMR (151 MHz, CDCl3): δ 195.79, 167.73, 152.80, 149.67, 144.87, 144.11,
142.24, 141.10, 134.17, 128.42, 127.22, 123.03, 119.35, 118.17, 112.96, 110.06, 88.37, 74.03, 70.63,
70.32, 69.94, 64.73, 43.50, 39.93, 38.28, 37.51, 33.93, 33.75, 19.94, 18.66, 14.98, 14.19. [α]20
D
=
















General procedure for the synthesis of alkyne-monomeric ligands
(o-/m-/p-78a,b). Compound 75 (10-20 µmol) was subjected to
DCM/TFA (2 mL, 1:1, v/v) for 30 min - 1 h, upon which TLC
indicated complete removal of the Boc-group. The mixture was
diluted with toluene and concentrated in vacuo. Silica column
chromatography (2.5% → 5% MeOH in DCM + 1% TEA) afforded
amine 76 (R f = 0.5 (10:1:1 DCM:MeOH:TEA). a: ESI-MS (m/z):
[M + H]+: 753.33. b: ESI-MS (m/z): [M + H]+: 797.33.). A
pre-activated mixture of propiolic acid (1.2 eq) and EEDQ (2 eq)
in DCM (2 mL) was added to monomeric amine 76 (1 eq). Upon
completion of the reaction (1-2 h), the mixture was loaded onto a silica column and purified (0 → 4%
MeOH in DCM). Title compounds were obtained as yellowish solids. R f = 0.5 (10:1 DCM:MeOH).
FT-IR (thin film) v 3285, 2920, 2855, 2360, 2344, 1648, 1497, 1381, 1275, 1125, 1047 cm−1.
2-((2-bromo-4-( (4R,7S) -3-cyano-2-methyl-5-oxo-7-propyl-1, 4, 5, 6, 7, 8-hexahydroquinolin-4-yl)
-6-ethoxyphenoxy) methyl)-N-(13-oxo-3, 6, 9-trioxa-12-azapentadec-14-yn-1-yl) benzamide (o-
78a). Yield: 6 mg, 7.5 µmol, 68%. 1H NMR (600 MHz, CDCl3): δ 7.65 (dd, J = 7.4, 1.2 Hz,
1H, CHar), 7.56 (s, 1H, NH), 7.40 - 7.33 (m, 2H, 2 x CHar), 7.31 (d, J = 7.3 Hz, 1H, CHar), 6.88
- 6.84 (m, 2H, 2 x NH), 6.80 (d, J = 1.8 Hz, 1H, CHar), 6.68 (s, 1H, CHar), 5.16 (s, 2H, CH2),
4.55 (s, 1H, CH), 4.03 - 3.89 (m, 2H, CH2), 3.69 (d, J = 9.1 Hz, 4H, 2 x CH2), 3.64 - 3.61 (m,
2H, CH2), 3.59 - 3.57 (m, 2H, CH2), 3.56 - 3.54 (m, 2H, CH2), 3.53 - 3.51 (m, 2H, CH2), 3.49
(t, J = 5.1 Hz, 2H, CH2), 3.43 - 3.40 (m, 2H, CH2), 2.80 (s, 1H, CH), 2.51 - 2.32 (m, 3H, CH2,
CH2-H
a), 2.20 (s, 1H, CH), 2.15 (s, 3H, CH3), 2.13 - 2.07 (m, 1H, CH2-H
b), 1.36 - 1.32 (m, 4H,
2 x CH2), 1.30 (t, J = 7.0 Hz, 3H, CH3), 0.90 (t, J = 6.9 Hz, 3H, CH3).
13C NMR (151 MHz,
CDCl3): δ 195.62, 169.24, 152.73, 152.53, 149.46, 144.86, 143.22, 142.51, 137.26, 133.82, 131.23,
130.18, 128.77, 128.57, 122.98, 119.24, 118.13, 112.57, 110.09, 88.31, 77.44, 73.74, 72.96, 70.61,
70.58, 70.50, 70.34, 69.96, 69.14, 64.50, 43.49, 40.07, 39.75, 38.23, 37.51, 33.91, 33.79, 19.93,
18.73, 14.69, 14.19 [α]20
D
= -83◦(c = 0.12, CHCl3). ESI-HRMS (m/z): calcd. for [C41H49BrN4O8 +
H]+ 805.28065; obsd. 805.28146.
2-((2-bromo-4-( (4R,7S) -3-cyano-2-methyl-5-oxo-7-propyl-1, 4, 5, 6, 7, 8-hexahydroquinolin-4-yl)
-6-ethoxyphenoxy) methyl)-N-(16-oxo-3, 6, 9, 12-tetraoxa-15-azaoctadec-17-yn-1-yl) benzamide
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(o-78b). Yield: 10 mg, 12 µmol, 78%. 1H NMR (600 MHz, CDCl3): δ 7.63 (d, J = 3.6 Hz, 1H,
CHar), 7.57 (s, 1H, NH), 7.37 (d, J = 10.6 Hz, 3H, 3 x CHar), 7.24 (s, 1H, NH), 7.12 (s, 1H, NH),
6.85 (s, 1H, CHar), 6.81 (s, 1H, CHar), 5.16 (s, 2H, CH2), 4.54 (s, 1H, CH), 4.02 - 3.89 (m, 2H,
CH2), 3.68 (s, 4H, 2 x CH2), 3.65 - 3.50 (m, 14H, 7 x CH2), 3.49 - 3.41 (m, 2H, CH2), 2.83 (s,
1H, CH), 2.49 - 2.42 (m, 2H, 2 x CH2-H
a), 2.38 - 2.30 (m, 1H, CH2-H
b), 2.16 - 2.06 (m, 5H, CH3,
CH, CH2-H
b), 1.36 - 1.27 (m, 7H, CH3, 2 x CH2), 0.90 (t, J = 6.9 Hz, 3H, CH3).
13C NMR (151
MHz, CDCl3): δ 195.73, 169.36, 152.71, 149.93, 145.25, 143.27, 142.63, 136.99, 134.10, 131.04,
130.21, 128.64, 128.41, 123.00, 119.43, 118.07, 112.58, 109.86, 87.98, 77.45, 73.85, 72.84, 70.55,
70.44, 70.34, 69.95, 69.27, 64.52, 43.51, 40.07, 39.78, 38.21, 37.51, 33.90, 33.63, 19.93, 18.61,
14.70, 14.21. [α]20
D
= -73◦(c = 0.2, CHCl3). ESI-HRMS (m/z): calcd. for [C43H53BrN4O9 + H]
+
849.30687; obsd. 849.30779.
3-((2-bromo-4-((4R,7S)-3-cyano-2-methyl-5-oxo-7-propyl-1, 4, 5, 6, 7, 8-hexahydroquinolin-4-yl) -
6-ethoxyphenoxy) methyl)-N-(13-oxo-3,6,9-trioxa-12-azapentadec-14-yn-1-yl)benzamide (m-78a).
Yield: 8 mg, 10 µmol, 90%. 1H NMR (600 MHz, CDCl3): δ 8.03 (s, 1H, CHar), 7.78 (d, J = 7.8
Hz, 1H, CHar), 7.65 (d, J = 7.6 Hz, 1H, CHar), 7.45 (t, J = 7.6 Hz, 1H, CHar), 7.03 (s, 1H, NH),
6.95 (s, 1H, NH), 6.92 (d, J = 1.6 Hz, 1H, CHar), 6.83 (d, J = 1.8 Hz, 1H, CHar), 6.81 (s, 1H, NH),
5.04 (s, 2H, CH2), 4.55 (s, 1H, CH), 4.17 - 4.09 (m, 2H, CH2), 3.71 - 3.66 (m, 8H, 4 x CH2), 3.65
- 3.62 (m, 2H, CH2), 3.59 - 3.56 (m, 2H, CH2), 3.48 (t, J = 5.2 Hz, 2H, CH2), 3.41 - 3.36 (m, 2H,
CH2), 2.79 (s, 1H, CH), 2.50 - 2.34 (m, 3H, CH2, CH2-H
a), 2.22 - 2.16 (m, 1H, CH), 2.14 (s, 3H,
CH3), 2.12 - 2.05 (m, 1H, CH2-H
b), 1.44 (t, J = 7.0 Hz, 3H, CH3), 1.34 - 1.28 (m, 4H, 2 x CH2),
0.91 - 0.87 (m, 3H, CH3).
13C NMR (151 MHz, CDCl3): δ 195.84, 167.88, 152.77, 152.53, 149.82,
145.01, 144.06, 142.48, 138.18, 134.78, 131.41, 128.72, 126.97, 126.91, 123.02, 119.45, 118.11,
112.96, 110.00, 88.25, 79.71, 74.17, 73.81, 70.63, 70.60, 70.38, 70.34, 69.99, 69.20, 64.69, 43.52,
39.97, 39.68, 38.35, 37.53, 33.94, 33.72, 19.91, 18.66, 14.97, 14.19. [α]20
D
= -63◦(c = 0.16, CHCl3).
ESI-HRMS (m/z): calcd. for [C41H49BrN4O8 + H]
+ 805.28065; obsd. 805.28139.
3-((2-bromo-4-( (4R,7S) -3-cyano-2-methyl-5-oxo-7-propyl-1, 4, 5, 6, 7, 8-hexahydroquinolin-4-yl)
-6-ethoxyphenoxy) methyl)-N-(16-oxo-3, 6, 9, 12-tetraoxa-15-azaoctadec-17-yn-1-yl) benzamide
(m-78b). Yield: 4 mg, 4.7 µmol, 47%. 1H NMR (600 MHz, CDCl3): δ 8.04 (s, 1H, CHar), 7.80 (d,
J = 7.7 Hz, 1H, CHar), 7.65 (d, J = 7.6 Hz, 1H, CHar), 7.44 (t, J = 7.7 Hz, 1H, CHar), 7.07 (d, J
= 10.6 Hz, 3H 3 x NH), 6.93 (d, J = 1.6 Hz, 1H, CHar), 6.83 (d, J = 1.8 Hz, 1H, CHar), 5.05 (s,
2H, CH2), 4.56 (s, 1H, CH), 4.17 - 4.08 (m, 2H, CH2), 3.70 - 3.66 (m, 10H, 5 x CH2), 3.64 - 3.61
(m, 2H, CH2), 3.57 (s, 4H, 2 x CH2), 3.52 (t, J = 5.0 Hz, 2H, CH2), 3.45 - 3.41 (m, 2H, CH2),
2.81 (s, 1H, CH), 2.49 - 2.33 (m, 3H, CH2, CH2-H
a), 2.18 (d, J = 3.9 Hz, 1H, CH), 2.15 (s, 3H,
CH3), 2.13 - 2.05 (m, 1H, CH2-H
b), 1.44 (t, J = 7.0 Hz, 3H, CH3), 1.36 - 1.30 (m, 4H, 2 x CH2),
0.89 (t, J = 6.0 Hz, 3H, CH3).
13C NMR (151 MHz, CDCl3): δ 195.81, 167.84, 152.77, 152.58,
149.78, 145.05, 144.11, 142.43, 138.18, 134.76, 131.36, 128.68, 127.01, 123.01, 119.47, 118.09,
113.01, 110.03, 88.22, 77.47, 74.19, 73.76, 70.64, 70.62, 70.39, 70.32, 70.11, 69.33, 64.71, 43.54,
40.00, 39.74, 38.31, 37.54, 33.97, 33.74, 19.92, 18.68, 14.99, 14.20 [α]20
D
= -100◦(c = 0.08, CHCl3).
ESI-HRMS (m/z): calcd. for [C43H53BrN4O9 + H]
+ 849.30687; obsd. 849.30767.
4-((2-bromo-4-((4R,7S)-3-cyano-2-methyl-5-oxo-7-propyl-1, 4, 5, 6, 7, 8-hexahydroquinolin-4-yl) -
6-ethoxyphenoxy) methyl)-N-(13-oxo-3,6,9-trioxa-12-azapentadec-14-yn-1-yl)benzamide (p-78a).
Yield: 6.1 mg, 7.6 µmol, 63%. 1H NMR (600 MHz, CDCl3): δ 7.80 (d, J = 8.2 Hz, 2H, 2 x CHar),
7.60 (d, J = 8.1 Hz, 2H, 2 x CHar), 6.91 (d, J = 1.6 Hz, 1H, CHar), 6.85 (t, J = 4.9 Hz, 1H, NH),
6.80 (d, J = 1.8 Hz, 1H, CHar), 6.71 (d, J = 5.2 Hz, 1H, NH), 6.30 (s, 1H, NH), 5.04 (d, J = 7.3 Hz,
2H, CH2), 4.55 (s, 1H, CH), 4.19 - 4.05 (m, 2H. CH2), 3.71 - 3.67 (m, 8H, 4 x CH2), 3.66 - 3.63 (m,
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2H, CH2), 3.61 - 3.58 (m, 2H, CH2), 3.51 (t, J = 5.1 Hz, 2H, CH2), 3.43 - 3.37 (m, 2H, CH2), 2.76
(s, 1H, CH), 2.52 - 2.32 (m, 3H, CH2, CH2-H
a), 2.26 - 2.08 (m, 5H, CH3, CH, CH2-H
b ), 1.43 (t, J
= 6.9 Hz, 3H, CH3), 1.38 - 1.31 (m, 4H, 2 x CH2), 0.91 (t, J = 7.0 Hz, 3H, CH3).
13C NMR (151
MHz, CDCl3): δ 195.72, 167.67, 152.80, 152.48, 149.36, 144.68, 144.10, 142.24, 141.19, 134.16,
128.50, 128.39, 127.28, 127.19, 123.03, 119.29, 118.18, 113.01, 110.20, 88.53, 74.01, 73.66, 70.64,
70.60, 70.37, 70.35, 69.97, 69.30, 64.71, 43.48, 39.93, 39.66, 38.31, 37.51, 33.93, 33.85, 19.95,
18.77, 14.97, 14.19. [α]20
D
= -51◦(c = 0.12, CHCl3). ESI-HRMS (m/z): calcd. for [C41H49BrN4O8
+ H]+ 805.28065; obsd. 805.28113.
4-((2-bromo-4-( (4R,7S) -3-cyano-2-methyl-5-oxo-7-propyl-1, 4, 5, 6, 7, 8-hexahydroquinolin-4-yl)
-6-ethoxyphenoxy) methyl)-N-(16-oxo-3, 6, 9, 12-tetraoxa-15-azaoctadec-17-yn-1-yl) benzamide
(p-78b). Yield: 9 mg, 11 µmol, quant. 1H NMR (600 MHz, CDCl3): δ 7.82 (d, J = 8.2 Hz, 2H, 2 x
CHar), 7.60 (d, J = 8.1 Hz, 2H, 2 x CHar), 7.09 (d, J = 3.8 Hz, 1H, NH), 7.02 (s, 1H, NH), 6.91 (d,
J = 1.6 Hz, 1H, CHar), 6.81 (d, J = 1.8 Hz, 1H, CHar), 6.65 (s, 1H, NH), 5.04 (s, 2H, CH2), 4.55 (s,
1H, CH), 4.15 - 4.08 (m, 2H, CH2), 3.71 - 3.66 (m, 10H, 5 x CH2), 3.65 - 3.62 (m, 2H, CH2), 3.60 -
3.57 (m, 4H, 2 x CH2), 3.52 (t, J = 5.0 Hz, 2H, CH2), 3.44 - 3.39 (m, 2H, CH2), 2.78 (s, 1H, CH),
2.52 - 2.32 (m, 3H, CH2, CH2-H
a), 2.23 - 2.17 (m, 1H, CH), 2.16 - 2.08 (m, 4H, CH3, CH2-H
b),
1.43 (t, J = 7.0 Hz, 3H, CH3), 1.39 - 1.31 (m, 4H, 2 x CH2), 0.90 (t, J = 6.9 Hz, 3H, CH3).
13C
NMR (151 MHz, CDCl3): δ 195.71, 167.68, 152.80, 152.49, 149.42, 144.76, 144.16, 142.24, 141.17,
134.19, 128.40, 127.26, 123.04, 119.32, 118.15, 113.02, 110.18, 88.47, 77.54, 74.01, 73.53, 70.64,
70.35, 70.34, 70.09, 69.41, 64.72, 43.49, 39.96, 39.71, 38.29, 37.51, 33.93, 33.82, 19.95, 18.75,
14.98, 14.19. [α]20
D

























General procedure for the synthesis of flu-
orescent ligands (o-/m-/p-79a,b). Com-
pound 78 (5-10 µmol, 1 eq) and azido-
BODIPY-benzyl 26 (1 eq) were dissolved in
degassed DCM/H2O (2 mL, 1:1, v/v) and
aqueous solutions of sodium ascorbate (1 eq)
and CuSO4 (20 mol%) were added. The re-
sulting mixture was stirred vigorously for 3 h,
after which TLC indicated complete conver-
sion of the reaction. The solvents were evap-
orated in vacuo, and the residue was taken
up in DCM and purified by silica column chromatography (0% → 5% MeOH in DCM) to yield the
fluorescent ligand as a purple solid. R f = 0.5 (10:1 DCM:MeOH). FT-IR (thin film) v 3302, 2923,
2363, 2342, 1648, 1607, 1497, 1458, 1387, 1256, 1145, 1044 cm−1.
Fluorescent ligand (o-79a). Yield: 5.6 mg, 4.1 µmol, 59%. 1H NMR (600 MHz, CDCl3): δ 8.05
(s, 1H, CHtrz), 7.86 (d, J = 8.4 Hz, 2H, 2 x CHar), 7.61 (s, 1H, CHar), 7.52 (s, 2H, 2 x NH), 7.35
(s, 3H, 3 x CHar), 7.30 - 7.22 (m, 3H, 3 x CHar), 7.19 (d, J = 7.2 Hz, 2H, 2 x CHar), 7.08 (s, 2H,
CHar, NH), 6.97 (d, J = 3.8 Hz, 1H, CHar), 6.92 (d, J = 8.2 Hz, 2H, 2 x CHar), 6.84 (s, 1H, CHar),
6.79 (s, 1H, CHar), 6.55 (d, J = 3.7 Hz, 1H, CHar), 5.91 (s, 1H, NH), 5.18 - 5.09 (m, 2H, CH2),
4.61 (s, 2H, CH2), 4.53 (s, 1H, CH), 4.39 (d, J = 5.6 Hz, 2H, CH2), 4.05 - 3.89 (m, 4H, 2 x CH2),
3.69 - 3.52 (m, 16H, 8 x CH2), 2.82 - 2.75 (m, 2H, CH2), 2.52 (s, 3H, CH3), 2.47 - 2.25 (m, 7H, 3 x
CH2, CH2-H
a), 2.18 (s, 3H, CH3), 2.14 (s, 1H, CH), 2.10 - 2.02 (m, 4H, CH3 , CH2-H
b), 1.31 - 1.26
(m, 7H, CH3 + 2 x CH2), 0.88 (d, J = 6.4 Hz, 3H, CH3).
13C NMR (151 MHz, CDCl3): δ 195.67,
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171.56, 169.25, 159.73, 159.15, 155.33, 152.74, 149.80, 145.25, 143.36, 142.45, 140.31, 138.14,
137.11, 135.09, 134.61, 134.09, 130.99, 130.93, 130.71, 130.12, 128.85, 128.60, 128.40, 128.05,
127.87, 127.67, 126.26, 125.85 (HSQC cross-coupling), 123.17, 122.88, 118.47, 118.12, 114.28,
112.52, 109.95, 87.96, 72.82, 70.63, 70.57, 70.50, 70.47, 69.96, 69.73, 64.52, 63.96, 47.57 (HSQC
cross-coupling), 43.82, 43.46, 40.08, 38.07, 37.50, 36.45, 33.88, 33.57, 29.84, 20.17, 19.91, 18.52,
14.70, 14.20, 13.37, 9.78. ESI-HRMS (m/z): calcd. for [C71H80BBrF2N10O10 + H]
+ 1361.53761;
obsd. 1361.54005.
Fluorescent ligand (o-79b). Yield: 9.5 mg, 7 µmol, 57%. 1H NMR (600 MHz, CDCl3): δ 8.05 (s,
1H, CHtrz), 7.86 (d, J = 8.5 Hz, 2H, 2 x CHar), 7.62 - 7.58 (m, 1H, CHar), 7.56 (s, 1H, NH), 7.50
(s, 1H, NH), 7.39 - 7.32 (m, 3H, 3 x CHar), 7.29 - 7.21 (m, 3H, 3 x CHar), 7.18 (d, J = 7.2 Hz,
3H, 2 x CHar, NH), 7.08 (s, 1H, CHar), 6.97 (d, J = 3.8 Hz, 1H, CHar), 6.93 (d, J = 8.5 Hz, 2H, 2
x CHar), 6.83 (s, 1H, CHar), 6.79 (s, 1H, CHar), 6.54 (d, J = 3.8 Hz, 1H, CHar), 5.94 (s, 1H, NH),
5.15 (s, 2H, CH2), 4.61 (s, 2H, CH2), 4.53 (s, 1H, CH), 4.39 (d, J = 5.6 Hz, 2H, CH2), 4.01 (t, J
= 5.1 Hz, 2H, CH2), 3.99 - 3.89 (m, 2H, CH2), 3.66 - 3.53 (m, 20H, 10 x CH2), 2.79 (t, J = 7.4
Hz, 2H, CH2), 2.52 (s, 3H, CH3), 2.44 - 2.25 (m, 7H, 3 x CH2, CH2-H
a), 2.18 (s, 3H, CH3), 2.13
(s, 1H, CH), 2.10 - 2.03 (m, 4H, CH3, CH2-H
b), 1.31 - 1.25 (m, 7H, CH3, 2 x CH2), 0.87 (t, J =
6.3 Hz, 3H, CH3).
13C NMR (151 MHz, CDCl3): δ 195.68, 171.58, 169.32, 159.73, 159.16, 155.33,
152.75, 149.91, 145.29, 143.41, 142.52, 140.30, 138.15, 136.99, 135.09, 134.61, 134.22, 130.93,
130.91, 130.70, 130.14, 128.84, 128.54, 128.31, 128.04, 127.87, 127.66, 126.26, 125.85, 123.16,
122.95, 119.41, 118.46, 118.10, 114.28, 112.57, 109.84, 87.92, 72.83, 70.64, 70.56, 70.52, 70.45,
64.51, 63.95, 47.71, 43.81, 43.48, 40.06, 39.15, 38.15, 37.52, 36.44, 33.89, 33.54, 29.93, 20.18,
19.91, 18.51, 14.69, 14.21, 13.37, 9.78. ESI-HRMS (m/z): calcd. for [C73H84BBrF2N10O11 + H]
+
1405.56383; obsd. 1405.56658.
Fluorescent ligand (m-79a). Yield: 6.9 mg, 5.1 µmol, 51%. 1H NMR (600 MHz, CDCl3): δ 8.03
(s, 1H, CHtrz), 8.01 (s, 1H, CHar), 7.85 (d, J = 8.6 Hz, 2H, 2 x CHar), 7.75 (d, J = 7.7 Hz, 1H,
CHar), 7.62 (d, J = 7.5 Hz, 1H, CHar), 7.56 (s, 1H, NH), 7.41 (t, J = 7.6 Hz, 1H, CHar), 7.29 -
7.25 (m, 3H, 3 x CHar), 7.25 - 7.21 (m, 1H, CHar), 7.18 (d, J = 7.2 Hz, 2H, 2 x CHar), 7.08 (s,
1H, CHar), 7.06 (s, 1H, NH), 7.01 (s, 1H, NH), 6.96 (d, J = 3.7 Hz, 1H, CHar), 6.93 - 6.90 (m, 3H,
3 x CHar), 6.81 (s, 1H, CHar), 6.54 (d, J = 3.8 Hz, 1H, CHar), 5.94 (s, 1H, NH), 5.05 - 4.98 (m,
2H, CH2), 4.58 (t, J = 6.6 Hz, 2H, CH2), 4.54 (s, 1H, CH), 4.39 (d, J = 5.6 Hz, 2H, CH2), 4.15 -
4.06 (m, 2H, CH2), 3.98 (t, J = 5.3 Hz, 2H, CH2), 3.70 - 3.63 (m, 12H, 6 x CH2), 3.61 (s, 4H, 2
x CH2), 2.78 (t, J = 7.4 Hz, 2H, CH2), 2.51 (s, 3H, CH3), 2.44 - 2.27 (m, 7H, 3 x CH2, CH2-H
a),
2.17 (s, 3H, CH3), 2.13 (s, 1H, CH), 2.09 - 2.01 (m, 4H, CH3, CH2-H
b), 1.42 (t, J = 6.9 Hz, 3H,
CH3), 1.30 - 1.25 (m, 4H, 2 x CH2), 0.86 (t, J = 6.5 Hz, 3H, CH3).
13C NMR (151 MHz, CDCl3):
δ 195.80, 171.59, 167.80, 160.28, 159.66, 159.19, 155.40, 152.77, 149.84, 145.12, 144.12, 143.35,
142.36, 140.26, 138.16, 138.14, 135.09, 134.79, 134.58, 131.29, 130.92, 130.66, 128.85, 128.64,
128.07, 127.87, 127.66, 126.92, 126.89, 126.20, 125.83, 123.16, 122.96, 119.47, 118.49, 118.10,
114.29, 112.98, 109.95, 88.09, 74.14, 70.72, 70.69, 70.55, 70.45, 69.93, 69.80, 64.69, 63.96, 47.67,
43.82, 43.48, 39.98, 39.09, 38.25, 37.52, 36.45, 33.92, 33.60, 29.91, 20.18, 19.88, 18.55, 14.96,
14.19, 13.36, 9.77. ESI-HRMS (m/z): calcd. for [C71H80BBrF2N10O10 + H]
+ 1361.53761; obsd.
1361.54020.
Fluorescent ligand (m-79b). Yield: 3 mg, 2.1 µmol, 60%. 1H NMR (600 MHz, CDCl3): δ 8.06 (s,
1H, CHtrz), 7.99 (s, 1H, CHar), 7.86 (d, J = 8.8 Hz, 2H, 2 x CHar), 7.77 (d, J = 7.8 Hz, 1H, CHar),
7.64 (d, J = 7.6 Hz, 1H, CHar), 7.60 (s, 1H, NH), 7.44 - 7.40 (m, 1H, CHar), 7.31 - 7.21 (m, 3H,
3 x CHar), 7.19 (d, J = 6.9 Hz, 2H, 2 x CHar), 7.09 - 7.05 (m, 1H, CHar), 7.03 (s, 1H, NH), 6.97
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(d, J = 4.0 Hz, 1H, CHar), 6.95 - 6.88 (m, 3H, 3 x CHar), 6.85 (s, 1H, NH), 6.81 (d, J = 1.8 Hz,
1H, CHar), 6.54 (d, J = 4.0 Hz, 1H, CHar), 5.86 (s, 1H, NH), 5.02 (d, J = 6.8 Hz, 2H, CH2), 4.60
(t, J = 6.9 Hz, 2H, CH2), 4.54 (s, 1H, CH), 4.40 (d, J = 5.7 Hz, 2H, CH2), 4.13 - 4.07 (m, 2H,
CH2), 3.99 (t, J = 5.7 Hz, 2H, CH2), 3.66 - 3.60 (m, 20H, 10 x CH2), 2.79 (t, J = 7.5 Hz, 2H,
CH2), 2.52 (s, 3H, CH3), 2.45 - 2.29 (m, 7H, 3 x CH2 , CH2-H
a), 2.18 (s, 3H, CH3), 2.15 (s, 1H,
CH), 2.11 - 2.04 (m, 4H, CH3, CH2-H
b), 1.43 - 1.41 (m, 3H, CH3), 1.31 - 1.27 (m, 4H, 2 x CH2),
0.89 - 0.87 (m, 3H, CH3).
13C NMR (151 MHz, CDCl3): δ 195.75, 171.56, 167.76, 160.32, 159.68,
159.20, 155.43, 152.79, 149.67, 144.99, 144.18, 143.42, 142.28, 140.27, 138.12, 135.11, 134.80,
134.60, 131.35, 130.93, 130.67, 130.06, 128.86, 128.65, 128.08, 127.90, 127.69, 127.00, 126.91,
126.22, 125.84, 123.17, 122.96, 119.42, 118.49, 118.11, 114.30, 113.00, 110.02, 88.22, 74.20, 70.75,
70.66, 70.62, 70.50, 70.42, 69.99, 69.91, 64.70, 63.97, 47.67, 43.85, 43.48, 39.97, 39.12, 38.23,
37.54, 36.48, 33.93, 33.66, 29.85, 20.17, 19.90, 18.59, 14.96, 14.20, 13.37, 9.78. ESI-HRMS (m/z):
calcd. for [C73H84BBrF2N10O11 + H]
+ 1405.56383; obsd. 1405.56641.
Fluorescent ligand (p-79a). Yield: 2.8 mg, 2 µmol, 29%. 1H NMR (600 MHz, CDCl3): δ 8.03 (s,
1H, CHtrz), 7.85 (d, J = 8.7 Hz, 2H, 2 x CHar), 7.77 (d, J = 7.9 Hz, 2H, 2 x CHar), 7.57 (d, J = 7.9
Hz, 3H, 2 x CHar, NH), 7.31 - 7.22 (m, 3H, 3 x CHar), 7.19 (d, J = 7.1 Hz, 2H, 2 x CHar), 7.08 (s,
1H, CHar), 6.97 (d, J = 4.0 Hz, 2H, CHar, NH), 6.94 - 6.88 (m, 3H, 3 x CHar), 6.80 (d, J = 1.4 Hz,
1H, CHar), 6.55 (d, J = 4.0 Hz, 1H, CHar), 6.50 (s, 1H, NH), 5.87 (s, 1H, NH), 5.02 (s, 2H, CH2),
4.57 (s, 2H, CH2), 4.54 (s, 1H, CH), 4.40 (d, J = 5.6 Hz, 2H, CH2), 4.13 - 4.06 (m, 2H, CH2), 3.97
(t, J = 5.2 Hz, 2H, CH2), 3.68 - 3.61 (m, 16H, 8 x CH2), 2.79 (t, J = 7.4 Hz, 2H, CH2), 2.52 (s,
3H, CH3), 2.47 - 2.26 (m, 7H, 3 x CH2, CH2-H
a), 2.16 (d, J = 16.8 Hz, 4H, CH3, CH), 2.09 (d, J
= 10.2 Hz, 4H, CH3, CH2-H
b), 1.41 (t, J = 6.9 Hz, 3H, CH3), 1.34 - 1.27 (m, 4H, 2 x CH2), 0.89
(t, J = 6.7 Hz, 3H, CH3).
13C NMR (151 MHz, CDCl3): δ 195.68, 171.57, 167.67, 159.61, 159.23,
155.49, 152.81, 149.36, 144.77, 144.16, 142.14, 141.07, 140.22, 138.12, 135.09, 134.56, 134.23,
130.92, 130.65, 128.87, 128.41, 128.29, 128.11, 127.90, 127.70, 127.17, 126.16, 125.79 (HSQC
cross-coupling), 123.15, 122.97, 119.28, 118.54, 118.16, 114.31, 112.98, 110.14, 88.40, 74.00, 70.75,
70.73, 70.59, 70.43, 69.96, 69.89, 64.71, 63.98, 47.52 (HSQC cross-coupling), 43.86, 43.46, 39.96,
39.09, 38.21, 37.51, 36.48, 33.91, 33.73, 29.85, 20.17, 19.91, 18.66, 14.96, 14.19, 13.38, 9.79.
ESI-HRMS (m/z): calcd. for [C71H80BBrF2N10O10 + H]
+ 1361.53761; obsd. 1361.54010.
Fluorescent ligand (p-79b). Yield: 4.6 mg, 3.3 µmol, 65%. 1H NMR (600 MHz, CDCl3): δ 8.05
(s, 1H, CHtrz), 7.85 (d, J = 8.4 Hz, 2H, 2 x CHar), 7.78 (d, J = 7.4 Hz, 2H, 2 x CHar), 7.61 (d,
J = 7.9 Hz, 1H, NH), 7.57 (d, J = 7.6 Hz, 2H, 2 x CHar), 7.30 - 7.23 (m, 3H, 3 x CHar), 7.19 (d,
J = 7.2 Hz, 2H, 2 x CHar), 7.08 (s, 2H, CHar, NH), 6.96 (d, J = 3.8 Hz, 1H, CHar), 6.95 - 6.89
(m, 3H, 3 x CHar), 6.80 (s, 1H, CHar), 6.70 (s, 1H, NH), 6.54 (d, J = 3.8 Hz, 1H, CHar), 5.92 (s,
1H, NH), 5.05 - 4.99 (m, 2H, CH2), 4.61 (s, 2H, CH2), 4.54 (s, 1H, CH), 4.39 (d, J = 5.5 Hz, 2H,
CH2), 4.14 - 4.05 (m, 2H, CH2), 3.99 (s, 2H, CH2), 3.67 - 3.61 (m, 20H, 10 x CH2), 2.79 (t, J =
7.4 Hz, 2H, CH2), 2.52 (s, 3H, CH3), 2.44 - 2.25 (m, 7H, 3 x CH2, CH2-H
a), 2.18 (s, 4H, CH3, CH),
2.11 - 2.05 (m, 4H, CH3, CH2-H
b), 1.41 (t, J = 6.9 Hz, 3H, CH3), 1.35 - 1.29 (m, 4H, 2 x CH2),
0.88 (t, J = 6.6 Hz, 3H, CH3).
13C NMR (151 MHz, CDCl3): δ 195.72, 171.59, 167.51, 159.68,
159.20, 155.41, 152.81, 149.52, 144.88, 144.15, 142.20, 141.11, 140.27, 138.15, 135.09, 134.59,
134.16, 130.93, 130.69, 128.86, 128.39, 128.08, 127.89, 127.68, 127.22, 126.20, 125.84 (HSQC
cross-coupling), 123.16, 123.01, 118.50, 118.14, 114.30, 112.97, 110.14, 88.33, 73.99, 70.76, 70.60,
70.47, 70.36, 64.72, 63.98, 47.53 (HSQC cross-coupling), 43.84, 43.47, 39.95, 38.23, 37.51, 36.46,
33.91, 33.71, 29.85, 20.18, 19.92, 18.64, 14.97, 14.20, 13.38, 9.78. ESI-HRMS (m/z): calcd. for
[C73H84BBrF2N10O11 + H]
+ 1405.56383; obsd. 1405.56634.
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O General procedure for the synthesis of fluo-
rescent ligands (m-/p-80a). Compound 78
(5-6 µmol, 1 eq) and azido-BODIPY-acid 88
(1 eq) were dissolved in degassed DCM/H2O
(2 mL, 1:1, v/v) and aqueous solutions of
sodium ascorbate (1.2 eq) and CuSO4 (20
mol%) were added. The resulting mixture
was stirred vigorously for 2 h, after which
TLC indicated complete conversion of the
reaction. The solvents were evaporated in
vacuo, and the residue was taken up in DCM
and purified by silica column chromatography (0% → 5% MeOH in DCM) to yield the fluorescent
ligand as a purple solid.
Fluorescent ligand (m-80a). Yield: 2.4 mg, 1.9 µmol, 38%. 1H NMR (600 MHz, CDCl3/MeOD):
δ 8.28 (s, 1H, CHtrz), 7.98 (s, 1H, CHar), 7.85 (d, J = 8.8 Hz, 2H, 2 x CHar), 7.77 (d, J = 7.8 Hz,
1H, CHar), 7.72 (d, J = 7.5 Hz, 1H, CHar), 7.45 (t, J = 7.7 Hz, 1H, CHar), 7.20 (s, 1H, CHar),
7.01 (d, J = 4.0 Hz, 1H, CHar), 6.94 (d, J = 8.9 Hz, 2H, 2 x CHar), 6.89 (dd, J = 5.8, 1.9 Hz,
2H, 2 x CHar), 6.55 (d, J = 4.1 Hz, 1H, CHar), 5.02 (s, 2H, CH2), 4.66 (t, J = 6.9 Hz, 2H, CH2),
4.54 (s, 1H, CH), 4.16 - 4.09 (m, 2H, CH2), 4.06 (dd, J = 11.5, 5.9 Hz, 2H, CH2), 3.72 - 3.57
(m, 16H, 8 x CH2), 2.75 (t, J = 7.8 Hz, 2H, CH2), 2.53 (s, 3H, CH3), 2.52 - 2.33 (m, 7H, 3 x
CH2, CH2-H
a), 2.26 (s, 3H, CH3), 2.20 (s, 1H, CH), 2.15 - 2.08 (m, 4H, CH3, CH2-H
b), 1.44 (t,
J = 7.0 Hz, 3H, CH3), 1.41 - 1.33 (m, 4H, 2 x CH2), 0.95 - 0.88 (m, 3H, CH3).
13C NMR (151
MHz, CDCl3/MeOD): δ 196.62, 174.73, 168.42, 159.24, 158.90, 154.97, 152.45, 151.41, 145.81,
143.74, 142.50, 139.98, 137.66, 134.82, 134.25, 134.18, 131.24, 130.46, 130.12, 128.27, 127.78,
126.74, 126.57, 125.97, 125.82, 122.96, 122.86, 118.59, 118.00, 117.63, 113.88, 112.42, 108.92,
87.03, 73.92, 70.27, 70.18, 70.00, 69.87, 69.44, 69.21, 64.33, 63.86, 47.59, 42.93, 39.61, 38.78,
38.03, 37.00, 33.65, 33.42, 32.48, 29.49, 19.54, 19.23, 17.38, 14.34, 13.57, 12.61, 9.07. ESI-HRMS
(m/z): calcd. for [C64H73BBrF2N9O11 + H]
+ 1272.47468; obsd. 1272.47697.
Fluorescent ligand (p-80a). Yield: 4.5 mg, 3.5 µmol, 59%. 1H NMR (600 MHz, CDCl3/MeOD):
δ 8.26 (s, 1H, CHtrz), 7.88 - 7.80 (m, 4H, 4 x CHar), 7.62 (d, J = 8.3 Hz, 2H, 2 x CHar), 7.24 (s,
1H, CHar), 7.02 (d, J = 4.1 Hz, 1H, CHar), 6.94 (t, J = 5.9 Hz, 2H, 2 x CHar), 6.89 (s, 2H, 2 x
CHar), 6.56 (d, J = 4.1 Hz, 1H, CHar), 5.02 (s, 2H, CH2), 4.65 (s, 2H, CH2), 4.53 (s, 1H, CH),
4.17 - 4.08 (m, 2H, CH2), 4.05 (t, J = 5.7 Hz, 2H, CH2), 3.71 - 3.61 (m, 16H, 8 x CH2), 2.75 (t,
J = 7.8 Hz, 2H, CH2), 2.55 - 2.50 (m, 4H, CH3, CH2-H
a), 2.48 - 2.36 (m, 6H, 3 x CH2), 2.26 (s,
3H, CH3), 2.21 (d, J = 7.5 Hz, 1H, CH), 2.17 - 2.10 (m, 4H, CH3, CH2-H
b), 1.44 (t, J = 7.0 Hz,
3H, CH3), 1.41 - 1.34 (m, 4H, 2 x CH2), 0.94 - 0.91 (m, 3H, CH3).
13C NMR (151 MHz, CDCl3):
δ 196.68, 174.72, 168.30, 160.54, 159.05, 158.81, 154.83, 152.33, 151.53, 145.78, 143.52, 142.44,
140.72, 139.92, 134.74, 134.12, 133.40, 130.33, 129.99, 127.88, 127.85, 127.74, 126.92, 126.87,
125.85, 125.65, 122.94, 122.73, 119.25, 117.89, 117.51, 113.73, 112.18, 108.70, 86.90, 73.60, 70.14,
70.05, 69.84, 69.72, 69.30, 69.13, 64.16, 63.68, 47.30, 42.78, 39.50, 38.59, 37.96, 36.87, 33.54,
33.32, 32.32, 29.39, 19.46, 19.10, 17.25, 14.22, 13.46, 12.48, 8.94.
Synthesis of propargyl glycine extended FSHβ33-53 peptides (C-,N-81).
Protected peptides were synthesized on an ABI-433A (Applied Biosystems, division of Perkin-Elmer)
automated peptide synthesizer using a standard Fmoc-based protocol. The peptides were prepared




- Removal of the Fmoc-group with 20% piperidine in NMP for 3 x 3 min.
- NMP wash
- Coupling of the appropriate amino acid (5 eq) with HCTU (5 eq) as the coupling agent, DiPEA (10
eq) as the base, in NMP as the solvent for 1 h.
- NMP wash
- Capping of remaining free amines with 5% (v/v) Ac2O and DiPEA (0.1 M) in NMP, for 3 min.
- NMP and DCM wash
After the final coupling and deprotection step, all acid-labile protecting groups were removed and the
peptide cleaved from the resin by treatment with TFA/H2O/TIS (95:2.5:2.5; v/v/v). Purification by
RP-HPLC and lyophilizing from AcOH/H2O yielded the peptides as white fluffy powders.
H-PraYTRDLVYKDPARPKIQKTSTF-CONH2 (N-81). Yield: 38.3 mg, 15 µmol, 15%. ESI-HRMS
(m/z): calcd. for [C120H189N33O33 + 2H]
2+ 1311.71523; obsd. 1311.71429.
H-YTRDLVYKDPARPKIQKTSTFPra-CONH2 (C-81). Yield: 22 mg, 8.4 µmol, 8%. ESI-HRMS
(m/z): calcd. for [C120H189N33O33 + 2H]
2+ 1311.71523; obsd. 1311.71414.
General procedure for the click reaction between azido-monomeric ligand m-74a,b and alkyne
FSHβ33-53 peptides (C-,N-82a,b). To a solution of 81 (1.5-2 µmol, 1 eq) and m-74 (1.1 eq)
in dioxane/water (5:1; v/v) aqueous solutions of sodium ascorbate (2 eq) and CuSO4 (20 mol%)
were added. The mixture was stirred for 20 h, upon which LC/MS showed complete consumption
of the peptide starting material. The solvents were removed in vacuo, and DCM was added to the
residue, thereby extracting most of the remaining DHP-monomer. The crude product was purified on a
Superdex-30 size exclusion column (30% ACN/ 0.05% TFA) and lyophilized to give the heterodimeric
product. R f = 0.3 (1:1:1:1 H2O:n-BuOH:EtOAc:AcOH)
H-Pra(-m-DHP)YTRDLVYKDPARPKIQKTSTF-CONH2 (N-82a). Yield: 5 mg, 1.5 µmol, 69%.
LC/MS analysis (linear gradient 10 → 90% ACN) tR : 5.84 min, ESI-MS (m/z): [M + 2 TFA]2+:
1814.13. ESI-HRMS (m/z): calcd. for [C158H236BrN39O40 + 2H]
2+ 1701.84869; obsd. 1701.84959.
H-Pra(-m-DHP)YTRDLVYKDPARPKIQKTSTF-CONH2 (N-82b). Yield: 2.95 mg, 0.86 µmol,
50%. LC/MS analysis (linear gradient 10 → 90% ACN) tR : 5.86 min, ESI-MS (m/z): [M + 2
TFA]2+: 1836.00. ESI-HRMS (m/z): calcd. for [C160H240BrN39O41 + 2H]
2+ 1723.86180; obsd.
1723.86189.
H-YTRDLVYKDPARPKIQKTSTFPra(-m-DHP)-CONH2 (C-82a). Yield: 2.7 mg, 0.79 µmol, 51%.
LC/MS analysis (linear gradient 10 → 90% ACN) tR : 5.93 min, ESI-MS (m/z): [M + 2 TFA]2+:
1813.33. ESI-HRMS (m/z): calcd. for [C158H236BrN39O40 + 2H]
2+ 1701.84869; obsd. 1701.84845.
H-YTRDLVYKDPARPKIQKTSTFPra(-m-DHP)-CONH2 (C-82b). Yield: 3.69 mg, 1.07 µmol,
69%. LC/MS analysis (linear gradient 10 → 90% ACN) tR : 5.94 min, ESI-MS (m/z): [M + 2
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for the follicle-stimulating hormone
receptor1
F
luorescent agonists for cell surface receptors allow visualization of the inter-
action between the ligand and its receptor as well as the processes that are
set in motion by receptor activation. This chapter describes the synthesis of a di-
verse set of fluorescent, low molecular weight ligands for the follicle-stimulating
hormone receptor (FSHR), based on a dihydropyridine (DHP) agonist. The flu-
orescent ligands were shown to be potent FSHR agonists, able to activate recep-
tor signaling with nanomolar potencies and to effect receptor internalization at
higher concentrations. The nature of the dye was shown to be of great impor-
tance for the selectivity of compound uptake. Although all compounds were in-
ternalized by FSHR-expressing cells, only the transport of Cy5-conjugated DHP
96 was mediated by the FSHR . The fluorescent DHP-Cy5 agonist was selectively
taken up by FSHR-expressing cells in complex with the receptor, opening up pos-





The use of fluorescent ligands to study receptor-related processes is an emerging field. Ad-
vancements in fluorescence-based microscopy techniques, such as confocal laser scanning
microscopy and fluorescence correlation microscopy, have opened up ways to study ligand-
protein interactions at the single cell or even single molecule level. 2,3 When the fluorescent
ligand retains the pharmacological properties of the parent ligand, real-time visualization
of receptor binding, internalization, trafficking and recycling is enabled. 4 Several fluores-
cent probes for G protein-coupled receptors (GPCRs) have emerged in the literature. Most
of these employ peptide-based ligands, mainly because the attachment of a fluorophore
to a peptide is a relatively minor increase in bulk and molecular weight compared to the
attachment of a dye to a small-molecule ligand. 5,6 Baker et al. have evaluated multiple
low molecular weight fluorescent ligands (both agonists and antagonists) for the study of
adenosine A1 receptors. They have shown that both the choice of linker to separate the
dye and the ligand and the nature of the fluorophore can have a profound influence on
the pharmacological properties of the probes. 7 Where antagonistic probes can be used to
study ligand-receptor binding, agonistic probes are useful tools for the study of receptor
internalization. Kozma et al. have synthesized a variety of adenosine A3 receptor agonists
incorporating different fluorophores, and found specific accumulation of fluorescence in
cells expressing the receptor for one of the probes. 8
The follicle-stimulating hormone receptor (FSHR) is a member of the GPCR family and
plays an important role in human reproduction. 9 Activation of this receptor by its endoge-
nous ligand follicle-stimulating hormone (FSH) leads to the dissociation of the bound Gs
protein and subsequent activation of adenylyl cyclase. To prevent overstimulation of the
receptor, the C-terminal domain is phosphorylated which leads to binding of β-arrestins
and uptake of the receptor-ligand complex in clathrin-coated pits. 10–12 The FSHR is mainly
present on granulosa cells in the ovaries and on Sertoli cells in the testes, but expression
has also been found on newly formed blood vessels of a variety of tumors. 13,14 As such,
fluorescent ligands for the FSHR could be used as diagnostic tumor markers. Fluorescent
agonists for the FSHR could also be used to study ligand-induced internalization and traf-
ficking of the receptor (Figure 6.1, Chapter 6). Only one example of a fluorescent ligand for
the FSHR has appeared in the literature and this is based on the FSHβ33-53 peptide ligand,
also described in Chapter 6. Although FITC-FSHβ33-53 was taken up more efficiently in
cells expressing the FSHR compared to cells without the receptor, the agonistic properties
of this fluorescent peptide and its ability to induce receptor endocytosis were not inves-
tigated. 15 Dihydropyridines (DHPs) are a class of low molecular weight agonists for the
FSHR which are very potent and selective. 16,17 Their pharmacological signaling proper-
ties have been investigated in depth and it has been shown that these allosteric ligands are
able to induce receptor internalization. 17 In Chapter 6 the structure-activity relationship of
different modes of attachment of a conjugation handle onto the parent DHP scaffold was
examined. From these studies, it became clear that meta-substituted monomeric ligand
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m-74a, with PEG spacer length n=3 was the most promising lead for further conjugation.
Attachment of a fluorescent BODIPY dye to this monomeric ligand resulted in a first series
of fluorescent agonists for the FSHR. However, from this SAR study it also became clear
that small modifications of the dye could have a big influence on the potency of the ligand.
For instance, an additional benzyl group to mask the free carboxylic acid of the BODIPY










































Figure 7.1: Overview of the different fluorescent dyes used in this study.
For cell or tissue imaging, organic dyes with red-shifted fluorescence absorption and
emission wavelengths are favored, because of lower levels of autofluorescence in the red
end of the spectrum. Figure 7.1 shows the structures of the fluorophores that were used in
this study for the development of fluorescent FSHR agonists. Among these are dyes from
three different classes: BODIPY dyes, cyanine dyes as well as a rhodamine dye. Emis-
sion wavelengths of these dyes vary between ∼580 nm (BODIPY-TMR 88, Rhodamine B
90) and >750 nm (Cy7 92) 18 and especially the physicochemical properties are expected
to be quite different. The synthesis of a water-soluble, red-shifted variant of bifunctional
azido-BODIPY-acid 19 is described, with the aim to reduce the lipophilicity while conserv-
ing the optimal fluorescence properties associated with the BODIPY core. 20 In this study
fluorescent ligands for the FSHR of various nature were synthesized and evaluated for their
agonistic potencies in a luciferase assay. Fluorescence-activated cell sorting (FACS) was
used to determine whether these probes were internalized by cells expressing the FSHR.
Furthermore, fluorescence confocal microscopy was used to study ligand-induced receptor
endocytosis and trafficking of the receptor-ligand complex. These experiments addressed
the question what the requirements are to develop a low molecular weight agonist for the
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FSHR that retains the profile of the parent DHP 55, while shedding light on the intricate
biological process of receptor activation.
7.2 Results and Discussion
Synthesis. The various dyes that were used for the synthesis of fluorescent-DHP probes
are shown in Figure 7.1. The bifunctional BODIPY dye 88 has been previously reported by
Verdoes et al. 19 Analogous to the work described in Chapter 3, 21 it was rationalized that
a water-soluble derivative of this BODIPY could be obtained by employment of a Knoe-
venagel condensation reaction with disulfonic acid benzaldehyde. The obvious advan-
tage hereof would be an increased hydrophilicity compared to the regular BODIPY, which
might have a beneficial effect in terms of background fluorescence arising from aspecific
membrane-interactions. Also, extension of the conjugated system by the Knoevenagel con-
densation reaction has previously been shown to lead to a red-shift in fluorescence. 21
Scheme 7.1: Optimized synthetic route towards azido-BODIPY-acid 88 followed by a Knoevenagel

















































Reagents and conditions: [a] (1,3-dioxan-2-ylethyl)-magnesium bromide (0.5 M in THF), THF, 0 ◦C
→ rt, 70%; [b] MnO2, DCM, 79%; [c] NH4OAc, acetic acid; [d] i) HBr (aq), MeOH; ii) TEA,
BF3 · OEt2, DCE, 90
◦C, 87: 44% from 84 and hydrolyzed 88: 10%; [e] Me3SnOH, toluene, reflux,
86%; [f] i) 4-formyl-1,3-benzenedisulfonic acid disodium salt, acetic acid, pyrrolidine, MeOH, 72 ◦C,
ii) Dowex-Na+, 62%.
Scheme 7.1 shows the followed synthetic route towards water-soluble dye 89. For this,
the synthesis of intermediate 88 was optimized. The Grignard reaction of azidobenzalde-
hyde 27 with (1,3-dioxane-2-ylethyl)-magnesium bromide was conducted at 0 ◦C → rt in-
stead of -10 ◦C → rt and for a shorter period of time, which significantly diminished elim-
ination of the azide by action of the Grignard agent as a base, resulting in 70% yield of
compound 83. Oxidation with manganese oxide gave ketone 84 that was subjected to a
very large excess of ammonium acetate (100 eq) in acetic acid to prevent byproduct for-
mation during the Paal-Knorr pyrrole synthesis. Pyrrole 85 proved to be very sensitive to
air and was used without excessive purification procedures in the condensation reaction
with pyrrole aldehyde 86. 22 The intermediate HBr salt was subjected to base and BF3 · OEt2
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under reflux conditions resulting in 44% yield of methyl ester 87 and an additional 10% of
hydrolyzed BODIPY 88, starting from 84. The methyl ester was saponified in high yield
(86%) using Me3SnOH. This improves the existing route that employed an ethyl ester that
required harsh conditions for saponification resulting in moderate yields (35%). 19 Knoe-
venagel condensation of azido-BODIPY-acid 88 with 4-formyl-1,3-benzendisulfonic acid
using acetic acid and pyrrolidine in methanol was followed by ion-exchange over Dowex-
Na+ to give the sodium salt of water-soluble BODIPY 89 in 62% yield.
Both rhodamine B 90 23 and Cy5 91 24 (Figure 7.1) were synthesized according to lit-
erature procedures and contained a carboxylic acid for ligation to the DHP agonist. To
minimize the differences in structures between the fluorescent probes, the bifunctional BO-
DIPY dyes 88 and 89 were also conjugated via their acid moieties. The only exception was
Cy7 92 which was synthesized with an additional azido-PEG spacer attached to the bulky
core 18 to diminish potential steric interactions. As shown in Scheme 7.2 standard peptide
coupling reagents were used to couple amino-DHP m-76a (Chapter 6) to the various dyes,
resulting in "DHP-BDP" 93, "DHP-water-soluble BDP" 94, "DHP-RhoB" 95 and "DHP-Cy5"
96. Cy7 dye 92 was used in a Cu(I)-catalyzed click reaction 25,26 with alkyne-DHP m-78a to
give "DHP-Cy7" 97. Yields varied between 40% and 92%, depending on ease of purification
of the fluorescent ligands.









































Reagents and conditions: [a] azido-BODIPY acid 88, EDC · HCl, HOBt, TEA, DCM, 48%; [b] water-
soluble BODIPY 89, EDC · HCl, HOBt, TEA, DMF, 92%; [c] Rhodamine B-acid 90, EDC · HCl,
HOBt, DiPEA, DMF, 82%; [d] Cy5-acid 91, PyBOP, DiPEA, DMF, 55%; [e] azido-Cy7 92, CuSO4,
sodium ascorbate, dioxane/H2O, 40%.
Biological evaluation. Fluorescent DHP ligands 93-97 were evaluated for their agonis-
tic activity in a CRE-luciferase assay. CHO cells stably expressing the human FSHR and
a CRE-luciferase reporter gene were cultured for 4 h in the presence of increasing con-
centration of probe. Cells were lysed and the cAMP-driven expression of luciferase was
detected by the addition of a luminescent substrate. Effects were normalized against the
maximum response obtained with recombinant FSH (200 pM). CHO cells without recep-
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tor but with the reporter gene were used to control for non-receptor-mediated increases in
cAMP levels and no response above background was detected in the control CHO cells for
all compounds tested at the highest concentration. Representative dose-response curves































Figure 7.2: Agonistic dose-response curves of
fluorescent ligands 93 - 97 on CHO cells stably
expressing the human FSHR. The response was
normalized against the maximal effect obtained
with rFSH (200 pM). Representative curves are
shown of at least three independent experiments
performed in duplicate.
As can be seen in Table 7.1, DHP-BDP
93 was the most potent agonist of the se-
ries with an EC50 value of 8 nM. This is
an improvement over the fluorescent li-
gand 80a (EC50 = 26 nM) described in
Chapter 6, which employed the azide-
ligation handle of the bifunctional BO-
DIPY dye to attach the DHP-ligand.
Next best was the Cy5 derivative 96
with an EC50 value of 15 nM, still a very
potent agonist for the FSHR. Attach-
ment of the more bulky fluorophores
rhodamine B, Cy7 or the water-soluble
BODIPY resulted in slightly higher EC50
values of 24-35 nM. Overall, fluorescent ligands could be synthesized with low nanomolar
potencies and without great differences between fluorophores used. Studies on other re-
ceptors have been reported where the nature of the fluorophore had a strong influence on
the potency of the ligand. 8,27 The use of spacers to separate the ligand and dye is therefore
often a requirement. The small differences in potency found here are in agreement with
the previous SAR study which led to the identification of a PEG-spacer with three ethylene
glycol units as the optimal spacer (Chapter 6) to connect bulk to the DHP lead compound.
Table 7.1: Mean agonistic potency (EC50) values of fluorescent ligands on CRE-luciferase activity in
CHO cells stably expressing hFSHR and a CRE-luciferase reporter gene.
Compound EC50 (nM) pEC50 N Compound EC50 (nM) pEC50 N
m-74a 6 8.22 ± 0.10 3 95 35 7.45 ± 0.51 3
93 8 8.10 ± 0.11 5 96 15 7.82 ± 0.09 5
94 24 7.62 ± 0.14 3 97 25 7.60 ± 0.12 3
The mean EC50 values are calculated from the pEC50 (mean ± SEM) values from N indepent exper-
iments performed in duplicate. The value for monomeric ligand m-74a from Chapter 6 is given for
comparison.
With potent agonistic fluorescent ligands in hand, it was investigated whether these
compounds could be used to induce FSHR internalization, and whether this would re-
sult in selective uptake of these ligands in the endolysosomal pathway of cells expressing
the receptor. A combination of fluorescence-activated cell sorting (Figure 7.3) and confo-
cal fluorescence microscopy (Figure 7.4) was used to study the uptake of the fluorescent
agonists in U2OS-FSHR cells stably expressing the rat FSHR fused to the N-terminus of
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enhanced green fluorescent protein (eGFP). As a biological control, wild-type U2OS cells
that do not express the FSHR were used. To test the ability of the ligands to induce re-
ceptor internalization, U2OS-FSHR cells were incubated with 10 µM of compound for 2
h. It has been shown before that concentrations of about two orders of magnitude higher
than the EC50 found in the luciferase assay are needed to induce ∼50% receptor internal-
ization by FSH and low molecular weight FSHR agonists. 17,28 In case of a lipophilic, LMW
agonist, the presence of serum albumin in the medium can lead to a rightward shift in
dose-response curves because of binding of the compound to the serum. 29 Since no serum
was included in the luciferase assay and 10% FCS was used for the internalization assay,
this difference might also result in the much higher dose required in the internalization
assay. Furthermore, receptors from different species were used in the luciferase (human)
versus internalization (rat) assays, which might have an influence on the potency of the
ligand. In the study by van Koppen et al., this was thoroughly evaluated for a compound
of the same DHP class, and no differences in potency were found between rat and human
FSHR. 17 As shown in Figure 7.4A, vehicle-treated cells showed mainly membrane fluores-
cence, whereas treatment with the endogenous ligand recombinant human FSH (rFSH,12
nM) led to the translocation of the receptor from the membrane to bright intracellular vesi-
cles, indicative of endocytosis. Treatment with the fluorescent ligands did also result in
the internalization of the receptor as seen by GFP fluorescence. Except for compound 97,
which could not be detected with this microscope, bright ligand fluorescence was present
inside the cells. Apparent from the micrographs are the non-homogeneous levels of recep-
tor expression in these cells, as judged by the intensity of the GFP signal. The intracellular
fluorescence intensities for compounds 93-95 did not seem to correlate well with the pres-
ence or absence of GFP signal, which prompted further experiments.
The best agonists 93, 96 and the Cy7-derivative 97 were subjected to flow cytometry
analysis to quantitatively correlate receptor expression levels with compound uptake/bind-
ing. To diminish potential background staining due to high concentrations of fluorophore,
the concentration was lowered to 1 µM and U2OS-FSHR or U2OS cells were incubated for
2 h. Cells were thoroughly washed and a single-cell suspension in PBS was analyzed by
FACS. The median fluorescence intensities of untreated versus compound-treated U2OS-
FSHR cells are shown in Figure 7.3B. The GFP signal was constant throughout the exper-
iments, indicating that no alterations in receptor expression levels were induced by the
compounds. A low fluorescence signal, due to autofluorescence, was detected in untreated
cells in BODIPY and Cy5 detection channels, and fluorescence increased ∼1000-fold upon
treatment with compound DHP-BDP or DHP-Cy5. For DHP-Cy7 the increase was much
less (untreated MFI: 5, treated MFI: 12), probably also because of suboptimal detection op-
tions for this near-IR dye. 18 Comparison of cells with and without receptor led to interest-
ing observations. An overlay of the histograms of U2OS-FSHR vs U2OS cells (Figure 7.3C)
showed similar shifts in population fluorescence for DHP-BDP and DHP-Cy7, indicating
that the compounds were taken up or binding to the cells, irrespective of the presence
of receptor. The population of U2OS-FSHR cells treated with fluorescent agonist DHP-
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Cy5 on the other hand, was >10-fold more fluorescent than the population of non-receptor
cells. This finding was further confirmed by quadrant analysis of 2D ligand-fluorescence
versus GFP-fluorescence intensity plots (Figure 7.3D, Table 7.2). Only for DHP-Cy5 96 a
linear relationship was found between receptor expression and compound fluorescence
(Figure 7.3D). Quantitative quadrant analysis is given in Table 7.2. For all three channels
(BODIPY, Cy5 and Cy7) quadrants were set such that 90-100% of the untreated U2OS cells
were negative for both GFP and dye fluorescence and 90-93% of untreated U2OS-FSHR
cells were positive for GFP but negative for dye fluorescence. Whereas 98% of the treated
Table 7.2: Quadrant analysis of FACS data.
untreated (%) treated (%)
Compound Quadrant U2OS U2OS-FSHR U2OS U2OS-FSHR
UL 0.06 ± 0.01 0.01 ± 0.01 99.83 ± 0.06 7.25 ± 1.14
DHP-BDP UR 0.08 ± 0.03 0.09 ± 0.02 0.11 ± 0.02 92.64 ± 1.07
93 LL 99.82 ± 0.03 6.36 ± 0.88 0.06 ± 0.05 0.03 ± 0.02
LR 0.05 ± 0.03 93.54 ± 0.87 0.00 0.08 ± 0.06
UL 0.00 0.00 1.56 ± 0.19 0.59 ± 0.35
DHP-Cy5 UR 0.03 ± 0.03 0.00 0.02 ± 0.01 88.08 ± 2.79
96 LL 99.87 ± 0.06 6.15 ± 0.83 98.36 ± 0.21 6.10 ± 1.26
LR 2.43 ± 2.33 93.94 ± 0.9 0.06 ± 0.02 5.24 ± 1.85
UL 9.99 ± 0.64 0.14 ± 0.13 73.35 ± 4.44 2.84 ± 0.33
DHP-Cy7 UR 0.07 ± 0.00 3.38 ± 2.52 0.09 ± 0.03 51.35 ± 0.6
97 LL 89.92 ± 0.65 5.91 ± 0.31 26.56 ± 4.46 3.28 ± 0.42
LR 0.02 ± 0.01 90.58 ± 2.95 0.00 42.63 ± 0.21
U2OS or U2OS-FSHR cells were either untreated or treated with 1 µM of compound and analyzed
by FACS. Contourplots of GFP vs fluorophore fluorescence were divided in quadrants (UL: upper left;
UR: upper right; LL: lower left; LR: lower right) as shown in Figure 7.3 D. Percentages (mean ± SEM)
calculated for three independent experiments performed in duplo are given. The main population in
each group is typeset in boldface.
U2OS cells were negative for both GFP and Cy5 fluorescence upon treatment with com-
pound 96, 99% and 73% of the control cells became positive for BODIPY and Cy7 fluores-
cence upon treatment with 93 or 97, respectively. In case of receptor-expressing cells, 88%
of the DHP-Cy5 treated cells became double positive, 93% of the DHP-BDP treated cells
and only 51% of the DHP-Cy7 treated cells. When the brightest population of cells in the
GFP channel was selected and marked in the cell populations in the respective dye fluo-
rescent channels, as shown in Figure 7.3E, a clear correlation was again found between the
amount of receptor and the amount of compound fluorescence for compound DHP-Cy5
but not for the other two compounds. FACS data do not provide information on the local-
ization of the fluorescent signal, therefore from these experiments it can not be concluded
whether the compounds are taken up by the cells or merely binding. However, it can be
concluded that only for compound DHP-Cy5 a clear relationship was found between dye
fluorescence intensities and FSHR expression levels, without considerable background in
cells that do not express the receptor. An important difference between the Cy5 and BO-
DIPY dyes used in this study is their lipophilicity. The Cy5 dye 91 contains three nega-
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Figure 7.3: FACS analysis. U2OS-FSHR (GFP channel) and U2OS cells were treated with 1 µM m-
DHP-BDP 93 (BODIPY channel), m-DHP-Cy5 96 (Cy5 channel) or m-DHP-Cy7 97 (Cy7 channel).
After treatment (2 h, 37 ◦C, 5% CO2), cells were washed with PBS (2 x) and harvested. A single
cell suspension in PBS (5 · 105 cells/ mL) was measured on a BD FACSCanto II FACS apparatus.
Representative plots are shown from three independent experiments measured in duplo. A) Forward
scatter (FSC) vs side scatter (SSC) plot used to set Gate 1; all subsequent data analysis was performed
on cells within this gate. Sample size within Gate 1 > 10000 cells. B) Median fluorescence intensities
(MFI) (mean ± SEM, N=3) of (un)treated U2OS-FSHR cells show similar GFP levels, but increased
fluorescence in the corresponding fluorescence channel (compared to control) upon treatment with
one of the compounds. C) Overlays of the histograms of treated U2OS-FSHR (black) and control
U2OS (grey) show that treatment with compounds 93 and 97, but not 96, resulted in a similar
fluorescent shift for both cell lines. D) Representative contour plots of dye fluorescence vs GFP of
treated U2OS-FSHR cells, including the quadrants that were used for the data shown in Table 7.2.
E) The correlation between the intensity of GFP versus dye fluorescence was further examined by
selection of an additional gate "GFP max". Cells within this gate are marked green in the population
(black) of each dye in its corresponding channel. Only for compound 96 it was found that cells with
maximum FSHR-GFP levels correspond to those cells that have maximum dye fluorescence.
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tively charged sulfonate groups and is highly water-soluble, whereas BODIPY dye 88 is
uncharged and very lipophilic. 20 Table 7.3 reflects the lipophilicity of the compounds in
calculated logD{7.4} values. Calculation of accurate values for the BODIPY dyes is hin-
dered by the ambiguity of the structure because of the coordinate bond between boron
and nitrogen. It is clear though that both Cy7 and BODIPY containing compounds (97 and
93) have much higher logD values than the corresponding Cy5 analogue 96. This result
illustrates that even though the physicochemical properties of these dyes in this case do
not influence the agonistic potency of the fluorescent ligands, they have a major influence
on the binding/uptake characteristics.
Table 7.3: Calculated logD{7.4} values.
Compound logD{7.4} dye class Compound logD{7.4} dye class
m-74a 4.7 none 95 4.0 Rhodamine B
93 5.8 BODIPY 96 3.6 cyanine (Cy5)
94 1.4 BODIPY 97 8.6 cyanine (Cy7)
logD values at pH 7.4 were calculated using MarvinSketch. The values for the compounds containing
a BODIPY dye (93 and 94) are less reliable due to structural ambiguity caused by the coordinate
bond between boron and nitrogen.
The ability of DHP-BDP 93 and DHP-Cy5 96 to induce receptor internalization as well
as the intracellular localization of the probes was further examined by confocal fluores-
cence microscopy. Illustrative examples of micrographs are shown in Figure 7.4B and D,
and quantification of FSHR internalization and global fluorescence levels under the dif-
ferent conditions used is shown in Figure 7.5. BDP-DHP 93 was shown to induce recep-
tor internalization in U2OS-FSHR cells as seen by the appearance of green intracellular
vesicles. Similar levels of internalization were found as when the cells were treated with
rFSH, confirming that DHP-BDP is a potent, functional FSHR agonist able to induce cAMP-
mediated signaling as well as subsequent receptor internalization. BODIPY fluorescence
was observed intracellularly in the perinuclear region in membrane-like structures, most
likely corresponding to the membranes of the endoplasmic reticulum (ER) or Golgi appa-
ratus. 30,31 Colocalization analysis of BODIPY fluorescence and GFP (receptor) fluorescence
as shown in Figure 7.5C and Table 7.4 indicated that only moderate colocalization existed
between the two dyes. 32 Indeed, the same intracellular localization pattern was seen when
control U2OS cells were treated with the compound at 37 ◦C (Figure 7.4B, right panel). No
difference in fluorescence levels was found between cells expressing the receptor and wild-
type cells (Figure 7.5B), confirming the FACS data. When U2OS-FSHR cells were treated
with compound at 4 ◦C, receptor internalization was inhibited (Figure 7.4B, middle panel
and Figure 7.5A), as well as compound uptake. Receptor internalization is an active pro-
cess, and the rate of internalization is dependent on the temperature. 33 The fact that also
compound uptake was abolished at low temperature, indicates that the compound was
not (only) taken up by passive diffusion but that other, active, processes played a role. Al-
though diffusion through the cell membrane could be expected to be slowed down at lower
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Figure 7.4: Compound uptake and FSHR internalization analysis by confocal microscopy. U2OS-
FSHR (F) or wild-type U2OS (U) cells were incubated with compounds for 2 h, 37 ◦C. A) Repre-
sentative micrographs of U2OS-FSHR cells that were treated with 10 µM of indicated compounds
show receptor internalization (green), but high compound background fluorescence in all cells (red/
magenta). B) Treatment of U2OS-FSHR cells with DHP-BODIPY 93 (1 µM) at 4 ◦C, prevented
receptor internalization as well as the uptake of the compound. Control U2OS cells at 37 ◦C be-
came brightly red fluorescent when treated with compound 93, indicating that the uptake process is
temperature-dependent, but not FSHR selective. C) Chemical structure of previously reported small-
molecule FSHR antagonist, THQ 98. D) Only DHP-Cy5 96 (1 µM) was shown to induce receptor
internalization in combination with selective uptake in receptor vs non-receptor cells (left vs right
panels). Furthermore, uptake was inhibited at 4 ◦C (second left panel), by pre-incubation with THQ
98 (10 µM, middle panel) and by inhibition of receptor-internalization by chlorpromazine (CPZ, 20
µM, second right panel).
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temperatures as well, this would not explain the complete lack of compound fluorescence
at 4 ◦C. Based on this data, though, it is very unlikely that the internalization is FSHR-
mediated. As shown in Figure 7.4A, the intracellular localization of compounds 94 and
95 is very similar to that found for 93. Since the membranes of ER and Golgi provide a
lipophilic environment inside the cell it is perhaps not surprising that the fluorescent lig-
ands incorporating apolar dyes 93 and 95 (calc. log D{7.4}: 5.8 and 4 respectively, Table 7.3)
accumulate here. 30 Apparently, the incorporation of the two sulfonic acids groups in BO-
DIPY dye 89 is enough to make ligand 94 soluble in water and much more hydrophilic
(logD{7.4} 1.4), but not to prevent it from binding to membrane structures. Most probably,
a complex interplay between structural properties such as lipophilicity, charge and polar
surface area as well as, potentially, affinity of the BODIPY core for certain membrane sub-
stituents or biomolecules forms the basis for the results obtained.
From the FACS analysis it was already apparent that DHP-Cy5 96 was a better suited
candidate for selective uptake by the FSHR than DHP-BDP 93 and its characteristics were
further examined by confocal microscopy. At 1µM concentration and 37 ◦C, the compound
was shown to induce receptor internalization to comparable levels as DHP-BDP and rFSH
(Figure 7.4D, Figure 7.5A). Compound fluorescence was also observed in intracellular vesi-
cles, in stark contrast to the fluorescence pattern found for DHP-BDP (Figure 7.4D vs B).
Colocalization analysis (Figure 7.5C, Table 7.4) showed strong colocalization between the
receptor and the ligand, 32 as well as a higher intensity correlation quotient (ICQ) compared
to DHP-BDP (0.2852 vs 0.1994, dependent staining: 0≤x≤0.5). 34 Treatment at 4 ◦C did not
lead to receptor internalization, whereas total levels of GFP fluorescence remained con-
stant, showing that this was not due to alterations in expression levels (Figure 7.5A,B). No
Cy5 fluorescence was observed under these conditions, which indicates that the compound
was taken up in an active manner. It is however, somewhat surprising that there was no or
very little membrane fluorescence of compound 96 bound to the receptor detectable at 4◦C.
It has been described that binding of FSH to the receptor becomes increasingly reversible
at low temperatures. Also, the free energy of binding was calculated to be endothermic
at temperatures below 12.5 ◦C. 35 This, in combination with the washing protocols might
result in complete dissociation of possibly low levels of bound ligand to the membrane.
Future experiments should therefore include an ’in between’ temperature such as 16 ◦C
to study receptor binding while internalization is still slowed down. Control U2OS cells
treated with 1 µM of DHP-Cy5 did not show any intracellular Cy5 fluorescence, in accor-
dance with the FACS data. These experiments strongly suggest FSHR-mediated uptake of
DHP-Cy5 in the endolysosomal pathway of cells expressing this receptor. Control experi-
ments with the Cy5 dye 91 alone or in combination with rFSH did not result in intracellular
Cy5 fluorescence, proving that ligand binding to the receptor is a requirement for its uptake
(data not shown). Additional proof was provided with the use of another low molecular
weight ligand for the FSHR of the tetrahydroquinoline (THQ) class of receptor antagonists
(Figure 7.4C). 36,37
Pre-incubation of U2OS-FSHR cells with 10 µM THQ 98 36 for 1 h, 37 ◦C, followed by in-
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Figure 7.5: Quantitative analysis of receptor internalization, global fluorescence and colocalization.
Confocal images of U2OS-FSHR (F) or U2OS (U) cells that were treated with 1 µM DHP-BODIPY
93 or DHP-Cy5 96 were quantified using ImageJ. Each data point represents an analyzed picture from
three independent experiments. A) FSHR internalization was determined by the ratio between GFP
signal on the membrane and in the cytoplasm. Only at 37 ◦C FSHR-internalization was observed,
and this could be inhibited by pre-treatment of the cells with FSHR-antagonist 98 or chlorpromazine
(20 µM). left: Images showing the different ROIs (white) that were set to define membranes or
cytoplasm, see the Experimental Section for more details on image analysis. B) Global fluorescence
levels were determined to exclude effects of the compounds on total receptor levels (GFP signal) and
to quantify the amount of aspecific compound uptake via active (37 ◦C, U2OS cells) or passive (4
◦C) processes. C) Colocalization analysis of FSHR-eGFP with 93 or 96 under various conditions.
Overlays showing colocalized pixels in white are shown; insert: fluorescence scatter plot. Values for
different colocalization parameters are given in Table 7.4.
cubation with DHP-Cy5 (1 µM, 2 h, 37 ◦C) strongly blocked receptor internalization and
reduced DHP-Cy5 uptake to background levels (Figure 7.4D, middle panel, Figure 7.5).
The relatively high dose of THQ 98 (10 µM) compared to DHP-Cy5 (1 µM) was chosen be-
cause its antagonistic potency (IC50: 39 nM) is lower than the agonistic potency of DHP-Cy5
(EC50: 8 nM). Colocalization analysis (Figure 7.5C, Table 7.4) confirmed that the low lev-
els of remaining Cy5 fluorescence were due to aspecific background. THQ is an allosteric
antagonist of the FSHR 37 and one explanation would be that the compound competes for
the same binding pocket as DHP on the receptor, thereby preventing binding of DHP-Cy5
and subsequent activation and internalization of the receptor. Alternatively, binding of the
antagonist might result in a conformational shift of the receptor for which the agonist has
reduced affinity. Further research is needed to elucidate the effect of THQ on DHP bind-
ing. In a final experiment, receptor internalization was blocked by pre-incubation with
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Table 7.4: Colocalization analysis of m-DHP-BODIPY 93 and m-DHP-Cy5 96 with eGFP-FSHR.
n (N) Rr M1 M2 ICQ
93 12 (3) 0.4838 ± 0.023 0.9072 ± 0.010 0.9409 ± 0.009 0.1994 ± 0.011
96 22 (5) 0.7271 ± 0.008 0.9460 ± 0.005 0.9164 ± 0.007 0.2852 ± 0.005
10 µM THQ + 96 6 (2) 0.4637 ± 0.029 0.9027 ± 0.014 0.5942 ± 0.019 0.1658 ± 0.004
10 µM CPZ + 96 10 (2) 0.7314 ± 0.013 0.9476 ± 0.006 0.9225 ± 0.008 0.2906 ± 0.006
20 µM CPZ + 96 9 (2) 0.7581 ± 0.020 0.9437 ± 0.010 0.9254 ± 0.007 0.3352 ± 0.005
n(N): number of pictures n from N independent experiments analyzed. Rr: Pearson’s colocalization
coefficient. Manders overlap coefficients (M) M1: red; M2: green. ICQ: intensity correlation quotient.
Mean +/- SEM is given.
chlorpromazine, a cationic amphiphilic drug that interferes with clathrin-mediated endo-
cytosis. 38 Inhibition is concentration-dependent and also varies with the cell line used. 38–41
Initial experiments were conducted with 10 µM of chlorpromazine, but this did not pre-
vent agonist-induced receptor endocytosis (Figure 7.5A). The concentration was increased
to 20 µM, which inhibited receptor internalization, but was clearly also toxic to the cells
as seen by profound changes in morphology. Although receptor internalization could be
blocked under these conditions, DHP-Cy5 was still able to bind to the FSHR as shown by
strong colocalized fluorescence on the membranes of the cells (Figure 7.4D, Figure 7.5C,
Table 7.4). Taken together, these results indicate that DHP-Cy5 induced FSHR internaliza-
tion in a clathrin-mediated fashion. This process could be inhibited by pre-blocking the
receptor (signaling) with the antagonist THQ, by disrupting clathrin-coated pit formation,
or by lowering the temperature. Furthermore, internalization of the receptor also led to
the selective uptake of the bound fluorescent agonist into intracellular vesicles of FSHR-
expressing cells.
7.3 Conclusion
The follicle-stimulating hormone receptor is very important in human reproduction and
has also been implied to play a role in tumor angiogenesis. As such, fluorescent FSHR lig-
ands would be valuable tools for receptor-visualization, to study receptor-mediated pro-
cesses, and ultimately, to visualize whether targeting of this receptor is a viable method
for selective delivery of drugs to FSHR-expressing tumors. The aim of the present study
was to synthesize and evaluate low molecular weight fluorescent analogues of the FSHR
agonist DHP 55. Using the information provided by the SAR study in Chapter 6 five fluo-
rescent DHP ligands, incorporating dyes from different classes (BODIPY, rhodamine and
cyanine dyes), were synthesized. Evaluation in a luciferase assay showed these ligands to
be nanomolar potent agonists for the FSHR. U2OS cells stably expressing a GFP-tagged
version of the FSHR were used to address questions regarding ligand-induced receptor
internalization and subsequent uptake of the ligand in the endocytic pathway. All fluores-
cent agonists were able to induce receptor endocytosis as seen by receptor fluorescence, but
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only one of the compounds, DHP-Cy5 (96) was selectively internalized together with the
receptor. This illustrates that even when agonistic potency is unaffected by the physic-
ochemical nature of the dye, other pharmacological parameters can be greatly altered.
DHP-Cy5 was not taken up by control U2OS cells without receptor or at low tempera-
ture in receptor-expressing cells. Furthermore, internalization of both ligand and receptor
could be inhibited by pharmacological intervention with either a LMW FSHR antagonist or
with chlorpromazine, an inhibitor of clathrin-mediated endocytosis. This study once more
shows that the incorporation of a dye can have a large influence on the properties of a small
molecule. By tuning the nature of the dye, a highly nanomolar potent fluorescent agonist
for the FSHR was successfully developed which was endocytosed in an FSHR-dependent
fashion. This opens up the possibility of selective drug targeting via agonist-induced FSHR
internalization, which will be explored in Chapter 8.
7.4 Experimental Section
Cell culture conditions. All cells were grown in a humidified atmosphere in 5% CO2 at 37
◦C.
CHO cells stably expressing the human FSH receptor together with a luciferase reporter gene (CHO-
hFSHR_luc cells) and control cells without receptor but with luciferase gene (CHO_luc cells) were
provided by MSD, Oss, The Netherlands. Cells were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) and Ham’s F12 medium (1:1) with glutamine, penicillin/streptomycin (0.1 mg/mL) and fetal
calf serum (FCS). CHO-hFSHR_luc cells were maintained under constant selection with Hygromycin
B (0.8 mg/mL). Cells were subcultured twice weekly at a ratio of 1:10-1:15. U2OS cells stably
expressing the rat FSHR fused to the N-terminus of eGFP (U2OS-FSHR cells) were obtained from
MSD, Oss, The Netherlands (FSHR redistribution assay, BioImage). Cells were grown in DMEM
(high glucose (4.5 g/L) and with stable glutamine, Invitrogen), pen/strep (0.1 mg/mL), G418 (0.5
mg/mL) and FCS (10%). Wild-type U2OS cells were grown under the same conditions, without
G418. Cells were subcultured twice weekly at a ratio of 1:8-1:10.
Measurement of CRE-induced luciferase expression. CHO_luc or CHO-hFSHR_luc cells were cul-
tured to ∼80% confluency before use in the assay. On the day of the experiment, cells were har-
vested using enzyme-free dissociation solution (Millipore), counted (Biorad TC10 automated cell
counter) and resuspended in assay medium (DMEM-F12 (1:1), without phenol-red, with pen/strep
(0.1 mg/mL) supplied with 1 µg/mL bovine insulin (Tebu-Bio) and 5 µg/mL human apo-transferrin
(Sigma)) to a concentration of 7.5 x 105 cells/mL. Experiments were conducted in 96-wells white
Optiplates (Perkin Elmer) and each well contained 30 µL of test compound, recombinant FSH (200
pM final concentration, positive control) or assay medium (negative control), 30 µL of assay medium
and 30 µL cell suspension. Final concentration of DMSO was 1% for all compounds, including con-
trols. After 4 h of stimulation, 50 µL Neolite (PerkinElmer) was added to each well and luminescence
signal was detected on a Microbeta Trilux 1450 Luminescence Counter (PerkinElmer). To control for
non-FSHR mediated effects on intracellular cAMP levels, highest compound concentrations used in
the dose-response experiments (typically 1 µM) were tested on CHO_luc cells. Data was analyzed
using GraphPad Prism 5 (GraphPad Software, La Jolla, USA), and values were normalized to the
maximal effect obtained for recombinant human FSH (200 pM, rFSH, Org32489, gift from MSD,
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Oss, The Netherlands). Each experiment was performed on duplicate plates and mean ± SEM values
of at least three independent experiments are given.
Fluorescence-activated cell sorting. U2OS or U2OS-FSHR cells were cultured as described under
"Cell culture". Cells were seeded onto 6-well plates (400.000 cells/well) and cultured for 48 h, before
start of the experiment. Compounds (as 2x stock solution in culture medium) 93,96 or 97 were added
to the cells (1 µM final concentration) and the cells were incubated for 2 h (37 ◦C, 5% CO2). Cells
were washed with ice-cold PBS (2x) and harvested using enzyme-free dissociation solution (Millipore).
After centrifugation (5 min, 1200 rpm), the pellet was resuspended in PBS to obtain a single-cell
suspension of ∼ 1 x 106 cells/mL. Cells were transferred to a 96-wells plate and samples measured
using a BD FACSCanto II flow cytometer (BD Biosciences, San Jose, USA). The following laser/filter
settings were used: GFP (FSHR): λex: 488 nm, λem: 530/30 nm; BODIPY (93): λex: 488 nm, λem:
585/42 nm; Cy5 (96): λex: 633 nm, λem: >670 nm; Cy7 (97): λex: 633 nm, λem: 780/60 nm and
values were compensated using the instrumentation software and mono-stained controls. Data was
analyzed using FCS Express 4 Flow Research Edition (De Novo Software, LA, USA). All samples were
measured twice and values were calculated from three independent experiments with a sample size
∼10000 cells.
Uptake and FSHR internalization microscopy experiments. U2OS-FSHR or U2OS cells were main-
tained as described under "Cell culture". 48 h before the experiment, cells were harvested (Trypsin-
EDTA), counted and seeded onto sterile Labtek II 4- or 8-chamber borosilicate coverglass systems
(Fisher Emergo) at a density of 25-50 x 104 cells/well. On the day of the experiment, cells were
incubated with the indicated concentration of compound (10 or 1 µM) or rFSH (12 nM) for 2 h at 37
or 4 ◦C, before being washed with PBS (2x), fixed (4% formaldehyde in PBS), washed again (PBS)
and nuclei stained with Draq5 (Thermo Scientific) (optional, only when the compound fluorescence
is detected in the dsRed channel). Cells were imaged on a Leica TCS SPE confocal microscope,
using GFP (FSHR), dsRed (BODIPY, rhodamine) or Cy5 (Cy5, water-soluble BODIPY, Draq5) fil-
ter settings (λex 488, 532 or 635 nm) with optimized detection range to exclude bleed-through of
dye signal in different channels. For competition experiments, cells were pre-incubated for 1 h with
THQ 98 (10 µM) or chlorpromazine (10 or 20 µM), before addition of DHP-Cy5 96 (1 µM) to
the medium. Images were taken under the same settings (laser power, gain, offset, pinhole) and
were analyzed using ImageJ. Global fluorescence was determined either for the whole picture or for
a specific region of interest (ROI), which only included regions with cells present, and corrected for
the selected area. Intensities were normalized to an average of ∼1 for untreated or rFSH-treated
U2OS-FSHR cells (GFP signal), DHP-BODIPY 93- treated U2OS-FSHR cells (BODIPY signal), or
DHP-Cy5 96- treated U2OS-FSHR cells (Cy5 signal), since these can be regarded as positive controls.
The percentage of GFP fluorescence signal on the membranes compared to that in the cytoplasm
was determined by selection of membranes (typically 5-7 cells/image that were inside the focal plane)
with the brush tool (ROI:’membranes’), followed by the creation of a ROI that included the selected
cells (ROI:’cells’). Two greyscale images were then tresholded according to Yen, 42 followed by se-
lection of the ’membranes’ ROI in each picture which was then either cleared (giving ’cytoplasm’)
or cleared outside (giving ’membranes’). Fluorescence intensities of cells/membranes within the ROI
were measured and calculated as a fraction of total GFP signal (membrane+cytoplasm = 100%).
For representative images showing the selected ROIs, see Figure 7.5. Colocalization was calculated
on background-corrected images using the intensity correlation analysis and colocalization treshold
plugins.
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Synthesis
General. All reagents were of commercial grade and used as received unless stated otherwise. Reaction
solvents were of analytical grade and when used under anhydrous conditions stored over flame-dried
3 Å molecular sieves. Dichloromethane was distilled over CaH2 prior to use. Solvents used for column
chromatography were of technical grade and distilled before use. All moisture and oxygen sensitive
reactions were performed under an argon atmosphere. Flash chromatography was performed on silica
gel (Screening Devices BV, 0.04-0.063 mm, 60 Å). Reactions were routinely monitored by TLC analysis
on DC-alufolien (Merck, Kieselgel60, F254) with detection by UV-absorption (254/366 nm) where ap-
plicable and spraying with a solution of (NH4)6Mo7O24 · 4 H2O (25 g/l) and (NH4)4Ce(SO4)4 · 2 H2O
(10 g/l) in 10% sulfuric acid in water followed by charring at ∼ 150 ◦C. 1H and 13C NMR spectra
were recorded on a Bruker AV-400 (400 MHz) or Bruker DMX-600 (600 MHz). Chemical shifts are
given in ppm (δ) relative to the residual solvent peak or TMS (0 ppm) as internal standard. Coupling
constants are given in Hz. Peak assignments are based on 2D 1H-COSY and 13C-HSQC NMR experi-
ments. IR measurements (thin film) were conducted on an IRaffinity-1 apparatus and evaluated using
IRSolutions software (Shimadzu, Kyoto, Japan). LC-MS measurements were conducted on a Thermo
Finnigan LCQ Advantage MAX ion-trap mass spectrometer (ESI+) coupled to a Surveyor HPLC
system (Thermo Finnigan) equipped with a standard C18 (Gemini, 4.6 mmD x 50 mmL, 5µ particle
size, Phenomenex) analytical column and buffers A: H2O, B: ACN, C: 0.1% aq.TFA. High resolution
mass spectra were recorded on a LTQ Orbitrap (Thermo Finnigan) mass spectrometer equipped with
an electronspray ion source in positive mode (source voltage 3.5 kV, sheath gas flow 10 mL min−1,
capillary temperature 250 ◦C) with resolution R=60000 at m/z 400 (mass range m/z=150-2000) and
dioctylphtalate (m/z = 391.28428) as a "lock mass". The high resolution mass spectrometer was
calibrated prior to measurements with a calibration mixture (Thermo Finnigan). For reversed-phase
HPLC purification of the final compounds a Gilson automated HPLC system equipped with a C18







zaldehyde 27 (1.54 g, 7.5 mmol) was dissolved in dry THF (30 mL) and cooled to
0 ◦C in an ice-bath. Grignard reagens (1,3-dioxan-2-ylethyl)-magnesium bromide
(0.5 M in THF, 15.5 mL, 7.75 mmol, 1.03 eq) was dropwise added over 1 h. The
mixture was stirred for an additional h, while warming up to rt. TLC analysis indi-
cated complete conversion of the reaction, so the reaction was quenched by addition
of NH4OAc (sat aq, 20 mL), followed by extraction with EtOAc (3 x 50 mL). The
combined organic layers were dried over MgSO4, filtered and concentrated under
reduced pressure. The crude product was purified by silica column chromatography
(20% EtOAc in toluene) resulting in compound 83 as a colorless oil in 70% yield (1.68 g, 5.2 mmol).
R f = 0.3 (2:1 toluene:EtOAc). 1H NMR (400 MHz, CDCl3): δ 7.28 - 7.21 (m, 2H, 2 x CHar ), 6.90
- 6.73 (m, 2H, 2 x CHar), 4.61 (dd, J = 7.1, 5.8 Hz, 1H, CH), 4.53 (t, J = 4.8 Hz, 1H, CH), 4.12
- 4.04 (m, 2H, CH2), 4.01 (t, J = 5.9 Hz, 2H, CH2), 3.77 - 3.66 (m, 2H, CH2), 3.49 (t, J = 6.7
Hz, 2H, CH2), 2.80 (s, 1H, OH), 2.12 - 1.96 (m, 3H, CH2, CH2- H
a), 1.91 - 1.78 (m, 2H, CH2),
1.78 - 1.55 (m, 2H, CH2), 1.35 - 1.25 (m, 1H, CH2-H
b). 13C NMR (101 MHz, CDCl3): δ 157.96,
137.26, 127.13, 114.35, 102.07, 73.63, 66.93, 64.56, 48.29, 33.40, 31.60, 28.83, 25.72. FT-IR (thin
film) v 3447, 2960 (N3), 2854, 2094, 1611, 1512, 1241, 1136 cm
−1. LC/MS analysis (linear gradient
10 → 90% ACN) tR : 7.46 min, ESI-MS (m/z): [M + H]+: 321.93. ESI-HRMS (m/z): calcd. for
[C16H23N3O4 + H]








1-(4-(3-azidopropoxy)phenyl)-3-(1,3-dioxan-2-yl)propan-1-one (84). Alcohol 83
(1.28 g, 4 mmol) was dissolved in dry DCM (40 mL) and MnO2 (3.47 g, 40 mmol,
10 eq) was added. The mixture was stirred for 24 h at room temperature, after
which another 10 eq of MnO2 were added (3.47 g, 40 mmol) and the reaction
continued for 20 h. Upon completion, the mixture was filtered over a plug of celite
and concentrated. Purification by silica column chromatography (10 → 20% EtOAc
in PE) resulted in compound 84 as a colorless oil that solidified over time, in 79%
yield (1.01 g, 3.16 mmol). R f = 0.5 (1:1 PE:EtOAc). 1H NMR (400 MHz, CDCl3):
δ 7.96 (d, J = 8.8 Hz, 2H, 2 x CHar), 6.92 (d, J = 8.8 Hz, 2H, 2 x CHar), 4.66 (t, J = 5.0 Hz, 1H,
CH), 4.20 - 4.02 (m, 4H, 2 x CH2), 3.88 - 3.68 (m, 2H, CH2), 3.53 (t, J = 6.6 Hz, 2H, CH2), 3.06
(t, J = 7.3 Hz, 2H, CH2), 2.14 - 1.96 (m, 5H, 2 x CH2, CH2- H
a), 1.44 - 1.17 (m, 1H, CH2-H
b).13C
NMR (101 MHz, CDCl3): δ 198.25, 162.52, 130.45, 130.36, 114.18, 101.23, 66.98, 64.79, 48.20,
32.37, 29.59, 28.76, 25.90. FT-IR (thin film) v 2960 (N3), 2854, 2360, 2098, 1675, 1600, 1508,
1252, 1134 cm−1. LC/MS analysis (linear gradient 10 → 90% ACN) tR : 8.51 min, ESI-MS (m/z):
[M + H]+: 320.07. ESI-HRMS (m/z): calcd. for [C16H21N3O4 + H]




2-(4-(3-azidopropoxy)phenyl)-1H-pyrrole (85). Ketone 84 (1.2 g, 3.8 mmol) was dis-
solved in glacial acetic acid (30 mL) and NH4OAc (30 g, 380 mmol, 100 eq) was added.
The mixture was heated to reflux for 7 h and then allowed to cool to rt, before being
poured into ice-water (100 mL). The solution was neutralized with Na2CO3 and extracted
with DCM (3 x 50 mL). The combined organic layers were dried (Na2SO4), filtered and
concentrated. The mixture was purifed by silica column chromatography (0 → 10% EtOAc
in PE) yielding both pyrrole 85 and acetoxypropane as an impurity. Because of the instable
nature of the pyrrole it was used as such, without any further purifications. R f = 0.45
(4:1 toluene:EtOAc). 1H NMR (400 MHz, CDCl3): δ 8.77 (s, 1H, NH), 7.38 (d, J = 8.7
Hz, 2H, 2 x CHar), 6.86 (d, J = 8.7 Hz, 2H, 2 x CHar), 6.76 (d, J = 1.2 Hz, 1H, CHar), 6.45 (s,
1H, CHar), 6.29 (dd, J = 5.5, 2.7 Hz, 1H, CHar), 3.99 (t, J = 6.0 Hz, 2H, CH2), 3.49 (t, J = 6.7
Hz, 2H, CH2), 2.04 - 2.00 (m, 2H, CH2).
13C NMR (101 MHz, CDCl3): δ 156.98, 131.71, 125.97,









4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (87). Azido-pyrrole 130 (crude,
3.8 mmol) was dissolved in MeOH (30 mL) and carboxyaldehyde pyrrole 86 22
(794 mg, 3.8 mmol, 1 eq) was added. After cooling of the mixture to 0 ◦C,
HBr (48% in H2O, 430 µL, 1 eq) was added and the reaction continued for
1.5 h at 0 ◦C. The crude purple HBr salt was filtered off, dissolved and co-
evaporated with DCE (3 x 50 mL). To a solution of the crude HBr-salt (1.65
g, 3.2 mmol) in DCE (20 mL) were added TEA (1.3 mL, 9.6 mmol, 3 eq)
and BF3.OEt2 (2 mL, 16 mmol, 5 eq) and the mixture was heated to 90
◦C for 15 min, before being
concentrated in vacuo and purified by silica column chromatography (0 → 2% EtOAc in toluene,
followed by 10% EtOAc in toluene + 1% AcOH). After purification both the title BODIPY-methyl
ester 87 (812 mg, 1.69 mmol, 44% over 3 steps) and hydrolyzed azido-BODIPY-acid 88 (185 mg,
0.4 mmol, 10%) were obtained as purple solids. R f = 0.6 (4:1 toluene:EtOAc). 1H NMR (400 MHz,
CDCl3): δ 7.86 (d, J = 8.8 Hz, 2H, 2 x CHar), 7.05 (s, 1H, CHar), 6.94 (d, J = 8.8 Hz, 2H, 2 x
CHar), 6.91 (d, J = 4.1 Hz, 1H, CHar), 6.51 (d, J = 4.0 Hz, 1H, CHar), 4.06 (t, J = 5.9 Hz, 2H,
CH2), 3.65 (s, 3H, CH3), 3.49 (t, J = 6.7 Hz, 2H, CH2), 2.69 (t, J = 7.7 Hz, 2H, CH2), 2.52 (s,
3H, CH3), 2.43 (t, J = 7.7 Hz, 2H, CH2), 2.16 (s, 3H, CH3), 2.03 (p, J = 6.3 Hz, 2H, CH2).
13C
NMR (101 MHz, CDCl3): δ 172.89, 159.49, 159.13, 155.52, 139.82, 135.05, 134.31, 130.78, 130.74,
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130.70, 129.93, 128.03, 125.71, 123.00, 118.30, 114.22, 64.50, 51.75, 48.24, 33.84, 28.76, 19.46,
13.12, 9.54. ESI-HRMS (m/z): calcd. for [C24H26BF2N5O3 + H]









oro-4-bora-3a,4a-diaza-s-indacene (88). BODIPY 87 (120 mg, 0.25
mmol) was dissolved in toluene (20 mL). After addition of Me3SnOH (99
mg, 0.55 mmol, 2.2 eq) the mixture was heated to reflux for 3h and sub-
sequently stirred for 16 h at rt. The organic layer was washed with HCl
(aq, 0.1 M, 3 x 30 mL), water (1 x 30 mL), dried (MgSO4), filtered and
concentrated under reduced pressure. Silica column chromatography (0 →
0.1% AcOH in 30% EtOAc in toluene) afforded azido-BODIPY-acid (100
mg, 0.21 mmol, 86%) as a purple solid. R f = 0.3 (4:1 toluene:EtOAc + AcOH). 1H NMR (400 MHz,
CDCl3): δ 7.87 (d, J = 8.9 Hz, 2H, 2 x CHar), 7.08 (s, 1H, CHar), 6.99 - 6.91 (m, 3H, 3 x CHar),
6.53 (d, J = 4.1 Hz, 1H, CHar), 4.09 (t, J = 5.9 Hz, 2H, CH2), 3.52 (t, J = 6.7 Hz, 2H, CH2),
2.71 (t, J = 7.6 Hz, 2H, CH2), 2.54 - 2.46 (m, 5H, CH3, CH2), 2.19 (s, 3H, CH3), 2.06 (p, J =
6.3 Hz, 2H, CH2).
13C NMR (101 MHz, CDCl3): δ 178.49, 159.59, 159.07, 155.85, 139.86, 135.17,
134.34, 130.85, 129.60, 128.24, 125.78, 123.14, 118.53, 114.31, 64.57, 48.34, 33.90, 28.86, 19.30,
13.22, 9.71. ESI-HRMS (m/z): calcd. for [C23H24BF2N5O3 + H]












BODIPY 88 (51 mg, 0.11 mmol) was dissolved in MeOH (5 mL) and
4-formyl-1,3-benzenedisulfonic acid, disodium salt hydrate (34 mg, 0.11
mmol, 1 eq) was added followed by acetic acid (63 µL, 1.1 mmol, 10 eq)
and pyrrolidine (92 µL, 1.1 mmol, 10 eq). After heating at 72 ◦C for 2 h,
an additional 0.5 eq of benzaldehyde (16 mg, 0.05 mmol) was added. All
starting BODIPY was consumed after 5 h, so the mixture was concentrated
and co-evaporated with toluene under reduced pressure. Repeated silica column chromatography (10
→ 30% MeOH in DCM) followed by cation exchange over Dowex-Na+ with water as the eluens
yielded the sodium salt of sulfonated-BODIPY 89 in 62% yield (53 mg, 0.068 mmol) as a dark blue
powder. R f = 0.2 (3:1 DCM:MeOH + AcOH). λabs(10 µM in MeOH): 609 nm; (10 µM in H2O):
601 nm. λem(100 nM in MeOH/H2O): 637 nm.
1H NMR (400 MHz, MeOD): δ 8.55 (d, J = 16.9
Hz, 1H, CH=), 8.50 (d, J = 1.4 Hz, 1H, CHar), 7.95 (d, J = 8.9 Hz, 2H, 2 x CHar), 7.92 - 7.85
(m, 2H, 2 x CHar), 7.72 (d, J = 16.8 Hz, 1H, CH=), 7.42 (s, 1H, CHar), 7.12 (d, J = 4.2 Hz, 1H,
CHar), 7.02 (d, J = 8.9 Hz, 2H, 2 x CHar), 6.68 (d, J = 4.2 Hz, 1H, CHar), 4.13 (t, J = 6.0 Hz,
2H, CH2), 3.53 (t, J = 6.7 Hz, 2H, CH2), 3.18 - 3.12 (m, 2H, CH2), 2.57 (t, J = 7.3 Hz, 2H, CH2),
2.30 (s, 3H, CH3), 2.06 (p, J = 6.4 Hz, 2H, CH2).
13C NMR (101 MHz, MeOD): δ 181.86, 161.22,
157.74, 154.19, 145.62, 144.65, 141.78, 138.06, 137.93, 136.73, 135.60, 133.98, 132.04, 130.02,
128.78, 127.22, 126.81, 126.51, 123.93, 123.42, 120.16, 115.30, 65.96, 49.34, 38.10, 29.80, 23.27,
9.57. ESI-HRMS (m/z): calcd. for [C30H28BF2N5O9S2 + Na]
























m-DHP-BODIPY-N3 (93). To a solution of amino-
DHP m-76a (8 mg, 10.6 µmol) and azido-BODIPY-
acid 88 (6 mg, 10.6 µmol) in DCM (1 mL) were
added EDC (4 mg, 21 µmol, 2 eq), HOBt (2.8 mg,
21 µmol, 2 eq) and TEA (3 µL, 21 µmol, 2 eq) .
The mixture was stirred for 3 h at room temperature,
and subsequently washed with HCl (aq, 1 M, 2 x 5
mL), water (1 x 5 mL), dried (MgSO4), filtered and
concentrated in vacuo. Purification by silica column
chromatography (0 → 5% MeOH in DCM), gave the
product as a purple solid (6.2 mg, 5.1 µmol, 48%). R f = 0.3 (20:1 DCM:MeOH). 1H NMR (600
MHz, CDCl3): δ 7.98 (d, J = 1.8 Hz, 1H, CHar), 7.88 - 7.84 (m, 2H, 2 x CHar), 7.76 (dt, J = 7.8,
1.4 Hz, 1H, CHar), 7.62 (dt, J = 7.8, 1.3 Hz, 1H, CHar), 7.41 (t, J = 7.7 Hz, 1H, CHar), 7.09 (s,
1H, CHar), 6.98 - 6.94 (m, 3H, 3 x CHar), 6.91 (d, J = 2.0 Hz, 1H, NH), 6.87 (d, J = 5.6 Hz, 1H,
CHar), 6.80 (d, J = 2.0 Hz, 1H, CHar), 6.53 (d, J = 4.1 Hz, 1H, CHar), 6.45 (s, 1H, CHar), 6.15 (t,
J = 5.6 Hz, 1H, NH), 5.02 (d, J = 2.0 Hz, 2H, CH2), 4.55 (s, 1H, CH), 4.13 - 4.07 (m, 4H, 2 x
CH2), 3.67 - 3.62 (m, 6H, 3 x CH2), 3.61 - 3.59 (m, 2H, CH2), 3.56 - 3.52 (m, 4H, 2 x CH2), 3.50
- 3.47 (m, 2H, CH2), 3.41 (t, J = 5.1 Hz, 2H, CH2), 3.34 - 3.29 (m, 2H, CH2), 2.72 (t, J = 7.2
Hz, 2H, CH2), 2.50 (s, 3H, CH3), 2.45 (dd, J = 16.1, 4.0 Hz, 1H, CH2-H
a), 2.32 - 2.24 (m, 4H, 2
x CH2), 2.18 (d, J = 7.2 Hz, 4H, CH3, CH), 2.10 - 2.05 (m, 6H, CH3, CH2-H
b, CH2), 1.42 (t, J =
7.0 Hz, 3H, CH3), 1.35 - 1.28 (m, 4H, 2 x CH2), 0.91 - 0.87 (m, 3H, CH3).
13C NMR (151 MHz,
CDCl3): δ 195.63, 171.89, 167.72, 159.80, 159.62, 155.46, 152.79, 149.35, 144.73, 144.14, 142.28,
140.15, 138.10, 135.05, 134.78, 134.58, 131.31, 130.87, 128.71, 128.01, 127.07, 126.71, 125.91,
123.01, 122.96, 119.27, 118.43, 118.07, 114.35, 113.03, 110.15, 88.41, 74.19, 70.56, 70.36, 70.29,
69.96, 69.83, 64.71, 64.65, 48.38, 43.48, 39.92, 39.45, 38.28, 37.54, 36.27, 33.93, 33.76, 28.92,
20.09, 19.93, 18.65, 14.96, 14.19, 13.34, 9.77. ESI-HRMS (m/z): calcd. for [C61H71BBrF2N9O9 +
























m-DHP-water-soluble BODIPY (94). To a solution
of amino-DHP m-76a (8 mg, 10 µmol) and water-
soluble BODIPY-acid 89 (7.8 mg, 10 µmol) in DMF
(1 mL) were added EDC (4 mg, 20 µmol, 2 eq),
HOBt (2.8 mg, 20 µmol, 2 eq) and TEA (7.5 µL,
75 µmol, 5 eq). The mixture was stirred for 4 h at
room temperature, before the same amounts of EDC,
HOBt and TEA were added again. After 48 h the
reaction was finished, the solvent removed in vacuo
and the residue purified by silica column chromato-
graphy (5 → 25% MeOH in DCM). Crystallization
from DCM/MeOH/Et2O, followed by lyophilization from water gave the product as a dark blue solid
(13.4 mg, 9.2 µmol, 92%). R f = 0.5 (5:1 DCM:MeOH). 1H NMR (600 MHz, MeOD): δ 8.52 (d,
J = 1.7 Hz, 1H, CHar), 8.43 (d, J = 16.9 Hz, 1H, =CH), 8.39 (s, 1H, NH), 8.31 (t, J = 5.4 Hz,
1H, NH), 7.95 - 7.88 (m, 4H, 4 x CHar), 7.84 (d, J = 8.2 Hz, 1H, CHar), 7.72 (s, 1H, CHar), 7.70
(d, J = 10.8 Hz, 1H, =CH), 7.63 (d, J = 7.6 Hz, 1H, CHar), 7.42 (s, 1H, CHar), 7.39 (t, J = 7.7
Hz, 1H, CHar), 7.14 (d, J = 4.2 Hz, 1H, CHar), 7.02 (d, J = 8.9 Hz, 2H, 2 x CHar), 6.90 (d, J =
1.8 Hz, 1H, CHar), 6.86 (d, J = 1.7 Hz, 1H, CHar), 6.69 (d, J = 4.2 Hz, 1H, CHar), 4.85 (s, 2H,
CH2), 4.47 (s, 1H, CH), 4.14 (t, J = 6.0 Hz, 2H, CH2), 4.06 - 3.99 (m, 2H, CH2), 3.59 - 3.50 (m,
14H, 7 x CH2), 3.45 (q, J = 5.5 Hz, 2H, CH2), 3.40 - 3.36 (m, 2H, CH2), 3.12 - 3.04 (m, 2H, CH2),
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2.61 - 2.53 (m, 3H, CH2, CH2-H
a), 2.46 - 2.38 (m, 2H, CH2-H
a, CH2-H
b), 2.26 (s, 3H, CH3), 2.19 -
2.13 (m, 1H, CH), 2.11 (s, 3H, CH3), 2.10 - 2.03 (m, 3H, CH2, CH2-H
b), 1.40 - 1.33 (m, 7H, CH3,
2 x CH2), 0.90 (t, J = 6.9 Hz, 3H, CH3).
13C NMR (151 MHz, MeOD): δ 198.30, 175.53, 170.12,
161.34, 158.56, 154.04, 153.69, 153.22, 147.55, 145.82, 145.16, 144.43, 144.25, 141.54, 139.14,
138.14, 137.64, 136.19, 135.54, 134.63, 132.53, 132.05, 131.72, 130.65, 129.32, 128.85, 128.29,
127.79, 127.08, 126.54, 126.48, 124.18, 124.12, 123.18, 120.61, 120.38, 118.65, 115.28, 113.61,
109.90, 88.23, 75.13, 71.12, 71.08, 71.05, 71.01, 70.94, 70.62, 65.94, 65.58, 49.28, 43.99, 40.84,
40.46, 39.61, 38.07, 37.45, 34.74, 33.51, 29.72, 23.63, 20.84, 18.00, 15.08, 14.36, 9.28. ESI-HRMS
(m/z): calcd. for [C68H75BBrF2N9O15S2 + H]





















m-DHP-Rhodamine B (95). Amino-DHP m-76a (8
mg, 10 µmol) was added to a pre-activated solu-
tion of Rhodamine B-acid 23 90 (6.1 mg, 10 µmol),
EDC (3.8 mg, 20 µmol, 2 eq), HOBt (2.7 mg, 20
µmol, 2 eq) and DiPEA (3.3 µL, 20 µmol, 2 eq) in
DMF (1 mL). The mixture was stirred for 16 h at
room temperature, before addition of another equiv-
alent of EDC (2 mg, 10 µmol) and DiPEA (1.5 µL,
10 µmol). After an additional 6 h, the solvent was
removed in vacuo and the residue purified by silica
column chromatography (0 → 7% MeOH in DCM).
The product was obtained as a bright pink solid (11
mg, 8.2 µmol, 82%). R f = 0.9 (5:1 DCM:MeOH). 1H NMR (600 MHz, CDCl3): δ 7.98 (s, 1H,
CHar), 7.81 (s, 1H, CHar), 7.69 - 7.58 (m, 3H, 3 x CHar), 7.50 (s, 1H, CHar), 7.39 (t, J = 7.7
Hz, 1H, CHar), 7.35 - 7.28 (m, 1H, CHar), 7.18 (s, 2H, 2 x CHar), 6.95 - 6.78 (m, 4H, 4 x CHar),
6.72 (d, J = 7.3 Hz, 2H, 2 x CHar), 5.01 - 4.86 (m, 2H, CH2), 4.53 (s, 1H, CH), 4.10 - 4.00 (m,
2H, CH2), 3.72 - 3.15 (m, 32H, 16 x CH2), 2.97 - 2.84 (m, 1H, CH2-H
a), 2.57 - 2.33 (m, 6H, 2 x
CH2, CH2-Hsuperb, CH2-H
a), 2.24 (s, 3H, CH3), 2.13 (s, 1H, CH), 2.07 - 1.96 (m, 1H, CH2-H
(b)),
1.44 - 1.22 (m, 19H, 5 x CH3, 2 x CH2), 0.85 (t, J = 6.8 Hz, 3H, CH3).
13C NMR (151 MHz,
CDCl3): δ 196.30, 167.72, 167.63, 157.85, 155.74, 152.94, 152.76, 147.72, 143.81, 143.67, 138.14,
135.04, 134.87, 132.21, 131.30, 130.41, 130.27, 128.74, 128.54, 127.82, 127.26, 126.84, 123.32,
120.62, 117.73, 114.29, 114.11, 113.88, 112.58, 108.57, 96.45, 86.10, 74.21, 70.64, 70.55, 70.39,
70.21, 69.78, 64.59, 46.27, 44.84, 43.68, 42.07, 41.80, 39.97, 39.37, 38.46, 37.63, 34.00, 33.15,
























m-DHP-Cy5 (96). Amino-DHP m-76a (5 mg, 6.6
µmol, 1.1 eq) was added to a pre-activated solution
of Cy5-acid 24 91 (5 mg, 6 µmol), PyBOP (3.4 mg,
6.6 µmol, 1.1 eq) and DiPEA (3 µL, 18 µmol, 3 eq)
in DMF (1 mL). The mixture was stirred for 3 h at
room temperature, before the solvent was removed
in vacuo and the residue purified by RP-HPLC (25
→ 45% ACN in 12’, buffer A: 10 mM NH4OAc) or
silica column chromatography (0 → 2% H2O in 40%
MeOH in CHCl3). Crystallization from DCM/MeO-
H/hexanes and lyophilization from H2O yielded the
product as a bright blue solid (5 mg, 3.3 µmol, 55%).
R f = 0.7 (1:1:1:1 EtOAc:n-BuOH:AcOH:H2O).
1H
NMR (600 MHz, MeOD): δ 8.27 (td, J = 13.0, 8.1 Hz, 2H, 2 x =CH), 8.03 (s, 1H, CHar), 7.92 -
7.85 (m, 4H, 4 x CHar), 7.79 (d, J = 7.8 Hz, 1H, CHar), 7.68 (d, J = 7.6 Hz, 1H, CHar), 7.46 (t, J
= 7.7 Hz, 1H, CHar), 7.37 (d, J = 8.8 Hz, 1H, CHar), 7.28 (d, J = 8.2 Hz, 1H, CHar), 6.89 (dd, J
= 15.7, 1.8 Hz, 2H, 2 x CHar), 6.68 (t, J = 12.4 Hz, 1H, =CH), 6.39 (d, J = 13.7 Hz, 1H, =CH),
6.31 (d, J = 13.7 Hz, 1H, =CH), 5.00 (s, 2H, CH2), 4.58 (s, 1H, SO3H), 4.47 (s, 1H, CH), 4.17 -
4.10 (m, 2H, CH2), 4.10 - 4.04 (m, 4H, 2 x CH2), 3.69 - 3.56 (m, 10H, 5 x CH2), 3.56 - 3.51 (m,
2H, CH2), 3.45 (t, J = 5.4 Hz, 2H, CH2), 3.29 - 3.26 (m, 2H, CH2), 2.90 (t, J = 6.8 Hz, 2H, CH2),
2.60 (dd, J = 16.8, 4.5 Hz, 1H, CH2-H
a), 2.47 - 2.40 (m, 2H, CH2-H
b, CH2-H
a), 2.17 (t, J = 7.3
Hz, 3H, CH2, CH), 2.15 - 2.09 (m, 4H, CH3, CH2-H
b), 1.99 - 1.93 (m, 4H, 2 x CH2), 1.80 - 1.70
(m, 14H, 4 x CH3, CH2), 1.67 - 1.62 (m, 2H, CH2), 1.41 (t, J = 7.0 Hz, 3H, CH3), 1.39 - 1.34 (m,
4H, 2 x CH2), 0.95 - 0.88 (m, 3H, CH3).
13C NMR (151 MHz, MeOD): δ 198.37, 175.80, 175.35,
175.15, 170.07, 156.31, 156.10, 154.16, 153.67, 147.56, 145.27, 144.93, 144.81, 144.49, 143.41,
143.34, 142.64, 142.60, 139.34, 135.82, 132.62, 129.58, 128.45, 128.09, 128.04, 128.01, 124.31,
121.33, 120.47, 118.74, 113.78, 111.72, 111.62, 109.98, 105.52, 105.33, 88.30, 75.27, 71.59, 71.57,
71.28, 71.19, 70.57, 70.53, 65.75, 50.59, 50.53, 45.07, 43.80, 40.97, 40.30, 39.79, 38.19, 36.63,
34.88, 33.57, 28.15, 27.89, 27.34, 27.13, 26.50, 23.53, 20.97, 18.06, 15.23, 14.47. LC/MS analysis
(linear gradient 10 → 90% ACN) tR : 6.67 min, ESI-MS (m/z): [M + H]+: 1501.27. ESI-HRMS
(m/z): calcd. for [C73H91BrN6O17S3 + H]
























m-DHP-Cy7 (97). Alkyne-DHP m-
78a (5.3 mg, 6.6 µmol) in dioxane
(0.5 mL) was added to a solution of
azido-Cy7 92 (7.22 mg, 6.7 µmol) in
dioxane/H2O(1 mL, 1:1, v/v). Af-
ter addition of aqueous solutions of
sodium ascorbate (130 µL 100 mM,
13 µmol, 2 eq) and CuSO4 (13 µL
100 mM, 1.3 µmol, 20 mol%) the
mixture was stirred for 16 h under
an argon atmosphere. Upon comple-
tion, the solvent was removed under
reduced pressure and the residue purified by silica column chromatography (4 → 20% MeOH in CHCl3
+ 0.5% H2O). Crystallization from DCM/MeOH/hexanes and lyophilization from H2O/dioxane
yielded the product as a green solid (4.9 mg, 2.6 µmol, 40%). R f = 0.4 (22:8:0.5 CHCl3:MeOH:H2O).
1H NMR (600 MHz, MeOD): δ 8.33 (s, 1H, CHtrz), 8.19 - 8.13 (m, 2H, CHar), 8.01 (d, J = 8.6
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Hz, 2H, CHar), 7.96 - 7.90 (m, 5H, 5 x CHar), 7.75 (d, J = 7.7 Hz, 1H, CHar), 7.61 (d, J = 8.8
Hz, 3H, 3 x CHar), 7.51 (t, J = 7.6 Hz, 2H, 2 x CHar), 7.45 - 7.37 (m, 5H, 5 x CHar), 7.28 (d, J
= 14.0 Hz, 2H, 2 x =CH), 6.89 (dd, J = 19.3, 1.8 Hz, 2H, 2 x CHar), 6.38 (d, J = 14.0 Hz, 2H,
2 x =CH), 4.93 (s, 2H, CH2), 4.52 - 4.48 (m, 2H, CH2), 4.46 (s, 1H, CH), 4.43 - 4.36 (m, 4H, 2
x CH2), 4.10 - 4.00 (m, 2H, CH2), 3.84 - 3.66 (m, 8H, 4 x CH2), 3.64 - 3.44 (m, 22H, 11 x CH2),
2.97 (t, J = 6.8 Hz, 4H, 2 x CH2), 2.78 (d, J = 5.6 Hz, 4H, 2 x CH2), 2.58 (dd, J = 16.7, 4.4 Hz,
1H, CH2-H
a), 2.47 - 2.36 (m, 2H, CH2-H
b, CH2-H
a), 2.25 (p, J = 6.8 Hz, 4H, 2 x CH2), 2.20 - 2.03
(m, 7H, CH3, CH2, CH2-H
b, CH), 1.49 (d, J = 7.4 Hz, 12H, 4 x CH3), 1.39 - 1.32 (m, 7H, CH3,
2 x CH2), 0.90 (t, J = 6.8 Hz, 3H, CH3).
13C NMR (151 MHz, MeOD): δ 198.29, 174.57, 170.01,
169.53, 162.51, 161.94, 154.14, 153.60, 148.38, 147.49, 145.28, 144.47, 144.41, 143.78, 141.03,
139.29, 135.79, 135.52, 134.48, 133.30, 133.20, 132.57, 131.77, 131.23, 131.08, 129.52, 129.32,
128.89, 128.62, 128.35, 127.96, 127.93, 125.86, 124.30, 123.32, 120.47, 118.76, 113.78, 112.07,
109.99, 101.12, 88.34, 75.22, 71.64, 71.57, 71.52, 71.41, 71.38, 71.28, 70.65, 70.56, 70.48, 70.07,
65.72, 51.74, 51.47, 44.14, 43.90, 41.29, 40.98, 40.04, 39.80, 38.20, 34.87, 33.56, 27.69, 25.87,
24.33, 22.61, 20.96, 18.07, 15.21, 14.48. LC/MS analysis (linear gradient 10 → 90% ACN) tR : 8.90
min, ESI-MS (m/z): [M + H]+: 1891.53. ESI-HRMS (m/z): calcd. for [C100H117BrN10O18S2 +
H]+ 1890.72784; obsd. 1890.72949.
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Small-molecule FSHR agonists as
targeting agents for BNCT1
B
oron neutron capture therapy (BNCT) is a binary therapy based on the abil-
ity of boron-10 to efficiently capture thermal neutrons. When sufficiently high
levels of 10B are accumulated within tumor tissues, these can be destroyed with
minimal damage to the surrounding tissue. This chapter presents a targeting strat-
egy for carboranes, suited for BNCT because of their high boron-content, by co-
valent attachment to a follicle-stimulating hormone receptor (FSHR) agonist. The
presence of the FSHR on tumor-associated tissues has been demonstrated and
agonist-induced internalization of the FSHR-ligand complex would result in se-
lective delivery of the BNCT agent into the tumor cells. Five m-DHP-fluorophore-
carborane constructs were synthesized and evaluated for their ability to activate
the FSHR. All constructs were FSHR agonists with an EC50 value below 100 nM,
and able to induce receptor-internalization. The Cy5-containing construct 116 was
shown to be endocytosed, at least partially, in a receptor-dependent fashion, illus-
trating the potential of DHP-conjugates for the targeted delivery of BCNT or other




Boron neutron capture therapy (BNCT) is a binary anticancer therapy based on the ability
of the boron-10 isotope to efficiently capture low-energy thermal neutrons. Both 10B and
slow neutrons are in themselves relatively harmless to cells and tissues, whereas a com-
bination of both leads to a nuclear reaction resulting in the release of lethal, high-energy
α-particles and 7Li ions (Figure 8.1A). These particles release all their energy along a trajec-
tory of ≤10 µm, corresponding to the approximate diameter of a cell. Meaning that if high
doses of boron-10 could be selectively accumulated within tumor tissues, focused irradia-
tion of these tissues would provide a very efficient and localized means to kill the tumor
cells. 2–4 Current clinically used BNCT agents include sodium mercaptoundecahydro-closo-
dodecaborate (BSH) and (L)-4-dihydroxy-borophenylalanine (BPA) (Figure 8.1B) which are
mainly used in the treatment of brain tumors. 5 The primary consideration in the design
of novel BNCT agents is the requirement of high local concentrations of boron inside the
tumor. It has been calculated that ∼20 µg 10B/g tumor is needed for the therapy to be ef-
fective. 6 Agents containing a relatively high amount of boron are therefore favored, as well




















Figure 8.1: A) General principle of BNCT. B) BNCT agents BPA and BSH. C) Structure of ortho-
carborane.
Over the last decades, the polyhedral dicarba-closo-dodecaboranes (carboranes), with
the general formula C2B10H12, have gained much interest as potential BNCT agents because
of their high boron content. Furthermore, they are catabolically stable and ample organic
chemical methods are available for their derivatization. 8,9 The most frequently used carbo-
rane is ortho-carborane, with the two carbon atoms adjacent to each other (Figure 8.1C),
that can be synthesized from a variety of alkynes and decaborane and is commercially
available. Carboranes are very lipophilic in nature, comparable to the adamantane group,
and slightly larger than a rotating phenyl group. 10 Conjugates of carborane and a variety
of biomolecules, such as carbohydrates, 11 amino acids, 12 nucleosides 13 and porphyrins, 14
for BNCT have been described. 4,8
Ovarian cancer is the fifth cause of cancer-related death in women and cancer sur-
vival rates are much lower than for other types of cancers. 15 The most common form is
ovarian epithelial cancer, which arises from the ovarian surface epithelium. 16 The factors
that lead to the onset and progression of the tumor are debated, but there is a body of
evidence indicative of a role for the gonadotropins (luteinizing hormone, LH and follicle
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stimulating hormone, FSH) and their receptors. 17,18 While the main expression site of the
follicle-stimulating hormone receptor (FSHR) in normal physiology is in granulosa cells of
the ovaries, 19 the presence of the FSHR on both normal and tumor ovarian surface epithe-
lium cells has been demonstrated. 20–23 The presence of the FSHR on ovarian cancer cells
has been exploited for targeted delivery of cytotoxic drugs to the receptor. Zhang et al.
have made used of FSHβ-peptides conjugated to nanoparticles to deliver paclitaxel to the
tumor site. 24,25 The recent notion that the FSHR is also expressed by vascular endothelial
cells of a wide range of tumors implicates that this receptor might have broader functions
in carcinogenesis than previously recognized. 26
In the previous Chapters 6 and 7, targeting of the FSHR has been investigated with the
use of a small-molecule agonist for the receptor. By appropriate introduction of a spacer
to the dihydropyridine (DHP) agonist, 27,28 nanomolar potent functionalized ligands were
established. It was also shown that incorporation of a fluorophore led to very potent fluo-
rescent ligands that could be used as diagnostic tools to study receptor-related processes.
The ultimate goal of the research was to arrive at the targeted delivery of BNCT agents to
FSHR-expressing tumor cells, by use of the low molecular weight ligand (Figure 6.2, Chap-
ter 6). Selective accumulation of carboranes in cells via the FSHR, followed by localized
irradiation with thermal neutrons would allow for a very efficient anti-tumor strategy with
minimal damage to surrounding tissues. In this chapter, chemical strategies for functional-
ization of ortho-carborane are presented as well as the synthesis and biological evaluation
of carborane-containing fluorescent ligands for the FSHR.
8.2 Results and Discussion
Synthesis. Incorporation of carboranes into larger constructs requires the presence of a
ligation handle on the carborane core. To keep a high level of flexibility in the design of the
final constructs, ortho–carboranes containing a variety of different groups for further conju-
gation were synthesized (Scheme 8.1). Commercially available o-carborane was used, and
reacted with TMS-protected propargyloxy benzaldehyde 99 and TBAF to give deprotected
alkyne-functionalized carbinol 100 as a racemic mixture. 29 Use of unprotected propargy-
loxy benzaldehyde did not result in product formation and the low yield of the reaction
(24%) was likely due to the concomitant deprotection of the silyl group, which occurred
faster than the addition of carborane to the aldehyde. Reaction times were kept short be-
cause of the reported cage-degradation upon prolonged exposure of the carborane cage
to fluoride ions. 8,30 Carboranes containing other functionalities were synthesized from a
common precursor, alcohol 102. 31 The CH-groups of o-carborane are weakly acidic (pKa
= 22.0) and can be deprotonated using a strong base such as n-butyllithium. The lithium
mono-anion of carborane is unstable and disintegrates to the more stable di-anion and
o-carborane, leading to di-substitution of the carborane cage. 8 With the use of the bulky
TBDMS protective group, this could be prevented. 32 Subsequent oxidation of alcohol 102
using reported conditions (NaIO4, RuCl3 · 3 H2O) was high yielding (86%), but complete
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removal of the ruthenium catalyst proved cumbersome. Alternative conditions using mild
TEMPO/BAIB oxidation were chosen and resulted in a clean conversion to acid 103 in 96%
yield. 33 Subsequent deprotection of the TBDMS group was accomplished using TBAF un-
der acidic conditions in near quantitative yield. The activated ester 105 was obtained in 88%
yield and was used to synthesize carborane peptide 111 (Scheme 8.1B). The peptide scaf-
fold 110 was synthesized using standard Fmoc-based solid-phase peptide synthesis (SPPS)
and was designed with three aspartic acid residues to compensate for the hydrophobicity
of the three incorporated carborane moieties. Also the peptide contained a terminal alkyne
for use in subsequent Cu(I)-catalyzed Huisgen 1,3-dipolar cycloaddition. 34,35 The route to-
wards azide and amine functionalized o-carborane started from common intermediate 102,
which was tosylated, TBDMS-deprotected with TBAF, and reacted with sodium azide to
give azido-o-carborane 108 in good overall yields. The Staudinger reduction of azide 108 to
primary amine 109 was low yielding, mainly because of deboronated by-products. 8 With
functionalized carboranes in hand, five m-DHP-fluorophore-carborane constructs were































































































Reagents and conditions: [a] TBAF, 99, THF, 24%; [b] i) n-BuLi, toluene/Et2O, 0
◦C → rt; ii)
TBDMS-Cl, toluene/Et2O, 87%; [c] i) n-BuLi, THF; ii) trimethyleneoxide, THF, 86%; [d] TEMPO,
BAIB, DCM/H2O, 96%; [e] TFA, TBAF, THF, -78
◦C → rt, 104: 98%, 107: 84 %; [f] N-
hydroxysuccinimide, EDC · HCl, DCM, 88%; [g] p-tosylchloride, DMAP, TEA, DCM, 96%; [h] sodium
azide, TBAI, acetone, reflux, 97%; [i] PPh3, toluene/H2O, 29%; [j] carborane-OSu 105, DiPEA, DMF,
quant.
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synthesized (Scheme 8.2). Different fluorophores and modes of attachment were chosen
to find the optimal combination of dye and carborane that would yield a potent agonist.
Amino-carborane 109 was reacted with bifunctional azido-BODIPY-OSu dye 36 36 and sub-
sequently clicked to alkyne-containing monomeric DHP ligand m-131a (Chapter 6) to give
compound 112. Alternatively, the other side of the BODIPY was used for ligation to the li-
gand (93, Chapter 7), which was then clicked to either alkyne-carborane 100 or carboranyl























































































































All compounds were synthesized using orthogonal Cu(I)-catalyzed Huisgen [3+2] cycloaddition
("click") and peptide coupling conditions in the order indicated. See the Experimental section for
experimental details of each step.
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peptide 111 to yield compounds 114 and 115, respectively. Although the bifunctional BO-
DIPY dye is a very convenient dye for incorporation in larger constructs because of its two
orthogonal ligation handles, studies using fluorescent ligand DHP-BDP 93 in Chapter 7
indicated that it was not selectively taken up by FSHR-expressing cells. pH-activatable
dyes, that become fluorescent at acidic pH have been used as tools to selectively visualize
the uptake of compounds in the endolysosomal pathway (Chapter 2). 37,38 Therefore, by at-
tachment of a pH-activatable dye to the FSHR-agonist, it might be possible to distinguish
between FSHR-mediated uptake of the construct and uptake by other processes, leading
to the ER/Golgi localization (Chapter 7). Bifunctional pH-activatable dye 32 (Chapter 3),
was clicked to azido-carborane 108, the methyl ester on the BODIPY dye was saponified
using mild basic conditions and the resulting carboxylic acid was coupled to amino-DHP
m-76a yielding pH-activatable construct 113. Attachment of a carborane to the DHP-Cy5
96 (Chapter 7) required the addition of an extra ligation handle. Amino-DHP m-76a was
coupled to 2-azido-6-(Boc-amino)hexanoic acid, the Boc group was removed and Cy5 91 39
was coupled using PyBOP. Crude azido-DHP-Cy5 was clicked to alkyne-carborane 100 in































Figure 8.2: Agonistic dose-response curves of
carborane-containing fluorescent ligands 112 -
116 on CHO cells stably expressing the human
FSHR and CRE-inducable luciferase. The re-
sponse was normalized against the maximal ef-
fect obtained with rFSH (200 pM). Representa-
tive curves of at least three independent experi-
ments performed in duplicate are shown.
Biological evaluation. The five DHP-
fluorophore-carborane constructs were
assessed for their agonistic potency on
the FSHR using a CRE-luciferase as-
say. CHO cells stably expressing the
human FSHR and a luciferase-reporter
gene, were incubated with increasing
concentrations of the compounds for 4
h (37 ◦C, 5% CO2). The luminescent
signal, corresponding to receptor acti-
vation, was measured and the result-
ing dose-response curves are depicted
in Figure 8.2. From these curves, the
pEC50 values were obtained that were
used to calculate the mean agonistic po-
tency (EC50) values of the compounds (Table 8.1).
All constructs were shown to be full agonists for the receptor with potencies ranging be-
tween 7.6 nM (113) and 88 nM (114). Except for the pH-activatable compound (113), at-
tachment of the fluorophore-carborane led to an order of magnitude decrease in potency,
compared to monomeric ligand m-74a. Attachment of bulk, as for the carboranyl peptide,
was well tolerated, again confirming that quite large extensions to the DHP core can be
made without detrimental effects on its potency. Although slightly less potent than the
parent molecule, EC50 values still were in a useful range for further experiments. To in-
duce receptor internalization, much higher concentrations in the assay are needed than the
EC50 values found in a luciferase assay, which is why only very potent agonists are feasible
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Table 8.1: Mean agonistic potency (pEC50 and EC50) values of carborane-containing fluorescent
ligands in increasing CRE-mediated luciferase activity in CHO cells stably expressing hFSHR and a
CRE-luciferase reporter gene.
Compound EC50 (nM) pEC50 N Compound EC50 (nM) pEC50 N
m-74a 6 8.22 ± 0.10 3 114 88 7.06 ± 0.14 3
112 18 7.74 ± 0.11 3 115 38 7.42 ± 0.09 3
113 8 8.12 ± 0.11 3 116 45 7.35 ± 0.04 4
The mean EC50 values are calculated from the pEC50 (mean ± SEM) values from N indepent exper-
iments performed in duplicate. The value for monomeric ligand m-74a from Chapter 6 is given for
comparison.
candidates. 27 At higher concentrations these small molecules form aggregates (as seen by
bell-shaped curves in a luciferase assay (data not shown)) and background fluorescence by
nonspecific interaction between the dyes and cell membranes increases.
The ability of BODIPY-based compounds 113-115 to induce receptor endocytosis was
studied using an internalization assay. U2OS cells stably expressing a green fluorescent
eGFP-tagged FSHR (U2OS-FSHR cells) were used for this purpose. Without stimulation,
the receptor is mainly present on the cell membrane, whereas activation leads to the occur-
rence of fluorescence in intracellular vesicles, indicative of endocytosis. 27 As illustrated in
Figure 8.3, treatment of U2OS-FSHR cells with 10 µM of compounds 113-115 indeed led to
translocation of the receptor from the membrane to the cytoplasm (GFP signal, middle pan-
els). At this concentration some membrane fluorescence remained, indicating that 1 µM
was not sufficient to induce full receptor internalization. For comparison, negative (DMSO
only) and positive (recombinant FSH, rFSH) controls are depicted as well. Somewhat sur-
prisingly, incorporation of a pH-activatable BODIPY dye in compound 113 did not result in
selective fluorescence (Figure 8.3, upper left panel). Fluorescence was less than for the "al-
ways on" BODIPY-containing compound 114 (middle left panel), but still fluorescence was
predominantly visible in membrane-like structures. This finding is in accordance with a
recent paper entitled ’pH-sensitive fluorescent dyes: are they really pH-sensitive in cells?’,
where Zhang et al. have found that fluorescence of an pH-activatable aza-BODIPY dye
was activated by intracellular membranes. 40 In contrast to the very large and polar man-
nose cluster-containing constructs described in Chapter 2 or the antibody-conjugates of
Urano et al., 37,38 which are not taken up by cells by other means than via receptor-mediated
endocytosis, the DHP-pH-activatable BODIPY-carborane construct described here is much
more lipophilic and could be expected to be taken up via different routes, leading to their
localization in the ER and Golgi regions of the cell. Also, the binding kinetics of these lig-
ands are not known, and since they are non-covalently bound to the receptor, they might
dissociate quickly once internalized and diffuse out of the endolysosomal vesicles into the
cytoplasm. Further research is needed to fully understand the mechanisms by which the
BODIPY-containing DHP ligands are taken up by cells and trafficked to the membrane-rich
regions of the cell. Comparison of the constructs containing only one carborane (114) or











Figure 8.3: Confocal fluorescence microscopy analysis of BODIPY-containing ligands. U2OS-FSHR
cells were treated with 10 µM of compounds 113, 114 or 115 for 2 h, followed by fixation with 4%
formaldehyde in PBS. Treatment led to internalization of the receptor (GFP, green), but no selective
uptake of the compounds (BODIPY, red) was found. Positive (rFSH) and negative (DMSO) controls
are given for comparison.
for the larger peptide-containing compound 115 (lower left panel, Figure 8.3). No correla-
tion with the GFP signal of the receptor was observed and areas without cells showed the
same fluorescence pattern (not shown), most likely representing compound aggregates. In
combination with the results described in Chapter 7, it can be concluded that the choice for
BODIPY dyes in these constructs resulted in nonselective cellular uptake of these ligands.
The uptake characteristics of the much more hydrophilic Cy5-containing carborane li-
gand were next examined using fluorescence-activated cell sorting (FACS). Either receptor-
expressing cells (U2OS-FSHR) or wild-type cells (U2OS) were incubated for 2 h with 1 µM
of DHP-Cy5-carborane 116, washed and analyzed by flow cytometry. As can be seen in
Figure 8.4A, which shows an overlay of the Cy5-fluorescence histograms of both cell lines,
cells with receptor were slightly more fluorescent than those without. To examine whether
this difference was correlated to receptor expression levels, the population of U2OS-FSHR
cells with highest GFP-fluorescence levels (and thus receptor expression) was selected and
depicted in green in the Cy5 scatterplot (Figure 8.4B). Indeed, cells with the highest levels
of receptors were also highest in Cy5 fluorescence, a similar result as found for the flu-
orescent DHP-Cy5 96 discussed in Chapter 7. Quadrant analyses of GFP vs Cy5 density
plots for U2OS-FSHR and control U2OS cells are depicted in Figure 8.4C. A linear rela-
tionship between the intensity of Cy5 and GFP was found, but only for higher receptor
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Figure 8.4: Uptake of 116 (2 h, 1 µM) in U2OS cells with or without FSHR-eGFP studied by
FACS analysis (A-C) and confocal fluorescence microscopy (D). A) Overlay of the histograms of
treated U2OS-FSHR (black) and U2OS (grey) cells shows a slightly bigger shift in population mean
for receptor cells compared to control cells. B) Scatterplot of Cy5 fluorescence vs forward scatter.
Cells with maximum GFP levels are depicted in green. C) Representative contour plots of Cy5 vs
GFP of treated U2OS-FSHR and U2OS cells, including the quadrants that were used to calculate the
population percentages in each quadrant (mean, N=3). D) Confocal microscopy images of treated
U2OS or U2OS-FSHR cells. Green corresponds to GFP (FSHR) and red to Cy5 (ligand) fluorescence.
Overlaying pixels are stained yellow for clarity, but no colocalization analysis was conducted.
expression levels. Attachment of the very apolar carborane clearly resulted in much in-
creased background levels in untransfected cells or cells with low receptor expression in
the U2OS-FSHR cell population. Confocal fluorescence microscopy of U2OS-FSHR cells
showed receptor internalization and a non-homogeneous distribution of intracellular Cy5
fluorescence (Figure 8.4D). Control U2OS cells treated with compound 116 were also flu-
orescent, in accordance with the FACS data. Due to the non-uniform compound fluores-
cence in the cells, a detailed colocalization analysis was not conducted. Taken together,
these results indicate that it is indeed possible to make larger constructs of the DHP-ligand
to target a BNCT agent to FSHR-expressing cells. In the design of such constructs polarity
should be an important parameter and care should be taken to compensate for the ex-
tremely lipophilic nature of the carborane cage.
8.3 Conclusion
Targeting of carboranes to FSHR expressing tumors presents a promising approach to se-
lectively deliver high levels of boron-10 needed for BNCT. The constructs described in this
chapter made use of the DHP low molecular weight agonist as targeting entity, combined
with a fluorophore, either BODIPY or cyanine dye based, for visualization. Incorporation
of one or more o-carborane moieties was successfully accomplished by the synthesis of a va-
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riety of functionalized carboranes. The resulting DHP-fluorophore-carborane ligands were
able to activate the FSHR, as determined by a luciferase assay, with slightly lower potencies
than the monomeric or fluorescent ligands that were reported in the previous chapters. At
higher (1 µM) concentrations of ligand, the receptor was (partially) internalized, as seen
by the appearance of green intracellular vesicles in an FSHR-internalization assay. Fluores-
cence of BODIPY-based ligands was detected intracellularly in membrane structures when
one o-carborane was introduced, and fluorescent clumps were visible in the medium when
the larger carboranyl peptide-containing ligand 115 was added to the cells, indicative of
aggregation. In case of Cy5-based ligand 116, a linear correlation between the intensity of
receptor fluorescence and the intensity of Cy5-ligand fluorescence was found using FACS.
Unfortunately, background levels in untransfected cells were high and the intracellular flu-
orescence pattern in U2OS-FSHR cells was ambigious. These findings illustrate the poten-
tial of the DHP ligand as targeting entity of cytotoxic drugs to tumors expressing the FSHR,
while also exemplifying that the properties of the drug influence the construct as a whole.
8.4 Experimental Section
Cell culture conditions. All cells were grown in a humidified atmosphere in 5% CO2 at 37
◦C.
CHO cells stably expressing the human FSH receptor together with a luciferase reporter gene (CHO-
hFSHR_luc cells) and control cells without receptor but with luciferase gene (CHO_luc cells) were
provided by MSD, Oss, The Netherlands. Cells were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) and Ham’s F12 medium (1:1) with glutamine, penicillin/streptomycin (pen/strep, 0.1
mg/mL) and fetal calf serum (FCS). CHO-hFSHR_luc cells were maintained under constant se-
lection with Hygromycin B (0.8 mg/mL). Cells were subcultured twice weekly at a ratio of 1:10-1:15.
U2OS cells stably expressing the rat FSHR fused to the N-terminus of eGFP (U2OS-FSHR cells) were
obtained from MSD, Oss, The Netherlands (FSHR redistribution assay, BioImage). Cells were grown
in DMEM (high glucose (4.5 g/L) and with stable glutamine, Invitrogen), pen/strep (0.1 mg/mL),
G418 (0.5 mg/mL) and FCS (10%). Wild-type U2OS cells were grown under the same conditions,
without G418. Cells were subcultured twice weekly at a ratio of 1:8-1:10.
Measurement of CRE-induced luciferase expression. CHO_luc or CHO-hFSHR_luc cells were cul-
tured to ∼80% confluency before use in the assay. On the day of the experiment, cells were har-
vested using enzyme-free dissociation solution (Millipore), counted (Biorad TC10 automated cell
counter) and resuspended in assay medium (DMEM-F12 (1:1), without phenol-red, with pen/strep
(0.1 mg/mL) supplied with 1 µg/mL bovine insulin (Tebu-Bio) and 5 µg/mL human apo-transferrin
(Sigma)) to a concentration of 7.5 x 105 cells/mL. Experiments were conducted in 96-wells white
Optiplates (Perkin Elmer) and each well contained 30 µL of test compound, recombinant FSH (200
pM final concentration, positive control) or assay medium (negative control), 30 µL of assay medium
and 30 µL cell suspension. Final concentration of DMSO was 1% for all compounds, including con-
trols. After 4 h of stimulation, 50 µL Neolite (PerkinElmer) was added to each well and luminescence
signal was detected on a Microbeta Trilux 1450 Luminescence Counter (PerkinElmer). To control for
non-FSHR mediated effects on intracellular cAMP levels, highest compound concentrations used in
the dose-response experiments (typically 1 µM) were tested on CHO_luc cells. Data was analyzed
using GraphPad Prism 5 (GraphPad Software, La Jolla, USA), and values were normalized to the
maximal effect obtained for recombinant human FSH (200 pM, rFSH, Org32489, gift from MSD,
156
Small-molecule FSHR agonists as targeting agents for BNCT
Oss, The Netherlands). Each experiment was performed on duplicate plates and mean ± SEM values
of at least three independent experiments are given.
Fluorescence-activated cell sorting. U2OS or U2OS-FSHR cells were cultured as described under
"Cell culture". Cells were seeded onto 6-well plates (400.000 cells/well) and cultured for 48 h, before
start of the experiment. Compound 116 (as 2x stock solution in culture medium) was added to the
cells (1 µM final concentration) and the cells were incubated for 2 h (37 ◦C, 5% CO2). Cells were
washed with ice-cold PBS (2x) and harvested using enzyme-free dissociation solution (Millipore).
After centrifugation (5 min, 1200 rpm), the pellet was resuspended in PBS to obtain a single-cell
suspension of ∼ 1 x 106 cells/mL. Cells were transferred to a 96-wells plate and samples measured
using a BD FACSCanto II flow cytometer (BD Biosciences, San Jose, USA). The following laser/filter
settings were used: GFP (FSHR): λex: 488 nm, λem: 530/30 nm; Cy5 (96): λex: 633 nm, λem: >670
nm and values were compensated using the instrumentation software and mono-stained controls. Data
was analyzed using FCS Express 4 Flow Research Edition (De Novo Software, LA, USA). All samples
were measured twice and values were calculated from three independent experiments with a sample
size of ∼10000 cells.
Uptake and FSHR internalization microscopy experiments. U2OS-FSHR or U2OS cells were main-
tained as described under "Cell culture". 48 h before the experiment, cells were harvested (Trypsin-
EDTA), counted and seeded onto sterile Labtek II 4- or 8-chamber borosilicate coverglass systems
(Fisher Emergo) at a density of 25-50 x 104 cells/well. On the day of the experiment, cells were
incubated with compound (10 µM) for 2 h at 37 ◦C, before being washed with PBS (2x), fixed (4
% formaldehyde in PBS), washed again (PBS) and nuclei stained with propidium iodide (optional,
only when the compound fluorescence is detected in the dsRed channel). Cells were imaged on a
Leica TCS SPE confocal microscope, using GFP (FSHR), dsRed (114, 115) or Cy5 (113, 116) filter
settings (λex 488, 532 or 635 nm) with optimized detection range to exclude bleed-through of dye
signal in different channels. Images were colored using ImageJ.
Synthesis
General. All reagents were of commercial grade and used as received unless stated otherwise. Reaction
solvents were of analytical grade and when used under anhydrous conditions stored over flame-dried
3 Å molecular sieves. Dichloromethane was distilled over CaH2 prior to use. Solvents used for column
chromatography were of technical grade and distilled before use. All moisture and oxygen sensitive
reactions were performed under an argon atmosphere. Flash chromatography was performed on silica
gel (Screening Devices BV, 0.04-0.063 mm, 60 Å). Reactions were routinely monitored by TLC analysis
on DC-alufolien (Merck, Kieselgel60, F254) with detection by UV-absorption (254/366 nm) where ap-
plicable and spraying with a solution of (NH4)6Mo7O24 · 4 H2O (25 g/l) and (NH4)4Ce(SO4)4 · 2 H2O
(10 g/l) in 10% sulfuric acid in water followed by charring at 150◦C. 1H and 13C NMR spectra were
recorded on a Bruker AV-400 (400 MHz) or Bruker DMX-600 (600 MHz). Chemical shifts are given
in ppm (δ) relative to the residual solvent peak or TMS (0 ppm) as internal standard. Coupling con-
stants are given in Hz. LC-MS measurements were conducted on a Thermo Finnigan LCQ Advantage
MAX ion-trap mass spectrometer (ESI+) coupled to a Surveyor HPLC system (Thermo Finnigan)
equipped with a standard C18 (Gemini, 4.6 mmD x 50 mmL, 5µ particle size, Phenomenex) analytical
column and buffers A: H2O, B: ACN, C: 0.1% aq.TFA. High resolution mass spectra were recorded
on a LTQ Orbitrap (Thermo Finnigan) mass spectrometer equipped with an electronspray ion source
in positive mode (source voltage 3.5 kV, sheath gas flow 10 mL min−1, capillary temperature 250
◦C) with resolution R=60000 at m/z 400 (mass range m/z=150-2000) and dioctylphtalate (m/z =
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391.28428) as a "lock mass". The high resolution mass spectrometer was calibrated prior to measure-
ments with a calibration mixture (Thermo Finnigan). For reversed-phase HPLC purification of the
final compounds a Gilson automated HPLC system equipped with a C18 semiprep column (Gemini





4-(3-Trimethylsilyl-propargyloxy)benzaldehyde (99). 4-hydroxybenzaldehyde (0.37
g, 3 mmol) was dissolved in acetone (15 mL). Potassium carbonate (0.58 g, 4.2 mmol,
1.4 eq) was added and the mixture was refluxed at 65 ◦C for 30 min. 3-Bromo-1-
trimethylsilylpropyne (0.54 mL, 3.3 mmol, 1.1 eq) was added and the mixture was
refluxed for 6 h. The solvent was removed in vacuo and the residue was dissolved
in water (10 mL) and extracted with EtOAc (4x). The combined organic layers
were dried (MgSO4), filtered and concentrated under reduced pressure. Purification by silica column
chromatography (1 → 2% EtOAc in PE) yielded the product as a colourless oil (0.50 g, 2.13 mmol,
71%). R f = 0.74 (5:1 toluene:EtOAc). 1H NMR (400 MHz, CDCl3): δ 9.75 (s, 1H, O=CH), 7.70 (d,
J = 8.8 Hz, 2H, 2 x CHar), 6.94 (d, J = 8.8 Hz, 2H, 2 x CHar), 4.63 (s, 2H, CH2), 0.05 (s, 9H, 3 x
CH3).
13C NMR (101 MHz, CDCl3): δ 190.37, 162.35, 131.56, 130.24, 114.99, 98.93, 93.45, 56.57,
-0.53. FT-IR (thin film) v 1734, 1693, 1508, 1265, 1163, 1033, 846, 731, 702 cm−1. ESI-HRMS
(m/z): calcd. for [C13H16O2Si + H]







methanol (100). o-Carborane (72 mg, 0.5 mmol) was dissolved in dry THF (2
mL). Tetra-n-butylammonium fluoride (1M in THF, 1.5 mL, 1.5 mmol, 3 eq)
was added and the mixture was stirred at rt for 5 min. Subsequently, a solution
of 99 (0.13 g, 0.55 mmol, 1.1 eq) in THF (1 mL) was added dropwise. After
stirring for 5 min, more 99 (0.55 M in THF, 0.25 mmol, 0.5 eq) was added and the mixture was
stirred for 5 min. The reaction was quenched with NH4Cl (sat aq, 2 mL), followed by extraction with
diethyl ether (3 x 2 mL). The combined organic layers were dried (MgSO4), filtered and concentrated
under reduced pressure. Purification by silica column chromatography (2 → 5% EtOAc in PE) yielded
the product as a racemic mixture (36 mg, 0.12 mmol, 24%). R f = 0.42 (4:1 PE:EtOAc). 1H NMR
(400 MHz, CDCl3): δ 7.27 (d, J = 8.6 Hz, 2H, 2 x CHar), 6.98 (d, J = 8.8 Hz, 2H, 2 x CHar), 5.21
(s, 1H, CH), 4.70 (d, J = 2.4 Hz, 2H, CH2), 3.80 (s, 1H, BCH), 2.98 - 1.35 (m, 10H, 10 x BH),
2.54 (t, J = 2.4 Hz, 1H, ≡CH). 13C NMR (101 MHz, CDCl3): δ 158.47, 131.61, 128.06, 115.13,
78.94, 78.21, 76.08, 74.78, 59.44, 56.02. 11B NMR (128 MHz, CDCl3): δ -3.40, -4.37, -8.70, -9.26,
-11.07, -12.47, -14.00. FT-IR (thin film) v 3298 (≡C-H)), 2924, 2573 (B-H)), 1608, 1508, 1219,





1-(tert-Butyldimethylsilyl)-1,2-dicarba-closo-dodecaborane (101). To a solution
of o-carborane (2.88 g, 20.0 mmol, 1 eq) in dry toluene and Et2O (18 mL, 2:1, v/v)
was added n-BuLi (2.5 M in hexane, 8.4 mL, 21.0 mmol, 1.05 eq) at 0 ◦C under
an argon atmosphere. The solution immediately became turbid and was stirred for
2 h while gradually warming to rt. The mixture was cooled again to 0 ◦C and
TBDMSCl (3.32 g, 22.0 mmol, 1.1 eq) in a 3 mL solution of toluene and Et2O (2:1, v/v) was added
with a syringe and stirred overnight at rt. After addition of water (50 mL), the aqueous layer was
extracted with Et2O (3 x 50 mL). The combined organic layers were dried over MgSO4, filtered and
concentrated in vacuo. Flash column chromatography (0 → 30% EtOAc in PE) afforded 101 as a
colourless oil, which solidified to a white powder upon standing (4.48 g, 17.3 mmol, 87%). R f = 0.8
(19:1 pentane:EtOAc). 1H NMR (400 MHz, CDCl3): δ 3.44 (s, 1H, CHB), 3.24 - 1.38 (m, 10H,
10 x BH), 1.02 (s, 9H, 3 x CH3), 0.23 (s, 6H, 2 x CH3).
13C NMR (101 MHz, CDCl3): δ 66.16,
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60.39, 27.11, 19.45, -4.42. 11B NMR (128 MHz, CDCl3): δ 0.18, -1.88, -7.10, -10.81, -12.34, -13.32.
FT-IR (thin film) v 3080 (BC-H), 2976, 2961, 2937, 2863, 2611, 2589, 2566 (B-H), 1468, 1364,
1265, 1256, 1072, 1030, 1003, 872 cm−1. ESI-HRMS (m/z): calcd. for [C8H26B10Si + CH3CN +







caborane (102). Compound 101 (2.59 g, 10.0 mmol) was dissolved in dry
THF (50 mL) and n-BuLi (1.6 M in hexane, 6.88 mL, 11.0 mmol, 1.1 eq)
was added slowly. Reaction mixture changed from colorless to bright or-
ange/red. After stirring for 1 h, trimethylene oxide (1.30 mL, 20.0 mmol, 2
eq) was added and the mixture was stirred overnight at room temperature
under an argon atmosphere. Subsequently, n-BuLi (1.6 M in hexane, 1.56 mL, 2.5 mmol, 0.25 eq)
and trimethylene oxide (0.33 mL, 5.0 mmol, 0.5 eq) were added and the mixture was stirred for 3
h. The mixture was diluted with diethyl ether and washed with water (1 x 40 mL). After the layers
were separated, the aqueous layer was extracted with diethyl ether (2 x 30 mL) and the combined
organic layers were dried (MgSO4), filtered and concentrated under reduced pressure. Flash column
chromatography (5 → 25% EtOAc in PE) afforded the alcohol 102 as a white powder (3.08 g, 8.6
mmol, 86%).R f = 0.3 (4:1 PE:EtOAc). 1H NMR (400 MHz, CDCl3): δ 3.61 (t, J = 5.9 Hz, 2H,
CH2), 3.09 - 1.58 (m, 10H, 10 x BH), 2.39 - 2.30 (m, 2H, CH2), 1.81 - 1.72 (m, 2H, CH2), 1.51
(s, 1H, OH), 1.06 (s, 9H, 3 x CH3), 0.33 (s, 6H, 2 x CH3).
13C NMR (101 MHz, CDCl3): δ 81.40,
76.58, 61.71, 34.74, 33.08, 27.72, 20.48, -2.35 11B NMR (128 MHz, CDCl3): δ 0.09, -4.06, -7.43,
-10.42. FT-IR (thin film) v 3560, 3323, 2936, 2569 (B-H), 1466, 1258, 1057 (C-O), 838 (Si-CH3)
cm−1. ESI-HRMS (m/z): calcd. for [C11H32B10OSi + CH3CN + H]








onic acid (103). To a solution of alcohol 102 (0.95 g, 3.00 mmol, 1 eq) in
DCM/H2O (15 mL, 2:1, v/v) under an argon atmosphere at rt, were added
TEMPO (96 mg, 0.60 mmol, 0.2 eq) and bis(acetoxy)iodobenzene (2.42 g,
7.50 mmol, 2.5 eq). The resulting orange mixture was stirred vigorously for
1.5 h, before being quenched with Na2S2O3 (sat aq, 15 mL). Water (15 mL)
was added and the aqueous layer was extracted with DCM (3 x 50 mL). The combined organic layers
were dried over MgSO4, filtered and concentrated in vacuo. Flash column chromatography (10 →
30% EtOAc in PE + 1% AcOH) afforded the carboxylic acid 103 as a white powder (2.87 mmol, 0.95
g, 96%). R f = 0.5 (2:1 PE:EtOAc + AcOH).1H NMR (400 MHz, CDCl3): δ 10.86 (s, 1H, COOH),
3.38 - 1.43 (m, 10H, 10 x BH), 2.67 - 2.52 (m, 4H, 2 x CH2), 1.07 (s, 9H, 3 x CH3), 0.34 (s, 6H, 2
x CH3).
13C NMR (101 MHz, CDCl3): δ 177.47, 79.37, 76.42, 34.15, 32.26, 27.63, 20.51, -2.39.
11B
NMR (128 MHz, CDCl3): δ 0.39, -3.65, -7.28, -10.23. FT-IR (thin film) v 3043, 2974, 2938, 2866,
2575 (B-H), 1714 (C=O), 1472, 1429, 1368, 1296, 1259, 1085, 1004, 928, 908, 858, 834 cm−1.
ESI-HRMS (m/z): calcd. for [C11H30B10O2Si + CH3CN + H]






3-(1-(1’,2’-Dicarba-closo-decaboranyl))propionic acid (104). Carboxylic acid 103
(435 mg, 1.32 mmol, 1 eq) was dissolved in dry THF (10 mL) under an argon
atmosphere and cooled to -78 ◦C. TFA (98 µL, 1.32 mmol, 1 eq) was added
followed by dropwise addition of TBAF (1M in THF, 1.58 mL, 1.58 mmol, 1.2
eq). After stirring for 5 min the cooling bath was removed and the reaction was
allowed to warm to rt overnight. Et2O (20 mL) was added and the organic layer
was washed with HCl (aq, 1 M, 3 x 30 mL). The combined aqueous layers were extracted with Et2O
(2 x 60 mL) and the ether layers were combined, dried over MgSO4, filtered and concentrated under
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reduced pressure. Silica column chromatography (10 → 30% EtOAc in PE + 1% AcOH) yielded
the carboxylic acid 104 as a white powder (281 mg, 1.30 mmol, 98%). R f = 0.3 (2:1 PE:EtOAc +
AcOH). 1H NMR (400 MHz, CDCl3): δ 10.30 (s, 1H, COOH), 3.67 (s, 1H, BCH), 3.13 - 1.44 (m,
10H, 10 x BH), 2.67 - 2.54 (m, 4H, 2 x CH2).
13C NMR (101 MHz, CDCl3): δ 176.93, 73.66, 61.74,
33.22, 32.43. 11B NMR (128 MHz, CDCl3): δ -2.03, -5.45, -9.27, -11.71, -12.82. FT-IR (thin film)
v 3053, 2926, 2580 (B-H), 1696 (C=O), 1436, 1320, 1236, 1223, 1197, 1127, 1077, 1019, 1001,








3-(1’,2’-Dicarba-closo-decaboranyl)propionic acid N-hydroxysuccinimide ester
(105). Carboxylic acid 104 (80 mg, 0.37 mmol, 1 eq) in dry DCM (3 mL) was
treated with N-hydroxysuccinimide (170 mg, 1.48 mmol, 4 eq) and EDC (283 mg,
1.48 mmol, 4 eq) and stirred for 3 h. DCM (10 mL) was added and the organic
phase was washed with HCl (aq, 0.5 M, 3 x 10 mL), dried over Na2SO4, filtered
and concentrated in vacuo. Silica column chromatography (5 → 40% EtOAc in
PE) afforded the OSu ester 105 (102 mg, 0.33 mmol, 88%) as a white powder. R f = 0.9 (4:1
PE:EtOAc). 1H NMR (400 MHz, CDCl3/MeOD): δ 3.82 (s, 1H, BCH), 3.01 - 1.33 (m, 10H, 10
x BH), 2.85 - 2.70 (m, 6H, CH2, 2 x CH2-OSu), 2.58 (t, J = 7.6 Hz, 2H, CH2).
13C NMR (101
MHz, CDCl3/MeOD): δ 169.39, 166.97, 72.92, 61.68, 31.96, 30.35, 25.49.
11B NMR (128 MHz,
CDCl3/MeOD): δ -2.21, -5.52, -9.36, -11.88, -12.84. FT-IR (thin film) v 3060, 2953, 2928, 2852,
2580 (B-H), 1818, 1785, 1736, 1429, 1386, 1359, 1299, 1203, 1071, 1047, 994, 881, 811, 724 cm−1.
ESI-HRMS (m/z): calcd. for [C9H19B10NO4 + CH3CN + H]







propyl 4-methylbenzensulfonate (106). Compound 102 (0.32 g, 1 mmol)
was dissolved in DCM (12.5 mL). Subsequently, p-tosylchloride (0.21 g,
1.1 mmol, 1.1 eq), triethylamine (0.28 mL, 2.0 mmol, 2 eq) and 4-
dimethylaminopyridine (60 mg, 0.5 mmol, 0.5 eq) were added. After stirring
for 3 h at room temperature, TLC showed completion of the reaction. The reaction mixture was
washed with HCl (aq, 1 M, 3 x 10 mL) and brine (1 x 10 mL), followed by extraction of the aqueous
layer with DCM (3 x 10 mL). The organic layers were combined, dried (MgSO4), filtered and concen-
trated under reduced pressure. Purification by silica column chromatography (2 → 3% EtOAc in PE)
yielded the product as a white powder (0.45 g, 0.96 mmol, 96%). R f = 0.6 (5:1 PE:EtOAc).1H NMR
(400 MHz, CDCl3): δ 7.75 (d, J = 8.3 Hz, 2H, 2 x CHar), 7.36 (d, J = 8.1 Hz, 2H, 2H, 2 x CHar),
3.99 (t, J = 5.6 Hz, 2H, CH2) , 3.11 - 1.42 (m, 10H, 10 x BH), 2.46 (s, 3H, CH3), 2.34 - 2.25 (m,
2H, CH2), 1.91 - 1.80 (m, 2H, CH2), 1.03 (s, 9H, 3 x CH3), 0.30 (s, 6H, 2 x CH3).
13C NMR (101
MHz, CDCl3): δ 145.30, 132.86, 130.13, 128.00, 80.11, 76.60, 68.87, 34.30, 29.51, 27.66, 21.80,
20.47, -2.38. 11B NMR (128 MHz, CDCl3): δ 0.21, -3.79, -7.34, -10.28. FT-IR (thin film) v 2937,







(107). Compound 106 (1.00 g, 2.12 mmol) was dissolved in THF (25 mL) and
cooled to -78 ◦C. After addition of TBAF (1 M in THF, 2.5 mL, 2.5 mmol, 1.2
eq), the mixture was gradually warmed to room temperature and stirred for 30
min. Subsequently, the mixture was diluted with diethyl ether, washed with HCl
(aq, 1 M, 3 x 20 mL) and brine (1 x 20 mL), dried (MgSO4), filtered and concentrated under reduced
pressure. Purification by silica column chromatography (2 → 30% EtOAc in PE) yielded the product
as a white powder (0.63 g, 1.78 mmol, 84%). R f = 0.35 (5:1 PE:EtOAc). 1H NMR (400 MHz,
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CDCl3): δ 7.77 (d, J = 7.5 Hz, 2H, 2 x CHar), 7.37 (d, J = 7.6 Hz, 2H, 2 x CHar), 4.02 - 3.97 (m,
2H, CH2), 3.53 (s, 1H, BCH) , 3.00 - 1.35 (m, 10H, 10 x BH), 2.47 (s, 3H, CH3), 2.31 - 2.23 (m, 2H,
CH2), 1.86 - 1.81 (m, 2H, CH2).
13C NMR (101 MHz, CDCl3): δ 145.42, 132.73, 130.17, 128.02,
73.98, 68.69, 61.76, 34.39, 28.74, 21.82. 11B NMR (128 MHz, CDCl3): δ -2.25, -5.63, -9.25, -11.98,






1-(3-Azidopropyl)-1,2-dicarba-closo-dodecaborane (108). Compound 107 (0.64
g, 1.8 mmol) was dissolved in acetone (100 mL). Sodium azide (0.58 g, 8.9 mmol,
5 eq) and tetrabutylammonium iodide (cat.) were added and the mixture was
refluxed overnight at 65 ◦C. After concentration of the mixture, the residue was
dissolved in water (30 mL) and the compound was extracted with diethyl ether (3
x 20 mL). Subsequently, the combined organic layers were dried (MgSO4), filtered and concentrated
in vacuo. Purification by silica column chromatography (1 → 5% EtOAc in PE) yielded the azide as
a white powder (0.39 g, 1.73 mmol, 97%). R f = 0.5 (5:1 PE:EtOAc). 1H NMR (400 MHz, CDCl3):
δ 3.58 (s, 1H, BCH), 3.31 (t, J = 6.3 Hz, 2H, CH2), 3.03 - 1.46 (m, 10H, 10 x BH), 2.31 - 2.25 (m,
2H, CH2), 1.80 - 1.69 (m, 2H, CH2).
13C NMR (101 MHz, CDCl3): δ 74.41, 61.64, 50.25, 35.32,
28.71. 11B NMR (128 MHz, CDCl3): δ -2.30, -5.72, -9.26, -11.76, -13.03. FT-IR (thin film) v 3065,






1-(3-Aminopropyl)-1,2-dicarba-closo-dodecaborane (109). Compound 108 (68
mg, 0.3 mmol) and triphenylphosphine (94 mg, 0.36 mmol 1.2 eq) were dissolved
in toluene (3 mL). After stirring for 1 h, water (2 mL) was added and conversion
to a white suspension occurred slowly. The mixture was stirred for 3 h and again
water (2 mL) was added, followed by stirring for 3 h. Subsequently, the mixture
was diluted with both EtOAc (4 mL) and water (4 mL) and the layers were separated. The aqueous
layer was extracted with EtOAc (3 x 8 mL). The combined organic layers were dried (Na2SO4),
filtered and concentrated in vacuo. Purification by silica column chromatography (10 → 20% MeOH
in DCM + 0.1% AcOH) yielded the product as a white powder (17 mg, 0.087 mmol, 29%).R f =
0.7 (1:1:1:1 EtOAc:H2O:n-BuOH:AcOH).
1H NMR (400 MHz, CDCl3/MeOD): δ 4.58 (s, 1H, BCH),
3.00 - 1.44 (m, 10H, 10 x BH), 2.89 (t, J = 8 Hz, 2H, CH2), 2.44 - 2.31 (m, 2H, CH2), 1.95 - 1.76
(m, 2H, CH2).
13C NMR (101 MHz, CDCl3/MeOD): δ 75.85, 63.98, 39.68, 35.36, 28.41.
11B NMR
(128 MHz, CDCl3/MeOD): δ 1.88, -3.04, -5.00, -6.12, -8.66, -9.82, -10.86, -12.11, -13.33. FT-IR
(thin film) v 3444 (N-H, 3014, 2576 (B-H), 1614, 1498, 1068, 1018, 721 cm−1. ESI-HRMS (m/z):
calcd. for [C5H19B10N + H]














CO(Asp-Lys)3Gly-propargyl (110). Starting from Tentagel S
Rink resin (0.25 mmol) the peptide (Asp(t-Bu)-Lys(Boc))3-Gly-Fmoc
was synthesized using an ABI-433A (Applied Biosystems, division of
Perkin-Elmer) automated peptide synthesizer. Each cycle consisted
of the following consecutive steps:
- Fmoc removal (20% piperidine in NMP (3 x 3 min)).
- NMP wash.
- Coupling of the appropriate amino acid (1 mmol, 4 eq) with HCTU
(4 eq) as the coupling agent and DiPEA (4 eq) as the base in NMP for 1 h.
- NMP wash.
- capping of the remaining amines with Ac2O (5% v/v), DiPEA (0.1 M) in NMP for 3 min.
- NMP and DCM wash.
The last coupling was manually performed on ∼0.05 mmol resin as follows:
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- Removal of the Fmoc groups with 20% piperidine in NMP for 20 min while shaking.
- Washing with NMP (2x), DCM (2x), NMP (1x).
- Coupling of propiolic acid (16 µL, 0.25 mmol, 5 eq) with EEDQ (62 mg, 0.25 mmol, 5 eq) in NMP
for 1 h, while shaking.
- Washing with NMP (2x), DCM (2x), NMP (1x).
The peptide was globally deprotected and cleaved off the resin by treatment with 2% TIS in TFA for
3 x 30 min, precipitated from ice-cold Et2O and spinned down to give a white pellet. Lyophilizing
from water/ACN/t-BuOH yielded the peptide (33 mg, 28 µmol, 56%). 1H NMR (400 MHz, MeOD):
δ 4.72 (dd, J = 8.6, 5.0 Hz, 1H, CH), 4.68 - 4.59 (m, 2H, 2 x CH), 4.33 - 4.18 (m, 3H, 3 x CH),
4.05 - 3.86 (m, 2H, CH2), 3.74 (s, 1H, ≡CH), 3.06 - 2.76 (m, 12H, 6 x CH2), 2.03 - 1.75 (m, 6H, 3
x CH2), 1.75 - 1.63 (m, 6H, 3 x CH2), 1.57 - 1.43 (m, 6H, 3 x CH2).
13C NMR (101 MHz, MeOD):
δ 175.53, 174.81, 174.55, 174.29, 174.26, 174.09, 173.91, 173.80, 173.65, 171.97, 155.35, 77.87,
77.07, 55.79, 55.63, 55.18, 52.24, 52.03, 51.37, 43.91, 40.59, 40.53, 40.46, 36.62, 35.97, 35.89,
31.56, 31.34, 28.02, 27.88, 27.83, 23.74, 23.62, 23.50. ESI-HRMS (m/z): calcd. for [C35H57N11O14
















Carboranyl-peptide (111). Peptide 110 (26 mg, 22 µmol) was sus-
pended in DMF (7 mL) and carborane-OSu 105 (34 mg, 0.1 mmol, 4
eq) and DiPEA (28 µL, 0.15 mmol, 6 eq) were added. The product
dissolved in DMF and LC/MS analysis indicated complete conversion
after 15 h. The product was crashed out of the solution with ice-
cold Et2O, collected and lyophilized from dioxane. Analysis showed
that the product (34 mg, 0.022 mmol, quant) was sufficiently pure
(∼90%) to be used in the next step without any further purification.
1H NMR (400 MHz, CDCl3/MeOD): δ 4.78 - 4.71 (m, 1H, CH), 4.24
- 4.06 (m, 6H, 3 x CHα, 3 x BCH), 3.93 (q, J = 16.3 Hz, 2H, CH2), 3.70 (s, 1H, ≡CH), 3.24 - 3.12
(m, 6H, 3 x CH2), 3.01-1.46 (m, 30H, 30 x BH), 2.96 - 2.79 (m, 6H, 3 x CH2),), 2.63 - 2.55 (m, 6H,
3 x CH2), 2.47 - 2.38 (m, 6H, 3 x CH2), 1.91 - 1.76 (m, 6H, 3 x CH2), 1.50 (s, 6H, 3 x CH2), 1.42
- 1.33 (m, 6H, 3 x CH2).
13C NMR (101 MHz, CDCl3/MeOD): δ 174.20, 173.44, 173.22, 173.09,
172.69, 172.59, 172.50, 171.48, 171.42, 170.48, 153.79, 76.51, 75.51, 74.68, 62.02, 55.19, 54.78,
54.64, 51.13, 50.89, 50.01, 42.56, 39.08, 39.01, 38.81, 35.58, 35.30, 35.10, 34.90, 33.04, 30.33,
30.15, 29.89, 28.50, 28.37, 22.83, 22.74, 22.66. 11B NMR (128 MHz, CDCl3/MeOD): δ -2.58, -5.83,
-9.64, -11.88. LC/MS analysis (linear gradient 10 → 90% ACN) tR : 10.69 min, ESI-MS (m/z):














Azido-BODIPY-carborane (132). Amino-carborane 109
(5.8 mg, 29 µmol, 1.1 eq) and azido-BODIPY-OSu 36 (14.6
mg, 26 µmol, 1 eq) were dissolved in DMF (1 mL) and Di-
PEA (5 µL, 29 µmol, 1 eq) was added. After 3 h the reaction
was concentrated and co-evaporated with toluene. Purifica-
tion by silica column chromatography (0 → 60% EtOAc in
PE) yielded BODIPY-carborane (10 mg, 15 µmol) as a pur-
ple solid in 56% yield. R f = 0.2 (1:1 PE:EtOAc) 1H NMR
(400 MHz, CDCl3): δ 7.89 - 7.84 (m, 2H, 2 x CHar), 7.11
(s, 1H, CHar), 6.99 (d, J = 4.1 Hz, 1H, CHar), 6.98 - 6.95 (m, 2H, 2 x CHar), 6.56 (d, J = 4.1
Hz, 1H, CHar), 5.40 (t, J = 6.0 Hz, 1H, NH), 4.11 (t, J = 5.9 Hz, 2H, CH2), 3.62 - 3.57 (m, 1H,
BCH), 3.54 (t, J = 6.6 Hz, 2H, CH2), 3.14 (q, J = 6.6 Hz, 2H, CH2), 3.00-1.00 (m, 10H, 10 x
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BH), 2.75 (t, J = 7.0 Hz, 2H, CH2), 2.49 (s, 3H, CH3), 2.28 (t, J = 7.1 Hz, 2H, CH2), 2.21 (s,
3H, CH3), 2.12 - 2.04 (m, 4H, 2 x CH2), 1.65 - 1.52 (m, 2H, CH2).
13C NMR (101 MHz, CDCl3):
δ 172.24, 171.58, 159.73, 158.98, 156.21, 139.79, 135.21, 134.21, 130.88, 130.17, 128.63, 125.63,
123.05, 118.93, 114.37, 74.53, 64.61, 61.49, 48.36, 38.66, 36.56, 35.22, 29.84, 29.40, 28.89, 25.52,
20.15, 13.29, 9.79. 11B NMR (128 MHz, CDCl3): δ 1.12 (t), -2.40, -5.78, -9.42, -11.88, -13.08.




























DHP-alkyne m-78a (6 mg, 7.5 µmol, 1.2 eq)
and azido-BODIPY-carborane 132 (3.9 mg,
6 µmol, 1 eq) were dissolved in DCM (1.5
mL) and water (1 mL), and sodium ascor-
bate (aq, 1.2 eq) and CuSO4 (aq, 20mol%)
were added. After 3 h the reaction was fin-
ished, the organic layer was washed with wa-
ter (2 x 5 mL), dried (Na2SO4), filtered and
concentrated. Purification by silica column
chromatography (0 → 3% MeOH in DCM)
yielded DHP-BODIPY-carborane (5.8 mg, 4 µmol) as a purple solid in 67% yield. R f = 0.2 (10:1
DCM:MeOH) 1H NMR (600 MHz, CDCl3): δ 8.05 (s, 1H, CHtrz), 8.01 (s, 1H, CHar), 7.84 (d, J =
8.8 Hz, 2H, 2 x CHar), 7.75 (d, J = 7.7 Hz, 1H, CHar), 7.62 (d, J = 7.6 Hz, 1H, CHar), 7.56 (s, 1H,
NH), 7.41 (t, J = 7.7 Hz, 1H, CHar), 7.10 (s, 1H, CHar), 6.99 - 6.94 (m, 2H, CHar, NH), 6.94 - 6.89
(m, 3H, 3 x CHar), 6.82 (d, J = 1.8 Hz, 1H, CHar), 6.55 (d, J = 4.1 Hz, 1H, CHar), 5.76 (s, 1H,
NH), 5.02 (s, 2H, CH2), 4.60 (t, J = 6.6 Hz, 2H, CH2), 4.54 (s, 1H, CH), 4.14 - 4.07 (m, 2H, CH2),
4.00 (q, J = 6.7, 4.9 Hz, 2H, CH2), 3.70 - 3.57 (m, 17H, 8 x CH2, BCH), 3.13 (q, J = 6.6 Hz, 2H,
CH2), 2.90-1.10 (m, 10H, 10 x BH), 2.74 (t, J = 7.1 Hz, 2H, CH2), 2.48 (s, 3H, CH3), 2.46 - 2.30
(m, 5H, 2 x CH2, CH2-H
a), 2.28 (t, J = 7.2 Hz, 2H, CH2), 2.21 (s, 3H, CH3), 2.17 - 2.13 (m, 1H,
CH), 2.11 - 2.03 (m, 6H, CH3, CH2, CH2-H
b), 1.61 - 1.51 (m, 2H, CH2), 1.42 (t, J = 6.9 Hz, 3H,
CH3), 1.34 - 1.22 (m, 4H, 2 x CH2), 0.87 (t, J = 6.9 Hz, 3H, CH3).
13C NMR (151 MHz, CDCl3):
δ 195.77, 172.09, 167.81, 160.30, 159.43, 159.26, 155.75, 152.79, 149.75, 145.10, 144.15, 143.36,
142.33, 140.09, 138.17, 135.15, 134.81, 134.38, 131.31, 130.95, 130.49, 128.68, 128.47, 126.91,
126.11, 125.86, 123.13, 122.98, 118.80, 118.10, 114.33, 113.01, 110.04, 88.17, 74.65, 74.16, 70.74,
70.71, 70.58, 70.48, 69.91, 69.80, 64.73, 63.99, 61.53, 47.67, 43.51, 40.01, 39.14, 38.59, 38.28,
37.54, 36.41, 35.28, 33.95, 33.69, 29.90, 29.44, 20.17, 19.91, 18.62, 14.98, 14.20, 13.35, 9.81. 11B
NMR (128 MHz, CDCl3): δ 1.12 (t), -2.41, -5.56, -9.44, -11.88. LC/MS analysis (linear gradient
50 → 90% ACN) tR : 9.17 min, ESI-MS (m/z): [M + H]+: 1457.60. ESI-HRMS (m/z): calcd. for
[C69H90B11BrF2N10O10 + H]





















BODIPY 32 (7 mg, 9.8 µmol) and azido-carborane
108 (2.3 mg, 10.1 µmol, 1.03 eq) were dissolved
in DCM (1 mL). The mixture was put under an ar-
gon atmosphere, followed by the addition of sodium
ascorbate (2 mg, 9.8 µmol) and a catalytic amount
of copper(II)sulfate. The mixture was stirred at rt
for 1 h when TLC analysis showed completion. The
product was purified by silica column chromatography (0.2 → 0.4% MeOH in DCM). Crystallization
from DCM/hexanes yielded the product as blue crystals (8.8 mg, 9.36 µmol, 93%). R f = 0.8 (1:1
PE : EtOAc) 1H NMR (400 MHz, CDCl3): δ 7.67 - 7.53 (m, 7H, 4 x CHar, 3 x =CH), 7.18 (d, J =
16.2 Hz, 2H, 2 x =CH), 7.05 (d, J = 8.7 Hz, 2H, 2 x CHar), 6.99 (d, J = 8.8 Hz, 2H, 2 x CHar), 6.93
(d, J = 8.8 Hz, 2H, 2 x CHar), 6.75 (d, J = 8.8 Hz, 2H, 2 x CHar), 6.61 (s, 2H, 2 x =CH), 5.25 (s,
2H, CH2), 4.68 (s, 2H, CH2), 4.33 (t, J = 6.5 Hz, 2H, CH2), 3.83 (s, 3H, CH3), 3.52 (s, 1H, BCH),
3.41 (q, J = 7.0 Hz, 4H, 2 x CH2), 3.00 - 1.45 (m, 10H, 10 x BH), 2.26 - 2.18 (m, 2H, CH2), 2.18
- 2.06 (m, 2H, CH2), 1.58 (s, 3H, CH3), 1.57 (s, 3H, CH3), 1.21 (t, J = 7.0 Hz, 6H, 2 x CH3).
13C
NMR (101 MHz, CDCl3): δ 169.31, 158.76, 158.41, 152.16, 152.06, 148.33, 144.60, 142.43, 142.36,
140.54, 134.99, 134.88, 134.22, 130.89, 130.46, 129.47, 129.08, 122.83, 121.46, 118.21, 118.02,
117.36, 115.25, 115.06, 112.05, 73.78, 65.46, 62.14, 61.82, 52.51, 49.20, 44.51, 35.09, 29.83, 15.13,
12.54. 11B NMR (128 MHz, CDCl3): δ 1.17 (t), -2.16, -5.43, -9.18, -11.93, -12.83. FT-IR (thin
film) v 2964, 2580 (B-H), 1749, 1598, 1508, 1481, 1197, 1161, 987, 817 cm−1. ESI-HRMS (m/z):
calcd. for [C48H59B11F2N6O4 + H]



















A solution of LiOH (0.2 mg, 25.5 µmol, 3 eq) in
water (1 mL) was added to a solution of 133 (8 mg,
8.5 µmol) in THF (2 mL). The mixture was stirred
for 4 h at rt, followed by addition of a solution of
LiOH (0.1 mg, 13 µmol, 1.5 eq) in water (8.5 µL).
After 1 h at rt, the mixture was diluted with diethyl
ether and acidified with HCl (aq, 1 M). The aque-
ous layer was extracted with diethyl ether (3 x 1.5 mL) and EtOAc (3 x 1.5 mL). The combined
organic layers were dried (Na2SO4), filtered and concentrated under reduced pressure. Subsequently,
the product was purified by silica column chromatography (2 → 6% MeOH in DCM). Crystallization
from DCM/hexanes yielded the product as blue crystals (6.1 mg, 6.6 µmol, 78%). R f = 0.2 (1:1
EtOAc:PE + 0.01% AcOH) 1H NMR (400 MHz, CDCl3/MeOD): δ 7.97 (s, 1H, =CH), 7.63 - 7.53
(m, 6H, 4 x CHar, 2 x =CH), 7.28 (d, J = 16.1 Hz, 2H, 2 x =CH), 7.12 - 7.03 (m, 4H, 4 x CHar), 6.99
(d, J = 8.5 Hz, 2H, 2 x CHar), 6.83 (d, J = 8.6 Hz, 2H, 2 x CHar), 6.70 (s, 2H, 2 x =CH), 5.24 (s,
2H, CH2), 4.67 (s, 2H, CH2), 4.41 (t, J = 6.6 Hz, 2H, CH2), 4.26 (s, 1H, BCH), 3.45 (q, J = 7.0 Hz,
4H, 2 x CH2) , 3.02 - 1.11 (m, 10H, 10 x BH), 2.31 - 2.24 (m, 2H, CH2), 2.17 - 2.08 (m, 2H, CH2),
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1.61 (s, 6H, 2 x CH3), 1.22 (t, J = 7.0 Hz, 6H, 2 x CH3).
13C NMR (151 MHz, CDCl3/MeOD):
δ 158.95, 152.34, 152.14, 148.54, 144.31, 142.73, 142.59, 140.64, 135.46, 135.23, 134.27, 134.22,
130.58, 129.55, 129.12, 123.70, 121.50, 117.81, 117.71, 117.57, 117.48, 115.36, 115.24, 112.34,
74.18, 62.20, 61.87, 44.63, 34.89, 29.89, 15.08, 12.44. 11B NMR (128 MHz, CDCl3/MeOD): δ 1.18
(t), -2.48, -5.65, -9.36, -11.85, -13.00. FT-IR (thin film) v 2958, 2586 (B-H), 1734, 1600, 1458,



























(113). To a solution of amino-DHP m-
76a (3 mg, 4 µmol, 1.2 eq) and BODIPY-
carborane-acid 134 (3 mg, 3.2 µmol, 1 eq)
in DCM (1 mL) were added EDC (1.2 mg,
6.4 µmol, 2 eq), HOBt (0.87 mg, 6.4 µmol,
2 eq) and DiPEA (1.1 µL, 6.4 µmol, 2 eq)
. The mixture was stirred for 16 h at room
temperature, and subsequently washed with
HCl (aq, 1 M, 2 x 5 mL), water (1 x 5
mL), dried (Na2SO4), filtered and concen-
trated under reduced pressure. Purification
by silica column chromatography (0.2 → 5%
MeOH in DCM), followed by crystallization from DCM/hexanes yielded the product as blue crystals
(2.8 mg, 1.7 µmol, 53%). R f = 0.6 (10:1 DCM:MeOH) 1H NMR (600 MHz, CDCl3): δ 7.98 (s, 1H,
CHar), 7.79 (d, J = 7.8 Hz, 1H, CHar), 7.64 - 7.52 (m, 6H, 6 x CHar), 7.45 - 7.40 (m, 1H, CHar),
7.26 - 7.13 (m, 7H, 7 x CHar), 7.09 (s, 1H, CHar), 7.04 - 6.97 (m, 3H, 2 x CHar, NH), 6.97 - 6.88
(m, 3H, 2 x CHar, NH), 6.83 - 6.72 (m, 3H, 2 x CHar, NH), 6.63 (d, J = 6.0 Hz, 1H, CHar), 5.25 (s,
2H, CH2), 5.03 (s, 2H, CH2), 4.51 (s, 2H, CH2), 4.49 (s, 1H, CH), 4.32 (t, J = 6.6 Hz, 2H, CH2),
4.14 - 4.07 (m, 2H, CH2), 3.68 - 3.48 (m, 19H, 9 x CH2, BCH), 3.45 - 3.41 (m, 2H, CH2), 2.48 -
1.80 (m, 22H, 4 x CH2, CH3, CH, 10 x BH), 1.59 (s, 6H, 2 x CH3), 1.42 (t, J = 7.0 Hz, 3H, CH3),
1.32 - 1.16 (m, 10H, 2 x CH2, 2 x CH3), 0.90 - 0.83 (m, 3H, CH3).
13C NMR (151 MHz, CDCl3):
δ 195.69, 168.19, 167.67, 159.00, 157.99, 152.80, 149.70, 145.00, 144.45, 144.14, 142.38, 138.03,
135.47, 134.89, 131.25, 130.98, 130.21, 129.19, 129.06, 128.73, 128.37, 127.26, 126.60, 125.44,
123.02, 122.99, 119.42, 118.18, 118.08, 117.71, 115.36, 115.25, 113.01, 109.97, 88.13, 74.22, 73.84,
70.70, 70.68, 70.45, 70.00, 69.72, 68.77, 68.24, 67.53, 64.75, 62.13, 61.85, 51.06, 49.22, 43.46,
39.94, 38.97, 38.26, 37.60, 35.05, 33.98, 33.66, 29.85, 19.90, 18.55, 15.18, 14.97, 14.23. 11B NMR
(128 MHz, CDCl3/MeOD): δ 1.19 (t), -2.24, -5.53, -9.21, -11.92. ESI-HRMS (m/z): calcd. for
[C85H104B11BrF2N10O10 + 2H]


































m-DHP-BODIPY-carborane (114). Compound 93
(2.73 mg, 2.27 µmol) and alkyne-carborane 100
(0.83 mg, 2.72 µmol, 1.2 eq) were dissolved in DCM
(1 mL) and sodium ascorbate (aq, 4.54 µmol, 2 eq)
and CuSO4 (aq, 0.45 µmol, 20 mol%) were added.
The mixture was stirred for 16 h, and subsequently
washed with water (2 x 5 mL), dried (MgSO4), fil-
tered and concentrated in vacuo. Purification by
silica column chromatography (0 → 4% MeOH in
DCM), gave the product as a purple solid (2.56 mg,
1.7 µmol, 75%). R f = 0.6 (10:1 DCM:MeOH) 1H
NMR (600 MHz, CDCl3/MeOD): δ 7.97 (s, 1H,
CHar), 7.85 (d, J = 8.9 Hz, 2H, 2 x CHar), 7.80 (s, 1H, CHtrz), 7.75 (d, J = 7.8 Hz, 1H, CHar),
7.71 (d, J = 7.7 Hz, 1H, CHar), 7.44 (t, J = 7.7 Hz, 1H, CHar), 7.26 (d, J = 8.7 Hz, 2H, 2 x
CHar), 7.19 (s, 1H, CHar), 6.99 (d, J = 4.1 Hz, 1H, CHar), 6.97 - 6.92 (m, 4H, 4 x CHar), 6.90 -
6.87 (m, 2H, 2 x CHar), 6.55 (d, J = 4.1 Hz, 1H, CHar), 5.19 (s, 2H, CH2), 5.13 (s, 1H, CH), 5.01
(s, 2H, CH2), 4.65 (t, J = 6.8 Hz, 2H, CH2), 4.53 (s, 1H, CH), 4.15 - 4.09 (m, 2H, CH2), 4.08 (s,
1H, BCH), 4.04 (t, J = 5.7 Hz, 2H, CH2), 3.96 (s, 1H, OH), 3.66 - 3.60 (m, 8H, 4 x CH2), 3.58
- 3.56 (m, 2H, CH2), 3.52 - 3.49 (m, 2H, CH2), 3.44 (t, J = 5.2 Hz, 2H, CH2), 3.32 (t, J = 5.2
Hz, 2H, CH2), 2.79 - 1.68 (m, 10H, 10 x BH), 2.73 (t, J = 7.5 Hz, 2H, CH2), 2.51 (s, 4H, CH3,
CH2-H
a), 2.48 - 2.43 (m, 3H, CH2, CH2-H
a), 2.40 - 2.35 (m, 1H, CH2-H
b), 2.31 (t, J = 7.5 Hz, 2H,
CH2), 2.22 (s, 4H, CH3, CH), 2.16 - 2.09 (m, 4H, CH3, CH2-H
b), 1.43 (t, J = 7.0 Hz, 3H, CH3),
1.39 - 1.33 (m, 4H, 2 x CH2), 0.94 - 0.90 (m, 3H, CH3).
13C NMR (151 MHz, CDCl3/MeOD):
δ 197.15, 173.36, 168.92, 160.09, 159.46, 158.80, 155.37, 152.99, 151.95, 146.38, 144.26, 144.05,
143.11, 140.69, 138.24, 135.32, 134.84, 134.68, 133.12, 131.80, 131.02, 130.96, 128.86, 128.40,
128.28, 127.22, 127.11, 126.38, 124.32, 123.42, 119.93, 118.50, 118.18, 114.78, 114.47, 112.99,
109.44, 87.58, 86.80, 80.63, 74.46, 74.18, 70.68, 70.65, 70.31, 70.26, 70.01, 69.92, 64.88, 64.39,
61.90, 59.74, 47.74, 43.50, 40.08, 39.59, 38.62, 37.57, 36.17, 33.98, 33.06, 29.95, 20.46, 20.10,
17.97, 14.92, 14.16, 13.16, 9.59. LC/MS analysis (linear gradient 10 → 90% ACN) tR : 11.54 min,














































BODIPY-azide 93 (4 mg, 3.5
µmol) and carboranyl pep-
tide 111 (6.85 mg, 4.7 µmol,
1.3 eq) were dissolved in
dioxane (1 mL) and sodium
ascorbate (aq, 9.4 µmol, 2
eq) and CuSO4 (aq, 0.9
µmol, 20 mol%) were added.
The mixture was stirred for
16 h and concentrated in
vacuo. Purification by sil-
ica column chromatography
(10 → 50% MeOH in DCM),
followed by lyophilizing from
dioxane/H2O gave the product as a purple solid (7.36 mg, 2.8 µmol, 79%).
1H NMR (600 MHz,
CDCl3/MeOD): δ 8.45 (s, 1H, CHtrz), 7.99 (s, 1H, CHar), 7.85 (d, J = 8.2 Hz, 2H, 2 x CHar), 7.77
(d, J = 7.6 Hz, 1H, CHar), 7.70 (d, J = 7.2 Hz, 1H, CHar), 7.45 (t, J = 7.3 Hz, 1H, CHar), 7.26 (s,
1H, CHar), 7.01-6.88 (m, 5H, 5 x CHar), 6.56 (s, 1H, CHar), 5.01 (s, 2H, CH2), 4.52 (s, 4H, 4 x CH),
4.40-4.20 (m, 6H, 3 x BCH, 3 x CH), 4.19 - 3.96 (m, 6H, 3 x CH2), 3.76 - 3.41 (m, 16H, 8 x CH2),
3.24 - 3.08 (m, 6H, 3 x CH2 ), 2.79 - 0.81 (m, 96H, 5 x CH3, 24 x CH2, CH, 30 x BH). LC/MS
analysis (linear gradient 10 → 90% ACN) tR : 11.98 min, ESI-MS (m/z): [M + H]2+: 1327.40.
ESI-HRMS (m/z): calcd. for [C111H170B31BrF2N20O26 + H]
















tert-Butyl (16-azido-1-(3-((2-bromo-4-( (4R,7S) -3-
cyano-2-methyl-5-oxo-7-propyl-1, 4, 5, 6, 7, 8-he-
xahydroquinolin-4-yl) -6-ethoxyphenoxy) methyl) phe-
nyl)-1,15-dioxo-5,8,11-trioxa-2,14-diazaicosan-20-yl) car-
bamate (135). Amino-DHP m-76a (9 mg, 12 µmol)
was added to a pre-activated solution of (S)-(-)-2-Azido-
6-(Boc-amino)hexanoic acid (dicyclohexyl ammonium) salt
(6 mg, 13 µmol, 1.1 eq), EDC (5 mg, 26 µmol, 2.2 eq),
HOBt (3.5 mg, 26 µmol, 2.2 eq) and TEA (3.6 µL, 26
µmol, 2.2 eq) in DCM (2 mL). The mixture was stirred
for 3 h at room temperature, before being purified by silica
column chromatography (0 → 5% MeOH in DCM), yielding compound 135 as a colorless solid (9
mg, 8.9 µmol, 74%). 1H NMR (400 MHz, CDCl3): δ 8.03 (s, 1H, CHar), 7.77 (d, J = 7.7 Hz, 1H,
CHar), 7.65 (d, J = 7.5 Hz, 1H, CHar), 7.45 (t, J = 7.7 Hz, 1H, CHar), 7.19 (s, 1H, NH), 6.93 (s,
2H, CHar, NH), 6.84 - 6.76 (m, 2H, CHar, NH), 5.04 (s, 2H, CH2), 4.69 (s, 1H, NH), 4.56 (s, 1H,
CH), 4.13 (dd, J = 6.9, 2.7 Hz, 2H, CH2), 3.96 - 3.84 (m, 1H, CHα), 3.77 - 3.29 (m, 16H, 8 x
CH2), 3.10 (d, J = 5.7 Hz, 2H, CH2), 2.52 - 2.27 (m, 3H, CH2, CH2-H
a), 2.24 - 2.02 (m, 5H, CH3,
CH2-H
b, CH), 2.03 - 1.74 (m, 4H, 2 x CH2), 1.54 - 1.38 (m, 14H, 4 x CH3, CH2), 1.36 - 1.24 (m, 4H,
2 x CH2), 0.88 (t, J = 6.7 Hz, 3H, CH3).
13C NMR (101 MHz, CDCl3): δ 195.68, 174.63, 169.51,
167.83, 152.79, 149.73, 144.97, 144.19, 142.38, 138.30, 134.81, 131.34, 128.69, 126.86, 123.06,
119.36, 118.09, 113.13, 110.08, 88.31, 74.16, 70.71, 70.68, 70.46, 70.43, 69.96, 69.60, 64.75, 64.22,
43.53, 40.01, 39.38, 38.33, 37.56, 33.98, 33.77, 31.88, 29.83, 28.59, 22.78, 19.92, 18.64, 14.97,
14.17. FT-IR (thin film) v 3285, 2928, 2872, 2104 (N3), 1648, 1533, 1497, 1385, 1275, 1126, 1045
167
Chapter 8
cm−1. LC/MS analysis (linear gradient 10 → 90% ACN) tR : 9.79 min, ESI-MS (m/z): [M + H]+:
1009.00. ESI-HRMS (m/z): calcd. for [C49H67BrN8O10 + H]



























135 (3 mg, 3 µmol) was dissolved in DCM
(2 mL) and TFA (0.5 mL) was added. Af-
ter 1 h the solvents were removed in vacuo,
followed by co-evaporation with toluene (3
x). After silica column chromatography (0
→ 10 % MeOH in DCM + 1% TEA) the
resulting free amine (LC/MS analysis (linear
gradient 10 → 90% ACN) tR : 7.34 min, ESI-
MS (m/z): [M + H]+: 909.20) was used
directly for the coupling with a pre-activated
mixture of Cy5 91 (1.9 mg, 2.2 µmol), Py-
BOP (1.3 mg, 2.5 µmol) and DiPEA (1.1
µL, 6.6 µmol) in DMF (1 mL). The mix-
ture was stirred overnight, before being con-
centrated in vacuo. Crude azido-DHP-Cy5
(LC/MS analysis (linear gradient 10 → 90% ACN) tR : 7.58 min, ESI-MS (m/z): [M + H]+: 1655.40)
was dissolved in water (0.5 mL) and carborane 100 (0.83 mg, 2.72 µmol) in dioxane (0.5 mL) and
aqueous solutions of sodium ascorbate (4.5 µmol) and CuSO4 (0.45 µmol) were added. After 16 h,
the solvents were removed under reduced pressure and compound 116 was isolated by silica column
chromatography (0 → 2% H2O in 40% MeOH in CHCl3) as a blue solid (1.33 mg, 0.68 µmol, 31%
over 3 steps). 1H NMR (600 MHz, MeOD): δ 8.32 - 8.18 (m, 3H, 2 x CH=, CHtrz), 8.02 (s, 1H,
CHar), 7.92 - 7.86 (m, 4H, 4 x CHar), 7.79 (d, J = 7.6 Hz, 1H, CHar), 7.67 (d, J = 7.6 Hz, 1H,
CHar), 7.45 (t, J = 7.7 Hz, 1H, CHar), 7.41 - 7.35 (m, 1H, CHar), 7.31 - 7.24 (m, 3H, 3 x CHar), 6.99
(d, J = 8.7 Hz, 2H, 2 x CHar), 6.95 - 6.86 (m, 2H, 2 x CHar), 6.64 (t, J = 12.3 Hz, 1H, CH=), 6.39
(d, J = 13.6 Hz, 1H, CH=), 6.33 (d, J = 13.6 Hz, 1H, CH=), 5.35 - 5.30 (m, 1H, CH), 5.15 (d, J
= 10.8 Hz, 3H, CH2, CH), 5.01 (s, 2H, CH2), 4.47 (s, 1H, CH), 4.41 (s, 1H, BCH), 4.16 - 4.03 (m,
6H, 3 x CH2), 3.68 - 3.55 (m, 12H, 6 x CH2), 3.55 - 3.51 (m, 2H, CH2), 3.51 - 3.45 (m, 2H, CH2),
3.11 - 3.04 (m, 2H, CH2), 2.91 (s, 2H, CH2), 2.60 (dd, J = 16.8, 4.4 Hz, 1H, CH2-H
a), 2.47 - 2.39
(m, 2H, CH2-H
b, CH2-H
a), 2.20 - 2.05 (m, 9H, CH3, 2 x CH2, CH2-H
b, CH), 1.96 (s, 4H, 2 x CH2),
1.82 - 1.78 (m, 4H, 2 x CH2), 1.72 (d, J = 7.7 Hz, 12H, 4 x CH3), 1.67 - 1.60 (m, 4H, 2 x CH2),
1.51 - 1.43 (m, 2H, CH2), 1.40 - 1.13 (m, 7H, 2 x CH2, CH3), 0.92 (t, J = 6.8 Hz, 3H, CH3).
13C
NMR (151 MHz, MeOD): δ 198.38, 175.68, 175.39, 175.07, 170.22, 170.11, 160.07, 156.27, 156.01,
154.16, 153.68, 147.56, 145.28, 144.97, 144.87, 144.78, 144.48, 143.43, 143.31, 142.66, 142.58,
139.34, 135.81, 134.43, 132.61, 129.59, 129.41, 128.39, 128.10, 128.02, 124.80, 124.31, 121.32,
120.46, 118.76, 115.50, 113.80, 111.72, 111.61, 109.99, 105.63, 105.39, 88.31, 82.22, 75.28, 75.13,
71.57, 71.31, 71.24, 70.55, 70.19, 65.76, 65.02, 62.53, 61.22, 51.70, 50.60, 45.08, 44.14, 40.98,
40.65, 39.79, 39.76, 38.20, 36.76, 34.89, 33.58, 33.25, 29.60, 28.18, 27.87, 27.38, 27.13, 26.55,
23.99, 23.54, 20.97, 18.07, 15.24, 14.48. LC/MS analysis (linear gradient 10 → 90% ACN) tR : 9.65
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From LMW to HMW ligands:
fluorescently tagged FSH by
sortase-mediated ligation1
T
he heterodimeric follicle-stimulating hormone (FSH) consists of a common
α-subunit and a unique β-subunit which are non-covalently linked to each
other. The C-terminus of the FSHβ-subunit is not involved in receptor binding
and was selected for introduction of a sortase recognition sequence (LPETGG)
and a His10-affinity tag. "FSH-LPETGG" was recombinantly expressed in HEK293
cells, semi-purified and subjected to sortase-mediated ligation with a synthetic
sortagging nucleophile (GGG-BDP-MC) to provide fluorescent "FSH-BDP-MC".
This protein was shown to be a full FSHR agonist with comparable potency as
wild-type FSH in stimulating cAMP production. FSH-BDP-MC was able to in-
duce FSHR-GFP internalization, and was trafficked together with its receptor in
the endolysosomal pathway as determined by fluorescence colocalization. The
versatility of a synthetic nucleophile combined with the selectivity and potency
of the endogenous ligand opens up novel possibilities for the study and manipu-




The glycoprotein follicle-stimulating hormone (FSH), which is secreted by the pituitary
gland, has important functions in human reproduction. FSH is a heterodimeric protein
that shares its α-subunit with the closely related proteins human chorionic gonadotrophin
(hCG), luteinizing hormone (LH) and thyroid-stimulating hormone (TSH). The unique β-
subunit confers its selectivity for the follicle-stimulating hormone receptor (FSHR), present
on granulosa cells in the ovaries and Sertoli cells in the testes. 2 The two subunits are non-
covalently bound to each other, and an intricate network of disulfide bridges in each sub-
unit allows for a strong interaction between the two. 3,4 Disruption of disulfide bonds Cys20-
104 or Cys28-82 in the FSHβ subunit, by mutation of the cysteines forming the bridge,
prevents correct folding of the subunit and heterodimer formation. 5 In mammals, FSH is
present as many different isoforms. Two N-linked glycosylation sites are present on both
the FSHα (Asn-52 and Asn-78) and FSHβ (Asn-7 and Asn-24) chains and the core struc-
tures and degree of sulfation and sialylation of the N-glycans are very heterogeneous. 2,6
Numerous functions of FSH glycosylation have been reported, such as proper protein fold-
ing, assembly and secretion and circulation half-lifes. 7–11 FSH is used clinically for the treat-
ment of anovulatory females and in assisted reproduction techniques (in-vitro fertilization,
intracytoplasmic sperm injection). 12,13 Originally, urine preparations containing FSH were
used, which have increased in purity and FSH content over the years. With the develop-
ment of a recombinant system for the production of FSH, access was gained to highly pure
protein with good batch-to-batch consistency. 13–16 Functionally important posttranslational
modifcations of recombinant human FSH (Puregon) produced by eukaryotic Chinese ham-
ster ovary (CHO) cells are remarkably similar to urinary or pituitary derived FSH. 17
Besides the well-established importance of the glycoproteins and their receptors in re-
production, they are thought to be implicated in cancer pathogenesis. The presence of
the FSHR on ovarian surface epithelial tumor cells has been reported, 18,19 as well as the
unexpected finding of ubiquitous FSHR expression on vascular endothelial cells of a va-
riety of tumors. 20 Visualization of the FSHR therefore presents an opportunity for tumor
diagnostics, whereas targeting of cytotoxic drugs to FSHR-expressing tumors enables ther-
apeutic intervention. In Chapters 6-8 a targeting strategy has been described based on a
small-molecule synthetic agonist for the FSHR. High ligand efficiency, oral bioavailability,
metabolic stability and synthetic access to large quantities of a chemically defined structure
(and derivatives) are amongst the arguments in favor of the use of a low molecular weight
ligand. However, in terms of receptor selectivity and potency the endogenous protein li-
gand is hard to beat.
The aim of the research described in this chapter is to combine the selectivity and po-
tency of FSH as a targeting ligand with the flexibility of synthetic ’cargo’, e.g. a fluorescent
dye, peptide or drug. Sortase-mediated ligation, also termed ’sortagging’, was the envis-
aged method of choice to accomplish this. The bacterial enzyme Sortase A binds to its C-
terminal recognition sequence on a target protein and catalyzes the transpeptidation with
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Figure 9.1: Left: Schematic representation of heterodimeric FSH bound to the N-terminal domain
(NTD) and a LMW ligand to the transmembrane domain of the FSHR. Detail: Reported crystal
structure of FSH bound to the receptor shows that the C-terminus of FSHβ is not involved in
receptor binding. 21,22 Structure was made with PyMOL and the grey ball at the C-terminus indicates
the ligation site. Right: Sortase-mediated ligation described in this chapter.
a (synthetic) triglycine nucleophile (Figure 9.1). 23,24 A recombinant version of FSH with a
C-terminally extendedβ-subunit has been reported with retention of receptor binding and
biological activity. 25,26 In addition, crystallographic data of FSH bound to the ectodomain
of the receptor support the hypothesis that the FSHβ C-terminus is not involved in recep-
tor binding (Figure 9.1). 21,22 In this chapter, sortase-mediated ligation of a synthetic fluo-
rescent peptide to the C-terminus of the FSHβ-subunit of recombinant FSH is described.
Functional assays are used to determine what the pharmacological properties of fluores-
cently labeled FSH are and whether this holds promise for use in future applications of
FSHR visualization and targeting.
9.2 Results and Discussion
Expression and sortagging of FSH-LPETGG. Recombinant human FSH suited for sortase-
mediated ligation ("FSH-LPETGG") was expressed using two plasmids, one encoding the
wild-type FSH α-subunit and one the FSHβ-subunit containing a C-terminal sortase se-
quence (LPETGG) and His10-tag for purification purposes. Chinese hamster ovary (CHO)
cells and human embryonic kidney (HEK293) cells are eukaryotic expression systems ca-
pable of introducing the required posttranslational modifications on the protein and have
been used before for the expression of fully active, recombinant FSH. 14,27 Small scale trans-
fection experiments in both cell lines were performed and the presence of FSH-LPETGG in
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cell lysates and medium was determined by immunoblotting. From these experiments, it
became apparent that both the heterodimeric FSH-LPETGG as well as monomeric FSHβ-
LPETGG were secreted into the medium. In previous reports on recombinant FSH expres-
sion it was noted that intact heterodimeric protein is secreted efficiently from the cells, but
monomeric, wild-type FSHβ very slowly and to a smaller extent. 14 However, fusion of a
hCG-derived peptide to the FSHβ C-terminus led to much higher levels of FSHβ-CGβ
secretion. 26 The enhanced secretion of FSHβ-LPETGG might thus be due to its C-terminal
extension. Assembly of the subunits appeared to be more efficient in HEK293 cells than in
CHO cells, based on the ratio of dimeric protein and FSHβ that were secreted, and thus
these cells were selected for larger scale expression experiments.
Adherent HEK293T cells were transiently co-transfected with FSHα and FSHβ-LPETGG
cDNA and from 24 h after transfection, cells were cultured in serum-free medium. Medium
was collected and refreshed every 24 h and FSH-LPETGG expression was detected using
antibodies against FSHα and FSHβ (Figure 9.3A). The detected bands were very diffuse,
indicating the presence of multiple isoforms, and higher in molecular weight than wild-
type recombinant FSH (rFSH, Org32489), because of the C-terminal extension. For clarity,
a schematic representation of all subsequent purification and sortagging steps is given in
Figure 9.2. Medium containing FSH-LPETGG was pooled, concentrated and subjected to
Ni-affinity purification (Figure 9.3B). Recombinant FSH-LPETGG and monomeric FSHβ-
LPETGG were captured very efficiently by a Ni-NTA agarose column, since no FSH-derived
protein was detected in both the flow-through (FT) and washing steps (wash) from the co-
lumn. Elution from the resin using imidazole resulted in a semi-pure protein preparation












Ni-NTA column Ni-NTA column
FSHβ FSHαβ His tag SrtA !uorescent BODIPY-MC
Figure 9.2: Schematic representation of the purification, sortagging and second purification steps
on FSH-LPETGG. From each step, a sample was taken and subjected to SDS-PAGE analysis, as
shown in Figure 9.3 B and C.
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Semi-purified FSH-LPETGG was subjected to sortase-mediated ligation using Sortase
A (SrtA) from Staphylococcus aureus, containing three mutations (P94S/D160N/ K196T). 28
As described in Chapter 4, this triple mutant SrtA has enhanced affinity for the LPETGG
sequence, which makes it much more suited for use in very diluted samples. As a nucle-
ophile, "GGG-BDP-MC" 40 (Scheme 4.1, Chapter 4) was used, enabling fluorescent visu-
alization because of the BODIPY dye ("BDP") while also containing a large peptide-based
synthetic mannose cluster ("MC", Chapter 2) as model cargo. The ligation reaction was
carried out for 2h at 37 ◦C with a large excess of nucleophile (100 µM), to diminish the
potential hydrolysis reaction (Figure 4.3, Chapter 4). Then, Ni-NTA agarose beads were
added to the mixture to capture any remaining His-tagged starting proteins, SrtA and the
SrtA-FSH intermediate. Everything C-terminally of the threonine residue in the sortase se-
quence was cleaved off during the transpeptidation (Figure 9.1) so the product "FSH-BDP-
MC" was not captured by the Ni-NTA resin (Figure 9.3). After nickel-affinity purification,
heterodimeric FSH-BDP-MC was obtained as determined by in-gel fluorescence scanning
and immunoblotting against the α- and β-subunits. Reduction of the protein sample with
dithiothreitol (DTT), resulted in the disappearance of the higher molecular weight band
and appearance of one lower running band, confirming the presence of heterodimeric pro-
tein (Figure 9.3).
Table 9.1: Protein concentrations of FSH-LPETGG and FSH-BDP-MC
FSH (µg/mL)a [FSH] (nM) Total protein (mg/mL) %FSH/total protein
FSH-LPETGG 14; 9 284; 180b 1.8; 1.2 0.3; 0.3
FSH-BDP-MC 12; 8 244; 167b 1.5; 1.6 0.3; 0.2
rFSH 112 2.5 0.1
aConcentrations (µg/mL) were determined using an FSH-ELISA assay. Values of two separate ex-
pression and sortagging experiments are given. bCalculated using estimated MW of 50 kDa.
The amounts of FSH-LPETGG and FSH-BDP-MC obtained were estimated by a sand-
wich ELISA assay against FSHβ (Table 9.1). Based on the expected increase in weight by the
C-terminal extention and the observed gelshift, an estimated molecular weight of 50 kDa
for FSH-LPETGG/FSH-BDP-MC was assumed to calculate the FSH concentration (nM)
(Table 9.1). The given values might be a slight overestimation of the actual heterodimer
concentration, because of potential cross-reactivity of the free β-subunit, present in both
samples besides the heterodimer, in the ELISA assay. The recombinant wild-type human
FSH (rFSH) preparation, which was used as a positive control througout the experiments, is
stabilized by the use of bovine serum albumin (BSA) as an additive. As seen in Table 9.1, the
estimated percentage FSH/total protein in the sample after Ni-affinity purification of both
FSH-LPETGG and FSH-BDP-MC was similar to that of the rFSH stock. Since the absolute
amounts of FSH-BDP-MC obtained were ∼2.6/1.8 µg (2 independent experiments, corre-
sponding to 35-40% yield of the sortase reaction) no further purification procedures were








































A) Expression of FSH-LPETGG











































































anti-FSHα WB anti-FSHβ WB
#uorescence
C) Sortase-mediated ligation of FSH-LPETGG 
Figure 9.3: Expression, purification and sortase-mediated ligation of FSH-LPETGG. A) Medium
of HEK293T cells transiently transfected with FSHα and FSHβ-LPETGG (t=0) was refreshed every
24 h and the presence of heterodimeric FSH-LPETGG as well as the respective monomers in the
medium was detected using monoclonal antibodies against FSHα (cyan) or FSHβ (magenta). B)
Combined and concentrated medium of A) was treated with Ni-NTA agarose to capture all His-tagged
proteins, washed and subsequently eluted with imidazole to yield semi-purified FSH-LPETGG, also
containing FSHβ-LPETGG. C) Sortase-mediated ligation of semi-purified FSH-LPETGG (as in B)
with GGG-BDP-MC followed by removal of SrtA, SrtA-FSH intermediate, unreacted FSH-LPETGG
and FSHβ-LPETGG using Ni-NTA agarose, yields fluorescently labeled FSH-BDP-MC (as well as
FSHβ-BDP-MC). Fluorescent proteins were detected by in-gel fluorescence scanning (red) and FSH-
derived proteins were visualized using immunoblotting against FSHα (cyan) or FSHβ (magenta).
Total protein was detected using silverstain, however, due to the low abundance of recombinant FSH
in these samples and the heterogeneity of their glycosylation pattern, no distinguishable band for the
various rFSH constructs was found. Reduction of the mixture with DTT (5 mM, 1 h, 37 ◦C) resulted
in dissociation of the heterodimer as seen by in-gel fluorescence (’FSH-BDP-MC reduced’).
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some FSH-sortase intermediate and unreacted FSH-LPETGG was eluted from the nickel
beads (’elution Ni’), thus optimization of the reaction conditions might lead to a slightly
improved yield.
Biological evaluation of FSH-LPETGG and FSH-BDP-MC. Agonistic activities of the FSH-
LPETGG and FSH-BDP-MC proteins were determined in a CRE-luciferase assay. For this,
CHO cells stably transfected with the human FSHR and a CRE-luciferase reporter construct
were treated with various concentrations (as calculated from the values given in Table 9.1)
of the recombinant proteins for 4 h (37 ◦C, 5 % CO2). The resulting dose-response curves,
depicted in Figure 9.4 (left), were very similar for both proteins and control rFSH. The
mean agonistic potencies (EC50) calculated from the pEC50 values determined from the
fitted curves, were 5 pM for both constructs (Figure 9.4), indicating that these C-terminal
modifications could be introduced without influencing the potency of the protein.










































apEC   values are given as mean ± SD determined 
from concentration-e"ect curves of N independent 
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50
Figure 9.4: Luciferase assay. Agonistic activities of FSH-LPETGG, FSH-BDP-MC and rFSH on CHO
cells stably expressing human FSHR and CRE-luciferase reporter. left: Representative dose-response
curves of the effect normalized to the maximal luciferase activity induced by rFSH. right: EC50 values
of the different constructs.
Upon activation of the receptor, signaling cascades are set in motion which result in the
phosphorylation of the FSHR. 29 It is believed that this leads to sequestering by β-arrestins
and the internalization of the receptor-ligand complex in clathrin-coated pits, thereby pre-
venting overstimulation of the receptor. 30–32 The ability of the FSH-LPETGG and FSH-BDP-
MC proteins to induce receptor internalization was examined next with the use of U2OS
cells that stably express the rat FSHR conjugated to enhanced green fluorescent protein
(eGFP) (U2OS-FSHR cells). The percentage of GFP fluorescence signal inside the cyto-
plasm was calculated as a measure for receptor internalization (Figure 9.5A). Untreated
cells showed bright membrane fluorescence and only ∼30% of the receptor fluorescence
was localized inside the cell, as observed before (Chapter 7). Treatment with FSH-LPETGG
or FSH-BDP-MC (11-14 nM) for 2 h induced receptor internalization to the same extent as
rFSH (∼80%) as seen by bright intracellular vesicles (Figure 9.5A,C). The total levels of GFP
fluorescence and BODIPY fluorescence were quantified (Figure 9.5B) and this showed that
the total amount of receptor, either on the membrane or internalized, remained constant
througout the experiments. Only for FSH-BDP-MC bright intracellular BODIPY fluores-
cent signal was detected (Figure 9.5B,C). Since a large excess of nucleophile GGG-BDP-MC













































































































































































Figure 9.5: Confocal microscopy of FSHR internalization and FSH-BDP-MC uptake. U2OS cells
stably expressing eGFP-conjugated rat FSHR were incubated with rFSH, FSH-LPETGG or FSH-BDP-
MC (11-14 nM), GGG-BDP-MC (3 µM) or a combination of rFSH (11 nM) and GGG-BDP-MC (3
µM) for 2 h, 37 ◦C, 5% CO2. For competition experiment cells were pre-treated with THQ 98 (10
µM, 1 h) followed by incubation with FSH-BDP-MC (4 nM, 2 h). Cells were washed, fixed (4%
formaldehyde in PBS) and imaged using a confocal fluorescence microscope. Images were analyzed
A) for the relative amount of receptor (GFP signal) inside the cytoplasm versus on the cell membrane
as a measure for receptor internalization and B) for total GFP (receptor expression levels) and BO-
DIPY signal intensities. Values were normalized to give mean GFP∼1 for untreated and rFSH-treated
cells and mean BODIPY∼1 for MC-BDP-GGG treated cells. Each dot represents a picture analyzed
from N=1 (THQ + FSH-BDP-MC) to N=5 (FSH-BDP-MC) independent experiments. C) Repre-
sentative images of all conditions showing receptor localization (GFP, green) and compound/protein
uptake/binding (BODIPY, red). Blue: Draq5 nuclear stain.
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the remaining nucleophile in the sample was not at the basis of receptor internalization
and intracellular BODIPY fluorescence. Cells were incubated with 3 µM of compound
40, corresponding to the maximum concentration that could be present in the FSH-BDP-
MC sample. As shown in Figure 9.5A-C, this did not result in receptor internalization or
any increase in BODIPY levels above autofluorescence background levels. Also, concomi-
tant exposure of U2OS-FSHR cells to rFSH (11 nM) and nucleophile 40 (3 µM) resulted in
rFSH-induced receptor internalization, but not in uptake of the nucleophile. These experi-
ments confirm the covalent attachment of GGG-BDP-MC to FSH, resulting in agonistically
active and fluorescent FSH-BDP-MC. It can not be excluded that remaining FSHβ-BDP-
MC is partly responsible for the observed effects. Wild-type FSHβ reportedly is able to
bind the FSHR albeit with a 100-fold less affinity, and literature evidence points to the het-
erodimeric protein as the only biologically active species. 33 Treatment of control U2OS cells
without FSHR with FSH-BDP-MC did not result in any intracellular BODIPY fluorescence
(Figure 9.5B), confirming the receptor-mediated uptake of the protein.
A low molecular weight FSHR antagonist has been reported that is based on the tetrahy-
droquinoline (THQ) scaffold and binds to an allosteric binding site on the receptor (Fig-
ure 9.1). 34,35 Using a THQ-derivative, compound 98 (Figure 7.4C, Chapter 7), in combina-
tion with the low molecular weight fluorescent agonist DHP-Cy5 96 (Chapter 7) resulted in
inhibition of DHP-Cy5 induced FSHR internalization. Furthermore, no Cy5 fluorescence
was observed indicating that THQ also prevented DHP-Cy5 from FSHR binding. An anal-
ogous experiment was conducted with THQ 98 (10 µM) and FSH-BDP-MC (4 nM) and
the results are shown in Figure 9.5. THQ was able to antagonize FSHR-internalization,
but unable to inhibit binding of FSH-BDP-MC to the receptor as seen by very bright BO-
DIPY membrane labeling. Colocalization analyses of receptor GFP fluorescence and FSH
BODIPY fluorescence for conditions with and without THQ are given in Figure 9.6 and
Table 9.2. In both cases strong colocalization was found, with values above 0.84 for Pear-
son’s colocalization coefficient and high intensity correlation quotients of ∼0.33 (dependent
staining: 0≤x≤0.5). 36,37 This further confirmed the specific interaction between FSH-BDP-
MC and the FSHR. In a final experiment, the low molecular weight agonist DHP-Cy5 96
and FSH-BDP-MC were combined. As shown in Figure 9.6B, this led to the colocalization
of all three fluorophores in intracellular vesicles, establishing that these two agonists share
the same target receptor, but not the binding site. Interestingly, some of the intracellular
vesicles were only positive for GFP and not for either ligand. This could reflect an intracel-
lular population of receptors or it could be caused by dissociation of the ligand from the
receptor during endocytosis and trafficking. Time-course studies could be used to examine
this in more detail.
Reports on the internalization and trafficking of the FSH-FSHR complex so far have
made use of radio-labeled [125I] or [131I]-FSH and immunostaining techniques for receptor
visualization. 38–41 Some of these indicate that the FSHR is recycled back to the membrane
intact, while FSH is trafficked to the lysosomes and degraded, 40 and others report recy-














FSH-BDP-MC + DHP-Cy5 96
Figure 9.6: Colocalization of FSH-BDP-MC with eGFP-FSHR. A) Overlays of pictures shown in
Figure 9.5 for FSH-BDP-MC (left) and THQ + FSH-BDP-MC (right) showing colocalized pixels
in white. Insert: fluorescence scatterplot. Colocalization parameters are given in Table 9.2. B)
Concomitant treatment of U2OS-FSHR cells with HMW ligand FSH-BDP-MC (14 nM) and LMW
ligand DHP-Cy5 96 (1 µM) (Chapter 7) led to internalization of the receptor and colocalization of
all three fluorophores.
Table 9.2: Colocalization analysis of FSH-BDP-MC with eGFP-FSHR.
n (N) Rr M1 M2 ICQ
FSH-BDP-MC 18 (5) 0.8448 ± 0.033 0.9368 ± 0.013 0.9689 ± 0.013 0.3372 ± 0.018
THQ 98 +
FSH-BDP-MC 8 (1) 0.8401 ± 0.035 0.9629 ± 0.010 0.9729 ± 0.012 0.3271 ± 0.021
n(N): number of pictures n from N independent experiments analyzed. Rr: Pearson’s colocalization
coefficient. Manders overlap coefficients (M) M1: red; M2: green. ICQ: intensity correlation quotient.
Mean ± SD is given.
fluorescently labeled FSH as a suited alternative for an in-depth study on the intracellular
localization and trafficking of FSH after internalization.
9.3 Conclusion
The expression of a recombinant heterodimeric protein potentially has many pitfalls be-
cause of the crucial assembly step. In this study a sortagging competent version of follicle-
stimulating hormone, FSH-LPETGG, was expressed in HEK293T cells. The intact het-
erodimer was secreted from the cells into the medium, as well as the free FSHβ-LPETGG
subunit. Since both proteins contained the His10-tag and the sortase sequence, separation
of the two was not possible with the little protein material that was obtained. Sortase-
mediated ligation of the semi-pure protein preparation with a synthetic nucleophile, GGG-
BDP-MC 40, resulted in the formation of FSH-BDP-MC. This protein was shown to be fully
active on the FSHR in terms of Gs-signaling and receptor internalization. Moreover, strong
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colocalization of the protein and the receptor under various conditions was established,
both in intracellular vesicles and on the cell membrane, proving the interaction between
the two. Fluorescently labeled FSH might find applications in the study of FSH-FSHR traf-
ficking and in FSHR visualization on (tumor) cells. Furthermore, by introduction of the
mannose cluster as a model for ’cargo’, it has been shown that large synthetic molecules
are tolerated at the FSHβ C-terminus without comprimising activity. The challenge now
lies in the optimization of protein expression and purification procedures to obtain larger
quantities of defined protein preparations. The synthetic nature of the sortagging nucle-
ophile allows for easy exchange of this cluster with a variety of other drugs (such as the
carboranyl peptide discussed in Chapter 8) or biological modulators. Combined with the
inherent selectivity and potency of FSH for the FSHR this might present a very powerful
approach for targeted drug delivery.
9.4 Experimental Section
Cell culture conditions. All cells were grown in a humidified atmosphere in 5% CO2 at 37
◦C.
CHO cells stably expressing the human FSH receptor together with a luciferase reporter gene (CHO-
hFSHR_luc cells) and control cells without receptor but with luciferase gene (CHO_luc cells) were
provided by MSD, Oss, The Netherlands. Cells were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) and Ham’s F12 medium (1:1) with glutamine, penicillin/streptomycin (pen/strep, 0.1
mg/mL) and FCS. CHO-hFSHR_luc cells were maintained under constant selection with Hygromycin
B (0.8 mg/mL). Cells were subcultured twice weekly at a ratio of 1:10-1:15. U2OS cells stably express-
ing the rat FSHR fused to the N-terminus of eGFP (U2OS-FSHR cells) were purchased from Thermo
Scientific (FSHR redistribution assay, Pierce Biotechnology). Cells were grown in DMEM (high glu-
cose) supplemented with L-glutamine (2 mM), pen/strep (0.1 mg/mL), G418 (0.5 mg/mL) and FCS
(10%). Wild-type U2OS cells were grown under the same conditions, without G418. Cells were sub-
cultured twice weekly at a ratio of 1:8-1:10. Adherent HEK293T cells were cultured in DMEM (high
glucose, 4.5 g/L) supplemented with pen/strep (0.1 mg/mL) and NBS (10%, iron-supplemented,
HyClone, Thermo Scientific).
FSH ELISA assay. Amounts of recombinant FSH in the various samples were estimated using an FSH
ELISA kit (IBL international GmbH, Germany) per manufacturer’s protocol. This kit encompasses a
solid-phase sandwich ELISA against human FSHβ. An estimated molecular weight of 50 kDa was
used to calculate molarities for FSH-LPETGG and FSH-BDP-MC samples.
Cloning, expression and purification of FSH-LPETGG-His10. The cDNA of FSH-α was amplified
by PCR with a forward primer: 5’-CATAAGCTTACCATGGATTACTACAG AAAATATGCAGCTATC
TTTCTGGTCACATTG TCGGTGTTTCTG CATGTTCT CCATTCCGCTCCTGAT GTGCAGGATT
GCCCAGAAT GCACG-3’ containing a Hind III site and a reverse primer: 5’-CATGGATCCGGTAC CT-
TAAGATTTG TGATAATAACAA GTACTGCAG TGGCACGCC GTGTGGTTCTCCAC TTTGAAAC-
CCCCCATT ACTGTGACCCTGTTATA TGATTTAGC-3’ containing a BamHI site. The fragment was
subcloned into Hind III-BamHI-digested pcDNA3.1(+) and sequenced in both directions (282-FSHα).
The cDNA of FSH-β was amplified by PCR with a forward primer: 5’-CATGCTAGCTAAGCTTTG
181
Chapter 9
GTACCGCCGC CACCATGAAGAC ACTGCAGTTTTTCTTCC-3’ containing a Hind III site and a re-
verse primer: 5’-ATCTCTAGA TTAGTGGTGATG GTGATGAT GATGGTGATGGTGATTCAGATC
CTCTTCTGAGAT GAGTTTTTGTTCTGT ACAACCGCCGGTCT CGGGCAGTTCTTTCATTTCAC
CAAAGG-3’ introducing a C-terminal sortase sequence, Myc-tag, His-tag and a XbaI site. The
fragment was subcloned into Hind III - XbaI-digested pcDNA3.1 Hygro(+) and sequenced in both
directions (288-FSHβ-LPETGG-Myc-His). HEK293T cells were transfected by addition of a pre-
made mixture of polyethylenimine (PEI, 25 kDa linear, Polysciences Inc.) and plasmids encoding
FSHα (282-FSHα) and FSHβ-LPETGG-His10 (288-FSHβ-LPETGG-Myc-His) (ratio PEI:DNA 3:1,
ratio α:β 1:1). After 24 h, cells were cultured in serum-free DMEM (high glucose + 0.1 mg/mL
pen/strep). Medium was collected every 24 h and concentrated using Amicon stirred ultracentrifu-
gation devices equipped with 10 kDa MWCO filters. Small samples were analyzed to determine
expression levels and fractions containing FSH-LPETGG-His10 were combined. Briefly, native sample
loading buffer (5 µL 4x, no β-mercaptoethanol) was added to samples ( 15 µL, ∼20x concentrated)
and proteins were separated, without boiling the samples, on 12.5% SDS-PAGE, followed by transfer
to a PVDF membrane using a Biorad Trans-blot Turbo transfer system. Membranes were blocked (1
h, rt, 5% milk in TBS + 0.1% Tween-20) and incubated (o/n, 4 ◦C) with primary antibodies against
either FSHα (1:1000 mouse monoclonal anti-FSHα antibody [ME.111], ab9500, Abcam) or FSHβ
(1:800 mouse monoclonal anti-FSH antibody [SP107], ab21587, Abcam). Membranes were washed
(3x 20’ TBST) and incubated with secondary antibody (1:5000 goat anti-mouse IgG-HRP, sc-2005,
Santa Cruz Biotech), followed by extensive washing (3x 20’ TBST, 1 x 20’ TBS) and developing
(luminol, ECL enhancer, H2O2). Luminescent signal was detected using a Chemidoc XRS (Biorad).
Image analysis and artificial coloring was done with ImageJ. In all experiments, rFSH was included as
a positive control.
After concentrating and pooling, 5x Ni-binding buffer was added (100 mM Tris pH 8.0, 750 mM NaCl,
100 mM imidazole) and the solution was applied on a Ni-NTA column (1 mL bed volume, Qiagen),
which was pre-equilibrated with binding buffer. The sample was allowed to flow by gravity, and the
flow-through was applied again to the column to ensure complete binding of all His-tagged proteins
("FT"). After binding, the column was washed with 10 column volumes (CV) of binding buffer (20
mM Tris, pH 8.0, 150 mM NaCl, 20 mM imidazole) ("wash"). The bound His-tagged proteins were
eluted with 4 CV of elution buffer (20 mM Tris pH 8.0, 150 mM NaCl, 500 mM imidazole) and con-
centrated/buffer exchanged to 20 mM Tris pH 8.0, 150 mM NaCl using Amicon ultracentrifuge tubes
(10 kDa MWCO, Millipore). Each step was monitored by SDS-PAGE/WB to detect the presence
of recombinant FSH. Also, gels were silverstained for total protein loading. This procedure yielded
semi-pure FSH-LPETGG-His10, including monomeric FSHβ-LPETGG-His10.
Sortase-mediated ligation of FSH-LPETGG-His10 with GGG-BDP-MC (40). Transpeptidation reac-
tions on FSH-LPETGG-His10 were carried out for 2 h, 37 ◦C, in the presence of mutant P94S/D160N/
K196T SrtAstaph 28 (11 µM), sortase ligand 40 (100 µM) in sortase reaction buffer (65 µL 50 mM
Tris, 150 mM NaCl, 10 mM CaCl2, pH 7.5). Then, nickel-binding buffer (5x: 100 mM Tris pH 8.0,
750 mM NaCl, 100 mM imidazole) was added and the mixture applied to Ni-NTA agarose beads
(100 µL bed volume) to capture remaining His-tagged starting materials, FSH-SrtA intermediates
and SrtA. After binding for 20 min at rt, the beads were spinned down (5 min, 14000 g) and the
supernatant was collected. The beads were washed twice with 1x binding buffer, and the washes
were combined with the supernatant, yielding FSH-BDP-MC (35-40%, based on ELISA of 2 indepen-
dent experiments). Beads were eluted with elution buffer (20 mM Tris pH 8.0, 150 mM NaCl, 500
mM imidazole). All steps were analyzed using 12.5% SDS-PAGE followed by fluorescence scanning
(Chemidoc MP, Biorad), western blot analysis or silverstaining, as described above. As a control for
the presence of heterodimeric fluorescent protein, a small aliquot of FSH-BDP-MC was reduced by
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addition of 50 mM Tris, pH 7.5, 0.5 mM EDTA, 25 mM NaCl and 5 mM DTT for 1 h, rt, and this
was also included on gel. Gel analysis and artificial coloring was done with ImageJ and overlays were
made in Adobe Photoshop.
Measurement of CRE-induced luciferase expression. CHO_luc or CHO-hFSHR_luc cells were cul-
tured to ∼80% confluency before use in the assay. On the day of the experiment, cells were har-
vested using enzyme-free dissociation solution (Millipore), counted (Biorad TC10 automated cell
counter) and resuspended in assay medium (DMEM-F12 (1:1), without phenol-red, with pen/strep
(0.1 mg/mL) supplied with 1 µg/mL bovine insulin (Tebu-Bio) and 5 µg/mL human apo-transferrin
(Sigma)) to a concentration of 7.5 x 105 cells/mL. Experiments were conducted in 96-wells white Op-
tiplates (Perkin Elmer) and each well contained 30 µL of recombinant FSH, 30 µL of assay medium
and 30 µL cell suspension. After 4 h of stimulation, 50 µL Neolite (PerkinElmer) was added to
each well and luminescence signal was detected on a Microbeta Trilux 1450 Luminescence Counter
(PerkinElmer). To control for non-FSHR mediated effects on intracellular cAMP levels, highest con-
centrations of dose-response curves were tested on CHO_luc cells. As a positive control, forskolin
(3 µM, gift from the Medicinal Chemistry department, Leiden University) was included. Data was
analyzed using GraphPad Prism 5 (GraphPad Software, La Jolla, USA), and values were normalized
to the maximal effect obtained for recombinant human FSH (200 pM, rFSH, Org32489, gift from
MSD, Oss, The Netherlands). Each experiment was performed on duplicate plates and mean ± sd
values of at least three independent experiments are given.
Uptake and FSHR internalization microscopy experiments. U2OS-FSHR or U2OS cells were main-
tained as described under "Cell culture". 48 h before the experiment, cells were harvested (Trypsin-
EDTA), counted and seeded onto sterile Labtek II 4- or 8-chamber borosilicate coverglass systems
(Fisher Emergo) at a density of 25-50 x 104 cells/well. On the day of the experiment, cells were
incubated with the indicated recombinant FSH (11-14 nM) for 2 h, before being washed with PBS
(2x), fixed (4 % formaldehyde in PBS), washed again (PBS) and nuclei stained with Draq5 (Thermo
Scientific). Cells were imaged on a Leica TCS SPE confocal microscope, using GFP (FSHR), dsRed
(BODIPY) or Cy5 (Draq5) filter settings (λex 488, 532 or 635 nm) with optimized detection range
to exclude bleed-through of dye signal in different channels. For competition experiments, cells were
pre-incubated for 1 h with THQ 98 (10 µM), before addition of FSH-BDP-MC (4 nM) to the medium.
For dual uptake experiments, cells were incubated with a combination of small molecule agonist DHP-
Cy5 96 (1 µM) or sortase ligand 40 (3 µM) and FSH-BDP-MC (14 nM) or rFSH (11 nM). Images
were taken under the same settings (laser power, gain, offset, pinhole) and were analyzed using Im-
ageJ. Global fluorescence was determined either for the whole picture or for a specific ROI, which only
included regions with cells present, and corrected for the selected area. Intensities were normalized to
an average of ∼1 for untreated or rFSH-treated cells (GFP signal) or FSH-BDP-MC-treated cells (BO-
DIPY signal), since these can be regarded as positive controls. The percentage of GFP fluorescence
signal on the membranes compared to in the cytoplasm was determined by selection of membranes
(typically 5-7 cells/image that were inside the focal plane) with the brush tool (ROI:’membranes’),
followed by the creation of a ROI that included the selected cells (ROI:’cells’). Two greyscale images
were then tresholded according to Yen, 42 followed by selection of the ’membranes’ ROI in each picture
which was then either cleared (giving ’cytoplasm’) or cleared outside (giving ’membranes’). Fluores-
cence intensities of cells/membranes within the ROI were measured and calculated as a fraction of
total GFP signal (membrane+cytoplasm = 100%). For representative images showing the selected
ROIs, see Chapter 7, Figure 7.5. Colocalization was calculated on background-corrected images using
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Summary, Work in Progress and
Future Prospects
Cell surface receptors function as communication channels between the outside and inside
of the cell. In response to ligand binding and activation, a variety of signaling cascades is
brought into action. In order to prevent overstimulation of the system, this might even-
tually result in endocytosis of the ligand-receptor complex from the cell membrane to in-
tracellular compartments. Besides, some types of receptors recycle constitutively between
the cell membrane and the intracellular environment, independent of ligand activation.
Chapter 1 describes different strategies that make use of synthetic small molecules as tar-
geting devices for cell surface receptors, to either visualize the endocytic processes or to
deliver cargo to an intracellular compartment. Successful examples include certain types
of G protein-coupled receptors, lectin binding receptors and the folate receptor. Receptors
belonging to the first two categories are central to the work described in this thesis.
The mannose receptor (MR) belongs to the family of C-type lectins and is expressed
by immune cells such as dendritic cells (DCs) and macrophages to recognize and capture
pathogens that contain mannosylated glycoproteins on their surface. 1,2 A previous report
by Hillaert et al., described a synthetic mannose containing peptide, termed ’mannose clus-
ter’ (MC), that was used to target the cysteine protease activity-based probe DCG-04 to
DCs, via the mannose receptor. A BODIPY dye was included in the construct to visual-
ize the labeled lysosomal cathepsins. 3 In Chapter 2 this work was extended by the use of
pH-activatable BODIPY dyes, which are quenched at neutral or basic pH and become flu-
orescent once protonated in acidic cellular compartments. 4 Different MC-pH-activatable
BODIPY-DCG-04 constructs were synthesized and evaluated for their in vitro pH-depen-
dency, their ability to bind cathepsins and their in situ fluorescence properties. The con-
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structs were found to have similar pKa-values as the original BODIPY dyes published
by Urano et al. and similar lysate cathepsin labeling as the ’always on’ MC-BDP-DCG-
04 probe. The main advantage of the incorporation of pH-activable BODIPY dyes in the
constructs became apparent by live-cell imaging experiments of dendritic cells incubated
with these probes. Indeed, fluorescence only occurred in intracellular vesicles, without any
background in the medium, enabling real-time visualization of receptor endocytosis and
trafficking. 5
The proven utility of the pH-activatable BODIPY dyes in Chapter 2 prompted the de-
velopment of a novel series of these dyes as described in Chapter 3. With the use of a
Knoevenagel-like condensation reaction, pH-activatable dyes containing an azide, alkyne
or carboxylic acid ligation handle could be synthesized. Double, consecutive, Knoevena-
gel condensation was employed to arrive at asymmetric, bifunctional pH-activatable dyes
that either contained an additional ligation handle or a charged, polar group to increase
water-solubility. These dyes were shown to have similar pH-dependency profiles but red-
shifted absorbance and emission maxima compared to the previously reported dyes, mak-
ing them more suited for imaging applications. 6 An area that could benefit from the use
of pH probes is that of glucosidase profiling. Activity-based probes for the lysosomal en-
zyme β-glucocerebrosidase (GBA1) have been described, based on the cyclophellitol in-
hibitor. 7 Attachment of a pH-activatable BODIPY dye to cyclophellitol would enable selec-
tive visualization of the acidic cellular compartments where GBA1 resides and could poten-
tially be used to ’probe’ the pH of these compartments in normal and diseased (Gaucher)
states. Furthermore, such probes could be used for a detailed study of recombinant GBA1
(Cerezyme) uptake and trafficking along the endolysosomal pathway of Gaucher cells. To
investigate this, a set of pH-activatable BODIPY-cyclophellitol probes 117 were synthesized
(Figure 10.1), based on the BODIPY dyes developed in Chapter 3.
Azido-cyclophellitol was synthesized as previously reported and attached to BODI-
PYs 29a-c,e via Cu(I)-catalyzed click reaction (Figure 10.1A). 7,8 In vitro characterization of
the pH-dependency of these probes showed no alterations compared to the unconjugated
dyes, confirming that attachment of these dyes via their conjugation handles could be done
without changing their pH profile (Figure 10.1B). In addition, in vitro biological evaluation
showed that these probes had comparable potencies for inhibition of GBA1 as the BODIPY-
cyclophellitol probes published by Witte et al. 7 Pre-incubation of recombinant GBA1 with
known inhibitors conditurol B epoxide (CBE), cyclophellitol or BODIPY-cyclophellitol abol-
ished labeling with probes 117, confirming that these bound to the active site of the protein.
Also, labeling of recombinant GBA1 with probes 117 only occurred between pH 3.5 and
pH 7.0, with optimal labeling around pH 5.5, which coincides with the pH activity profile
for GBA1 towards the fluorogenic substrate 4-methylumbelliferyl β-D-glucopyranoside. 7
Thus, potent activity-based pH-activatable probes for GBA1 had been developed which
were put to use in microscopy experiments to visualize endogenous lysosomal GBA1 or
the uptake and trafficking of pre-labeled Cerezyme into the lysosomal pathway of dendritic
cells. These preliminary experiments showed, however, that the in-situ pH-dependency of
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these probes did not correlate to the profiles found in vitro. Fluorescence was predomi-
nantly detected in membranous areas of the cells when these probes were added to cells,
even at 10 nM concentrations. No vesicular staining, characteristic of endolysosomes, was
observed and when binding of the probes to GBA1 was prevented by pre-incubation with
CBE, this resulted in the same fluorescence pattern. Incubation of dendritic cells with pre-
labeled Cerezyme also resulted only in non-specific fluorescence although substoichiomet-
ric amounts of probe were used for labeling to ascertain that no unbound probe was present
in solution. The pH-dependency profiles of these probes in a more complex system such
as a cell or the active site of a protein are clearly not as evident as in a test tube. It is very
well possible that these dyes are ’activated’ by apolar membrane constituents, leading to
the background fluorescence. 9 On the other hand, appropriately positioned acidic or ba-
sic residues in the enzyme’s active site might protonate or deprotonate the BODIPY dye
leading to an increase or decrease in fluorescence which is not correlated to the pH of the
organelle. Similar results were obtained when a pH-activatable dye was used in Chapter
8 illustrating that the in situ pH-dependency should be carefully evaluated for each novel
construct.
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Figure 10.1: A) Structure of (pH-activatable) BODIPY-cyclophellitol probes 117a-d. B) Comparison
of fluorescence intensity vs p[TFA] curves for unconjugated BODIPYs 29b,c,e and probes 117b-d.
In Chapter 4, the mannose cluster was again used as a targeting entity towards mannose-
binding lectins on dendritic cells. However, instead of the delivery of a synthetic activity-
based probe as in Chapter 2, the research in this chapter was aimed at the targeted delivery
of a 70 kDa protein, Heat shock protein 70 (Hsp70). Recombinant Hsp70 with a C-terminal
extension containing a sortase A recognition sequence (LPETGG) and a His-affinity tag,
was expressed and purified to yield Hsp70-LPETGG. Synthetic triglycine nucleophiles con-
taining either a BODIPY dye (GGG-BDP 38) or a BODIPY dye linked to the mannose cluster
(GGG-BDP-MC 40) were synthesized and used for small-scale optimization of the sortase-
mediated ligation. Large scale sortase-mediated ligation of Hsp70-LPETGG and GGG-
BDP-MC was conducted using the optimized conditions, resulting in the formation of
Hsp70-BDP-MC. Repeated chromatography steps were needed for complete removal of
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the excess of nucleophile, which would otherwise interfere in the uptake experiments. Pu-
rified Hsp70-BDP-MC was subsequently shown to be taken up in a mannose-receptor de-
pendent fashion by dendritic cells. Its presence in intracellular vesicles was demonstrated
by fluorescence confocal microscopy. The next step would be to determine what the func-
tional consequences are of targeted delivery of Hsp70 into the endolysosomal pathway.
Hsp70 has been shown to have a stabilizing effect on lysosomes with clinical potential in
the treatment of Niemann Pick disease, a lysosomal storage disorder. 10 It is of great interest
to determine whether the stabilizing effects of Hsp70 also affect other lysosomal enzymes,
such as GBA1. Hsp70-BDP-MC would be an excellent candidate to study this in Gaucher
cells, which are macrophage-like cells that express the mannose receptor. Potential out-
comes of Hsp70-assisted (mutant) GBA1 stabilization include enhanced catalytic activity,
diminished protein turnover resulting in longer half-lifes or increased levels of correctly
folded (and thus catalytically active) protein. The activity of GBA1 could be addressed
with the activity-based cyclophellitol or aziridine probes. 7,11 Lipid analysis of lysosomal
sphingolipids provides an additional means to look at the effects of Hsp70 on GBA1 ac-
tivity. Control experiments with recombinant Hsp70 without the mannose cluster can be
used to measure the additional effects induced by targeted delivery via the mannose recep-
tor. The research described in Chapter 4 should be easily extendable to other proteins, and
sortase-mediated ligation of a synthetic mannose cluster to other proteins might present
an alternative to glycan remodeling for delivery to MR-expressing cells.
Although the research described in Chapters 2 and 4 illustrates the convenience of the
synthetic mannose cluster, it is undisputedly a very artificial ligand compared to natural
occurring mannosides. Whereas the mannose receptor is known for its broad ligand speci-
ficity, 1 other mannose-binding C-type lectins such as DC-SIGN and DC-SIGNR have been
shown to have narrower specificity and a strong preference for high mannose oligosaccha-
rides. 12 Synthetic oligomannosides, containing different amounts of mannoses, could be
used to examine substrate specificity of the different C-type lectins. Furthermore, if taken
up in the endocytic pathway, these could be substrates for lysosomal mannosidases, lead-
ing to degradation of the glycan and subsequent release of the cargo attached to it. In anal-
ogy with the research presented in Chapter 2, three mann=1/3/7-BODIPY-DCG-04 constructs
were synthesized with the aim of targeting mannose-binding C-type lectins present on den-
dritic cells (Figure 10.2A). Lysate labeling experiments showed concentration-dependent
labeling of cathepsins as seen for other DCG-04 derivatives (Figure 10.2B). Both the man3-
(119) and man7-oligomannoside (120) constructs were taken up by dendritic cells, as seen
by confocal microscopy and SDS-PAGE cathepsin labeling (Figure 10.2C). Competition with
mannan abolished the labeling, indicating that uptake was receptor-dependent. The man1-
BDP-DCG-04 construct 118 however was poorly taken up and many aspecific background
bands were detected (data not shown). Further experiments using specific blocking anti-
bodies against the mannose receptor or DC-SIGN are needed to determine which receptor
is responsible for the uptake of the man3- and man7-BDP-DCG-04 compounds.
In Chapter 5 a synthetic route towards the mannose-6-phosphate analogue of the man-
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Figure 10.2: A) Structures of man1-, man3-, and man7-BODIPY-DCG-04. B) Concentration-
dependent labeling of cathepsins with probes 118-120. Mouse liver lysate (10 µg) was labeled
with indicated concentrations of probes at pH 5.5 for 1 h, 37 ◦C, resolved on 12.5% SDS-PAGE
and scanned for fluorescence. C) Confocal fluorescence microscopy analysis of compound 119 up-
take. Mouse immmature dendritic cells were incubated with 1 µM of probe 136 (2 h, 37 ◦C) in the
presence or absence of mannan (3 mg/mL, 1 h, 37 ◦C pre-incubation), washed and imaged.
nose cluster was described. The resulting mannose-6-phosphate cluster (M6PC) was con-
jugated to BODIPY-DCG-04 to study its uptake and trafficking in the endolysosomal path-
way. Introduction of the M6PC did not interfere with cathepsin labeling, as shown by lysate
labeling experiments. Introduction of the phosphates led to the uptake in dendritic cells
via other means than the mannose receptor, since uptake could not be inhibited by addition
of mannan. Furthermore, M6PC-BDP-DCG-04 was taken up by COS cells, a fibroblast-like
cell line, as seen by fluorescence microscopy, flow cytometry and cathepsin labeling experi-
ments, whereas the mannose cluster analogue was inactive. Uptake of M6PC-BDP-DCG-04
in COS cells was shown to be inhibited by addition of mannose-6-phosphate, confirming
that the uptake was mediated by the mannose-6-phosphate receptor. These results indicate
that by a synthetic modification the receptor-binding characteristics of a ligand can be com-
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pletely altered. Glycoengineering of recombinant enzymes, such as already successfully
employed for glucocerebrosidase in Gaucher disease, is a viable method for improved tar-
geting and efficiency of enzyme replacement therapy. Delivery of recombinant enzymes to
various endothelial cells that are affected by Pompe or Fabry disease most likely occurs via
the CI-MPR. Although both the cation-dependent and the cation-independent mannose-
6-phosphate receptors cycle to and from the cell membrane, it has been shown that only
the CI-MPR is able to bind ligands at the surface, because of the pH-dependency for ligand
binding of the CD-MPR. 13,14
Literature examples make use of oxime ligation of a synthetic M6P-bearing oligosac-
charide to recombinant acid α-glucosidase 15,16 or introduction of an IGF-II derived pep-
tide fused to human β-glucoronidase 17 to target these enzymes to the CI-MPR. Sortase-
mediated ligation of a sortagging ligand containing the mannose-6-phosphate cluster might
provide an alternative to these methods in targeting the CI-MPR. In line with the work in
Chapter 4, introduction of the mannose-6-phosphate cluster on Hsp70 would allow for tar-
geted delivery of Hsp70 into Niemann-Pick fibroblast.





















































A potential drawback of the use of mannose-6-phosphate containing ligands is their
susceptibility to dephosphorylation by phosphatases. To prevent this, synthetic M6P ana-
logues have been proposed that retain receptor affinity but are not recognized by dephos-
phorylating enzymes. Of these, the isosteric mannose-6-phosphonate was shown to be the
most promising candidate. 18–22 Synthesis of propargyl mannose-6-phosphonate, followed
by click reaction to the common peptide scaffold of the mannose and mannose-6-phosphate
cluster, would provide a means for the development of a mannose-6-phosphonate clus-
ter with, presumably, the same binding characteristics as the M6PC, but enhanced stabil-
ity. Preliminary experiments in the development of such a cluster have shown that the
anomeric propargyl group, which was installed early in the synthetic route towards propar-
gyl mannose(-6-phosphate), is likely to interfere with the installment of the C-phosphonate
and limits the choice of suitable protective groups. Therefore, a synthetic route where the
propargyl is introduced in a later stage should present a more viable alternative, as shown
192
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in Scheme 10.1. The acetyl protected sugar could be employed directly in the click reac-
tion with resin bound 48, followed by Fmoc removal and coupling with propiolic acid as a
click handle, before cleaving the cluster from the resin. Mild basic hydrolysis of the acetyls
as described for the benzoyls on the mannose-6-phosphate cluster should result in a fully
deprotected mannose-6-phosphonate cluster, containing a click handle for further conju-
gation.
In Chapters 6-9 various approaches towards targeting of the follicle-stimulating hor-
mone receptor (FSHR) were described. The first three chapters concerned the use of low
molecular weight ligands, based on the agonistic dihydropyridine 55 core structure, as tar-
geting ligands, whereas in the last chapter, Chapter 9, the endogenous ligand FSH was
employed. To arrive at potent agonists containing a ligation handle for further conjuga-
tion, a structure-activity relationship (SAR) study was performed in Chapter 6. Evaluation
of the synthesized compounds in a luciferase assay led to the identification of meta-DHP
74a, with PEG spacer length n=3, as the optimal monomeric ligand. Further conjugation
of this ligand to either another copy of the DHP agonist, FSHβ33-53 peptide or fluorescent
BODIPY dye resulted in homo- and hetero-dimeric ligands as well as fluorescent ligands.
Evaluation of these compounds showed that attachment of bulk to the optimized DHP li-
gand was tolerated without big loss in potency. No clear bivalency effect was observed
for the dimeric compounds. Somewhat surprisingly, the monomeric FSHβ33-53 peptides
were inactive in the luciferase assay. A fluorescent analogue of FSHβ33-53 has been used
by Zhang et al. and was shown to be selectively taken up by FSHR expressing cells. In
that study, the naturally occurring cysteine in the sequence was used as the ligation site for
attachment of a FITC dye, whereas this residue was replaced by a serine in the peptides
described in Chapter 6 and an additional propargyl glycine residue was added as a click
handle. 23 The FSHβ33-53 sequence is part of a loop structure in FSHβ which is believed
to play a role in conferring receptor selectivity. 24,25 It would be of interest to use circular
dichroism (CD) to examine the secondary structure of the monomeric peptides 81 as well
as the heterodimeric DHP-FSHβ33-35 ligands. Comparison to the known structural ele-
ments in the wildtype FSHβ33-53 sequence might provide an explanation for the lack of
agonistic activity of compounds 81. 26
In Chapter 7 several fluorescent ligands based on the optimal meta-DHP structure from
Chapter 6 were synthesized and evaluated for their agonistic potencies for the FSHR. It
was shown that both DHP-BODIPY (93) and DHP-Cy5 (96) were low nanomolar potent
agonists for the FHSR, capable of inducing receptor internalization. However, the inter-
nalization properties of the ligands themselves turned out to be highly dependent on the
nature of the fluorophore. Only when the charged and hydrophilic cyanine dye was used
other non-FSHR mediated endocytic processes could be prevented, resulting in the selec-
tive uptake of DHP-Cy5 in cells expressing the FSHR, in an FSHR-mediated fashion. This
selective fluorescent agonist could find its use in the study of internalization and trafficking
of the receptor-ligand complex and as a diagnostic tool to visualize the FSHR on healthy
and tumor cells. Based on the knowledge gained in this chapter, it would be interesting
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to synthesize a Cy5-derivative of low molecular weight antagonist THQ 98. A selective
fluorescent antagonist might find its use in cell-surface receptor visualization, without in-
ducing the biological effects as done by an agonist. Additional in depth pharmacological
experiments with DHP-Cy5 should include a selectivity profile for the FSHR versus the
closely related TSHR or LHR. Also, microscopy experiments at 16 ◦C instead of 4 ◦C to
study receptor binding without internalization are recommended. Immunostaining for
markers of the various endolysosomal compartments together with colocalization analysis
might reveal the intracellular route of the ligand-receptor complex. The use of antagonist
THQ or chlorpromazine in an luciferase assay might give further insight in the action of
these agents on DHP-induced FSHR signaling as opposed to internalization.
Receptor-mediated endocytosis of the fluorescent agonists reported in Chapter 7 opened
up the way for the development of carborane containing analogues described in Chap-
ter 8. Uptake of DHP-fluorophore-carborane constructs in the endolysosomal pathway of
FSHR-expressing cells would provide a means for the selective delivery of a high concen-
tration of boron needed for boron neutron capture therapy (BNCT). Several BODIPY-based
constructs were synthesized, as well as one Cy5 construct. All compounds were agonists
for the FSHR, albeit with slightly lower potencies than their fluorescent counterparts in
Chapter 7. Again, only the Cy5 containing DHP-Cy5-carborane was shown to be taken
up by cells in an FSHR-dependent fashion, although much higher background levels in
non-receptor cells were observed than for DHP-Cy5 96. The highly lipophilic nature of
the carborane cage most likely is at the basis of this result, increasing the lipophilicity
of the construct as a whole. 27 A possible solution for this would be to convert the closo-
carborane cage to its charged nido-analogue, an approach met with success in the develop-
ment of water-soluble carborane-thymidine analogues for BNCT. 28 Alternative cytotoxic
drugs might be attached to the DHP core to ensure their delivery in FSHR-expressing cells.
Examples might include doxorubicin, a DNA intercalating drug of the anthracycline fam-
ily, or paclitaxel, a mitotic inhibitor of the taxane diterpene family. Since the site of action
of these drugs is not within the endolysosomes, the incorporation of a scissile linker that
is cleaved either at acidic pH (e.g. hydrazone, cis-aconityl) or by action of a lysosomal
enzyme (e.g. cathepsin B) might prove essential. 29,30 Although these drugs are both struc-
turally quite different from the cargo that has been introduced onto the DHP ligand in
this thesis, their molecular weights are well within the limits of what could successfully be
attached without loss in potency. Considering their polarities, doxorubicin might be the
best candidate since it is soluble in water (10 mg/mL), in contrast to paclitaxel which is
water-insoluble. 31
Besides its use as a BNCT agent, there has been interest in the carborane cage as a phar-
macophore. Due to its size and lipophilicity ortho-carborane is often used as a mimic for
either a phenyl or an adamantane group. 32–34 Because of its non-classical electron distribu-
tion, the CH-groups are weakly acidic whereas the BH-vertices are considered hydridic in
nature. This allows for the participation of the BH-groups in dihydrogen bonding with typ-
ical proton donors. 33,35,36 Besides, stacking interaction between the acidic C-H hydrogens
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Figure 10.3: Carboranyl derivatives of adamantyl-deoxynojirimicin (MZ-21 and MZ-31), incorporating
different alkyl spacers.
and the aromatic π-system of a benzene ring have been described, providing another means
of a potential favorable interaction between o-carborane and other (bio)molecules. 37,38 The
various functionalized carboranes described in Chapter 8 were an excellent starting point
for the design of bio-active molecules containing a carborane as phenyl or adamantyl mimic.
The first set of compounds were carborane-containing analogues of previously reported a-
damantyl-deoxynojirimicin, a potent inhibitor of the enzymes glucosyl ceramide synthase
(GCS), glucocerebrosidase (GBA1) and β-glucosidase 2 (GBA2) involved in glycospingho-
lipid metabolism. 39 Six different analogues were synthesized, which shared the pentyl-
oxy spacer connected to either D-gluco- or L-ido-deoxynojirimicin (DNJ), but with varying
lengths (n=1-3) of alkyl spacers attached to the o-carborane core (Figure 10.3). Biologi-
cal evalution showed these to be very potent inhibitors of all three enzymes, with similar
trends in enzyme selectivity profiles as observed for adamantyl-DNJs (MZ-21 and MZ-31,
Figure 10.3) but with a smaller influence of the spacer length (data not shown).
In a second example, the carborane cage was introduced as a mimic for a phenyl group
in the proteasome inhibitor bortezomib (Scheme 10.2). This peptide-based inhibitor con-
tains a phenylalanine residue, which, according to the crystal structure of the inhibitor
in the proteasome β1 and β5 subunits, is not involved in binding. 40 A novel synthetic
route towards carboranylalanine was designed based on the asymmetric Strecker reac-
tion, using CsF and TMSCN, on a chiral carborane sulfinimine. 41,42 The abolute stereo-
chemistry of the cyanosulfinamides was established by X-ray crystallography, confirming
the anti-addition of the cyanide with respect to the sulfoxide. Both stereoisomers of Boc-
protected carboranylalanine were readily obtainable in high yields and enantioselectivity
via this route (Scheme 10.2). In situ formation of the activated OSu-ester, followed by re-
action with L-boronoleucine, Boc-removal and TBTU coupling with 2-pyrazinecarboxylic
acid resulted in reasonable yields of bortezomib analogue, "carbortezomib". Competition
experiments between this novel inhibitor and a fluorescently tagged pan-reactive protea-
some activity-based probe (MVB003) 43 showed concentration-dependent inhibition by car-
bortezomib of the proteasome β1 and β5 subunits as well as the immunoproteasome
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analogues β1i and β5i. The epoxomicin-based MVB003 is a covalent, irreversible probe
where (car)bortezomib is a covalent, reversible inhibitor. Upon prolonged exposure of
bortezomib-labeled proteasome to MVB003, the fluorescent signal increased because of
this inequality. It is therefore necessary to use a different assay, such as a fluorogenic sub-
strate assay, to determine the IC50 values of carbortezomib for the different subunits. These
two examples showed that the incorporation of carborane in structurally diverse molecules
can lead to potent bio-active compounds. It would be of interest to use these compounds
in a more complex environment, such as in cells or in organisms, to examine their pharma-
cokinetic and pharmacodynamic properties.


























































Reagents and conditions: [a] n-BuLi, 1-bromo-2,2-dimethoxyethane, Et2O, 96%; [b] i)TBAF, TFA,
THF; ii) 37% HCl, AcOH, 93%; [c] (R)-tert-butylsulfinamide, DCM, 94%; [d] TMSCN, CsF, DMF,
-50 ◦C, 98% overall (dr: 93:7), 48% after crystallization (de: >99%); [e] i) 6M HCl, H2O, ∆; ii)
Boc2O, Et3N, THF/H2O, 85%.
The research described in Chapter 9, employed sortase-mediated ligation to attach flu-
orescent cargo to recombinant FSH-LPETGG. Successful ligation resulted in fluorescent
FSH-BDP-MC, which was shown to be a picomolar potent FSHR agonist in a luciferase
assay and capable of inducing receptor internalization at low nanomolar concentrations.
Bright BODIPY fluorescence was observed inside the cells, colocalized with the GFP signal
of the GFP-tagged receptor. No background was observed in control cells without FSHR,
confirming the selective uptake of this protein together with its receptor. This would thus
present a feasable alternative for the use of the LMW DHP agonist in FSHR visualization
and targeting. Furthermore, because FSH and DHP bind to allosteric binding sites on the
receptor, fluorescent analogues of both could be used in the same experiment as shown in
Figure 9.6, Chapter 9. In the study by van Koppen et al. it was shown that the presence
of DHP Org 214444-0 increased FSH binding to the receptor. 44 It would be of interest to
also conduct a detailed study of internalization kinetics and EC50 values for DHP-Cy5 and
FSH-BDP-MC alone and in combination.
Due to low expression levels of FSH-LPETGG and the presence of free FSHβ-LPETGG
which also contained the His-affinity tag and sortase sequence it was not possible to ob-
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Figure 10.4: N-terminal sortagging using a single chain variant of FSH and depsipeptide 127.
tain a pure FSH-BDP-MC protein preparation. An alternative approach would be to make
use of a single chain variant of FSH, which would circumpass the assembly step and would
therefore result in the presence of only the intact, full-length, protein. 45,46 Single chain vari-
ants, with the C-terminus of FSHβ fused either directly or via a linker sequence to the
N-terminus of FSHα are as active as the heterodimeric protein. 47 The N-β-C-N-α-C con-
formation is based on the notion that the C-terminus of the α-subunit of the glycoprotein
hormones is crucial for receptor binding and activity. 46,48 A sortagging-compatible vari-
ant of a single chain FSH was designed, which contained three additional glycine residues
at the N-terminus of FSHβ allowing for N-terminal sortagging. 49 A depsipeptide sortase
sequence containing both a biotin and BODIPY dye, compound 127, was synthesized as
sortagging partner (Figure 10.4). 50 However, transfection of HEK293 cells with the single
chain construct did not result in any observable protein expression and only proteins of
lower molecular weight were detected, possibly indicative of splice variants. Alternative
expression systems could be considered as well as the incorporation of alternative linker
sequences between the sortase sequence and the N-terminus of FSHβ, which might result





General. All reagents were of commercial grade and used as received unless stated otherwise. Reaction
solvents were of analytical grade and when used under anhydrous conditions stored over flame-dried
3 Å molecular sieves. Dichloromethane was distilled over CaH2 prior to use. Solvents used for column
chromatography were of technical grade and distilled before use. All moisture and oxygen sensitive
reactions were performed under an argon atmosphere. Flash chromatography was performed on silica
gel (Screening Devices BV, 0.04-0.063 mm, 60 Å). Reactions were routinely monitored by TLC analysis
on DC-alufolien (Merck, Kieselgel60, F254) with detection by UV-absorption (254/366 nm) where ap-
plicable and spraying with a solution of (NH4)6Mo7O24 · 4 H2O (25 g/l) and (NH4)4Ce(SO4)4 · 2 H2O
(10 g/l) in 10% sulfuric acid in water followed by charring at ∼150 ◦C. 1H, 13C NMR and 31P spectra
were recorded on a Bruker AV-400 (400 MHz) or Bruker DMX-600 (600 MHz). Chemical shifts are
given in ppm (δ) relative to the residual solvent peak or TMS (0 ppm) as internal standard. Coupling
constants are given in Hz. Peak assignments are based on 2D 1H-COSY and 13C-HSQC NMR exper-
iments. Chloroform was neutralized by filtration over basic Al2O3 before use with t-butyl-protected
phosphates. IR measurements (thin film) were conducted on an IRaffinity-1 apparatus and evaluated
using IRSolutions software (Shimadzu, Kyoto, Japan). LC-MS measurements were conducted on a
Thermo Finnigan LCQ Advantage MAX ion-trap mass spectrometer (ESI+) coupled to a Surveyor
HPLC system (Thermo Finnigan) equipped with a standard C18 (Gemini, 4.6 mmD x 50 mmL, 5µ
particle size, Phenomenex) analytical column and buffers A: H2O, B: ACN, C: 0.1% aq.TFA. High
resolution mass spectra were recorded on a LTQ Orbitrap (Thermo Finnigan) mass spectrometer
equipped with an electronspray ion source in positive mode (source voltage 3.5 kV, sheath gas flow
10 mL min−1, capillary temperature 250 ◦C) with resolution R=60000 at m/z 400 (mass range
m/z=150-2000) and dioctylphtalate (m/z = 391.28428) as a "lock mass". The high resolution mass
spectrometer was calibrated prior to measurements with a calibration mixture (Thermo Finnigan). For
reversed-phase HPLC purification of the final compounds an automated HPLC system equipped with a
C18 semiprep column (Gemini C18, 250x10 mm, 5µ particle size, Phenomenex) was used. HPLC-MS
purifications were performed on an Agilent Technologies 1200 series automated HPLC system with a
Quadropole MS 6130, equipped with a semi-preparative Gemini C18 column (Phenomenex, 250x10,
5µ particle size). Optical rotations were measured on a Propol automatic polarimeter (Sodium D-















General procedure for the synthesis of (pH-activatable) BODIPY-
cyclophellitol (117a-d).
Azidocyclophellitol (1 eq) and BODIPY-alkyne 29 (1 eq) were dis-
solved in t-BuOH/toluene/H2O (1-2 mL, 1:1:1, v/v/v) and sonicated
for 30 min under argon. CuSO4 (0.1 eq, 100 mM in H2O) and sodium
ascorbate (0.15 eq, 100 mM in H2O) were added and the mixture was
heated to 80 ◦C. After 2 h an additional amount of CuSO4 (0.1 eq)
and sodium ascorbate (0.15 eq) were added. After 2 h the mixture
was concentrated in vacuo and co-evaporated with toluene. HPLC-
MS purification and lyophilizing from t-BuOH/H2O resulted in 117a-d
as purple powders. R f = 0.35 (9:1 DCM:MeOH).
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’always on’-BODIPY-cyclophellitol (117a). Yield: 2.74 mg, 4.1 µmol, 26%. 1H NMR (600 MHz,
MeOD): δ 8.13 (s, 1H, CHtrz), 7.57 (dd, J = 7.4, 5.0 Hz, 5H, 5 x CHar), 7.50 (d, J = 16.2 Hz, 1H,
CH=), 7.38 - 7.30 (m, 3H, CH=, 2 x CHar), 7.07 (d, J = 8.8 Hz, 2H, 2 x CHar), 6.75 (s, 1H, CH),
6.08 (s, 1H, CH), 5.24 (s, 1H, OCH2), 4.67 (dd, J = 13.9, 8.6 Hz, 2H, NCH2), 3.62 (d, J = 8.2 Hz,
1H, CH), 3.24 (dd, J = 10.0, 8.2 Hz, 1H, CH), 3.15 (t, J = 9.8 Hz, 1H, CH), 3.07 - 3.00 (m, 2H,
2 x CH), 2.53 (s, 3H, CH3), 2.42 (td, J = 9.2, 8.5, 4.5 Hz, 1H, CH), 1.46 (s, 3H, CH3), 1.42 (s,
3H, CH3).
13C NMR (151 MHz, MeOD): δ 160.69, 155.86, 154.79, 144.84, 144.16, 143.78, 141.83,
137.34, 136.39, 133.93, 132.80, 131.34, 130.40, 130.25, 129.90, 129.50, 126.38, 122.12, 118.69,
118.07, 116.43, 116.33, 78.23, 72.53, 68.70, 62.49, 57.59, 55.44, 50.96, 44.68, 14.78, 14.64, 14.53.
ESI-HRMS (m/z): calcd. for [C36H36BF2N5O5 + H]
+ 668.28503; obsd. 668.28553.
pH-activatable BODIPY-cyclophellitol (117b). Yield: 5.44 mg, 7.66 µmol, 30%. 1H NMR (600
MHz, MeOD): δ 8.15 (s, 1H, CHtrz), 7.56 (d, J = 8.7 Hz, 2H, 2 x CHar), 7.49 (d, J = 16.3 Hz, 1H,
1x CH=), 7.33 (d, J = 16.4 Hz, 1H, 1x CH=), 7.11 (d, J = 8.6 Hz, 2H, 2 x CHar), 7.07 (d, J = 8.7
Hz, 2H, 2 x CHar), 6.91 (d, J = 8.6 Hz, 2H, 2 x CHar), 6.74 (s, 1H, CH), 6.07 (s, 1H, CH), 5.24 (s,
2H, OCH2), 4.87 (dd, J = 13.8, 3.8 Hz, 1H, NCH2-H
a), 4.67 (dd, J = 13.9, 8.6 Hz, 1H, NCH2-H
b),
3.62 (d, J = 8.2 Hz, 1H, CH), 3.26 - 3.20 (m, 1H, CH), 3.14 (t, J = 9.8 Hz, 1H, CH), 3.03 (d, J =
6.3 Hz, 8H, 2 x CH, 2 x NCH3), 2.52 (s, 3H, CH3), 2.42 (td, J = 9.2, 8.7, 2.5 Hz, 1H, CH), 1.57
(s, 3H, CH3), 1.52 (s, 3H, CH3).
13C NMR (151 MHz, MeOD): δ 160.56, 155.31, 154.13, 152.61,
144.86, 144.22, 143.96, 143.37, 136.73, 134.64, 133.59, 131.45, 130.11 , 129.79, 126.37, 123.37,
121.81, 118.29, 116.42, 113.69, 78.23, 72.53, 68.69, 62.49, 57.58, 55.45, 50.95, 44.67, 40.55, 15.07,
14.84, 14.62. FT-IR (thin film) v 3300.0, 1599.8, 1539.5, 1505.8 cm−1. LC/MS analysis (linear
gradient 10 → 90% ACN) tR : 7.80 min, ESI-MS (m/z): [M + H]+: 711.33. ESI-HRMS (m/z):
calcd. for [C38H41BF2N6O5 + H]
+ 711.32723; obsd. 711.32738.
pH-activatable BODIPY-cyclophellitol (117c). Yield: 2.43 mg, 3.35 µmol, 18%. 1H NMR (600
MHz, MeOD): δ 8.15 (s, 1H, CHtrz), 7.56 (d, J = 8.7 Hz, 2H, 2 x CHar), 7.49 (d, J = 16.4 Hz, 1H,
CH=), 7.32 (d, J = 16.3 Hz, 1H, CH=), 7.08 (dd, J = 11.3, 8.7 Hz, 4H, 4 x CHar), 6.89 (d, J = 8.7
Hz, 2H, 2 x CHar), 6.74 (s, 1H, CH), 6.07 (s, 1H, CH), 5.24 (s, 2H, OCH2), 4.87 (dd, J = 13.9, 3.8
Hz, 1H, NCH2-H
a), 4.67 (dd, J = 13.9, 8.6 Hz, 1H, NCH2-H
b), 3.62 (d, J = 8.2 Hz, 1H, CH), 3.51
(q, J = 7.0 Hz, 2H, CH2), 3.24 (dd, J = 9.9, 8.2 Hz, 1H, CH), 3.14 (t, J = 9.9 Hz, 1H, CH), 3.04
(q, J = 3.8 Hz, 2H, 2 x CH), 2.99 (s, 3H, NCH3), 2.52 (s, 3H, CH3), 2.42 (td, J = 9.8, 4.3 Hz, 1H,
CH), 1.58 (s, 3H, CH3), 1.54 (s, 3H, CH3), 1.16 (t, J = 7.0 Hz, 3H, CH3).
13C NMR (151 MHz,
MeOD): δ 160.56, 155.27, 154.09, 151.14, 144.87, 144.21, 143.97, 143.49, 136.69, 134.67, 133.62,
131.46, 130.23, 129.79, 126.37, 122.92, 121.80, 118.28, 116.42, 113.63, 78.24, 72.53, 68.70, 62.49,
57.59, 55.45, 50.96, 47.61, 44.68, 37.72, 15.08, 14.84, 14.61, 11.22. FT-IR (thin film) v 3025.7,
2362.3, 1600.6, 1539.2, 1158.8, 1065.7 cm−1. LC/MS analysis (linear gradient 10 → 90% ACN) tR :
7.21 min, ESI-MS (m/z): [M + H]+: 725.33. ESI-HRMS (m/z): calcd. for [C39H43BF2N6O5 +
H]+ 725.34288; obsd. 725.34305.
pH-activatable BODIPY-cyclophellitol (117d). Yield:3.46 mg, 4.68 µmol, 14%. 1H NMR (600
MHz, MeOD): δ 8.13 (s, 1H, CHtrz), 7.55 (d, J = 8.7 Hz, 2H, 2 x CHar), 7.49 (d, J = 16.3 Hz, 1H,
CH=), 7.31 (d, J = 16.3 Hz, 1H, CH=), 7.06 (dd, J = 8.8, 3.2 Hz, 4H, 4 x CHar), 6.85 (d, J =
8.7 Hz, 2H, 2 x CHar), 6.72 (s, 1H, CH), 6.06 (s, 1H, CH), 5.23 (s, 2H, OCH2), 4.67 (dd, J = 13.9,
8.6 Hz, 2H, NCH2), 3.62 (d, J = 8.1 Hz, 1H, CH), 3.45 (q, J = 7.0 Hz, 4H, 2 x CH2), 3.24 (dd, J
= 9.9, 8.2 Hz, 1H, CH), 3.15 (t, J = 9.8 Hz, 1H, CH), 3.04 (d, J = 3.7 Hz, 2H, 2 x CH), 2.52 (s,
3H, CH3), 2.42 (td, J = 9.1, 8.6, 4.4 Hz, 1H, CH), 1.60 (s, 3H, CH3), 1.56 (s, 3H, CH3), 1.20 (t,
J = 7.0 Hz, 6H, 2 x CH3).
13C NMR (151 MHz, MeOD): δ 160.54, 155.20, 154.03, 149.80, 144.87,
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144.21, 143.97, 143.62, 136.63, 134.70, 133.65, 131.47, 130.34, 129.78, 126.37, 122.32, 121.78,
118.26, 116.41, 113.22, 78.23, 72.53, 68.70, 62.49, 57.59, 55.45, 50.95, 45.35, 44.67, 31.12, 15.11,
14.88, 14.62, 12.71. FT-IR (thin film) v 1653.9, 1506.0 cm−1. LC/MS analysis (linear gradient
10 → 90% ACN) tR : 6.62 min, ESI-MS (m/z): [M + H]+:739.47. ESI-HRMS (m/z): calcd. for
[C40H45BF2N6O5 + H]
+ 739.35853; obsd. 739.35866.
Synthesis of Man1-BODIPY-DCG-04 (118). Propargyl mannose (1.75 mg, 8 µmol) and BODIPY-
DCG-04 22 (8.6 mg, 7.6 µmol) were dissolved in DMF/H2O (3 mL, 1:1 v/v) and sodium ascorbate
(160 µL, 100 mM in H2O, 2 eq) and CuSO4 (16 µL, 100 mM in H2O, 0.2 eq) were added. The re-
sulting mixture was stirred for 2 h at room temperature, before being concentrated and co-evaporated
with toluene. Purification by HPLC-MS (A: 25 mM NH4OAc, B: linear gradient 20 → 35% ACN in
12’) and lyophilization from H2O yielded the final compound (4.3 mg, 3.2 µmol, 42%). R f = 0.9
(2:1 DCM:MeOH) 1H NMR (600 MHz, CDCl3/MeOD): δ 8.02 (s, 1H, CHtrz), 7.92 (t, J = 5.6 Hz,
1H, NH), 7.86 (d, J = 7.5 Hz, 2H, 2 x CHar), 7.83 (d, J = 7.6 Hz, 1H, NH), 7.76 (t, J = 5.6 Hz,
1H, NH), 7.40 (s, 1H, CHar), 7.06 (d, J = 4.1 Hz, 1H, CHar), 7.01 (d, J = 8.5 Hz, 2H, 2 x CHar),
6.95 (d, J = 8.9 Hz, 2H, 2 x CHar), 6.69 (d, J = 8.5 Hz, 2H, 2 x CHar), 6.59 (d, J = 4.1 Hz, 1H,
CHar), 4.80 (d, J = 12.4 Hz, 1H, CH2-H
a), 4.67 - 4.60 (m, 3H, CH2, CH2-H
b), 4.45 (t, J = 7.5 Hz,
1H, CH), 4.40 - 4.36 (m, 1H, CH), 4.30 - 4.19 (m, 3H, CH2, CH), 4.08 (t, J = 5.8 Hz, 2H, CH2),
3.85 (dd, J = 11.8, 2.1 Hz, 1H, CH2-H
a), 3.82 - 3.77 (m, 1H, CH), 3.74 - 3.65 (m, 3H, CH2-H
b, 2 x
CH), 3.64 - 3.55 (m, 3H, 3 x CH), 3.15 - 3.11 (m, 3H,CH2, CH2-H
a), 3.06 - 3.01 (m, 1H, CH2-H
b),
2.99 - 2.93 (m, 1H, CH2-H
a), 2.86 - 2.80 (m, 1H, CH2-H
b), 2.75 (t, J = 7.4 Hz, 2H, CH2), 2.50
(s, 3H, CH3), 2.42 (p, J = 6.5 Hz, 2H, CH2), 2.33 (t, J = 7.3 Hz, 2H, CH2), 2.25 (s, 3H, CH3),
2.21 - 2.16 (m, 2H, CH2), 1.78 - 1.69 (m, 1H, CH2-H
a), 1.62 - 1.48 (m, 6H, 2 x CH2, CH2-H
b, CH),
1.46 - 1.41 (m, 2H, CH2), 1.41 - 1.35 (m, 2H, CH2), 1.31 - 1.29 (m, 5H, CH2, CH3), 1.22 - 1.15
(m, 2H, CH2), 0.92 (d, J = 6.4 Hz, 3H, CH3), 0.88 (d, J = 6.4 Hz, 3H, CH3).
13C NMR (151
MHz, CDCl3/MeOD): δ 177.02, 176.02, 174.68, 173.56, 172.96, 168.66, 168.31, 160.68, 160.59,
157.16, 156.37, 145.22, 141.69, 136.49, 135.67, 131.84, 131.81, 131.78, 131.68, 131.30, 129.27,
128.81, 127.14, 125.60, 124.63, 119.12, 116.19, 115.14, 100.70, 74.84, 72.42, 71.93, 68.54, 65.67,
63.19, 62.90, 60.64, 56.36, 54.34, 54.11, 53.33, 53.14, 48.49, 41.56, 40.15, 40.12, 38.14, 36.86,
36.58, 32.64, 30.93, 29.87, 29.74, 27.32, 26.39, 25.80, 24.17, 23.29, 22.02, 21.29, 14.35, 13.28,
9.62. ESI-HRMS (m/z): calcd. for [C65H88BF2N11O17 + H]
+ 1344.64935; obsd. 1344.65139.
Synthesis of Man3-BODIPY-DCG-04 (119). Man3-propargyl (2.4 mg, 4.5 µmol) and BODIPY-
DCG-04 22 (5.12 mg, 4.5 µmol) were dissolved in DMF/H2O (2 mL) and sodium ascorbate (90 µL,
100 mM in H2O, 2 eq) and CuSO4 (2.2 µL, 100 mM in H2O, 0.5 eq) were added. The resulting
mixture was stirred for 1 h at room temperature, before being concentrated and co-evaporated with
toluene. Purification by HPLC-MS (A: 25 mM NH4OAc, B: linear gradient 20 → 35% ACN in 12’)
and lyophilization from H2O yielded the final compound (1.8 mg, 1.1 µmol, 24 %). R f = 0.25 (1:1
DCM:MeOH). 1H NMR (600 MHz, MeOD): δ 8.08 (s, 1H, CHtrz), 7.88 (d, J = 8.9 Hz, 2H, 2 x
CHar), 7.43 (s, 1H, CHar), 7.07 (d, J = 4.0 Hz, 1H, CHar), 7.01 (d, J = 8.5 Hz, 2H, 2 x CHar), 6.97
(d, J = 8.9 Hz, 2H, 2 x CHar), 6.69 (d, J = 8.5 Hz, 2H, 2 x CHar), 6.62 (d, J = 4.1 Hz, 1H, CHar),
5.05 (s, 1H, CH), 4.85 - 4.77 (m, 3H, CH2-H
a, 2 x CH), 4.69 - 4.61 (m, 3H, CH2, CH2-H
b), 4.45
(t, J = 7.6 Hz, 1H, CH), 4.38 (dd, J = 9.3, 5.7 Hz, 1H, CH), 4.29 - 4.23 (m, 3H, CH2, CH), 4.09
(t, J = 5.9 Hz, 2H, CH2), 4.05 (d, J = 2.5 Hz, 1H, CH), 3.98 - 3.90 (m, 2H, CH2-H
a, CH), 3.88 -
3.54 (m, 17H, CH2-H
b, 2 x CH2, 12 x CH), 3.16 - 3.09 (m, 3H, CH2, CH2-H
a), 3.07 - 2.99 (m, 1H,
CH2-H
b), 2.99 - 2.93 (m, 1H, CH2-H
a), 2.86 - 2.80 (m, 1H, CH2-H
b), 2.76 (t, J = 7.3 Hz, 2H, CH2),
2.51 (s, 3H, CH3), 2.42 (p, J = 6.5 Hz, 2H, CH2), 2.33 (t, J = 7.3 Hz, 2H, CH2), 2.26 (s, 3H, CH3),
2.20 - 2.14 (m, 2H, CH2), 1.77 - 1.70 (m, 1H, CH2-H
a), 1.64 - 1.47 (m, 6H,2 x CH2, CH2-H
b, CH),
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1.47 - 1.41 (m, 2H, CH2), 1.41 - 1.35 (m, 2H, CH2), 1.32 - 1.29 (m, 5H,CH2, CH3), 1.20 - 1.15 (m,
2H, CH2), 0.92 (d, J = 6.4 Hz, 3H, CH3), 0.88 (d, J = 6.4 Hz, 3H, CH3).
13C NMR (151 MHz,
MeOD): δ 177.14, 176.13, 174.79, 173.69, 173.08, 168.74, 168.43, 165.61, 163.01, 160.81, 160.67,
157.29, 156.48, 150.29, 145.18, 142.19, 136.59, 135.75, 131.90, 131.77, 131.36, 129.35, 128.91,
127.23, 125.71, 124.73, 119.16, 116.24, 115.22, 103.97, 101.33, 100.79, 80.67, 74.96, 74.39, 73.70,
72.66, 72.46, 72.10, 71.27, 68.80, 68.64, 67.48, 67.14, 65.75, 63.23, 62.91, 60.71, 56.47, 54.38,
54.21, 53.42, 53.19, 41.62, 40.20, 38.19, 36.91, 36.63, 32.71, 31.05, 29.95, 29.82, 27.40, 26.48,
25.88, 24.25, 23.30, 22.02, 21.34, 14.35, 9.59. LC/MS analysis (linear gradient 10% → 90% ACN)
tR : 6.53 min, ESI-MS (m/z): [M + H]+: 1668.40.
Synthesis of Man7-BODIPY-DCG-04 (120). Man7-propargyl (4 mg, 3.4 µmol)and BODIPY-DCG-
04 22 (3.8 mg, 3.4 µmol) were dissolved in H2O/DMF (2 mL, 1:1 v/v) followed by addition of sodium
ascorbate (68 µL, 100 mM in H2O, 2 eq) and CuSO4 (6.8 µL, 100 mM in H2O, 0.2 eq). The resulting
mixture was stirred for 8 h at room temperature, before being concentrated and co-evaporated with
toluene. Purification by HPLC-MS (A: 25 mM NH4OAc, B: linear gradient 20 → 35% ACN in 12’)
and lyophilization from H2O yielded man7-BDP-DCG-04 (2.5 mg, 1.1 µmol, 32%). R f = 0.4 (1:1:1:1
EtOAc: H2O: n-BuOH: AcOH).
1H NMR (600 MHz, MeOD): δ 8.28 (s, 1H), 8.09 (d, J = 8.1 Hz,
1H), 7.95 (s, 1H), 7.90 - 7.85 (m, 2H), 7.79 (t, J = 5.6 Hz, 1H), 7.42 (s, 1H), 7.07 (d, J = 4.1 Hz,
1H), 7.01 (d, J = 8.5 Hz, 2H), 6.98 (d, J = 8.9 Hz, 2H), 6.69 (d, J = 8.5 Hz, 2H), 6.62 (d, J =
4.1 Hz, 1H), 5.11 (s, 1H), 5.07 (s, 1H), 4.99 (s, 1H), 4.81 - 4.64 (m, 8H), 4.50 - 4.43 (m, 1H), 4.41
- 4.36 (m, 1H), 4.31 - 4.23 (m, 3H), 4.19 (d, J = 2.8 Hz, 1H), 4.12 - 4.07 (m, 4H), 4.03 - 3.53 (m,
41H), 3.16 - 3.10 (m, 3H), 3.07 - 3.02 (m, 1H), 3.00 - 2.94 (m, 1H), 2.88 - 2.80 (m, 1H), 2.76 (t,
J = 7.3 Hz, 2H), 2.51 (s, 3H), 2.44 (q, J = 6.4 Hz, 2H), 2.34 (t, J = 7.2 Hz, 2H), 2.26 (s, 3H),
2.21 - 2.17 (m, 2H), 1.78 - 1.71 (m, 1H), 1.66 - 1.47 (m, 6H), 1.47 - 1.41 (m, 2H), 1.41 - 1.36 (m,
2H), 1.33 - 1.28 (m, 5H), 1.23 - 1.17 (m, 2H), 0.92 (d, J = 6.4 Hz, 3H), 0.88 (d, J = 6.4 Hz, 3H).
ESI-HRMS (m/z): calcd. for [C101H148BF2N11O47 + H]







methoxyethane (121). To a solution of TBDMS-carborane 101 (4.27 g, 16.5
mmol, 1 eq) in Et2O (60 mL) was added n-BuLi (2.5 M in hexane, 7.9 mL, 19.8
mmol, 1.2 eq) at rt under an argon atmosphere. The solution was stirred for 1.5
h turning from colourless to yellow. The mixture was cooled to 0 ◦C after which
2-bromo-1,1-dimethoxyethane (2.9 mL, 24.8 mmol, 1.5 eq) was added and the solution was stirred
for 16 h at rt. After addition of water (200 mL), the aqueous layer was extracted with Et2O (3 x
200 mL) and the combined organic layers were washed with brine (1 x 500 mL). The organic phase
was dried over MgSO4, filtered and concentrated in vacuo. Flash column chromatography (100%
pentane → 8% EtOAc in pentane) yielded acetal 121 as a colourless oil (5.47 g, 15.7 mmol, 96%).
R f = 0.6 (19:1 pentane:EtOAc). 1H NMR (400 MHz, CDCl3): δ 4.42 (t, J = 5.0 Hz, 1H, CH), 3.31
(s, 6H, 2 x OCH3), 2.47 (d, J = 5.0 Hz, 2H, CH2), 3.18 - 1.44 (m, 10H, BH), 1.07 (s, 9H, 3 x CH3),
0.33 (s, 6H, 2 x CH3).
13C NMR (101 MHz, CDCl3): δ 103.11, 77.43, 76.10, 53.44, 41.48, 27.66,
20.45, -2.32. 11B NMR (128 MHz, CDCl3): δ 0.34, -3.42, -7.32, -10.18. FT-IR (thin film) v 2953,
2934, 2864, 2610, 2567 (B-H), 1474, 1465, 1446, 1395, 1383, 1365, 1257, 1190, 1120, 1084, 1057,
941, 930, 910, 876, 837, 818, 794, 775, 731 cm−1. ESI-HRMS (m/z): calcd. for [C12H34B10O2Si +
CH3CN + H]








2-(1’,2’-Dicarba-closo-dodecaboranyl)-ethanal (122). Acetal 121 (5.47 g, 15.7
mmol, 1 eq) was dissolved in THF (60 mL) and cooled to -78 ◦C under an argon
atmosphere. TFA (1.17 mL, 15.7 mmol, 1 eq) was added followed by the dropwise
addition of TBAF (1 M in THF, 18.8 mL, 18.8 mmol, 1.2 eq). The mixture was
allowed to warm up for 1 h, after which the cooling bath was removed and stirring
was continued at rt. After 3 h TLC showed complete conversion of the starting material and water
(200 mL) was added. The aqueous layer was extracted with Et2O (2 x 200 mL). The combined
organic layers were washed with brine (1 x 400 mL), dried over MgSO4, filtered and concentrated.
The deprotected carborane was dissolved in 25 mL AcOH at rt under and argon atmosphere and HCl
(37% v/v in water, 3.9 mL, 47.1 mmol, 3 eq.) was added carefully. TLC showed complete conversion
after 3 h and after the addition of toluene (100 mL), the mixture was concentrated to dryness under
reduced pressure. Water (100 mL) was added and extracted with Et2O (2 x 100 mL). The combined
organic layers were washed with sat. aq. NaHCO3 (1 x 200 mL), brine (1 x 200 mL), dried over
MgSO4, filtered and concentrated in vacuo. Flash column chromatography (10% → 40% EtOAc in
pentane) afforded aldehyde 122 as a colourless oil (2.69 g, 14.4 mmol, 92%). Deprotected acetal:
R f = 0.6; aldehyde: R f = 0.3 (9:1 pentane:EtOAc). FT-IR (thin film) v 3059 (BC-H), 2572 (B-H),
1726 (C=O), 1395, 1244, 1124, 1079, 1044, 1018, 1000, 959, 943, 940, 908, 881, 722 cm−1. 1H
NMR (400 MHz, CDCl3): δ 9.57 (t, J = 1.9 Hz, 1H, O=CH), 4.17 (s, 1H, BCH), 3.29 (d, J = 1.8
Hz, 2H, CH2), 3.07 - 1.48 (m, 10H, BH).
13C NMR (101 MHz, CDCl3): δ 194.53, 67.44, 60.20,
48.29. 11B NMR (128 MHz, CDCl3): δ -2.06, -4.64, -8.91, -11.08, -12.69. ESI-HRMS (m/z): calcd.
for [C4H14B10O + CH3CN + H2O + H]









amide (123). To a solution of aldehyde 122 (0.96 g, 5.18 mmol, 1 eq) in DCM
(30 mL) was added (R)-tert-butylsulfinamide (0.69 g, 5.7 mmol, 1.1 eq) and
anhydrous CuSO4 (2.7 g, 16.6 mmol, 3.2 eq.) at rt under an argon atmosphere
for 16 h. The suspension was vacuum filtrated over a Whatman cellulose filter,
washed with DCM and concentrated under reduced pressure. Flash column chromatography (10%
→ 50% EtOAc in pentane) afforded sulfinimine 123 as a white powder (1.41 g, 4.88 mmol, 94%).
mp 143-145 ◦C. R f = 0.8 (1:3 pentane:EtOAc). [α]20D = -231.4
◦(c = 1.0, DCM). FT-IR (thin film)
v 3028 (BC-H), 2978, 2966, 2590, 2581 (B-H), 1627 (N=H), 1472, 1455, 1428, 1393, 1365, 1181,
1099, 1057, 1019, 995, 723, 704 cm−1. 1H NMR (400 MHz, CDCl3): δ 7.93 (t, J = 5.3 Hz, 1H,
N=CH), 3.84 (s, 1H, BCH), 3.54 - 3.29 (m, 2H, CH2), 3.16 - 1.48 (m, 10H, BH), 1.21 (s, 9H, 3 x
CH3).
13C NMR (101 MHz, CDCl3): δ 162.29, 69.85, 60.55, 57.73, 42.69, 22.55.
11B NMR (128
MHz, CDCl3): δ -1.82, -4.92, -8.87, -11.31, -12.69. ESI-HRMS (m/z): calcd. for [C8H23B10NOS +










(Rs) -(+) -N-[(S)-1-cyano-2-(1’,2’-dicarba-closo-dodecaboranyl)ethyl] -tert -
butylsulfinamide (124). Sulfinimine 123 (1.01 g, 3.50 mmol, 1 eq) was dissolved
in DMF (18 mL) and cooled to -50 ◦C under an argon atmosphere. CsF (0.69
g, 4.60 mmol, 1.3 eq.) was added, followed by the dropwise addition of TMSCN
(0.57 mL, 4.60 mmol, 1.3 eq.). The mixture turned bright yellow and stirring
was continued at -50 ◦C. After 24 h additional TMSCN (0.13 mL, 1.10 mmol, 0.3 eq) was added
and stirring was continued at -50 ◦C for 60 h. TMSCN (0.3 eq) was added two times more after 92
h and 97 h until TLC showed complete conversion of the starting material after 99 h. The reaction
was quenched with a sat. aq. NH4Cl solution (30 mL) and water (60 mL) was added. The aqueous
layer was extracted with EtOAc (3 x 100 mL) and the combined organic layers were washed with
brine (1 x 300 mL), dried over MgSO4, filtered and concentrated in vacuo. The product was co-
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evaporated three times with toluene to remove leftover DMF which gave cyanosulfinamide 124 as an
orange/yellow solid which was pure according to 1H-NMR analysis in a diastereomeric ratio of 93:7
(1.09 g, 3.43 mmol, 98%). Recrystallization from EtOH/pentane at -20 ◦C afforded cyanosulfinamide
124 as yellow crystals (0.54 g, 1.69 mmol, 48%) as a single diastereomer (de > 99%). mp 170 ◦C. R f
= 0.5 (1:1 pentane: EtOAc). [α]20
D
= -59.4◦(c = 2.2, MeOH). FT-IR (thin film) v 3451, 3400, 3059
(BC-H), 2982, 2573 (B-H), 2319, 2071, 1471, 1456, 1439, 1366, 1118, 1024, 986, 907, 880, 851,
825, 795, 723 cm−1. 1H NMR (400 MHz, MeOD): δ 4.70 (s, 1H, BCH), 4.50 (dd, J = 9.1, 5.0 Hz,
1H, CH), 3.00 (dd, J = 15.4, 9.2 Hz, 1H, CH2-H
a), 2.89 (dd, J = 15.4, 5.0 Hz, 1H, CH2-H
b), 3.20
- 1.47 (m, 10H, BH), 1.25 (s, 9H, 3 x CH3).
13C NMR (101 MHz, MeOD): δ 119.17, 72.15, 63.68,
58.21, 48.03, 42.18, 22.68. 11B NMR (128 MHz, MeOD): δ -2.36, -4.97, -9.33, -11.71, -12.71.
ESI-HRMS (m/z): calcd. for [C9H24B10N2OS + H]






(S)-(-)-N-Boc-o-Carboranylalanine(125). Cyanosulfinamide 124 (520 mg, 1.64
mmol, 1 eq) was dissolved in 6 M HCl (aq., 6 mL) at rt and refluxed for 4.5 h.
The mixture was co-evaporated three times with toluene to remove all solvent to
afford the unprotected amino acid as the HCl salt. Subsequently, the amino acid
was redissolved in THF/water (6 mL, 1:1, v/v) at rt under an argon atmosphere
and Boc2O (536 mg, 2.46 mmol, 1.5 equiv.) and Et3N (0.92 mL, 6.56 mmol, 4 eq) were added and
the mixture was stirred for 16 h. The solvent was removed under reduced pressure and co-evaporated
with toluene (3x). Flash column chromatography (100% EtOAc → 30% MeOH in EtOAc) gave the
Boc-protected amino acid as an off-white powder (462 mg, 1.39, 85%). R f = 0.3 (EtOAc + 3 drops
AcOH). [α]20
D
= -19.7◦(c = 2.3, MeOH). FT-IR (thin film) v 3061 (BC-H), 2981, 2932, 2585 (B-H),
1716 (C=O), 1511, 1395, 1370, 1290, 1255, 1158, 1069, 1022, 851, 781, 725 cm−1. 1H NMR (400
MHz, MeOD): δ 4.52 (s, 1H, BCH), 4.15 (d, J = 8.8 Hz, 1H, CHα), 2.92 (d, J = 15.2 Hz, 1H,
CH2-H
a), 2.64 (dd, J = 15.0, 10.6 Hz, 1H, CH2-H
b), 3.14 - 1.56 (m, 10H, BH), 1.46 (s, 9H, 3 x CH3).
13C NMR (101 MHz, MeOD): δ 157.67, 80.90, 74.51, 63.18, 54.60, 39.55, 28.71. 11B NMR (128
MHz, MeOD): δ -2.64, -5.55, -9.57, -11.40, -13.00.ESI-HRMS (m/z): calcd. for [C10H25B10NO4 +
CH3CN + H]
+ 373.31250; obsd. 373.31299.
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Een chemisch biologische aanpak voor doelgerichte
ligand-medicijn constructen
Membraangebonden receptoren aan de buitenkant van een cel functioneren als een com-
municatiekanaal tussen de intra- en extracellulaire ruimte. Als een receptor wordt geac-
tiveerd door binding van een ligand, leidt dit tot een scala aan intracellulaire signaler-
ingscascades. Om te voorkomen dat de cel te sterk gestimuleerd raakt, kan het ligand-
receptor complex geïnternaliseerd worden, van de membraan naar intracellulaire compar-
timenten. Synthetische liganden die selectief kunnen binden aan een bepaald type receptor
kunnen potentieel ingezet worden om een fluorescent molecuul of een medicijn te sturen
naar de cel van interesse. In hoofdstuk 1 worden verschillende strategieën besproken voor
het gebruik van synthetische liganden voor receptoren. Deze liganden worden ofwel ge-
bruikt voor visualisatie van ligand binding en het transport van het ligand-receptor com-
plex door de cel, ofwel om doelgerichte therapie mogelijk te maken.
De mannose receptor (MR) behoort tot de familie van C-type lectine-bindende recep-
toren en wordt tot expressie gebracht door cellen van het immuunsysteem, zoals den-
dritische cellen en macrofagen. Glycoeiwitten op pathogenen worden herkend door de
MR en vervolgens geïnternaliseerd en afgebroken, wat leidt tot een immuunrespons. In
een eerdere studie is een synthetisch ligand beschreven, het zogenaamde mannose cluster
(MC), dat kan binden aan de MR. Dit cluster is vastgemaakt aan een fluorescente remmer
van lysosomale cathepsines (BODIPY-DCG-04) en dit leidde tot de selectieve opname van
het construct in dendritische cellen. In hoofdstuk 2 wordt op dit onderzoek voortgebor-
duurd met de synthese van een aantal vergelijkbare constructen. Door gebruik te maken
van pH-afhankelijke BODIPYs kon het proces van opname bestudeerd worden zonder te
wassen, omdat de constructen alleen fluorescent zijn in een zuur milieu, zoals in de lyso-
somen. Er kon worden aangetoond dat de constructen cathepsines remmen, zowel in lysaat
als in de cel, en dat de opname in dendritische cellen receptor-afhankelijk is.
Het bewezen nut van de pH-afhankelijke BODIPYs in hoofdstuk 2 leidde tot de ont-
wikkeling van een nieuwe serie kleurstoffen, zoals beschreven in hoofdstuk 3. Door ge-
bruik te maken van een Knoevenagel-achtige condensatiereactie konden pH-afhankelijke
BODIPYs worden gesynthetiseerd met verschillende handvatten voor verdere conjugatie,
zoals een azide, alkyn of zuurgroep. Door middel van twee, elkaar opvolgende, Knoevena-
gel-reacties kon bovendien een extra handvat of een water oplosbare groep geïntroduceerd
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worden. De gesynthetiseerde kleurstoffen hadden een vergelijkbare pH-afhankelijkheid als
die beschreven in hoofdstuk 2. Bovendien waren de excitatie- en emissiespectra verschoven
richting het rood, wat deze stoffen zeer geschikt maakt voor microscopie toepassingen.
In hoofdstuk 4 wordt het mannose cluster wederom gebruikt als doelgericht ligand
voor de mannose receptor. Echter, in plaats van een klein molecuul zoals in hoofdstuk 2
werd er nu een 70 kDa groot eiwit, Hsp70, aan vastgemaakt. Recombinant Hsp70, voorzien
van een C-terminale extensie met een sortase A herkenningssequentie (LPETGG) en een
His-affiniteitssequentie erin, werd tot expressie gebracht en gezuiverd. Vervolgens werd
dit ’Hsp70-LPETGG’ eiwit geligeerd aan dan wel BODIPY, dan wel BODIPY-mannose clus-
ter met behulp van het bacteriële enzym sortase. De reactie werd eerst geoptimaliseerd
op kleine schaal en vervolgens op grote schaal uitgevoerd. Het product, Hsp70-BDP-MC,
werd gezuiverd en vervolgens toegevoegd aan het medium van dendritische cellen. Er
kon worden aangetoond dat dit eiwit werd opgenomen door de cellen met behulp van mi-
croscopie. Blokkering van de receptor (met het natuurlijk voorkomende ligand mannan)
zorgde ervoor dat Hsp70-BDP-MC niet meer werd opgenomen, wat een indicatie is voor
receptor-gemedieerde opname.
In hoofdstuk 5 werd onderzocht of een synthetische verandering van het mannose
cluster er toe kon leiden dat een andere receptor dan de mannose receptor bereikt werd.
Daarvoor werd een mannose-6-fosfaat cluster (M6PC) ontworpen en gesynthetiseerd en
wederom geconjugeerd aan BODIPY-DCG-04. Cathepsine labelingsexperimenten in lever
lysaat lieten zien dat introductie van de fosfaatgroepen op het cluster geen effect had op
de labelingsefficiëntie. Experimenten met COS cellen lieten zien dat M6PC-BODIPY-DCG-
04, in tegenstelling tot MC-BODIPY-DCG-04, door de cellen werd opgenomen, wat resul-
teerde in de labeling van lysosomale cathepsines. Voorbehandeling van de COS cellen met
mannose-6-fosfaat remde de opname van het construct, wat aangeeft dat het construct in-
derdaad via de mannose-6-fosfaat receptor werd opgenomen. Voorbehandeling van den-
dritische cellen met mannan, om de mannose receptor te blokkeren, resulteerde niet in
remming van de opname. In conclusie toonden deze experimenten aan dat door een kleine
synthetische modificatie de receptor selectiviteit van het ligand kon worden veranderd van
de mannose receptor naar de mannose-6-fosfaat receptor.
In de hoofdstukken 6-9 worden verschillende strategieën besproken om doelgerichte
moleculen voor de follikelstimulerend hormoon (FSH) receptor te ontwikkelen. In de eerste
drie hoofdstukken worden laag moleculair gewicht (LMW) liganden gebruikt, gebaseerd
op een eerder gepubliceerde dihydropyridine (DHP) agonist en in hoofdstuk 9 het endo-
gene hormoon FSH. In hoofdstuk 6 werd een reeks aan verbindingen gebaseerd op DHP
gesynthetiseerd om erachter te komen wat de beste plek was om het molecuul te function-
aliseren zonder de activiteit op de receptor aan te tasten. De gesynthetiseerde verbindingen
werden getest in een luciferase assay en hieruit kon een structuur-activiteitsrelatie wor-
den gedestilleerd. Het bleek dat meta-gefunctionaliseerde DHPs in combinatie met een
polyethyleenglycol linker van lengte n=3 de meest potente agonisten opleverde. Met deze
bouwsteen konden dimere en fluorescente FSH receptor agonisten worden gemaakt zon-
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der dat dit ten koste ging van de activiteit.
Hoofdstuk 7 beschrijft het onderzoek naar de meest optimale kleurstof om vast te maken
aan het ligand geïdentificeerd in hoofdstuk 6. Verschillende kleurstoffen konden worden
geïntroduceerd wat resulteerde in potente fluorescente agonisten. Deze agonisten waren
tevens in staat om de receptor te laten internaliseren, zoals gedemonstreerd in een micro-
scopie internalisatie assay. Het bleek echter dat de meeste van deze fluorescente ligan-
den ook geïnternaliseerd werden in cellen die geen receptor expressie hadden. Alleen in
het geval van de hydrofiele en geladen kleurstof Cy5 werd het resulterende ligand DHP-
Cy5 selectief via de FSH receptor opgenomen. Deze stof is daarmee een zeer geschikte
kandidaat als diagnostisch gereedschap om de aanwezigheid van de FSH receptor op bi-
jvoorbeeld eierstoktumorcellen aan te tonen. Of het mogelijk is om naast een fluorescente
kleurstof ook een medicijn te sturen naar cellen die de FSH receptor tot expressie brengen
met behulp van het DHP ligand, is beschreven in hoofdstuk 8. Verscheidene moleculen
werden gesynthetiseerd welke naast de DHP en de kleurstof ook een of meerdere carbora-
nen bevatten. Carboranen kunnen gebruikt worden in een tweedelige therapie genaamd
"boron neutron capture therapy (BNCT)" voor de bestrijding van kanker. Helaas bleek dat
het toevoegen van de vette carboraan structuur resulteerde in de aspecifieke opname van
de constructen in cellen die geen receptor bevatten. Een lage mate van selectiviteit kon
alleen worden bereikt door Cy5 als kleurstof te gebruiken.
Om te voorkomen dat iedere (kleine) modificatie van het ligand grote invloed heeft op
de opname eigenschappen, kan worden gekozen voor een hoog moleculair gewicht (HMW)
ligand. Deze strategie is beschreven in hoofdstuk 9 waar sortase werd gebruikt om FSH
fluorescent te labelen met BODIPY-MC. Het resulterende FSH-BDP-MC bleek een zeer po-
tente agonist voor de FSH receptor en werd bovendien zeer selectief, samen met de receptor,
door de cellen opgenomen. Het werk beschreven in dit proefschrift is samengevat in hoofd-
stuk 10 en er is tevens een vooruitblik geschetst voor mogelijk vervolgonderzoek. Conclu-
derend laat het hier beschreven onderzoek zien dat doelgerichte moleculen zeer waardevol
zijn in het selectief sturen van fluorescente of therapeutisch interessante moleculen naar re-
ceptoren op specifieke cellen of weefsels.
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